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The alteration of intracellular cyclic adenosine monophosphate (cAMP) levels plays important 
regulatory roles in both physiological and pathological conditions, such as cancer. As the most 
aggressive form of brain tumour, glioblastoma is currently incurable due to limited treatment 
modalities. Low level of intracellular cAMP levels has been reported to be a feature of brain 
tumours. Thus, it is hypothesised that increasing cAMP concentrations by targeting regulatory 
proteins involved in the cAMP signalling pathways may offer advantages in preventing or 
treating glioblastoma. The overarching goal of this study therefore is to determine the dynamic 
effects of cAMP modulation on glioblastoma cell proliferation.  
The efficacies of compounds targeting various proteins involved in cAMP pathways 
were first investigated. The mechanisms explored were elevation of cAMP level through 
phosphodiesterases (PDEs) inhibition, adenylyl cyclase (AC) activation, as well as modulation 
via β-adrenoceptor (β-AR) and G proteins. A series of compounds were evaluated applying 
various assaying techniques and pharmacological tools using cAMP accumulation assays, cell 
proliferation, caspase-3/7 activation, and flow cytometry to determine cell cycle. It was 
demonstrated that increasing cAMP levels by multiple PDE inhibition or AC stimulation resulted 
in cell growth suppression on both rat and human glioblastoma models. The study was also 
extended to identify the role of possible crosstalk between calcium through SOCE (store-
operated calcium entry) and cAMP pathways, which both were found to contribute to cell 
growth modulation.  
The effect of the elevation of intracellular cAMP on cell proliferation was further 
explored through the direct activation of adenosine A2A receptor (A2AR) and inhibition of cAMP 
degradation via PDE10A. Previous computational studies revealed that the 
triazoloquinazoline-based compounds (compound 1-6), initially known as PDE10A inhibitors, 
are bound at the orthosteric site of A2AR. To validate the computational results, these 
compounds were characterised using NanoBRET-based ligand binding studies with HEK293T 
expressing Nluc-A2AR and functional assays in lung cancer cell lines and glioma/glioblastoma 
cell models, which both cell models expressed endogenous levels of PDE10A and A2AR. The 
study highlighted that compounds 1 and 5 were dual-target ligands to A2AR and PDE10A, 
whereas compound 3 appeared to be a pan-agonist of adenosine receptors (ARs), and 
compound 4 was more potent when A2BR was expressed. Compound 2 seems to possess 
toxic effects that may be independent of action to A2AR or PDE10A.  
Lastly, preliminary studies were conducted to investigate the possibility of biased 
signalling by RAMPs on protease-activated receptor 4 (PAR4) and calcitonin-like receptor 
(CLR). Using PAR4 transiently transfected HEK293T cells, both cognate ligand and agonist 
peptide were used to profile PAR4 signalling including RAMPs-trafficking to the plasma 
membrane, promoting intracellular calcium release and recruiting β-arrestins.  The effects of 
RAMPs were also investigated in HUVECs and cardiomyocytes focusing on the effect of 
endogenous ligands on cell growth. Whilst RAMPs altered PAR4 initial signalling events in 
promoting β-arrestin recruitment, the study on heterodimer complex of RAMPs and CLR on 
cell growth further corroborated that signalling bias can be translated into physiological 
responses in HUVECs and cardiomyocytes.  
To conclude, these studies provided evidence on how the alterations of intracellular 
cAMP levels affected cell proliferation in numerous cancer models, and that the cAMP-
mediated anti-proliferative effect was cell-line dependent. Targeting multiple PDEs suppressed 
cell growth in cancer-derived cells, therefore providing a viable target to reduce tumour 
progression. Given the critical role of PAR4 in platelet aggregation and pro-proliferative of 
 iv 
calcitonin peptide family, this research may have important implications for the role of RAMPs 
in cardiovascular pathologies. 
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1.1 Cellular signalling 
As the smallest unit of a living organism, cells can sense changes in their environment, 
leading to an adjustment of their function. Stimuli or signals come in a range of forms 
including chemicals, light and pressure. Whilst a cell can recognise these changes, it 
also can produce signalling molecules that induce different cells to respond – so 
forming a cellular communication network (Lodish; et al., 2016). Significantly, signalling 
molecules synthesised by these cells are not only limited to affect neighbouring cells 
but also function intracellularly, controlling fundamental processes, including gene 
transcription, cell growth, and metabolism. 
 In order to recognise extracellular signalling molecules, cells possess integral 
proteins embedded in the plasma membrane, known as cell-surface receptors. These 
receptors bind molecules on the extracellular side of the cell and transmitting the signal 
intracellularly to cytoplasmic proteins or other affecters, including enzymes or 
transcription factors. This hypothesis was first introduced in the mid-19th century when 
Langley used the term “receptive substance” as the first concept of receptors (Rang, 
2006). Cell surface receptors generally consist of 3 regions: an extracellular ligand-
binding domain, a plasma-membrane-spanning domain, and an intracellular domain. 
A number of receptors have been identified and can be classified into two main 
families: intracellular receptors (nuclear receptor) and transmembrane receptors. The 
latter can be categorised into receptor tyrosine kinases (RTKs), G protein-coupled 
receptor (GPCRs), ion channels, and cytokine receptors (Arey, 2014). The following 
sections will focus upon GPCR-mediated signalling cascade.  
 
1.2 Overview of signal transduction through G protein-coupled receptor 
(GPCRs) 
GPCRs, are seven-transmembrane (TM) proteins, and account for 
approximately 4% of proteins encoded in the human genome (Matthews and Sunde, 
2012). The family is one of the most numerous proteins that have been identified, of 
the 826 approximately 400 are non-sensory GPCRs with the remaining being olfactory 
receptors (Yang et al., 2021). As one of the most identifiable targets for treating various 
diseases, GPCRs have contributed to more than 40% of drugs which are currently 
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available in the market (Hauser et al., 2017). GPCRs have various endogenous 
ligands, including odour, light, hormones, neurotransmitters, chemokines, 
carbohydrates, lipids, amines, peptides, and proteins. The physiological roles of 
GPCRs are numerous and consequently they have been implicated in many diseases, 
including type 2 diabetes mellitus (T2DM), obesity, cancer, Huntington’s disease, 
Alzheimer’s disease, and others (Rosenbaum, Rasmussen and Kobilka, 2009; 
Sebastiani et al., 2018).   
GPCRs mediate their signalling though activation of a heterotrimeric G protein 
complex that consists of a Gα subunit bound to a Gβɣ dimer. In the resting state, the 
Gα subunit is bound to GDP which facilitates tight binding to the Gβɣ heterodimer. Not 
only does this interaction help to anchor Gα subunit to the plasma membrane, but it 
also serves as a guanine nucleotide dissociation inhibitor (GDI) by slowing the rate of 
GDP release from the Gα (Brandt and Ross, 1985; Higashijima, Ferguson and 
Sternweis, 1987). Upon conformational changes after an agonist binds to the GPCR, 
it becomes a guanine nucleotide exchange factor, promoting the exchange of 
guanosine diphosphate (GDP) to guanosine triphosphate (GTP) at Gα subunit, and 
resulting in dissociation of Gα-GTP from the Gβɣ subunits (McCudden et al., 2005). 
Subsequently, both GTP-bound Gα and Gβɣ can activate an array of downstream 
signalling events. Conformational changes of Gα subunit are tightly regulated by 
nucleotide-binding and have be implicated in signal transduction (Goricanec et al., 
2016). However, a recent study on vasopressin V2 receptor (V2R) demonstrated that 
formation of V2R-Gα12 complexes generate unproductive signalling which is 
independent of guanine nucleotide binding (Okashah et al., 2020).  The signal from 
the Gα is terminated by the enzymatic activity of intrinsic GTPase of Gα, hydrolysing 
GTP into GDP, which allows re-association with the Gβɣ dimer. The schematic 
illustration of this process is depicted in Figure 1.1. Apart from its intrinsic enzymatic 
activity, proteins called Regulator of G protein signalling (RGS) serve as GTPase 
activating proteins (GAPs) for specific Gα subunits. GPCRs have been shown to 
activate diverse downstream signalling pathways through canonical G protein 
mediated signalling or non-canonical β-arrestin pathways. 
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Figure 1.1 GPCR signalling cycle. It is postulated that in resting state, Gα is bound 
to GDP and forming heterotrimeric complex with Gβɣ subunits (1). Upon agonist 
binding, it promotes conformational changes of the receptor into the active states. This 
process induces recruitment of heterotrimeric Gαβγ protein, which is followed by the 
exchange of GDP for GTP in the Gα subunit protein (2). GTP-bound Gα protein 
stabilises the active form of receptor and further induce Gα and Gβγ dissociation. This 
process allows both Gα and Gβγ proteins to activate their respective effectors (3). 
Signal transduction is terminated by the intrinsic GTPase activity of Gα subunit, 
accelerated by RGS proteins (4). The hydrolysis of GTP to GDP returns to the Gα 
resting state, allowing it to re-associate with Gβγ heterodimer. The figure was created 
with BioRender.com 
 
Based on the phylogenetic tree, GPCRs can be classified into five classes which 
are commonly known as GRAFS systems: glutamate, rhodopsin, adhesion, frizzled, 
and secretin class (Fredriksson et al., 2003). Another more common nomenclature 
classifies GPCRs into class A-F. It consists of class A (rhodopsin), class B (secretin), 
class C (glutamate), class D (fungal mating pheromone receptors), class E (cAMP 
receptors), and class F (frizzled/smoothened). This classical A-F systems was 
determined based on sequence homology and functional similarity (Attwood and 
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 GPCRs have been studied for almost 40 years and it is widely accepted that 
GPCR activation allows physical association with a heterotrimeric G protein (De Lean, 
Stadel and Lefkowitz, 1980; Limbird, Gill and Lefkowitz, 1980; Gether and Kobilka, 
1998). Although the study of GPCRs has expanded, the understanding of receptor and 
G protein dynamic is not without debate. Currently, at least two different models have 
been suggested. The first concept, that has been widely accepted, postulates that the 
G protein and the GPCR only interact following agonist binding to the receptor - the so 
call collision coupling model. In contrast, the second model conjectures that GPCR 
and G proteins exist in pre-coupled complexes prior to agonist-binding (Hein and 
Bünemann, 2009; Ayoub, Al-Senaidy and Pin, 2012; Lohse, Nuber and Hoffmann, 
2012).  
 Whatever the mechanism both models lead to G protein activation as described 
above initiating post-GPCR signal transduction. Typically, this will involve second 
messengers, enabling signal amplification. These second messengers comprise four 
classes: cyclic nucleotides (cyclic adenosine 3’,5’ monophosphate (cAMP) and cyclic 
guanosine 3’,5’ monophosphate (cGMP)) and other soluble molecules, lipid 
messengers, ions, and gases-free radicals (Newton, Bootman and Scott, 2016). The 
particular section about cAMP and cGMP will be introduced later.  
 
1.2.1 G protein-mediated signalling 
Heterotrimeric G proteins consist of α, β, and ɣ subunits. In humans, there are 16 Gα 
genes encoding 23 Gα proteins; 5 genes encoding 5 Gβ, and 12 genes encoding Gɣ 
subunits (Downes and Gautam, 1999). Gα subunits are varied in range of 39-45 kDa 
with many, but not all, being post-translationally modified to contain myristate/palmitate 
at their N-terminal, which aids membrane localisation (Peitzsch and McLaughlin, 1993; 
Nürnberg, Gudermann and Schultz, 1995; Wedegaertner, Wilson and Bourne, 1995). 
Gα proteins, fall into 4 subclasses based on structure similarities: Gαs that stimulates 
adenylyl cyclase (AC) generating cAMP, Gαi that inhibits AC therefore reduces cAMP 
production, Gαq that stimulates phospholipase C-β (PLC-β) thus mediating intracellular 
Ca2+ release from endoplasmic reticulum (ER), and G12/13 that triggers small Rho-
GTPase (Simon, Strathmann and Gautam, 1991). The following sections provides a 
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1.2.1.1. The Gαs family 
The activation of this Gα subunit mediates AC-activation that leads to an increase in 
cAMP synthesis. Gαolf also belongs to this protein family but is mainly expressed in 
olfactory sensory neurons (Jones and Reed, 1989). Aside from stimulating AC, the Gαs 
subunit has also been shown to regulate Ca2+ channels, through direct and indirect 
mechanisms (Yatani and Brown, 1989). Currently, 3 different isoforms of the Gαs 
subunit have been identified, consisting of Gs(s), Gs(L), Gs(XL). Their activities have been 
suggested to differ with Gs(XL) being reported to be involved in brachydactyly, trauma-
related bleeding, and various neurological problems (Milligan and Kostenis, 2006) 
while activation of Gs(L) has shown to activate the Src kinase family – so called non-
tyrosine kinases (Romero, 2014).  
In order to dissect the role of Gαs-mediated responses, cholera toxin (CTx) can 
be utilised as a pharmacological tool. CTx mediates ADP-ribosylation on the Gαs 
subunit by targeting a specific arginine residue (Arg201) which significantly decreases 
the intrinsic GTPase activity of Gα subunit, leaving Gαs permanently activated. As a 
result, the production of cAMP is continuously increased. In addition, the use of 
selective inhibitors has become an invaluable approach to investigating the 
involvement of G proteins in mediating cellular responses. NF449 and NF503 have 
both been demonstrated to inhibit Gαs coupling to the β-adrenoceptors (β-ARs), 
although subsequently they have been shown to also influence on Gαi/Gαo- and Gαq-
coupled receptor signal transduction (adenosine A1 receptor (A1R) and angiotensin II 
receptor, respectively) (Hohenegger et al., 1998). 
 
1.2.1.2. The Gαi/o family of G proteins 
Gαi/o has been reported to be the most diverse Gα subtypes. This family consists of 
Gαi1, Gαi2, Gαi3, Gαo (which has 2 splice variants), Gαt-rod, Gαt-con (transducin), Gαgust 
(gustucin) and Gαz (McCudden et al., 2005). Gαt is involved in photoreception in the 
eyes, whereas Gαgust is commonly known as the taste specific G protein, highly 
expressed in the taste buds. Both Gαt and Gαgust are involved in the activation of 
cGMP-specific phosphodiesterases (PDEs) (Rarick, Artemyev and Hamm, no date; 
Yan et al., 2001).  
All Gαi/o family members are myristoylated at their N-terminus, except for Gαt 
which contains a palmitate that is reversibly attached near the N-terminus. Unlike Gαs, 
this family inhibits the activity of AC, except Gαo, thereby reducing the production of 
cAMP. Gαo has been demonstrated to increase phosphoinositide release (Birnbaumer 
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et al., 1990). Although Gαz displays a resemblance to this subfamily, its GTPase 
activity is significantly lower compared to other Gαi/o family members (Simon, 
Strathmann and Gautam, 1991).  
All member of the Gαi/o class (with the exception of Gαz) possess a cysteine 
residue 4 amino acids sites from their C-terminus that is susceptible to modification by 
pertussis toxin (PTx). PTx is a toxin produced by Bordetella pertussis in an inactive 
form and catalyses ADP-ribosylation on a cysteine residue at C-terminal of Gαi/o 
(Mangmool and Kurose, 2011). This modification causes G protein – GPCR uncoupling 
and blocks its signal transduction because of steric hindrance between both proteins 
(Campbell and Smrcka, 2018) so preventing further interaction with AC (Hsia et al., 
1984; Burns, 1988). Inhibition of Gαi/o activity by PTx is usually slow onset. Although 
PTx has been widely used to determine Gαi/o signalling, a recent finding identified that 
PTx has a Gαi/o-independent effect with other proteins by binding B-oligomer with cell 
surface-specific proteins (Mangmool and Kurose, 2011). BIM-46174 and BIM-46187 
have been demonstrated to target all Gα subtype families (Prévost et al., 2006). 
 
1.2.1.3. The Gαq/11 family 
This subfamily comprises of Gαq, Gα11, Gα14, Gα15, and Gα16 subunits. Of all G 
proteins, this family shares the most sequence homology, with Gαq, Gα11, Gα14, Gα15/16 
displayed 90, 80, and 57% similarities (Kamato et al., 2015). The Gαq/11 family does 
not have cysteine residue four amino acids from the C-terminus, mediating its resistant 
towards PTx (Simon, Strathmann and Gautam, 1991). All Gαq/11 members have shown 
to activate PLC-β, leading to the mobilisation of Ca2+ from the ER into the cytoplasm 
via inositol 1,4,5-trisphosphate (IP3) production. Besides activating PLC-β, Gαq/11 also 
has been reported to interact with p63RhoGEF, activating Rho through the action of 
RhoGTPase (Campbell and Smrcka, 2018). This interaction appears to be cell-type 
dependent. Gα15 and Gα16, on the other hand, can couple to a wide variety of GPCRs. 
For instance, these two Gα proteins mediate the production of IP3 through β2-
adrenoceptor (β2-AR) and M2-muscarinic receptors leading to elevation of intracellular 
Ca2+ in COS-7 cells (COS cells are fibroblast like cells derived from monkey kidney 
tissue, COS refers to cells being CV-1 (simian) in Origin and carrying the SV40 genetic 
material) (Gluzman, 1981; Offermanns and Simon, 1995). 
The most common Gαq/11 inhibitor that has been widely used is YM-254890, a 
cyclic depsipeptide that inhibits the GDP to GTP exchange on the α subunit of Gαq/11 
complex. However, recent findings argued the compound's selectivity properties as it 
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also inhibited Gαs and exhibited biased inhibition on Gαi/o (Peng et al., 2021). In 
addition, U73122 has also been identified to inhibit the activity of Gαq/11 by blocking 
PLC-β (Wu, Pei and Fan, 1998). Whilst BIM-46187 has been reported to be a pan-Gα 
inhibitor and depending on the cellular context, it elicits selectivity towards Gαq/11 over 
the remaining Gα protein subfamily (Schmitz et al., 2014). However, no known Gα 
inhibitor are available for Gα14, Gα15, and Gα16. Therefore, a genetic approach of 
knocking down the genes encoding G proteins may be required, but this strategy is not 
not without challenges. 
 
1.2.1.4. The Gα12/13 subfamily 
Analogous to the Gαq/11 family, Gα12/13 also lacks a cysteine residue at its C-terminal 
and is insensitive towards PTx (Simon, Strathmann and Gautam, 1991). Both Gα12 and 
Gα13 are ubiquitously expressed in many tissues and are currently known to interact 
with p115RhoGTPase proteins, PDZ-RhoGEF (PDZ for postsynaptic density 95, PSD-
95; Discs large, Dlg; Zonula occludens-1, ZO-1; GEF for guanine nucleotide exchange 
factor), and leukaemia associated RhoGEF (LARG) (Suzuki et al., 2003). Gα12 
activates the small monomeric G protein (Rho) through its RhoGTPase mediating 
catalysis of Rho-GDP for Rho-GTP. Besides interacting with RhoGEF family proteins, 
Gα12/13 family also activates PLCε and PLCδ, phosphatase 5, and A-kinase anchoring 
proteins 110 (AKAP110) (Milligan and Kostenis, 2006). Gα12/13 are also known as gep 
proto-oncogenes and serves as prognostic tools for cancer patients (Y. M. Yang et al., 
2020). These family members have also demonstrated their role as regulators in 
energy metabolism and immune-mediated responses (Healy et al., 2016; Y. M. Yang 
et al., 2020). 
 
1.2.1.5. The Gβ subunit 
To date, at least 5 Gβ subunits have been identified in the human genome (Downes 
and Gautam, 1999). The Gβ subunit comprises of N-terminal α-helix and seven bladed 
β-propeller sheets. Each blade is composed of four antiparallel strands containing 
multiple tryptophan/aspartate (WD-40) motifs (Simon, Strathmann and Gautam, 1991). 
These motifs are specifically responsible for the structure of the Gβ subunit generating 
a so-called propeller shape and are implicated as the region where Gβ and Gɣ may 
interact. Of the five different Gβ subunits, β5 is not homologous compared to the other 
four subunits and is believed to have different roles. Unlike other Gβ subunits, β5 
dissociates from Gɣ and is known to be able to interact with RGS proteins that contain 
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a G protein-ɣ-like domain, C-A-A-X motif (Milligan and Kostenis, 2006). Gβ3 has been 
suggested to be involved in atherosclerosis, hypertension, and metabolic syndrome 
(Milligan and Kostenis, 2006).  
 
1.2.1.6. The Gɣ subunit 
The Gɣ subunit protein is only stable in the form of dimer with Gβ subunits. There are 
currently 12Gɣ identified. Each Gɣ subunit undergoes post-translational modification, 
either a 15-carbon farnesyl or 20-carbon geranylgeranylisoprenoid, that is attached to 
the cysteine residue of C-A-A-X motif (Simon, Strathmann and Gautam, 1991), all of 
which leads to membrane targeting. The presence of Gɣ is necessary for correct 
folding of Gβ subunit protein. Gβ and Gγ form a heterodimer and are not found as 
individual units in the natural settings. (Schmidt et al., 1992; Higgins and Casey, 1994).  
Most cells express multiple types of Gβ and Gɣ subtypes. Since Gβ and Gɣ are 
commonly found in dimers, little is known about the functions of each subunit. Upon 
dissociation with Gα, Gβγ complex transduces to their downstream affecters. G protein 
coupled-gated inwardly rectifying potassium channel (GIRK) are opened through direct 
binding with the Gβγ heterodimer after stimulation of muscarinic acetylcholine 
receptors, γ-aminobutyric acid (GABA) receptors, dopamine receptors, and opioid 
receptors (Lüscher and Slesinger, 2010). In addition, voltage-dependent inhibition of 
N-type Ca2+ channels was also mediated through Gβγ activation (Ikeda, 1996). 
Activators of G protein signalling 3 (AGS3) is a non-receptor protein activated by Gβγ 
subunits. Silencing AGS3 protein has been implicated to disruption of apical-basal 
cellular division though its control in spindle orientation (Sanada and Tsai, 2005).  
Small molecule Gβγ inhibitors have been developed to selectively block their 
interactions with their effectors, this includes M119 and its analogue, gallein (Lehmann, 
Seneviratne and Smrcka, 2008). Later, Blattermann also discovered Gue1645 a 
compound that selectively prevents Gβγ-mediated signalling without having any effect 
on Gα (Blättermann et al., 2012).  
 
1.2.2 Non-canonical GPCR signalling 
Although it was first thought that GPCR signalling was solely dependent on G proteins, 
currently, the paradigm has shifted, demonstrating multidimensional signalling of 
GPCRs. This notion has been implicated in biased signalling, formation of oligomers 
with other receptors, and sustained signalling from intracellular compartments 
(Shchepinova et al., 2020). 
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1.2.2.1. The role of G protein receptor kinase (GRKs) 
G protein receptor kinase (GRKs) are known to interact with GPCRs upon their 
activation. Upon agonist-binding, GPCRs typically engaged to the G proteins, undergo 
phosphorylation by GRKs, and bind with β-arrestin to mediate desensitisation or 
internalisation. β-arrestins can bind to active GPCRs and phosphorylated GPCRs and 
promote receptor internalisation via clathrin-coated pits (Paccauds et al., 1993). 
Together with β-arrestin, GRKs are key modulators in controlling the rate and 
desensitisation of GPCRs. To promote receptor desensitisation, the receptor 
intracellular loop 3 (ICL3) and the C-terminal tail have been reported to be the 
interaction sites with GRKs (Komolov and Benovic, 2018).  
The first GRKs originally called the “opsin/rhodopsin kinase” was found in 1972 
but has subsequently been renamed to GRK1. It was shown to mediate 
phosphorylation of rhodopsin, a prototypical GPCR (Kühn and Dreyer, 1972). GRK1s 
main function was first thought to mediate rhodopsin deactivation, however, later 
GRK1 was found to be associated with a broader range of receptors. Although GRKs 
are classified in the AGC kinase super family (the AGC protein group is a family of 
serine/threonine protein kinases that is closely related to protein kinase A (PKA), 
protein kinase G (PKG), and protein kinase C (PKC) (Manning et al., 2002)), the 
presence of the RGS homology (RH) domain in GRKs makes them different from any 
of the other kinases in the family (Gurevich et al., 2012). There are 7 members of the 
GRKs (GRK1-7), with only four classes that are thought to be involved in recognising 
active GPCRs: GRK1, GRK2, GRK3, and GRK7 (Gurevich and Gurevich, 2019).  
All GRKs share the N-terminal domain, catalytic kinase domain, RH domain and 
a C-terminal domain (Figure 1.2). A pleckstrin homology (PH) domain, is also present 
in GRK2 and GRK3, as part of their C-terminal domain (Touhara et al., 1994). 
However, it is reported that the RH domain is only functional in GRK2/3 to regulate 
phosphorylation-independent GPCR desensitisation, whereas the PH domain is 
responsible for the binding to the Gβγ dimer (Gurevich and Gurevich, 2017; Sun and 
Kim, 2021). GRK2, in particular, has shown to have kinase activity to non-GPCR 
desensitisation that is important to maintain a balance between receptors and signal 
transduction (Han et al., 2016). GRK2 has also been suggested to be involved in a 
negative feedback regulatory mechanism that influences extracellular signal-regulated 
kinase (ERK) signalling, as demonstrated in human embryonic kidney 293 (HEK293) 
cells (Pitcher et al., 1999).  
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Figure 1.2 Schematic illustration of GRK family proteins. All GRK family members 
shares three domains consisting of N-terminal domain, catalytic domain, and C-
terminal domain that is vary amongst member of GRK family.  Figure was adapted 
from (Sun and Kim, 2021) and created with BioRender.com 
 
Although GRK2 and GRK3 are homologous proteins, they only share 39% similarities 
(Pitcher, Freedman and Lefkowitz, 1998). Within the PH domain (residue 553-656), a 
19 amino acid motif is involved in Gβγ dimer binding. In in vitro studies, the PH domain 
has also been demonstrated to display specific binding to phosphatidylinositol 4,5-
bisphosphate (PIP2) so suggesting multiple sites for phosphorylation. Several other 
molecules have been identified as ligands of the PH domain, these include receptor 
for C activated kinase 1 (RACK1), PKC, Gα12, and F-actin (Yang et al., 2003). The PH 
domain is not only present in GRK2/3 but also in other proteins including some 
serine/threonine kinase proteins, tyrosine-specific kinase, all known mammalian PLCs, 
RGS proteins, and a number of cytoskeletal proteins (Pitcher, Freedman and 
Lefkowitz, 1998).  
GRK4 and GRK6 are associated with the plasma membrane due to the 
presence of palmitoylation on their C-terminal and N-terminal lipid-binding region 
(Figure 1.2) (Gurevich et al., 2012). However, the molecular mechanism on GRK4 and 
GRK6 cellular localisation remains to be established. GRK5 is also a membrane-bound 
kinase anchored through PIP2 binding domain near its N-terminal (Stoffel, Pitcher and 
Lefkowitz, 1997) and amphipathic helix membrane-binding domain at its C-terminal 
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1.2.2.2 The arrestin subfamily 
Arrestins are small family of cytosolic proteins that regulate GPCR signalling. Due to 
their preferential binding to an active receptor, the recruitment of this protein family 
prevents the coupling of phosphorylated receptors to their respective G proteins. In 
mammalian cells, there are at least four arrestin paralogs that can be classified into 2 
major classes: visual arrestins and β-arrestins. Visual arrestins comprised of arr-1 and 
arr-4 are expressed mainly in the retina, whereas β-arrestins consist of β-arrestin1 and 
2 (or also known as arr-2 and arr-3) play crucial roles to recognise GPCRs in most 
human cells (Indrischek et al., 2017; Aydin and Coin, 2021). Arrestins inhibit GPCR 
coupling mainly by two mechanisms: i) preventing GPCR activation (desensitisation) 
by binding to the receptor C-terminal so blocking G protein activation and ii) serving as 
scaffolds for protein kinases and mediators for receptor internalisation. Furthermore, it 
has been suggested that both β-arrestins, when bound to an agonist-coupled GPCR 
may also elicit distinct signalling capabilities (Gurevich and Gurevich, 2020). GPCR-β-
arrestin complexes can promote activation of ERK1/2 and mitogen-activated protein 
kinase (MAPK) signalling cascade through direct and indirect mechanisms (Luttrell et 
al., 2001; Song et al., 2009; Gurevich and Gurevich, 2019). The indirect mechanism is 
provided by RTK transactivation by β-arrestin (Wetzker and Böhmer, 2003; Shah and 
Catt, 2004; Werry, Sexton and Christopoulos, 2005). Interestingly, some reports also 
indicated that β-arrestins can interact directly to the ERK1/2 and c-Jun N-terminal 
kinase 3 (JNK3) that belong to MAPK family (DeFea et al., 2000; McDonald, 2000). 
The N-terminus of β-arrestin2 peptide (T1A) also acts as a scaffold for ASK1/MKK4/7-
JNK3 that activate JNK3 to control apoptosis, cell division, and synaptic changes in 
neurons (Zhan et al., 2016).  
Signalling through β-arrestin is thought to be separable from G protein-mediated 
signalling given the fact that β-arrestins “arrest” GPCR activation by interfering with G 
protein binding. However, recent evidence has shown that the Gαi family, but not other 
Gα proteins, form a complex with β-arrestin at the plasma membrane upon stimulation 
with V2R agonist. This interaction generates a productive ERK1/2 signalling and cell 
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1.2.2.3 Other regulatory proteins that promote non-canonical GPCR signalling 
The EBP50 (for ezrin-radixin-moesin (ERM)-binding phosphoprotein-50) 
phosphoprotein is known to be able to bind to the C-terminus of the β2-AR through its 
PDZ domains (Reczek, Berryman and Bretscher, 1997; Cao et al., 1999). Other 
proteins that contain a PDZ motif, such as Na+/H+ exchange regulatory factor-1 
(NHERF) and NHE3 kinase A regulatory protein (E3KARP), bind to the cytoplasmic 
side of the β2-AR promoting/activating particular pathways (Hall et al., 1998). EBP50 
is also reported to involve platelet activating receptor (PAFR) internalisation (Dupré, 
Rola-Pleszczynski and Stankova, 2012) and promote receptor recycling in δ-opioid 
receptors (Lauffer et al., 2009). Another protein, AGS3-6 has been reported to compete 
with Gβɣ to bind the Gα promoting Gβɣ to activate its downstream signalling and has 
been shown to modulate immune systems (Boularan and Kehrl, 2014). In some cases, 
transactivation of RTKs by GPCRs leads to the recruitment of scaffold proteins, such 
as Shc, Grb2, and Sos, which together activates MAPK signalling (Natarajan and Berk, 
2006) 
 
1.2.3 Modulatory action of receptor activity-modifying proteins (RAMPs) in 
regulating GPCR signalling 
RAMPs are single transmembrane proteins that were first studied to interact with 
calcitonin receptor-like receptor (CLR) (McLatchie et al., 1998). Initially it was thought 
that RAMPs solely acted as chaperones for CLR. However, RAMPs are now known to 
play important roles in altering many GPCRs pharmacology. The Human genome 
encodes for three RAMP isoforms (RAMP1, RAMP2 and RAMP3) (McLatchie et al., 
1998; Klein, Matson and Caron, 2016). RAMPs share ~30% sequence homology, with 
RAMP2 being slightly larger (175 amino acid residues) compared to RAMP1 and 
RAMP3 (140 amino acid) (McLatchie et al., 1998). All RAMPs share three domains 
which include an extracellular domain (ECD), a single transmembrane domain (TMD), 
and a short C-terminal domain that comprises about 10 residues.  The N-terminal has 
been shown to be responsible for determining ligand specificity, whereas the C-
terminus is important to alter downstream signalling (Udawela et al., 2006).  
 RAMPs have been reported to allosterically alter CLR signalling and provide a 
point for direct binding that further modulates G protein-coupling, changes ligand 
binding, affects receptor trafficking, receptor internalisation and signalling capabilities 
(Simms et al., 2009; Klein, Matson and Caron, 2016; Weston et al., 2016; Woolley et 
al., 2017; Garelja et al., 2018). The best characterised site of interaction between 
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RAMPs and CLR has been suggested to be the ECD (Hay et al., 2016). However, 
other reports have highlighted other possibilities of RAMP-CLR interaction regions. 
Through molecular dynamics (MD) simulation, Weston and colleagues demonstrated 
the interaction occurs on the RAMP transmembrane (TM) helix and CLR TM6/TM7 
(Weston et al., 2016). The study also highlighted Helix 8 (H8) involvement with Gαs 
suggesting RAMP may contribute to bias in G protein-coupling by the CLR (Weston et 
al., 2016). Notably, the C-terminal domain of the RAMPs may also be involved in 
interaction with GPCRs, although this requires further elucidations (Bomberger, 
Spielman, et al., 2005; Udawela et al., 2006).   
 Aside from CLR, recent findings by Harris and colleagues further dissect the 
mechanism of RAMP in regulating signalling bias and internalisation of gastric 
inhibitory polypeptide receptor/ glucose-dependent insulinotropic polypeptide receptor 
(GIPR) (Harris et al., 2021). RAMPs have been demonstrated to modulate G protein 
activations and influence cell surface expressions. The alteration of GIPR signalling at 
the molecular level has been implicated both for acute and prolonged responses, as 
demonstrated in overexpression surrogate systems and in vivo studies.   
RAMP-GPCR interaction has been well studied, especially with class B GPCRs 
(secretin family). Interestingly, the interaction is not limited to the class B but also has 
been shown to form heteromers with class A and C GPCRs (Poyner et al., 2002; Hay 
et al., 2016; Barbash et al., 2017; Mackie et al., 2019). Current RAMPs interacting 
partners are summarised in Table 1.1 
 
Table 1.1 






A GPR30/GPER RAMP3 (Lenhart et al., 2013) 




(Mackie et al., 2019) 
 
A CCR1 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR2 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR3 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 







A CCR4 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR5 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR6 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR7 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR8 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR9 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CCR10 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CXCR1 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CXCR2 RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A CXCR3 RAMP2, 
RAMP3 
(Mackie et al., 2019), 
(Lorenzen et al., 2019a) 
A CXCR4 RAMP1, 
RAMP3 
(Mackie et al., 2019) 
A CXCR5 RAMP3 (Mackie et al., 2019) 
A CXCR6 RAMP3 (Mackie et al., 2019) 
A CX3CR1 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A XCR1 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A ACKR1 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 







A ACKR2 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A ACKR3 RAMP1, 
RAMP2, 
RAMP3 
(Mackie et al., 2019), 
(Lorenzen et al., 2019a) 
A ACKR4 RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A ACKR5 RAMP2, 
RAMP3 
(Mackie et al., 2019) 
A GPR4 RAMP1, 
RAMP2, 
RAMP3 
(Lorenzen et al., 2019a) 
A GPR182 RAMP1, 
RAMP2, 
RAMP3 
(Lorenzen et al., 2019a) 
B CLR RAMP1 
RAMP2 
RAMP3 
(McLatchie et al., 1998) 
B CTR RAMP1 
RAMP2 
RAMP3 
(Christopoulos et al., 
1999) 
B CRF1R RAMP2 (D Wootten et al., 2013) 
B CRF2R RAMP3 (Lorenzen et al., 2019a) 
B GCGR RAMP2 (Christopoulos et al., 
2003; Cegla et al., 2017) 
B GLP-1R RAMP1 
RAMP2 
RAMP3 
(Lorenzen et al., 2019a) 
B GLP-2R RAMP1 
RAMP2 
RAMP3 
(Lorenzen et al., 2019a) 
B GIPR RAMP1 
RAMP2 
RAMP3 
(Lorenzen et al., 2019a), 
(Harris et al., 2021) 
B PTH1R RAMP2 (Christopoulos et al., 
2003) 
B PTH2R RAMP3 (Christopoulos et al., 
2003) 
B GHRHR RAMP2 
RAMP3 
(Lorenzen et al., 2019a) 
B Secretin Receptor RAMP3 (Harikumar et al., 2009) 







B VPAC1R RAMP1 
RAMP2 
RAMP3 
(Christopoulos et al., 
2003) 
B VPAC2R RAMP1 
RAMP2 
RAMP3 
(D. Wootten et al., 2013)  
B PAC1R RAMP1 
RAMP2 
RAMP3 
(Lorenzen et al., 2019a) 
C CaSR RAMP1 
RAMP3 







(Lorenzen et al., 2019a) 
GPER, G protein oestrogen receptor 1; CCR, chemokine receptor; CXCR, CXC chemokine 
receptor; ACKR, atypical chemokine receptor; CLR, calcitonin-receptor like receptor; CTR, 
calcitonin receptor; CRFR, corticotropin releasing factor receptor; GCGR, glucagon receptor; 
GLP(1/2)R, glucagon-like receptor (1/2); GIPR, gastric inhibitory polypeptide receptor/ 
glucose-dependent insulinotropic polypeptide receptor; PTHR, parathyroid hormone receptor; 
PAC1R, pituitary adenylate cyclase-activating peptide receptor; VPACR, vasoactive intestinal 
peptide receptor; CaSR, calcium-sensing receptor; ADGRF5, adhesion G protein- 
coupled receptor F5  
 
The study of RAMP interactions has been intensively studied in CLR. Neither 
CLR nor RAMP1/2 are able to traffic to the plasma membrane (Pioszak and Hay, 
2020). RAMP3 does appear to display some plasma membrane localisation 
independent of GPCR interaction. RAMP1 has demonstrated Gαs-mediated responses 
of calcitonin gene related peptide receptor (CGRP-R) and Gαi coupling of 
adrenomedullin (AM1-) and adrenomedullin 2 (AM2-) receptor (Weston et al., 2016; 
Pioszak and Hay, 2020). Furthermore, recent studies emphasised that physical 
engagement of RAMP to CLR in human umbilical vein endothelial cells (HUVECs) and 
human cardiomyocytes (hCMs) acted as a “signalling barcode” selectively activating 
particular cascades (Clark et al., 2021). 
 
1.2.4. The hallmark of cancer  
More than 367,000 new cancer cases were reported in the UK between 2015 and 2017 
1. The incidence rate was envisaged to increase by 2% between 2014 and 2035. 
 
1 https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-Zero 
(accessed 5 September 2021) 
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Worldwide, the mortality rate is between 100 to 350 per 100,000 people per year. As 
one of the most complicated pathological conditions, it is due to cellular regulation loss 
to control cell growth and proliferation. Cell proliferation alone may not be causing 
cancer, however, sustained growth in an environment in the presence of inflammatory 
cells, growth factors, DNA damaging agents, as well as activated stroma increases the 
risk of neoplasticism (Coussens and Werb, 2002).   
Hanahan and Weinberg proposed in their review that at least there are eight 
biological capabilities of cells in tumour development (Hanahan and Weinberg, 2011), 
, which genetic predispositions become the underlying issue. The hallmark of cancers 
includes (Figure 1.3):  (i) cancer cells can maintain chronic proliferation, somatic 
mutations may be involved to activate growth factor-mediated signalling pathways, to 
disrupt negative feedback loop in order to sustain pro-proliferative actions, and to 
overexpress genes and signals that trigger cells to enter senescence, (ii) the ability to 
circumvent suppressor of proliferation, disruptions of TGF-β signalling that results in 
malignancy, and attenuation of apoptosis, (iii) activating invasion and metastasis, (iv) 
enabling replicative immortality, (v) promoting angiogenesis, (vi) resisting cell death, 
(vii) reprogramming of energy metabolism, and (viii) evading immune destruction 
(Hanahan and Weinberg, 2011). 
 
 
Figure 1.3. The hallmark of cancer. During tumourigenesis, there are eight biological 
capabilities that are present in cancer cells. While some of these changes exist, it may 
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result in less destructive phenotypes. The figure was adapted from (Hanahan, 2011) 
and created with BioRender.com.  
 
In tumourigenesis, genetic predisposition and the interaction between host and cancer 
cells in the tumour microenvironment play crucial roles. The protection by the natural 
immune defence against cancer development was debatable in the early '80s, 
however, the concept gained more recognition leading to the notion of cancer 
immunosurveillance. Later the concept develops to the broader process called cancer 
immunoediting as an evolutionary pressure enabling cancer cells to be adaptable 
against the host's immune system. While it serves as a protective mechanism, it also 
has dual actions to sculpt the tumour microenvironment (Gavin P. Dunn, Old and 
Schreiber, 2004; Vinay et al., 2015). Due to the critical roles of immune cells in tumour 
development, immunotherapy has emerged to aid host immune systems in eliminating 
cancer.  An extensive review has been published to cover the process of 
immunoediting during tumour development that involves elimination, equilibrium, and 
escape processes or commonly known as "three E's of immunoediting (Gavin P Dunn, 
Old and Schreiber, 2004). The immunotherapies below have been used in clinical 
settings to treat cancer, and these include the use of immune checkpoint inhibitors that 
target PD-1/PDL-1, CTL-4; T-cell transfer therapy, monoclonal antibody, vaccines, and 
immunomodulatory agents2.  
 
1.2.5 Overview of relevant GPCRs in this study 
A number of the GPCRs that have been studied in this thesis will be described in more 
detail in the following sections. These GPCRs included: adenosine A2A receptor 
(A2AR), protease-activated receptor 4 (PAR4), and CLR. The study on A2AR is part of 
the work in Chapter 5 exploring the multi-target ligands and their implication on cell 
growth. Whereas PAR4 and CLR were studied in Chapter 6 as interacting partners of 
RAMP. Here the impact of RAMP interactions on downstream signalling for PAR4 and 
the functional consequences of CLR on cell growth were examined.  
 
1.2.6 Adenosine A2A receptor (A2AR)  
The adenosine A2A receptor (A2AR) is a class A GPCR that, together with the other 3 
subtypes, A1R, A2BR, and A3R, comprise the adenosine receptor family (ARs). All ARs 
are activated by the endogenous agonist adenosine although they display different 
 
2 https://www.cancer.gov/about-cancer/treatment/types/immunotherapy  
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affinities. Many ARs are related to vital organ functions in the cardiovascular and 
nervous system, also being involved in inflammatory responses (Sebastiao and tiberiro 
2009, Headrick 2013, Sachdeva and Gupta 2013). A2AR was first isolated in 1976 
(Hejtmancik and Comstock, 1976) as depicted in Figure 1.4 and since then, it has 
become one of the most studied receptors. Yet, the mechanism of action if A2AR being 
internalised remains poorly understood.  
 
 
Figure 1.4. The exemplary structure of adenosine A2A receptor. (A) The A2AR model 
bound with G protein heterotrimeric (PDB 6GDG). (B) Snake structure of A2AR, the 
figure was taken from gpcrdb.com.  
 
The A2AR is predominantly coupled to Gαs and its activation promotes the elevation of 
intracellular cAMP via AC stimulation. A2AR has been reported to couple to Gαs in the 
peripheral system but is engaged to Gαolf in the striatum (Kull, Svenningsson and 
Fredholm, 2000). The A2AR contains a long intracellular C-terminus (122 amino acids), 
that is thought to provide sites for phosphorylation. This region has been proposed to 
be involved in receptor desensitisation and internalisation mechanisms (Borea et al., 
2018). Notably, Klaasse highlighted that A2AR does not undergo palmitoylation at its 
C-terminus (Klaasse et al., 2008). Although some studies remarked prolonged 
exposure with CG21680 triggered A2AR desensitisation, indicated by loss of AC activity 
and reduction of Gαs levels, however, no change in A2AR expression was observed 
(Ramkumar et al., 1991; Chern et al., 1993; Mundell, Benovic and Kelly, 1997; Mundell 
and Kelly, 1998). In contrast, Carvalho and colleagues reported that there was no A2AR 
internalisation observed upon stimulation by NECA and adenosine (Carvalho et al., 
A. B.




Chapter 1  Introduction 
 20 
2020). Currently, desensitisation and/or internalisation of the A2AR remains 
inconclusive, therefore this notion needs to be addressed further.  
The A2AR binds to the endogenous ligand, adenosine, which is also a cognate 
ligand for all ARs subtypes. A1R, A2AR, and A3R displayed high affinity to adenosine, 
whereas A2BR has a weaker binding. A2AR-mediated production of cAMP results in 
activation of PKA. Several reports also suggested A2AR to be involved in the 
modulation of MAPK (Merighi et al., 2002). The cAMP/PKA pathway activated by A2AR, 
induces phosphorylation of cAMP responsive element binding protein (CREB), PDEs, 
and dopamine- and cAMP-regulated phosphoprotein (DARPP-32) (Preti et al., 2015). 
Activation of aforementioned transcription factors further phosphorylate a wide range 
of proteins leading to various cellular responses such as regulating hormones, 
stimulating bone growth, regulating blood pressure, responding to olfactory stimuli and 
regulating blood glucose levels (Conti et al., 1991, 1995; Ahlstrom et al., 2005).  
CGS21680 is a moderately A2AR-selective agonist that is commonly used as a 
pharmacological tool. Currently, new compounds including ATL-146e and PSB-
077777 have shown higher affinity at the A2AR than CGS21680 (El-Tayeb et al., 2011). 
ZM241385 and SCH 58261 are highly potent A2AR antagonists (Baraldi et al., 1998; 
Jacobson and Gao, 2006), even though ZM241385 also shows a weak affinity towards 
A1R and A2BR (Baraldi et al., 1998; Jacobson and Gao, 2006).  
 A2AR has been reported to form heteromers, either with other ARs subtypes and 
other GPCRs. The best characterised examples of heterodimers containing the A2AR 
are with the A1R or the dopamine D2 receptor (D2R). In the brain, A2AR colocalises with 
D2R and together they control motor functions (Borea et al., 2018). A2AR activation 
decreased the binding affinity of D2R for its agonist; therefore, the use of antagonists 
was firstly developed from this concept to treat Parkinson’s disease (Ferre et al., 1991). 
A2AR has also been found to have a protective effect caused by immunosuppressive 
actions leading to inflammatory processes (Melani et al., 2014). Beyond 
neurodegenerative diseases, A2AR also has potential as a target to treat cardiovascular 
disease and cancer (De Lera Ruiz, Lim and Zheng, 2014; Antonioli et al., 2021).  
 
1.2.5.1 The role of A2AR signalling in cancer 
It has been suggested that the A2AR plays a significant role in cancer progression. It is 
now widely accepted that tumour progression involves various aspects of the tumour 
microenvironment (TME). The complexity is not only limited to the cell proliferation in 
affected areas but also in the surrounding environment enriched with inflammatory 
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cells, growth factors, harmful substances to promote DNA damage, all of which 
promote cancer cells progression. 
Some reports highlighted the involvement of A2AR activation in reducing cancer 
cell viability through apoptotic signalling mediated by PKC and MAPK pathways 
(Merighi et al., 2002; Trincavelli et al., 2003). Cancer sometimes occurs when some 
tissues suffer from prolonged inflammation (Coussens and Werb, 2002). The presence 
of inflammation may excacerbate cancer. Therefore, anti-inflammatory agents may 
decrease cancer proliferation, alter cellular signalling, circumvent cell migration or 
induce cell death. In agreement with this, activation of A2AR has demonstrated anti-
inflammatory effects following acute lung injury (Friebe et al., 2014; Borea et al., 2018). 
Since pro-tumour inflammation occurs in cancers, it can promote cancer survival, 
growth, and metastasis (Grivennikov, Greten and Karin, 2010; Greten and 
Grivennikov, 2019). Therefore, drugs that can interfere with prolonged inflammatory 
process maybe beneficial. Activation of A2AR decreases lung T helper cell number and 
expanded Treg during allergen exposure, suggesting that A2AR agonists can improve 
immunotherapies for inflammatory-related pathologies (Pei and Linden, 2016; Borea 
et al., 2018).  
Due to limited number of cancer treatments as well as chemoresistance, the 
evolutionary pressure that enable cancer cells to evade immune system adds another 
layer of complexity to tackle this disease (Allard et al., 2016). The latter has been 
reported to occur due to high adenosine levels produced by ectonucleotidases CD39 
and CD73 (R. Yang et al., 2020). Both enzymes mediate the conversion of ATP into 
adenosine. A2AR, in particular, is highly expressed in immune cells, especially T cells. 
A2AR signalling can inhibit T-cell activation, proliferation, and production of 
inflammatory mediators, particularly in the central nervous system (CNS) (Jacobson 
and Gao, 2006), thereby providing an opportunity for cancer cells to escape from the 
natural immune system to eliminate cancerous cells (Beavis et al., 2013; Steingold and 
Hatfield, 2020).  
It is apparent that activation of A2AR may have contradictory actions by inducing 
anti-inflammatory actions and being immunosuppressive. However, there has been 
growing evidence demonstrating that blocking A2AR signalling may improve the ability 
of immune cells (dendritic cells, NK cells, T cells, etc) to recognise and eliminate cancer 
cells. As a result, many compounds have been developed to antagonise/inhibit A2AR 
signalling. Currently, therapies have been focused on antagonising A2AR to reverse 
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adenosine-mediated immune suppression. Therefore, A2AR antagonist may enhance 
the efficacy of immune checkpoint inhibitors (Leone et al., 2018; Fong et al., 2020). 
 
1.2.5.2 Triazoloquinazolines’ dual action on A2AR and PDE inhibitors 
Triazoloquinazoline are a tricyclic heteroaromatic moiety that have been shown to bind 
to the ARs. The triazoloquinazoline-based compound, CGS15943, was first 
synthesised in the late 1980s to be a non-xanthine adenosine antagonist (Ghai et al., 
1987; Williams et al., 1987). Since then, substitutions on this backbone structure have 
been developed to block ARs, such as MRS1220, an A3R antagonist (Jacobson et al., 
1997). Interestingly, a series of compounds with a triazoloquinazoline-based structure 
have also been established as inhibitors of PDE10 (Kehler et al., 2011). Starting from 
this viewpoint, and as part of a collaborative work programme with Dr. Kalash 
(University of Cambridge), we explore the possibility of triazoloquinazoline-based 
compounds to act as dual-action ligands of the A2AR and PDE10A. An in-depth 
analysis of this approach is presented in Chapter 5.  
 
1.2.7 Protease-activated receptor 4 (PAR4) 
1.2.7.1 An overview of PAR4 
Protease-activated receptor 4 (PAR4) comprises 385 amino acids. Together with other 
PAR isotypes (PAR1-3), they are classified as class A GPCRs and are expressed in 
numerous tissues such as adipose, breast, and lung3. The expression of PAR4 is 
especially enriched in platelets and endothelial cells, suggesting a role in 
cardiovascular physiology (Coughlin, 1999). PAR4 is activated by the endogenous 
serine protease thrombin with a putative cleavage site at R47/G48 revealing tethered 
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Figure 1.5. Structure of PAR4.The tethered ligand (highlighted in purple) is exposed 
after proteolysis by thrombin leading to conformational changes and activation of 
PAR4. Picture was taken f from www.gpcrdb.org 
 
Thrombin and trypsin cleave at the same specific sites at the N-terminal of the receptor 
(Heuberger and Schuepbach, 2019). Unlike the other PARs that are digested 
preferentially by thrombin or trypsin, PAR4 shows similar sensitivity towards both 
enzymes (French and Hamilton, 2016). This occurs due to the thrombin binding site 
that is absent in PAR4. Activation of PAR4 by different agonists may activate different 
signalling cascades and are reported to influence receptor trafficking (Zhao, Metcalf 
and Bunnett, 2014).  
Since the 1990s, there has been a concerted effort to develop PAR modulators 
related to their role in thrombus formation (Coughlin, 1999). The discovery of 
vorapaxar, a PAR1 antagonist, has shown efficacy as an antiplatelet drug. However, 
its propensity to cause severe bleeding has limited its use in the clinic (Cunningham et 
al., 2012). On the other hand, PAR4 is another thrombin receptor that shows slower 
kinetics than PAR1 (Xu et al., 1998; Shapiro et al., 2000). The lack of a thrombin 
binding domain on the PAR4 structure was believed to be responsible for this action 
(Faruqi et al., 2000; French and Hamilton, 2016). In human, PAR1 and PAR4 are the 
primary thrombin receptors, whilst in mice PAR3 and PAR4 play as the primary 
receptor systems (Kahn et al., 1998). Interestingly, although PAR4 is also involved in 
platelet aggregation, inhibition on PAR4 does not induce bleeding like PAR1. This 
evidence has demonstrated the potential of targeting PAR4 in preventing 
cardiovascular events. 
Peptide agonists for PAR4 are currently limited and the low potency synthetic 
peptide AYPGKF-NH2 has been widely used as an agonist to activate PAR4 without 
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proteolysis (Faruqi et al., 2000; Hollenberg and Saifeddine, 2001). Recent 
modifications based on the AYPGKF-NH2 backbone have been published using 
compound libraries so providing a toolkit to investigate PAR4 signalling (Thibeault et 
al., 2019). Whereas ML354, BMS-986120, and YD-3 are usually used to inhibit PAR4 
activation (Wu et al., 2000; Moschonas et al., 2017; Lin et al., 2019). 
 
1.2.7.2 A novel strategy to manipulate PAR4 pharmacology 
PAR4, together with PAR1, is expressed in human platelets. Both receptors play 
essential roles in platelet activation, thereby blocking their signalling has been 
suggested to be beneficial in preventing thrombus formation and cardiovascular 
events. Since vorapaxar has shown excessive bleeding, PAR4 maybe an alternative 
target.  
Despite many strategies available, biased signalling has become an attractive 
approach to modify receptor pharmacology. A few approaches have been developed, 
these include the use of peptidomimetics, small molecules, pepducins, and 
parmodulins (Heuberger and Schuepbach, 2019). Although these strategies are 
applicable for PAR1 and PAR2, this has not been validated in PAR4. To date, the most 
depicted biased agonism comes from synthetic drugs.  
With the concept of the two-state receptor model, receptors were thought to 
have two distinct states: two states and extended ternary complex. However, recent 
development showed that receptors are conformationally flexible, generating a 
multitude of conformations by different ligands. Biased agonism can only be applied in 
the ternary complex model where the receptor can act as an allosteric microprocessor 
with pluridimensional efficacy (Smith, Lefkowitz and Rajagopal, 2018). Thus, they may 
adopt a specific conformational state and stabilised by particular ligands to promote 
signal transduction for different pathways. 
The plasticity of GPCR has demonstrated that GPCR can engage in multiple 
active states mediating both short-term signalling and long-term regulatory mechanism 
that specific ligands can achieve. Biased agonism is believed to associate with the 
different ligand's ability to differentially or selectively activate signalling cascades, 
including mediating alteration in receptor trafficking and the fate of receptors. The 
formation of different protein complexes upon ligand bind to the receptor, including G 
proteins, arrestins, GRKs, and kinases, triggers different signalling events. To date, 
the most depicted biased agonism comes from synthetic drugs.  
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Interestingly, there has been growing evidence that RAMPs can also modulate 
a number of GPCRs, as mentioned earlier. Numerous receptors have demonstrated 
the advantages of biased signalling, for instance, activation of μ-opioid receptor 
mediated analgesia, but β-arrestin signalling induced causes respiratory depression 
(Bohn et al., 1999; Bohn, Lefkowitz and Caron, 2002). An additional example is, 
carvedilol, a β-blocker, that has been shown to increase the survival rate from patients 
with heart failure, by antagonising G protein activation but still enabling β-arrestin 
recruitment (Wisler et al., 2007). 
Given that RAMPs are expressed in the platelets but without known GPCR 
interacting partners (Rowley et al., 2011), it is of great interest to investigate whether 
PAR4 interacts with RAMP. The study in Chapter 6 focused upon determining if PAR4 
and RAMP show interactions and investigating the consequences of the interaction on 
receptor signalling profile. 
 
1.2.8 The calcitonin receptor-like receptor (CLR) 
1.2.8.1 An overview of CLR 
CLR is class B1 GPCR that has been shown to interact with RAMPs (McLatchie et al., 
1998) to generate new complexes with differential affinities towards peptide CGRP, 
AM, and AM2. Like other class B1 GPCRs, CLR has a large N-terminal ECD that 
serves essential roles for peptide binding. According to the crystal structure of the CLR 
and RAMP, they form heterodimers with a stoichiometry ratio of 1:1 (ter Haar et al., 
2010). However, later Heroux and colleagues demonstrated that complexes consist of 
two CLR and a single RAMP1 (Héroux et al., 2007a). Although the stoichiometry has 
not been fully elucidated, other possibilities that CLR and RAMP may interact with a 
higher degree of stoichiometry should be taken into account (Héroux et al., 2007b; 
Sexton et al., 2009).  
It has been reported that the ECD and TMD of the RAMP are key determinant 
of ligand selectivity, however, the possibility of other regions cannot be ruled out 
(Pioszak and Hay, 2020). Mutagenesis studies have implicated that the C-terminus of 
each peptides and RAMP1 W84, RAMP2 E101, and RAMP3 E74 are fundamental as 
a points of interaction for the peptide and receptor (Liang et al., 2018). Regardless of 
these finding, the major question of how RAMPs modulate CLR pharmacology remains 
unanswered and requires further elucidation.  
CLR does not translocate alone to the cell surface without association with one 
of RAMP1/2/3 (McLatchie et al., 1998). These heteromers formation produced new 
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receptors: CGRP-R, AM1-R, and AM2-R, which elicited differential affinities towards 
the following peptides: CGRP, AM, and AM2. CGRP (α and β) are potent 
neuropeptides that elicit vasodilation and cardioprotective actions and are mainly 
expressed in trigeminal neurons (Edvinsson et al., 2018). Both AM and AM2 also play 
essential roles in cardiovascular functions in adults, including vasodilators, 
cardioprotective, and being involved in the heart development (Pioszak and Hay, 
2020). Currently, CGRP-based targeted therapies have been developed to treat 
migraine, either as CGRP antagonists (such as ubrogepant) or monoclonal antibody 
therapies against CGRP (eptinezumab, fremanezumab, galcanezumab) or CGRP-R 
(erenumab) (Edvinsson et al., 2018; Serafin et al., 2020; Bhakta et al., 2021).  
  
1.2.8.2 Physiological consequences of CLR-RAMP complex formation on cell 
growth: studies in human glioblastoma model and cardiovascular cells 
RAMPs have been extensively studied, mainly with CLR. Many studies have been 
performed to dissect the interaction between CLR and RAMP by using the 
heterologous overexpression systems. Currently, CLR-RAMP complexes have been a 
target to treat migraines and suggested to play an essential role in cardiovascular 
systems. Several reports also highlighted the upregulation of CTR families in 
numerous cancers (Ostrovskaya et al., 2016, 2019; Y. Zhang et al., 2020). Although 
the correlation between the CTR family expression and cancer is not clearly elucidated, 
it would be of interest to explore if the interaction of RAMP and CLR, in particular, 
maybe the target with therapeutic benefits in the field of cancer. As part of a 
collaborative study with Dr. Ashley Clark (University of Cambridge), we investigated 
the downstream signalling properties of CLR-based agonists to promote cell 
proliferation in cardiovascular-derived cell lines. We extended the study to explore the 
potential targeting of RAMP-CLR complexes in human glioblastoma models. 
 
1.3 Signal transduction through second messenger 
Upon receptor activation by the “first message”, the signals are converted and 
transduced into an intracellular process. The process of relaying the signal is mainly 
mediated by second messengers, in the form of small molecules or ions, as well as 
other proteins. The physicochemical properties of second messengers allow them to 
transduce signals within membranes, cytosol, or between the membrane and the 
cytosol (e.g. gases and free radicals) (Newton, Bootman and Scott, 2016). As 
previously mentioned, there are four types of second messengers: cyclic nucleotides 
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(cAMP and cGMP) and other soluble molecules, lipid messengers, ions, and gases-
free radicals (Newton, Bootman and Scott, 2016). The main topic in this thesis relates 
to cAMP signalling, the proteins involved in maintaining the intracellular concentration 
of cAMP and how this may impact upon cell growth and proliferation. 
 
1.4 cAMP, a key regulator second messenger 
The second messenger concept was first introduced by Sutherland and colleagues 
(1958), implying its function to transduce signals after stimuli were received by a 
plasma membrane receptor (Rall and Sutherland, 1958; Sutherland and Rall, 1958). 
As a ubiquitous second messenger, cAMP is synthesised from adenosine triphosphate 
(ATP) within the cells by the membrane-bound enzyme called adenylyl cyclase (AC). 
Together with cAMP, other second messengers, including cGMP, IP3 and 
diacylglycerol (DAG), are produced upon activation at the receptor level, to modulate 
various cellular effector system. cAMP, in particular, is an essential component for 
signalling cascades within the cells, influencing various effector proteins, which will be 
discussed later. 
 
1.4.1 Homeostasis of cAMP concentration 
The intracellular concentrations of cAMP are maintained through the balance of its 
synthesis and degradation. AC generates cAMP in response to its direct activation or 
through GPCRs which are themselves activated through stimulation by drugs, 
hormones, and neurotransmitter.  
 AC is a heptahelical enzyme predominantly bound to the plasma membrane. In 
mammals, there are currently ten types of AC isoforms: types 1-9 are embedded in the 
plasma membrane, whereas type 10 also known as soluble AC (sAC), is present in the 
cytoplasm (Khannpnavar et al., 2020). All AC isoforms generally contain between 1064 
and 1610 amino acid residues. AC isoforms appear to be widely distributed in most 
tissues (Taussig, 2013).  
As previously explained, GPCRs can engage with different G proteins. Of all G 
protein classes, Gαs and Gαi, in particular, directly modulate AC activity. Whilst Gαs 
stimulates AC to promote cAMP production, activation of Gαi results in reduced cAMP 
levels. Aside from GPCRs, activation on RTKs has also been reported to influence the 
activity of some particular types of AC isoforms (Tan et al., 2001). However, the 
mechanism is poorly understood.  
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In order to characterise the activity of AC, many pharmacological tools have 
been developed. Of all tools, forskolin, a labdane diterpene that is an active substance 
from Coleus forskohlii sp, has been the most widely used experimentally. Forskolin is 
a pan-AC activator, thereby stimulating the production on cAMP (Singh and Tandon, 
1982). Other pharmacological tools that inhibit AC activity are currently available, for 
instance, SQ 22536 (non-competitive antagonist) (Haslam, Davidson and Desjardins, 
1978), NKY80 (Klotz and Kachler, 2016). Interestingly, KH7 is a selective activator of 
sAC (Stessin et al., 2006). 
 
1.4.2 Overview of PDEs structure and function 
Following synthesis cAMP diffuses within cells and is hydrolysed to 5’-adenosine 
monophosphate (5’AMP) by PDEs. PDEs are a subfamily of ectonucleotidases 
consisting of 11 isoforms (PDE1–11) in mammals and are encoded by 21 different 
genes (Beavo, 1995). PDEs are distributed in many types of tissue (Soderling and 
Beavo, 2000). Each isoenzyme possesses different: i) affinities for cAMP and/or 
cGMP, ii) kinetic characteristics, iii) allosteric regulation by cAMP/cGMP, iv) 
phosphorylative control by various protein kinases, and v) cellular location. All these 
properties dictates their response to a stimulus (Menniti, Faraci and Schmidt, 2006; K 
Omori and Kotera, 2007a). To date, there are three classes of PDEs subdivided 
according to their substrate specificities: cAMP-specific PDEs (PDE4, PDE7 and 
PDE8), cGMP-specific PDEs (PDE5, PDE6 and PDE9), and dual-substrate PDEs 
(PDE1, PDE2, PDE3, PDE10 and PDE11) (Francis, Blount and Corbin, 2011). 
Through metabolising both cAMP and cGMP, PDEs generate intracellular gradients 
and microdomains for these second messengers to regulate their spatio-temporal 
signalling (Conti, Mika and Richter, 2014). PDEs prevent non-specific activations, 
enabling both specificity and selectivity toward intracellular targets (Ladilov and 
Appukuttan, 2014). The summary of preference of each PDEs to cAMP and cGMP are 
summarised in Table 1.2. 
 
Table 1.2 




Characteristics Km (µM) cAMP/cGMP 
PDE1 (3) Ca2+/calmodulin-stimulated 0.3–124/0.6–6 
PDE2 (1) cGMP-stimulated 15/15 




Characteristics Km (µM) cAMP/cGMP 
PDE3 (2) cAMP-selective, cGMP-inhibited 0.2/0.1 
PDE4 (4) cAMP-specific, cGMP-insensitive 2/>300 
PDE5 (1) cGMP-specific 150/1 
PDE6 (6) cGMP-specific, transducin activated 2000/60 
PDE7 (2) cAMP-specific, high-affinity 
rolipram-insensitive 
0.2/>1000 
PDE8 (2) cAMP-selective, IBMX insensitive 
rolipram-insensitive 
0.06/NA 
PDE9 (1) cGMP-specific, IBMX insensitive NA/0.07–0.17 
PDE10 (1) cGMP-sensitive, cAMP-selective 0.02–1/13 
PDE 11 (1) cGMP-sensitive, dual specificity 0.5–2/0.3–1 
(N) = gene numbers. The summary of PDE activities was adapted from (T Keravis and Lugnier, 
2012) and updated accordingly. NA – not applicable 
*Km is the concentration of substrate where the enzyme achieves half of Vmax 
Vmax is the maximum rate of enzymatic activity when it is fully saturated by the substrate 
 
 
Currently there are ten crystal structure of PDEs available in the databases. 
These are, PDE1B (Zhang et al., 2004), PDE2A (Iffland et al., 2005), PDE3B (Scapin 
et al., 2004), PDE4B (Xu et al., 2000; Card et al., 2004), PDE4D (Lee et al., 2002; 
Huai, Colicelli and Ke, 2003; Huai, Liu, et al., 2004), PDE5A (Sung et al., 2003; Card 
et al., 2004; Huai, Liu, et al., 2004; Zhang et al., 2004), PDE7A (Wang et al., 2005), 
PDE8A (Wang et al., 2008), PDE9A (Huai, Wang, et al., 2004), and PDE10A 
(Yoshikawa et al., 2016). However, to date, there are no structures of any PDE 
holoenzymes available. In general, PDEs contain three regions consisting of a catalytic 
domain, which is shared within all PDE isoenzymes, an N-terminal regulatory domain 
and a C-terminal domain, whose length depends on the specific PDE subfamilies 
(Figure 1.6). The regulatory domain is close to the N-terminal, whilst highly conserved 
catalytic subunit are located near the C-terminal of the enzymes. For enzymes that 
belong to the same gene family, approximately 80% similarity has been reported 
compared to different PDE family, which only account for ~25% - 40% (Cheng and 
Grande, 2007).  
The catalytic domain for all PDEs have similar motifs: H(X)3H(X)25-35D/E, where 
the active site pocket contains 11 of the 17 conserved residues (Jin, Swinnen and 
Conti, 1992). The catalytic domain can be further classified into three helical 
subdomains, which include an N-terminal cyclin-fold region, a linker region, and a C-
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terminal helical region, as depicted in Figure 1.6. At the subdomain interface, a deep 
hydrophobic pocket is formed consisting of four sites, where the M site is served for 
metal binding, the Q site as core pocket, the hydrophobic H pocket, and the lid L region 
(Y H Jeon et al., 2005).  
Figure 1.6 Exemplary of PDE catalytic domain from apo-PDE5A structure. The 
catalytic domain displays the interaction regions with sildenafil (compound in green) 
and tadalafil (red). The catalytic domain contains: N-terminal cyclin-fold domain, linker 
helical domain, and C-terminal helical bundle. There are two metal ions represented 
as green spheres in the centre of the catalytic domain structure. The picture was taken 
from (Y. H. Jeon et al., 2005) from original structure with the accession code 1T9S 
published by (Zhang et al., 2004).  
 
There is a glutamine residue within the Q pocket which is postulated to be a descriptor 
for enzyme selectivity towards cAMP, cGMP, or both cyclic nucleotides. The notion is 
known as a "glutamine switch". Zhang suggested that the side chain's orientation on 
glutamine residues dictated the substrate specificity by forming two hydrogen bonds 
with either cAMP or cGMP (Zhang et al., 2004). While the glutamine switch mechanism 
was observed in PDE4B, PDE5A, and PDE1B structures, several lines of evidence 
were reported against the glutamine switch concept (Iffland et al., 2005; Zoraghi, 
Corbin and Francis, 2006; Wang et al., 2007). The mechanism of selectivity of PDEs 
remains unsolved.  
Within the PDE catalytic domain, it was observed that at the end of its cleft, there 
was a bound ion, Zn2+ or Mg2+, which plays a crucial function for catalysis. The latter 
has a weaker affinity to the catalytic pocket (Xu et al., 2000; Ke, 2004; Wang et al., 
2005). The regulatory domains function are essential for cAMP/cGMP binding, 
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The presence of the cGMP-specific PDEs, ACs and FhlA (GAF) domain in 
particular PDEs serve to enable cyclic nucleotide recognition. For instance, cGMP acts 
as an allosteric modulator of PDE2 and occupies GAF-B domain switching the kinetics 
for the cyclic nucleotide hydrolysis resulting in increased activity at lower substrate 
concentrations. This regulatory action, where cGMP can negatively modulate cAMP, 
makes PDE2 known as a cGMP-stimulated PDE (M Conti and Beavo, 2007). A distinct 
regulatory domain is unique for each PDEs. While some PDEs contain the GAF 
domain in their N-terminal, some particular PDEs have distinct motifs. For example, 
PDE1 has a calmodulin-binding domain, providing a crosstalk point with Ca2+ 
signalling. The upstream conserved region (UCR) and Per-Arnt-Sim (PAS) domain are 
only observed in PDE4 and PDE8, respectively. On the contrary, PDE9 does not 
contain a specific regulatory domain at its N-terminal (Figure 1.7). Different from the 
remaining PDEs, the PDE3 catalytic domain contains an additional 44-amino acid 
insert (Perry, biology and 1998, no date; Degerman, Belfrage and Manganiello, 1997; 
Torphy, 1998; Dousa, 1999; Cheng and Grande, 2007). Hung and colleagues reported 
that this insert maybe involved in substrate binding and PDE3 conformational changes 
(Hung et al., 2006).  
 
 
Figure 1.7 The schematic representation of 11 subfamilies of PDEs. In general, 
all PDE family has the conserved catalytic domain, located near C-terminal domain. 
Phosphorylation sites are depicted as P symbol. Abbreviations: UCRs, upstream 
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conserved regions; PAS, period, aryl-hydrocarbon receptor nuclear translocator 
(ARNT), and single minded; CaM, calmodulin; cG, cGMP; cA, cAMP; GAF, cGMP-
activated PDEs, adenylyl cyclase, and Fh1A; TM, transmembrane domain of PDE3; 
Pɣ, PDEɣ subunit. Figure was adapted from (M Conti and Beavo, 2007) and modified 
accordingly.  
 
Their structure, function, and spatial heterogeneity enables PDEs to have modulatory 
roles, both temporally and spatially, upon secondary messenger signalling (Menniti, 
Faraci and Schmidt, 2006). Intracellular cAMP levels are tightly regulated and 
balanced between formation, degradation, and modulation of other pathways. Cyclic 
nucleotides, cAMP and cGMP, are metabolised into 5-AMP and 5-GMP, respectively, 
allowing the cellular signal to be terminated (M Conti and Beavo, 2007; Moorthy, Gao 
and Anand, 2011). It has been revealed that PDEs are involved in signalling, creating 
micro-domains and cyclic nucleotide gradients within cells (Menniti, Faraci and 
Schmidt, 2006). Due to this gradient, cells can transmit the signal into specific areas 
within cells and activate particular pathways, exhibiting biological responses.  
 
1.4.2.1 PDE1 
PDE1 was previously known as calmodulin-stimulated PDE (CaM-PDE) due to the 
presence of CaM binding site at the N-terminal regulatory domain (Bender and Beavo, 
2006). PDE1 is encoded by three different genes - PDE1A, PDE1B, and PDE1C. 
Whilst PDE1A and PDE1B preferably hydrolyse cGMP, PDE1C exhibits similar affinity 
for both cAMP and cGMP (Thérèse Keravis and Lugnier, 2012b). This PDE family is 
expressed in many tissues, including brain, olfactory epithelium, heart, vascular 
smooth muscle, testis, and liver (Bender and Beavo, 2006; Menniti, Faraci and 
Schmidt, 2006). Its responsivity to modulate cyclic nucleotides based on Ca2+ levels is 
believed to be a point for cross-talking with the Ca2+ signalling cascade. It has been 
demonstrated that PDE1 was involved in the smooth muscle contractile responses that 
were mediated by noradrenaline (Noguera et al., 2001).  
 
1.4.2.2 PDE2 
PDE2 exists as a homodimer comprised of approximately 105kDa and is encoded by 
the PDE2A gene that has three different variants: PDE2A1, PDE2A2, and PDE2A3. 
PDE2A1 variant is cytosolic whereas the remaining are membrane-bound (Thérèse 
Keravis and Lugnier, 2012b). The N-terminal domain of PDE2 consists of GAF-A and 
GAF-B as cGMP-binding domain. Aside from facilitating binding to cGMP, GAF-A is 
Chapter 1  Introduction 
 33 
reported to mediate PDE2 dimerisation. GAF-B mediates cAMP hydrolysis due to 
allosteric modulation by cGMP (Marco Conti and Beavo, 2007). PDE2 is widely 
distributed in adrenal gland, heart, lung, liver, platelets, endothelial cells (Thérèse 
Keravis and Lugnier, 2012b).  
 
1.4.2.3 PDE3 
Similar to PDE1 and PDE2, PDE3 is also a dual-substrate PDE hydrolysing both cyclic 
nucleotides. The PDE3 family is encoded by two genes: PDE3A and PDE3B. The Vmax 
(the maximum rate of activity when enzyme is fully saturated with the substrate) of 
cAMP hydrolysis is 10-fold faster than that of cGMP, yet the substrate affinity for cGMP 
is higher than cAMP. Given this action, cGMP acts as a competitive inhibitor for cAMP 
hydrolysis. Therefore, PDE3 is also known as a cGMP-inhibited PDE. It has been 
reported that upon PKA activation by cAMP, PKA also activates PDE3 to give negative 
feedback regulation in maintaining intracellular cAMP levels. Besides PKA, PDE3 may 
also be activated by the action of protein kinase B (PKB) and PKC. PDE3B in particular, 
is involved as a protein scaffold with phosphatidylinositol 3′ kinase (PI3K) (Wilson et 
al., 2011).  
 The structure of the catalytic domain of PDE3B is the only structure available 
for this PDE family. It contains three subdomains, consisting of 16 α-helices, similar to 
the remaining established PDE structures (Scapin et al., 2004). Between helices 6 and 
7, there is an insert of 44 amino acid residue (Arg755 – Ser798), a typical motif that PDE3 
family possess.  
PDE3 is highly expressed in the heart and found in other tissues including 
smooth muscle, lung, liver, platelets, adipocytes, immunocytes (Thérèse Keravis and 
Lugnier, 2012b). PDE3B plays a role in potentiating cAMP-enhancement of glucose-
stimulated insulin release from pancreatic β-cells (Härndahl et al., 2002). Inhibition of 
PDE3 by amrinone and milrinone in the heart has been shown to improve inotropy and 
lusitropy, which is also supported by the vasodilation effects making it a potential 
treatment for patient with heart failure (Silver, 1989; Wynands, 1994). PDE3 inhibitors 
have been also shown to increase lipolysis in adipocytes (Degerman et al., 2011).  
 
1.4.2.4 PDE4 
PDE4 is known as a cAMP-specific PDE and has four isoforms. These include, 
PDE4A, PDE4B, PDE4C and PDE4D. All of them possess different promoters and 
they are alternatively spliced with Bolger and colleagues discovering 25 splice variants 
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from PDE4 gene (Bolger, Conti and Houslay, 2019). PDE4 is the only family that 
consists of a signature motif at the N-terminal called the upstream conserved 
sequences (UCR). Notably, the various isoforms encoded by each PDE gene can be 
classified further into long, short, and super-short forms (Figure 1.8). Long forms 
comprise both UCR1 and UCR2, whereas short forms only contain UCR2, and the 
super-short forms contain half of UCR2. Both UCRs do not play a direct role in 
catalysis. Instead, they are known to be authentic protein domains for PDE4. Their 
action is equivalent to other protein domains, such as SH2 and SH3 domains, while 
having the ability to undergo self-folding (Pawson and Scott, 1997). 
 
Figure 1.8. The schematic illustration of PDE4 isoenzymes. Long forms contain 
UCR1 and UCR2, whilst short forms only haveUCR2. The truncated N-terminal of 
UCR2 only presents in the super-short forms of PDE4. Sites for phosphorylation by 
PKA and ERK are displayed at residue S54 and S579, respectively. The high affinity 
binding rolipram site is located close to the C-terminal of UCR2, as indicated. The 
Illustration was adapted and modified accordingly (Gurney et al., 2011). Figure was 
created with BioRender.com 
 
Many studies reported that PDE4 forms a signalosome with other proteins. Dodge-
Kafka et al revealed that this PDE family formed an ERK5-PDE4D3-EPAC1-mAKAP 
complex (EPAC for exchange protein activated by cAMP; mAKAP for muscle A kinase 
anchoring protein), although the function remains unclear (Dodge-Kafka et al., 2005). 
Similarly, the formation of a PDE4D5-β-arrestin-β2-AR complex in cardiac myocytes 
has been suggested to be involved in cardiac remodelling and stress-induced cardiac 
hypertrophy (Shi et al., 2017).  
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1.4.2.5 PDE5 
PDE5 is one of the PDEs that specifically hydrolyses cGMP. PDE5 is allosterically 
activated by cGMP. Similar to PDE2, PDE5 also contains two GAF domains: GAF-A 
and GAF-B. While GAF-A is responsible for allosteric cGMP binding, GAF-B 
contributes to PDE5 dimerisation. The binding of cGMP at GAF-A domain triggers 
phosphorylation of PDE5 leading to activation of catalytic activity to enhance cGMP 
binding affinity further. This sequence of processes stabilises an active form of PDE5. 
This enzyme is highly expressed in male reproductive organs, lung, platelets, smooth 
muscle, heart, endothelial cells, and brain (Thérèse Keravis and Lugnier, 2012b). Of 
all PDE inhibitor, sildenafil - under the brand name Viagra, has been known to treat 
erectile dysfunction and pulmonary arterial hypertension.  
 
1.4.2.6 PDE6 
PDE6 plays an essential role in phototransduction. It has been long known as 
photoreceptor PDE and its expression is mainly restricted to the eyes and pineal 
glands (Thérèse Keravis and Lugnier, 2012b). Beyond the eyes, PDE6 subtypes have 
been found in HEK293 cells (Wan et al., 2001) and mouse lung (Tate, Arshavsky and 
Pyne, 2002). PDE6 is encoded by a number of PDE6 genes: PDE6A-D, G and H, that 
together contribute to produce each component for PDE6 holoenzymes (αβɣ2). In 
terms of structure, PDE6 has 2 large catalytic subunits (PDE6αβ heterodimer) and 2 
small inhibitory (PDE6γ) subunits (Lugnier, 2006). To relay the signal, upon activation 
of rhodopsin (a GPCR) by light, it triggers the activation of PDE6 and lead to reduction 
of cGMP levels (Baehr, Devlin and Applebury, 1979). These steps induce the closure 
of a cyclic nucleotide gated channel (CNGCs), (CNGCs will be introduced in the 
section 1.4.4.3) leading to hyperpolarisation, thereby converting a light signal into an 
electrical signal.  
 
1.4.2.7 PDE7 
Although classified as a cAMP-specific PDE, there is no known regulatory domain at 
its N-terminal (as depicted in Figure 1.5). PDE7 is commonly known as a bifunctional 
protein. Besides its activity to hydrolyse cAMP, the N-terminal interacts with the 
catalytic (C) subunit of PKA (discussed later) directly leading to kinase activity 
blockage (Thérèse Keravis and Lugnier, 2012b). Due to its expression in the brain, 
PDE7 elicits an important role in neurotransmission (Nozal et al., 2021). The 
expression of this family is also described in peripheral blood cells and T cells, which 
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may indicate PDE7 involvement in T cell function (Szczypka, 2020). However, the 
precise role of this PDE family remains to be established.   
 
1.4.2.8 PDE8 
PDE8 shows the highest affinity to cAMP and is insensitive to the non-selective PDE 
inhibitor 3-isobutyl-1methylxanthine (IBMX) (Vasta, Shimizu-Albergine and Beavo, 
2006). The regulatory domain contains the N-terminal receiver (REC) and PAS 
domain, yet its function remains to be established. PDE8 has been reported to have 
numerous variant splices: PDE8A1-A5, A2, B1-B4, all of which are diverse regarding 
the presence of REC and PAS domain (Wang et al., 2001; Hayashi et al., 2002; 
Gamanuma et al., 2003). In addition, three putative phosphorylation sites are available 
located between the PAS domain and the catalytic domain. This enzyme family is 
widely distributed in testes, eye, liver, skeletal muscle, heart, kidney, ovary, brain, T 
lymphocytes, and thyroid (Thérèse Keravis and Lugnier, 2012b). 
 
1.4.2.9 PDE9 
Amongst all cGMP specific PDEs, PDE9 has been demonstrated to display the highest 
affinity towards cGMP. Similar to PDE8, this PDE family is also insensitive to IBMX. 
About twenty-one variants of PDE9 N-terminal have been identified, but little is known 
about the characterisation of this enzyme family. No known regulatory sequence has 
been discovered in the N-terminal domain and no phosphorylation sites are known in 
the PDE9 protein family (Bender and Beavo, 2006; Kenji Omori and Kotera, 2007). 




PDE10 is known as a dual-substrate PDE. PDE10A contains two GAF domains at the 
N-terminal. Unlike other GAF domains in other PDEs that are responsible for cGMP 
binding, GAF-A in PDE10 is essential for cAMP binding. Opposite to the action of 
PDE3, PDE10 is known as a cAMP-inhibited cGMP PDE. PDE10 subfamily only has 
one member, PDE10A, which is found in brain, testes, and thyroid (Thérèse Keravis 
and Lugnier, 2012b). Due to its prominent expression in the central nervous system, 
PDE10A has become the target for numerous neurological disorders. Several studies 
have shown that inhibition of PDE10 improves striatal and cortical pathology in 
Huntington’s disease model (Niccolini et al., 2015; Deb, Frank and Testa, 2017), 
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Parkinson’s disease (Lee et al., 2019), and psychiatric disease (Farmer et al., 2020). 
A very potent and specific PDE10 inhibitor, TP-10, was investigated preclinically for 
schizophrenia treatment (Schmidt et al., 2008).  
 
1.4.2.11 PDE11 
PDE11 is classified as a dual-substrate PDE. However, it resembles PDE5 more 
closely than PDE10A. To date, there are four N-terminal variants of the PDE11A genes 
producing PDE11A1-4, all of which vary in the number of GAF domains in their N-
terminal. Whilst PDE11A2 and PDE11A3 have one complete and one incomplete GAF 
domain (Kenji Omori and Kotera, 2007), there are two GAF domains at N-terminal of 
the PDE11A4 (Yuasa et al., 2001). However, the function of the GAF domain in 
PDE11A has not been fully elucidated. PDE11 is expressed in various tissues 
including skeletal muscle, prostate, pituitary gland, liver, and heart (Thérèse Keravis 
and Lugnier, 2012b). 
 
1.4.2.12 Small molecule PDE inhibitors 
Selective PDE inhibitors have been developed either as pharmacological tools to 
dissect the involvement of PDE in cellular signalling or as therapeutic agents. A 
number of PDE inhibitors available are summarised in Table 1.3, some of which were 
used for the studies presented in Chapter 3 and 4. Aside from compounds that 
selectively inhibit specific PDEs, compounds including caffeine, IBMX, theophylline 
(weak activity), dipyridamole, zaprinast, trequinsin, and zardaverine display non-
selective actions. Whilst caffeine inhibits all PDEs (Soderling, Bayuga and Beavo, 
1999), dypiridamole acts as PDE5/6/8/10/11 inhibitor (Meester et al., 1998; Fujishige 
et al., 1999; Soderling, Bayuga and Beavo, 1999), zaprinast inhibits PDE5/6/9/11 and 
activates GPR35 (Lugnier, 2006; Taniguchi, Tonai-Kachi and Shinjo, 2006), while 
zardaverine acts as dual-selective inhibitor of PDE3 and PDE4 (Galvan and Schudt, 
1990). Interestingly, none of compound that selectively targeting PDE6 are available 
without eliciting actions towards other PDEs. Some of these inhibitors are also used in 
clinical setting, such as amrinone and milrinone for congestive heart failure through 
their action to improve inotropy, lusitropy, and vasodilation (Levy, Ramsay and Bailey, 
1990). Rolipram, a prototypic PDE4 inhibitor, was firstly used as an antidepressant in 
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the early 1990 but discontinued due to narrow therapeutic index. Rolipram is currently 
in clinical trial for multiple sclerosis as immunomodulatory therapy4. 
 
Table 1.3 
The summary of small molecule that selectively inhibit each PDE subfamily protein 
Family (N) Inhibitor 
PDE1 (3) MMPX, vinpocetine, IC86340, IC295, dioclein, 
nimodipin 
PDE2 (1) EHNA, PF 05180999, BAY60-7550, ND7001 
PDE3 (2) Anagrelide hydrocholride, cilostamide, cilostazol, 
enoximone, amrinone, milrinone, trequinsin, 
motapizone 
PDE4 (4) Rolipram, CDP840 HCl, CGH2466 HCl, CP 80633, 
eggmanone, etazolate HCl, ibudilast, roflumilast, 
piclamislast, RO 20-1724 
PDE5 (1) Gysadenafil besylate, sildenafil, tadalafil, T 0156 
PDE6 (6) No selective PDE6 inhibitor is available 
PDE7 (2) TC3.6, BRL-50481, IC242, ASB 16165 
PDE8 (2) BC 11-38 
PDE9 (1) (S)-C33, PF 04449613 
PDE10 (1) TC0E 5005, PF 2545920 
PDE 11 (1) PH 04671536 
MMPX, 8-Methoxymethyl-3-isobutyl-1-methylxanthine; EHNA, erythro-9-(2-hydroxy-3-nonyl) 
adenine.  
 
Despite their complexity, PDEs regulate many fundamental physiological processes  
in various pathophysiological states such as cardiovascular diseases, 
neurodegenerative diseases, and asthma (Torphy and Undem, 1991; Menniti, Faraci 
and Schmidt, 2006; Knight and Yan, 2013). Differential expression and localisation of 
PDEs have been found throughout the brain (Menniti, Faraci and Schmidt, 2006) and 
act in a very complex manner. Also, abnormalities in PDEs expression, that can lead 
to disruption of cellular signalling have reportedly been associated with changes in 
pathophysiology (for example in cancers and some neurological disorders).  
In many types of diseases, especially in cancer, PDE’s divergent expression has 
been linked with malignancy (Savai et al., 2010a) although the complete picture is 
complicated by the cross-talk between cAMP and cGMP signalling systems. The 
 
4 https://clinicaltrials.gov/ct2/show/NCT00011375 
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recent discovery of a range of particular PDE inhibitors promises to clarify this situation 
(DeNinno, 2012), providing the tools to manipulate the two cyclic nucleotides 
intracellular concentrations. 
 
1.4.3 Cyclic nucleotide extrusion  
Aside from formation and degradation, the intracellular concentration of cAMP is also 
controlled by the ability of cells to extrude cAMP extracellularly. This extrusion 
mechanism has been reported to involve an efflux transporter called multidrug-
resistant protein (MRP), a member of the ATP-binding cassette (ABC) superfamily of 
efflux transporters. 
 Almost all species express ABC protein families. They are found in bacteria, 
yeast, plants, and mammals (Davidson et al., 2008; Moussatova et al., 2008; Eitinger 
et al., 2011; Teichmann et al., 2017; Feng et al., 2020). In the latter, ABC transporters 
are responsible for transporting anticancer drugs (Borst and Oude Elferink, 2002). 
These proteins use the energy from ATP hydrolysis to transport drugs across the 
plasma membrane. MRPs share similar homology with members of ABC family 
including multiple TMDs and a nucleotide binding (CNB) domain for ATP binding and 
hydrolysis. MRP4, together with MRP5, are known as “short MRPs” since their TMD8 
and TMD9’s lacks an additional N-terminal TMD0. Not only do MRPs extrude 
xenobiotics, but these proteins also pump endogenous substances, including cAMP, 
into the extracellular space. 
Wang and colleagues summarised in their review that at least 4 MRP classes 
were found to be responsible for transporting cyclic nucleotides out of cells, including 
MRP1, MRP4 (ABCC4), MRP5 (ABCC5), and MRP8 (ABCC11) (Kruh and Belinsky, 
2003; Wang et al., 2021). MRP4 also plays an important role for cellular protection by 
exporting exogenous compounds and harmful substances (Bloise et al., 2016; Kochel 
et al., 2017; Khoury et al., 2018). In cardiomyocytes (CMs), MRP4 has been suggested 
to increase cAMP concentrations, so modulating cardiac muscle contraction and 
hypertrophy. It has also been reported that β-AR are colocalised with MRP4 and are 
internalised together in caveolin pits (Sassi et al., 2008; Sellers et al., 2012). Both 
MRP1 and MRP4 have been demonstrated to be overexpressed in various cancers 
(glioma, breast cancer, pancreatic ductal carcinoma), leading to significant 
suppression on cAMP levels (Calatozzolo et al., 2005; Andric, Kostic and Stojilkovic, 
2006; Decleves et al., 2008; Carozzo et al., 2019). In comparison, MRP5 up-regulation 
may associate with cisplatin resistance in patients with non-small lung cancer (NSCLC) 
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(Masetto et al., 2020). In the male reproductive organ system, the role of MRP5 was 
highlighted to regulate cGMP levels in smooth muscle to modulate erectile function 
(Gupta, Singh-Gupta and Sabbah, 2019). 
 
1.4.4 Downstream affecters of cAMP 
1.4.4.1 Protein kinase A (PKA) 
It has been long known that protein kinase A (PKA) is the major effector of 
cAMP. Activated PKA phosphorylates serine and threonine residues on substrate 
proteins. In the inactive form, PKA is a holotetramer consisting of 2 regulatory (R) and 
two catalytic (C) subunits. Two isoforms of R have been identified, type I and II, and 
further classified into two different subtypes: α and β (Hofmann et al., 1975). In 
mammals, three different isoforms of C subunits have been identified: Cα, Cβ, and Cɣ 
(Uhler, Chrivia and McKnight, 1986; Beebe et al., 1990). Each R subunit has a CNB 
domain that allows this enzyme to bind four cAMP molecules. Upon binding, the C 
subunit will dissociate due to conformational changes of PKA (Murray, 2008). Whilst 
the catalytic monomer binds to ATP, this subunit becomes active and is able to 
phosphorylate serine and threonine residues on their respective protein substrate. 
AKAPs are also expressed within the cell to ensure PKA phosphorylates the correct 
regulatory proteins (Wong and Scott, 2004). This mechanism ensures local subcellular 
action of PKA is attributed to specific signalling events. A few examples of downstream 
substrates that PKA mainly phosphorylates are the transcription factors CREB, cAMP-
responsive element modulator (CREM), and activating transcription factor 1 (ATF1) 
(Sassone-Corsi, 2012). In addition, PKA can also phosphorylate the Ras superfamily 
of small GTPases Rap1 at its C-terminal to facilitate cAMP-mediated ERK activation 
(Y. Li et al., 2016). 
PKA is reported to form macromolecular interactomes that involve GPCRs, 
GTPases, protein phosphatase, PDEs, and other protein kinases (Newton, Bootman 
and Scott, 2016). For instance, the PDE4 isoform PDE4D and PDE4C has been 
reported to form a complex with the PKA subunit PKA-RII in COS1 cells. The study 
also indicates that this complex is tethered via AKAP450 to the perinuclear space 
(McCahill et al., 2005). In addition, PDE4D5 specifically interacts with β-arrestins and 
suppresses PKA activity in phosphorylating β2-AR (Lynch et al., 2005). By forming a 
signalosome that comprises AKAP, PKA, and PDE; PKA may activate PDEs that  
reduced cAMP levels so localising the signal (Sunahara, Dessauer and Gilman, 1996; 
Boularan and Gales, 2015).  
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Since its discovery, PKA has been implicated in various cellular processes 
including the modulation of other kinases, calcium, and transcription factors (Murray, 
2008). PKA inhibitors have been predominantly used as the primary tool to 
characterise downstream cAMP signalling. A few compounds have been widely 
applied to inhibit PKA activity, including H89, KT 5720, and Rp-8-Br-cAMPS. The latter 
has been reported to be a potent and specific inhibitor for PKA. These compounds, 
however, have a distinct mechanism to block PKA activity. While H89 (isoquinolone 
backbone) and KT5720 (firstly isolated from fungus Nocardiopsis sp) competitively 
bind to the ATP binding site in catalytic subunit (Kase et al., 1987; Engh et al., 1996), 
Rp-8-Br-cAMPS acts as a competitive antagonist to the CNB domain at the R unit, 
preventing the release of C subunits. Another PKA inhibitor class, the protein kinase 
inhibitors (PKIs), are also available to bind to free catalytic subunits and prevent further 
phosphorylation of PKA substrate (Dalton and Dewey, 2006).  
Currently, a number of reporters to determine PKA activities have been 
developed, of which the best-in-class Förster-resonance energy transfer (FRET)-
based reporters include: tAKARα (Ma et al., 2018), AKAR3-EV (Komatsu et al., 2011), 
and AKAR4 (Depry, Allen and Zhang, 2011). The AKAR3 sensor consists of four 
regions: a donor fluorophore (CFP), a phosphopeptide binding domain (FHA1), a PKA 
specific phosphorylatable sequence, and an acceptor (Venus or other YFP). Upon 
phosphorylation by PKA, the substrate of PKA binds to the FHA1 domain leading to an 
increase of FRET signal. Chen and colleagues further modified the AKAR3 biosensor 
to be compatible with 2 photon microscopy therefore is applicable to quantify PKA 
activity in tissue, namely FLIM-AKAR3 (Yao Chen et al., 2014). The newest fluorescent 
protein-based PKA biosensors, ExRai-AKAR2 (based on excitation-ratio metric PKA 
activity reporter) has been developed and is reported to show an enhanced dynamic 
range compared to other reporters (Zhang et al., 2021).  
 
1.4.4.2 Exchange protein activated by cAMP (EPAC) 
Although EPAC is a relatively newly identified effector of cAMP, this protein family, 
similar to PKA, have high affinity for cAMP. Structurally similar to PKA, EPAC possess 
a CNB domain that binds cAMP and an analogous R subunit. In mammalian cells, two 
isoforms have been identified, EPAC1 and EPAC2. Upon binding to cAMP, EPACs 
serve as gunanine nucleotide exchange proteins for the Ras GTPase homologous, 
Rap1 and Rap2, mediating conversion from inactive GDP- to active GTP-bound forms 
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(Bos, 2003). EPAC1 and EPAC2 differentially bind to both types of Rap (Cheng et al., 
2008) 
While EPAC1 is ubiquitously expressed, EPAC2 expression is limited to specific 
tissues including brain, neuroendocrine and endocrine tissues such as pancreatic cells 
(de Rooij et al., 1998; Kawasaki et al., 1998). Similar to other enzymes, both EPACs 
contain an N-terminal regulatory unit and a C-terminal catalytic region. The difference 
between both EPACs lies in the structure of the N-terminal domain. Whilst EPAC1 and 
EPAC2 contain the Dishevelled/EGl-10/pleckstrin (DEP) domain which is followed by 
the CNB domain, EPAC2 has an additional CNB domain CBD-A, that binds cAMP with 
low affinity (De Rooij et al., 2000).  
A number of small molecules EPAC inhibitors have been developed and used 
as pharmacological tools in many studies. ESI-05 is a specific inhibitor of EPAC2 and 
has been shown to have no effect on EPAC1 nor PKA (Tsalkova et al., 2012). In 
comparison, ESI-09 elicits non-selective activity over both EPAC isoforms (Almahariq 
et al., 2013). Another compound identified in 2012, CE3F4, inhibits EPAC1 without 
affecting PKA (Courilleau et al., 2013). Finally, HJC 0350 has been reported to be a 
specific antagonist of EPAC2 (Chen et al., 2013).  
The discovery of EPAC adds to the complexity of cAMP-mediated signalling. 
EPAC elicited cAMP-mediated responses independent of PKA to modulate cell growth, 
cell adhesion, cell-cell-junction, cell differentiation, apoptosis, and neurotransmission. 
In CMs, EPAC is responsible for gap junction formation, where ion channels present, 
and therefore indirectly it regulates cardiac contractions (Somekawa et al., 2005). 
EPAC has also been shown to enhance intracellular Ca2+ release through the 
activation of both calcium-calmodulin-dependent protein kinase II (Pereira et al., 2007) 
and phospholipase Cε (Oestreich et al., 2007). 
Both PKA and EPAC are known to be acceptors of cAMP and therefore provide 
precise and integrated controlling mechanism of cAMP signalling cascades. 
Intriguingly, EPAC has been reported to show contradictive outcomes with that of PKA-
mediated signalling. The mechanism between PKA and EPAC has added more layers 
of complexity to cAMP regulation and raised further questions of whether the 
responses on cells are generated through the net effect of PKA and EPAC individually 
or all together. In another study, both EPAC and PKA antagonistically controlled 
insulin-stimulated PKB and cell proliferation (Omar et al., 2009). In contrast, some 
authors have reported that EPAC and PKA could also have synergistic effects on 
downstream signalling of neurotensin secretion and attenuation of cAMP signalling 
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through phosphodiesterase (Li et al., 2007; Cheng et al., 2008). However, how these 
two cAMP acceptors elicit antagonistic effects requires further elucidation. 
 
1.4.4.3 Cyclic nucleotide gated channels (CNGCs)  
CNGCs are non-selective cation channels that specifically bind to cyclic nucleotides. 
These channels have been reported to play a pivotal role in the olfactory and visual 
systems, and are highly expressed in sensory neurons but can be found in other 
tissues such as heart, brain, testis, and kidney (Murray, 2008; Biel, 2013). In general, 
CNGC comprises two subtypes of channels, including cyclic nucleotide-gated (CNG) 
channels and the hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels. 
Both channels are the six transmembrane superfamily and contain a CNB domain at 
the C-terminal. CNGC is heterotrimeric complex of subunits identified as A-type and 
B-type. There are four types of A subunits (further categorised as CNGA1-4), whereas 
the B subunits consist of CNGB1 and CNGB3 in mammals (Bradley et al., 2001). To 
be activated, the CNGC requires binding of either cAMP or cGMP, which promotes ion 
gating. CNG channels are voltage-gated ion channels that share high homology with 
voltage-gated K+ channels (Flynn, Johnson and Zagotta, 2001). While CNG allows the 
transport of Na+/K+ and preferentially binds cGMP compared to cAMP (Podda, 2013), 
HCN channels open upon hyperpolarization with cAMP enhancing their activity by 
enabling activation at more positive voltages (Scicchitano et al., 2012).  
 
1.4.4.4 The popeye domain containing protein (POPDC) and cyclic nucleotide 
receptor involved in sperm function (CRIS) 
The Popeye domain-containing proteins (POPDC) are a new member of cAMP effector 
family alongside PKA, EPAC, and CNCG. Although this protein was firstly identified 
decades ago, POPDC function remains poorly understood. POPDC is highly 
expressed in heart and skeletal muscle (Swan et al., 2019) and contains conserved 
intracellular POPEYE domain that elicits high binding affinity to cAMP (Froese et al., 
2012; Brand and Schindler, 2017; Brand, 2018; Tibbo et al., 2020). Brand and 
colleagues reported that POPDC1 acted as an anchoring protein, similar to AKAP, that 
together with PDE4 formed a macromolecule complexes regulating cAMP signalling 
(Brand and Schindler, 2017).  
POPDC consists of 3 protein subtypes which include POPDC1, POPDC2 and 
POPDC3. It has two invariant sequence motifs (FL/IDSPEW/F) and (FQVT/SL/I) in the 
cAMP-binding pocket (Brand and Schindler, 2017). In general, it has a binding affinity 
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comparable to that of PKA (IC50 120 nM vs 100nM, respectively) (Froese et al., 2012). 
POPDC displays weaker binding affinity for cGMP with a reported IC50 of approximately 
5μM obtained using a radioligand binding competition assay. This has also been 
corroborated using a FRET sensor (Froese et al., 2012). The C-terminal domain of 
POPDC is subjected to different splicing and seems to be responsible for 
phosphorylation mediated by β1-adrenoceptor (β1-AR). The POPDC protein family all 
appear to be phosphorylated upon stimulation with adrenergic agonists. POPDC1 has 
nine phosphorylation sites, POPDC2 and POPDC3 contains four sites and single 
residue for phosphorylation, respectively (Lundby et al., 2013).  
Recent findings suggested an association of POPDC1 with cancer, where it acts 
as a tumour suppressor (Tucker and Zorn, 2021). Downregulation of POPDC1 or 
POPDC3 has been correlated with poor clinical prognosis in numerous cancers: gastric 
cancer, lung cancer, hepatocellular carcinoma, and colorectal cancer (Kim et al., 2010; 
Williams et al., 2011; Luo et al., 2012; Han et al., 2014). Although there are potential 
therapeutic benefits by targeting the POPDC protein family, the concurrence between 
low expression of POPDC and cancer requires further elucidations. To date, there are 
no inhibitors of POPDC that can be used as pharmacological tools to dissect their 
activities, thus the use of small interfering RNA technology may be the only approach 
to manipulate POPDC-mediated responses.  
 Finally, the cyclic nucleotide receptor involved in sperm function (CRIS) is 
another family protein that possesses a highly conserved CNB domain (Krähling et al., 
2013). CRIS has been identified in all published mammalian genomes. CRIS is highly 
expressed in spermatocytes and round spermatids playing a fundamental 
physiological function during spermatogenesis (Krähling et al., 2013). To summarise 
the homeostasis of intracellular cAMP levels and its effecters, the illustration is 
depicted in Figure 1.9.  
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Figure 1.9 The summary of cyclic nucleotide signalling network. cAMP: cGMP, 
AC: adenylyl cyclase, PDE, CNGC: cyclic nucleotide gated channel, MRP: multidrug 
resistant protein, PKA: protein kinase A, PKC: protein kinase C, PKG: protein kinase 
G, EPAC:exchange protein directly activated by cAMP , POPDC: POPEYE-domain 
containing protein, MEK: , ERK: extracellular signal-regulated kinase, CREB: cAMP 
response element binding protein, CREM: cAMP response element modulator, ATF1: 
activating transcription factor-1, PI3K: phosphatidylinositol 3′ kinase; JNK, c-Jun N-
terminal kinases. 
 
1.4.5 Interconnection with other second messenger pathways 
1.4.5.1 cGMP signalling 
cGMP is another second messenger that, together with cAMP, often works in balance 
to maintain cellular functions. cGMP is synthesised by two types of guanylyl cyclase 
(GCs): receptor GC (RGC) and soluble GC (sGC). sGC resembles AC in terms of its 
structure. Upon production, similar to that of cAMP, cGMP will bind to several effectors 
including protein kinase G (PKG), ion channels and Ras guanine nucleotide exchange 
factors (CNRasGEF), and HCNs, all of which contain CNB domains (Pham et al., 
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2000). PKG was firstly characterised by (Kuo and Greengard, 1969) as the major 
effector of cGMP.   
Elevated cGMP levels occur upon stimulation of sGC by nitric oxide (NO) and 
natriuretic peptides at RGCs (Takimoto, 2012). cGMP signalling appears to modulate 
specific functions in maintaining cardiac contractility and cardio-protection, transducing 
signals in olfactory and sensory neurons, and it has been associated with intestinal 
epithelial injury and neoplasia (Meyer et al., 2000; Takimoto, 2012; Rappaport and 
Waldman, 2018). Although cAMP and cGMP play an essential role in cellular 
physiology, these cyclic nucleotides often exert opposing effects. In addition, the 
presence of dual-substrate PDEs serves the interconnection between cAMP and 
cGMP so adding more complexity to cAMP regulation. 
 
1.4.5.2 Calcium (Ca2+) signalling 
Ca2+ ions are a versatile small molecule that controls a myriad of physiological roles. 
Ca2+ has been demonstrated to control muscle contraction, NO production, fertilisation, 
cell growth, neurogenesis, synaptic plasticity, and secretion of saliva (Whitaker, 2006; 
Ambudkar, 2016; Berridge, 2016; Toth, Shum and Prakriya, 2016). While resting cells 
maintain Ca2+ gradients between intra- and extracellular space (~100 nM vs 1-2 mM 
range, respectively), high levels of cytoplasmic Ca2+  has been reported to trigger 
apoptosis (Rizzuto et al., 2003; Clapham, 2007). Ca2+ is mainly generated after 
activation of GPCRs and RTKs, which in turn activate PLCβ1, hydrolysing PIP2 in the 
plasma membrane to IP3 and DAG (Berridge, 2012). ER-bound IP3 receptors (IP3Rs) 
recognises IP3 molecules and acts as a Ca2+-channel, together with the ryanodine 
receptor (RYR), allowing Ca2+ release from the ER. The process is initially thought to 
be one-directional; however, in the past decade, it has been highlighted that control of 
Ca2+ is more complex and modulated through several regulatory proteins. These 
include the classical transient receptor potential channel (TRPC), store-operated Ca2+ 
entry (SOCE), and Ca2+ voltage-gated (CaV) ion channel (Clapham, 2007; Rahman, 
2020).  
Cytosolic Ca2+ interacts with many proteins, two of which are PKC and 
calmodulin (CaM) (Clapham, 2007). PKC is one of the Ca2+ sensors that, upon binding, 
will activate the Ras/Raf protein complex. This signalling cascade has been 
established to activate ERK1/2 through MEK1/2 phosphorylation. ERK1/2 has been 
implicated to be responsible for controlling cell cycle, cell proliferation and cell 
differentiation (Meloche and Pouysse´gur, 2007; Mebratu and Tesfaigzi, 2009). 
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Besides Ras, PKC can also directly activate transcription factor p50 and p65, which 
are fundamental in gene expression and intracellular signalling in the nucleus. In 
addition, CaM recognises the elevation of Ca2+ levels and further phosphorylates 
CREB through Ca2+ /calmodulin-dependent protein kinase type IV (CaMKIV). A 
summary of Ca2+ signalling is illustrated in Figure 1.10.  
The concept of interconnection between second messengers, especially cAMP 
and Ca2+ signalling has been suggested, but the mechanisms require further 
characterisation. Willoughby highlighted the possibility of crosstalk through cAMP-
mediated SOCE activation (Willoughby et al., 2012). As an alternative, the 
interconnection between two pathways has been reported to occur through store-
operated cAMP (SOcAMP) mechanism (Lefkimmiatis et al., 2009; Maiellaro et al., 
2012). Whilst SOCE requires the changes in cytosolic Ca2+ to be activated, SOcAMP 
occurs independently of Ca2+ dynamics but acquires the stromal interaction molecule1 
(STIM1) to be interconnected to cAMP signalling (Nichols et al., 2015). In addition, the 
activity of PDE1 that is also regulated by calmodulin provides another aspect that is 





Figure 1.10. The summary of calcium signalling pathways. Ca2+ is generated 
through the activation of either GPCRs or RTKs, as well as regulatory transport within 
the cell mediated by IP3R and RYR. Subsequently, calcium activates PKC or bind to 
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CaM to modulate further signalling cascades. GPCR, G protein-coupled receptor; RTK, 
receptor tyrosine kinase; PLC, phospholipase C; PKC, protein kinase C; PIP2, 
phosphatidylinositol biphosphate; IP3, inositol triphosphate; DAG, diacyl glycerol; 
MEK, mitogen activated protein; ERK, extracellular signal-regulated kinase; CaM, 
calmodulin; CaN, calcineurin; NFAT, Nuclear factor of activated T-cells; IP3R, IP3 
receptor; RYR, ryanodine receptor.  Picture was adapted from (https://www.creative-
diagnostics.com/calcium-signaling-pathway.htm). The figure was created with 
BioRender.com. 
 
1.5 Multimodal function of cAMP pathways 
Depending on the cell type, cAMP may play a role in either promoting or suppressing 
cell proliferation. This incongruity can be explained by two theories related to the cAMP 
signalling cascade. The first theory proposes that elevation of intracellular cAMP is 
beneficial for suppressing cell proliferation in most mesenchymal and epithelial cell 
lines, such as glioblastoma (Kang et al., 2014), thyroid cells (Sawa et al., 2017), 
ovarian granulosa cells (Zwain and Amato, 2001), fibroblasts (Huston et al., 2006), and 
primary cardiomyocytes (Ding et al., 2005). In contrast, the second theory proposes 
that cAMP promotes cell survival, which has been observed in myeloid cells, 
pancreatic b-cells, hepatocytes, gastric and intestinal cells, spinal motor, superior 
cervical ganglion sympathetic, dorsal root ganglion, dopaminergic neurons, cerebral 
granule and septal cholinergic neurons (Lerner and Epstein, 2006). These two 
divergent roles of cAMP may be crucial in both physiological maintenance and 
pathological conditions, but whether these signalling cascades are interconnected 
remains unclear.  
 Since there were several reports highlighting the potential role of cAMP in 
inhibiting tumour progression, the work presented in this thesis focused efforts to 
elevate intracellular concentration of cAMP, mainly through PDE inhibition. Given that 
the production of cAMP is also regulated via G protein-dependent mechanisms, the 
study also explored upstream signalling at the receptor levels, that included β-ARs and 
A2AR.  
 
1.6 Glioma/glioblastoma and alteration on cAMP signalling 
Glioblastoma is the most high-grade form of brain tumour in adults and originates from 
astrocytes. Glioblastoma belongs to a group of brain tumours known as glioma and is 
considered grade IV cancer by World Health Organisation (WHO) due to its 
invasiveness. Whilst glioblastoma only represents 15% of brain tumour cases, it shows 
high recurrence reaching 85% and 5-year survival rate less than 5%. Poorly 
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reproducible diagnoses and the resistance to chemotherapy regiments have 
contributed to insufficient outcomes of glioblastoma therapy (Lombardi and Assem, 
2017).   
Glioma, a type of brain tumour that is developed from glial cells, can be 
classified into several classes according to the type of glial cell it originates from: 
astrocytoma (originates from astrocytes), ependymoma (from ependymal cells), 
oligodendroglioma (from oligodendrocytes), and mixed type (normally a mixture of 
astrocytes and oligodendrocytes). Glioma can be graded from low to high and it may 
progressively lead to death if not treated early (Mamelak and Jacoby, 2007; Harris et 
al., 2018). Meanwhile glioblastoma, the most common type of glioma, has been 
reported to be the deadliest, with a 5-year survival rate of only 5% (Schwartzbaum et 
al., 2006; Delgado-López and Corrales-García, 2016).  
Regardless of advanced diagnosis modality, current treatments do not improve 
progression-free survival and/or overall survival. Conventional radiotherapy alone or in 
combination with temozolomide – an alkylating agent- have been established as 
standard therapies for glioma, however, there is little progress made for this disease 
(Stupp et al., 2017). Despite its ability to be able to penetrate into brain tissue, patients 
still experience many adverse effects from temozolomide treatment including fatigue, 
haematological and thromboembolic events, and increased rate of infection (HartMG, 
2016). In addition, platinum-based treatments may increase the risk of cardiovascular 
incidents and hypersensitivity (Herradón et al., 2017; Ruggiero et al., 2017) leading to 
poor quality of life. All of these symptoms are correlated with the lack of selective 
properties of anti-neoplastic agents. 
Current treatment modalities are limited to the surgery and radiotherapy 
with/without temozolomide chemotherapy. Another treatment that has shown 
promising results is the addition of tumour-treating fields (TTFields) to maintain 
temozolomide therapy. Concurrent application of TTFields with temozolomide 
significantly improves progression-free survival and overall survival (Stupp et al., 
2017). Despite advancement in innovation in both diagnosis and new therapies, it has 
been a challenge to successfully cure glioblastoma. Understanding more about 
targeting cellular signalling that is disrupted at the cellular levels would be beneficial 
for finding better therapies.  
Many signalling pathways have been reported to be altered in association with 
glioblastoma pathogenesis. These include, those involved in oncogenic pathways, 
intra-tumour heterogeneity, and even transition from epithelial to mesenchymal 
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phenotypes. Oncogenic pathways involve activation/overexpression of RTKs or 
mutations on the receptor that causes increased in constitutive activity of RTKs, Ras 
pathway, retinoblastoma (pRB) pathway, the phosphatidylinositol-4,5-bisphosphate 3-
kinase/phosphatase and tensin homolog/serine threonine kinase Akt (PI3K/PTEN/Akt) 
pathway, and cAMP signalling cascade. 
Alteration in cyclic nucleotide signalling has been also reported to occur in 
glioma resulting in suppression of intracellular cAMP levels. Whilst normal brain tissue 
contained cAMP approximately 98.8 pmole/mg protein, the concentration of cAMP was 
suppressed up to 4-fold (Furman and Shulman, 1977). It is postulated that many 
regulatory proteins involved in cAMP regulation may become potential targets to 
reverse the abnormalities in cell growth. 
Abnormal expression of PDEs has been linked with malignancy (Savai et al., 
2010), although the complete picture is made complicated by the crosstalk between 
cAMP and cGMP signalling systems. Relevance with the clinical settings, about 6% of 
samples collected, all PDE genes were upregulated in glioma patients (Figure 1.9). 
The recent discovery of a range of highly specific PDE inhibitors promises to clarify 
this situation (DeNinno, 2012), providing the tools to manipulate intracellular 
concentrations of the two cyclic nucleotides, particularly with cAMP. Moon and 
colleagues reported that applying PDE inhibitors, IBMX and rolipram, reduced the 
survival percentage of U87 glioblastoma cells (Moon et al., 2012). It has been 
proposed that cell death on glioblastoma could be associated with PKA and 
EPAC1/Rap1-mediated pathways (Moon et al., 2012), which is activated by cAMP.  
The following data, that were composed from 731 samples collected from 724 
patients with glioblastoma, have shown the cumulative percentage of alteration for all 
PDE isoforms (accessed from cBioportal). These studies were selected to be not 
overlapping with each other. In brain tumours patient-derived xenograft (PDX) studies, 
about 30% PDEs have been mutated, whereas 7.26% of PDEs have been reported to 
be amplified with 5.74% genes were found to be mutated in TCGA studies. About 
3.13% PDEs gene were reported to be mutated found from Columbia studies (Figure 








250APDE11A&geneset_list=%20&profileFilter=0&tab_index=tab_visualize (accessed in 30 July 2020) 
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pathogenesis of glioma/glioblastoma. Therefore, targeting PDEs may offer therapeutic 




Given that suppression of cAMP has been associated with malignancy, the work 
presented in this thesis focused on efforts to enhance the concentration of intracellular 
cAMP. It is postulated that elevation of cAMP level may restore cellular function to 
control cell growth. The study mainly focused on phosphodiesterase given that PDE 
genes were generally up-regulated the clinical settings that might contribute to the 
lower level of cAMP intracellularly. This work was not only limited to PDEs, but also 









Figure 1.11 The summary of overall PDE
expressions on GBM database. (A)
percentage of alterations found from 3
different studies, (B) Percentage of
alterations based on type of brain tumours.
Figure was generated by submitting
enquiries of each PDE gene via cBioportal.
There was no overlap in data between
studies.
A. B.
1 – Brain tumour PDX studies (Mayo clinic, 2019)
2 – GBM (TCGA, Firehose Legacy)
3 – Glioblastoma (Columbia, Nat. Med. 2019)
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Figure 1.12. The illustration of the framework between glioma/glioblastoma and 
cellular network in regulating cAMP concentration. Since there may be an 
association between lower level of cAMP and malignancy, the main focus of this thesis 
would be to reinstate balance of cAMP through modulation on various proteins. These 
include the activation at AC, PDE inhibition, GPCR stimulations, and the blockade of 
MRP4 efflux transporter. The figure was created with BioRender.com 
 
1.7 Aims 
Given the possible therapeutic benefits of modulating cAMP pathways in cancer, the 
primary objective of this study was to investigate the potential of targeting crucial 
proteins involved in cAMP pathways, and its impact upon cell growth in numerous 
cancer models. The specific aims are as follows:  
§ Evaluate the potential of PDE inhibitors to modulate cell proliferation in a rat 
glioma cell model 
§ Dissect the mechanism of action of cAMP-mediated inhibition of cell 
proliferation in glioma cells.   
§ Investigate if concomitant targeting of PDE with other proteins, is a feasible 
approach to potentiate cell growth suppression. This particular point would be 
expanded to observe combinatorial effect of PDE and AC; and synergistic action 
of inhibiting PDE and agonising A2AR through multi-target ligand design.   
§ Determine the role of PDEs in human glioblastoma models  
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As a second section of this thesis, I also sought to explore the following aims related 
to RAMP interactions with GPCRs. The specific aims were: 
§ Investigate the role of RAMP and PAR4 as a novel interacting partners of RAMP 
and how this interaction influence PAR4 signalling, especially in affecting 
intracellular calcium mobilisation and β-arrestin 
§ Characterise the impact of CLR and RAMP interactions on cell growth in two 








MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 General reagents 
All reagents used in this study were analytical grade and unless specifically stated, 
were obtained from Sigma Aldrich (UK).  
 
2.1.2 Compounds 
The compounds used in this study was summarised in Table 2.1. Unless stated, the 
compounds used in this study were pro-analytic grade with >99% purity. 
 
Table 2.1  
List of chemical compounds and protein used for this study 
Compounds Source Stock concentration 
Amb236403 Ambinter, France 10 mM in DMSO 
Amb212236 Ambinter, France 10 mM in DMSO 
Amb9792412 Ambinter, France 10 mM in DMSO 
Amb4051701 Ambinter, France 10 mM in DMSO 
Amrinone  Sigma-Aldrich, UK 100 mM in DMSO 
AYPGKF-NH2 Cambridge 
Bioscience, UK 
10 mM in PBS 
BAY 41-8543  Tocris, UK 100 mM in DMSO 
BAY 73-6691 Sigma-Aldrich, UK 100 mM in DMSO 
BC 11-38 Tocris, UK 100 mM in DMSO 
Brequinar Na Tocris, UK 10 mM in DMSO 
BRL-50481 Sigma-Aldrich, UK 100 mM in DMSO 
Caffeine  Sigma-Aldrich, UK 100 mM in DMSO 
CA200645 HelloBio, UK 100 mM in DMSO 
CE3F4 Sigma-Aldrich, UK 10 mM in DMSO 
Cholera Toxin (CTX) Sigma-Aldrich, UK 35 μg/ml in water 
Cilostamide  Sigma-Aldrich, UK 10 mM in DMSO 
Cisplatin Cambridge 
Bioscience, UK 
3 mM in PBS 
EHNA Sigma-Aldrich, UK 100 mM in DMSO 
ESI-09 Sigma-Aldrich, UK 10 mM in DMSO 
Forskolin Sigma-Aldrich, UK 100 mM DMSO 
HJC0350  Sigma-Aldrich, UK 10 mM in DMSO 
Hoechst 33342 VWR International, 
UK 
17.79 mM in water 
Human α-Thrombin  Thermo Fisher 
Scientific, UK 
0.2 mM in water 
IBMX Sigma-Aldrich, UK 100 mM in DMSO 
Ibudilast Sigma-Aldrich, UK 100 mM in DMSO 




100 mM in ethanol 
absolute 
Isoprenaline hydrochloride  Sigma-Aldrich, UK 10 mM in water 
KT5720 Insight 
Biotechnology, UK 
100 mM in DMSO 
KT5823 Insight 
Biotechnology, UK 
1 mM in DMSO 
Milrinone Sigma-Aldrich, UK 100 mM in DMSO 
MK571 Tocris, UK 50 mM in DMSO 
Pertussis Toxin (PTX) Sigma-Aldrich, UK 100 μg/ml in water 
PF 04671536 Tocris, UK 100 mM in DMSO 
PF-04449613  Sigma-Aldrich, UK 100 mM in DMSO 
PF-2545920 Sigma-Aldrich, UK 100 mM in DMSO 
Piclamilast Sigma-Aldrich, UK 100 mM in DMSO 
Propidium Iodide Sigma Aldrich, UK 1.5 mM in water 
PU23 Tocris, UK 50 mM in DMSO 
Pyr6 SelleckChem, UK 35 mM in DMSO 
Roflumilast Sigma-Aldrich, UK 100 mM in DMSO 
Rolipram  Sigma-Aldrich, UK 100 mM in DMSO 
Sildenafil Sigma-Aldrich, UK 100 mM in DMSO 
Staurosporine  Tocris, UK 100 mM in DMSO 
SQ22536 Sigma-Aldrich, UK 100 mM in DMSO 
Tadalafil Sigma-Aldrich, UK 100 mM in DMSO 
Teriflunomide Tocris, UK 100 mM in DMSO 
TC3.6 Sigma-Aldrich, UK 100 mM in DMSO 
Trequinsin Sigma-Aldrich, UK 50 mM in DMSO 
Trypsin Sigma-Aldrich, UK 0.2 mM in NaCl 
Vinpocetine Sigma-Aldrich, UK 100 mM in DMSO 
Vidoflunimus SelleckChem, UK 10 mM in DMSO 
YC-1 Tocris, UK 100 mM in DMSO 
Zaprinast  Sigma-Aldrich, UK 100 mM in DMSO 
ZM241354 Tocris, UK 10 mM in DMSO 
 
2.1.3 Growth media 
Sterile LB (Luria-Bertani) medium, either as solution or agar plate, was used for 
Escheriscia coli cultivation for cloning and plasmid DNA propagation.  
The following media were used for mammalian cell culture including Gibco® 
Minimum Essential Medium (MEM, Thermo Fisher Scientific, UK), Gibco® Dulbecco’s 
modified Eagle’s Medium (DMEM)/F12 1:1 (1X) – GlutamaxTM (Thermo Fisher 
Scientific, UK), MEM (Sigma, UK), Gibco® RPMI 1640 (Thermo Fisher Scientific, UK), 
and in Gibco® DMEM high glucose with GlutamaxTM (Thermo Fisher Scientific, UK). 
Unless specified, growth media was supplemented with 10% v/v Foetal Bovine Serum 
(FBS, Sigma-Aldrich, UK), 1% v/v antibiotic/antimycotic (Sigma, UK). Growth media 
for each cell lines in this study was explained in detail in section 2.2.1. 
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2.1.4 DNA expression constructs 
The plasmid and DNA expression constructs used in this study were obtained from 
sources listed in Table 2.2. 
 
Table 2.2  
Plasmid/construct used in this study  
Construct Source 
pcDNA3.1-PAR4-T120 (PAR4 
mutant variant having threonine 
residue at position 120) 
Dr. Margaret Cunningham 
 
pcDNA3.1-PAR4-A120 Generated in this study 
pcDNA3.1-PAR4-T120-Nluc Generated in this study 
pcDNA3.1-PAR4-A120-Nluc  Generated in this study 
pcDNA3.1-FLAG-RAMP1 (D Wootten et al., 2013) 
pcDNA3.1-FLAG-RAMP2 (D Wootten et al., 2013) 
pcDNA3.1-FLAG-RAMP3 (D Wootten et al., 2013) 
pcDNA3.1-HA-CLR Harriet Watkins 
pcDNA3.1-A2AR Prof. David Poyner  
pcDNA3.1-Nluc-A2AR Dr. Steve Briddon  
pEYFPN1β-arrestin1 Dr. Kathleen Caron 
pEYFPN1β-arrestin 2 Dr. Kathleen Caron 
GIPR-Nluc in pcDNA3.1 Generated by Matthew Harris 
pBK(A)mGRK5 Dr. Kathleen Caron 
pCDNA3.1(-)-Zeo Invitrogen 
MCS-Nluc in pcDNA3.1(-)-zeo Modified by Abigail Pearce 
 
2.2 Methods 
2.2.1 Cell lines 
Procedures relating to cell culture were conducted using proper aseptic technique in a 
flow laminar tissue culture hood in accordance with safe laboratory practices and 
standard microbiological procedures. All solutions and equipment that come into 
contact with cells were sterile and growth medium was prewarmed in a water bath 
37°C prior use. Unless otherwise stated, all cells were maintained in growth complete 
medium at 37°C in humidified 95% air and 5% CO2. 
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C6 glioma cells (a gift from Prof. Colin Taylor, University of Cambridge) were 
cultured in Gibco® MEM (Thermo Fisher Scientific, UK) supplemented with 10% FBS, 
2 mM L-glutamine (Sigma-Aldrich, UK), and 1% antibiotic/antimycotic.  
Human embryonic kidney 293S (HEK-293S) cells were a gift from Astra Zeneca, 
HEK-293T and CV-1 in origin and carrying the SV40 genetic material (COS-7) cells 
were gifts from Prof. David Poyner. U87 glioblastoma cells were purchased from 
Sigma-Aldrich (UK). These cells were grown in Gibco® DMEM/F12 1:1 (1X) – 
GlutamaxTM (Thermo Fisher Scientific, UK), supplemented with 10% FBS and 1% 
antibiotic/antimycotic.  
T98 glioblastoma cells were purchased from American Type Culture Collection 
(ATCC) and were grown in MEM (Sigma, UK) containing 2 mM L-glutamine, 1 mM 
sodium pyruvate (Thermo Fisher Scientific, UK), 10% FBS, and 1% 
antibiotic/antimycotic.   
LK2 and H1792 cells (LUAD, lung adenocarcinoma), and H520 and H1563 cells 
(LUSC, lung squamous carcinoma) were all provided by Dr. Walid Khaled (Department 
of Pharmacology, University of Cambridge, UK). All cells were grown in Gibco® RPMI 
1640 supplemented by L-Glutamine, 10% FBS, and 1% antibiotic/antimycotic.  
ST14A cells (rat-derived striatal cells (Tissue and Cell Biotechnologies, Italy) 
were grown in Gibco® DMEM/F12 1:1 (1X) – Glutamax TM (Thermo Fisher Scientific, 
UK), supplemented with 10% FBS and 1% antibiotic/antimycotic. ST14A cells were 
grown at 33°C in humidified 95% air and 5% CO2 because propagation of ST14A cells 
at 37°C has been shown to induce differentiation into glial cells (Ehrlich et al., 2001) 
 In general, cell lines were propagated in T25 or T75 flasks (Corning, UK) and 
were subcultured before they reached confluency. For harvesting or subculturing 
purposes, culture medium was discarded, and phosphate buffer saline (PBS) was 
added to wash the cells. Briefly, trypsin/ethylenediaminetetraacetic acid (EDTA) 
solution was used to detach monolayer cells for 1 to 3 minutes, meanwhile cell 
dissociation buffer was added when working with cell expressing PARs. Prewarmed 
complete medium was added to deactivate trypsin before collecting all cells and 
centrifuging at 1400 rpm for 4 minutes. Subsequently, supernatant was withdrawn, and 
the cell pellet was resuspended to the appropriate seeding concentration. 
 
2.2.2 Long-term storage and recovery 
Cells were grown to ~90% confluency in appropriate complete media in a culture 
vessel (T25 or T75 flask). Cells were detached using trypsin/EDTA or cell dissociation 
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buffer. All cells were harvested and centrifuged before resuspending cells in freezing 
medium and aliquoted into cryogenic storage vials. Freezing medium consisted of 90% 
of complete medium and 10% dimethyl sulfoxide DMSO (v/v). Cells were frozen 
gradually in an insulated box in -70 to -80°C freezer before transferring to liquid 
nitrogen storage or -140°C cryo-freezer. 
To recover, cells from long-term storage were thawed as rapidly as possible by 
gently swirling the vial in 37°C water bath to minimize intracellular ice crystal growth 
during the warming process. The cell suspension was then diluted slowly after thawing 
process using prewarmed complete medium. Cell suspension was centrifuged at 1400 
rpm for 4 minutes and subsequently, supernatant was decanted without disturbing the 
cell pellet. Cells were then resuspended in complete growth medium and transferred 
into appropriate culture vessel.  
 
2.2.3 E. coli transformation 
Competent E. coli DH5α cells (Stratagene, San Diego, California, US) were used to 
amplify plasmids in this study. E. coli were propagated using standard methods as 
described (Glover, 1991).   
Before use, competent cells were slowly defrosted on ice. Approximately 100 
ng of plasmid was added into 100 μl E. coli suspension and the mixture was incubated 
on ice for 5 minutes. Heat shock was performed at 42 °C for 1.5 to 2 minutes on water 
bath. The cell suspension was then returned to ice and further incubated for 5 minutes. 
Bacterial culture was propagated in LB media with constant shaking at 180 rpm or on 
LB agar plates containing either ampicillin (final concentration of 100 μg/ml) or 
kanamycin (final concentration 50 μg/ml), as appropriate, and incubated overnight at 
37°C. 
 
2.2.4 Plasmid DNA purification 
Plasmid purification was performed using QIAprep Spin Miniprep Kit (Qiagen, UK) 
following the manufacturer’s instruction. Overnight bacterial culture was centrifuged at 
3200 rpm for 5 minutes to collect the cell pellet. Briefly, bacterial pellet was lysed under 
alkaline conditions using buffer P1, subsequently neutralized using buffer P2, and 
adjusted to high-salt binding solution using buffer N3. After high-speed centrifugation 
(13000 rpm for 10 minutes), the supernatant was then purified on QIAprep silica 
membrane (QIAprep minispin column), washed with ethanol-based buffer PE, and 
eluted in 30 μl of warm water. Yield of purification was determined using NanoDropTM 
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Lite spectrophotometer (Thermo Scientific, UK). Samples that have yield value 
minimum of 100 ng/μl and A260/280 > 1.8 were used for further experiment.  
 
2.2.5 RNA extraction, quality determination, and reverse transcriptase 
polymerase chain reaction (RT-PCR) 
RNA was extracted from cells using RNAqueous®-4PCR Total RNA Isolation Kit (Life 
Technologies, UK) according to manufacturer’s instructions. In order to remove any 
contaminating genomic DNA, all RNA samples were treated with DNAse I included in 
the kit. The purity of RNA samples was quantified using a NanoDropTM Lite 
spectrophotometer and only samples that had a minimum yield of 100 ng/µL and 
A260/280 > 1.9 were used in the experiments. Complementary DNA was synthesized 
using a QuantiTect reverse transcription kit (Qiagen, UK), as per the manufacturer’s 
instructions.  
The oligonucleotides (Sigma, UK) used for polymerase chain reaction (PCR) 
were designed specifically either for human or rat, which were listed in Table 2.3  
 
Table 2.3  
Oligonucleotides used to amplify gene of interests within this study 
Gene of 
interest 




Rats    
GAPDH Forward - 
TCCCTCAAGATTGTCAGCAA 














A2AR  Forward: 
CCATGCTGGGCTGGAACA 







160 (Dixon et al., 
1996) 



























































103 (Tian et al., 
2011) 
 Reverse:   
















PDE 4B Forward: 
CAGCTCATGACCCAGATAAGTGG 






PDE 4C Forward: 
ATGGCCCAGATCACTGGGCTGCGG 





PDE 4D Forward: 
CCCTCTTGACTGTTATCATGCACACC 





PDE 5A Forward: 
CCCTGGCCTATTCAACAACGG 





PDE 7A Forward: 
GAAGAGGTTCCCACCCGTA 





PDE 7B Forward: 
GGCTCCTTGCTCATTTGC 





PDE 8A Forward: 
TGGCAGCAATAAGGTTGAGA 
97 (Tian et al., 
2011) 
 Reverse:   









PDE 8B Forward: 
CTCGGTCCTTCCTCTTCTCC 





PDE 9A Forward: 
GTGGGTGGACTGTTTACTGGA 





PDE 10A Forward: 
GACTTGATTGGCATCCTTGAA 





PDE 11A Forward: 
CCCAGGCGATAAATAAGGTTC 





Human     





















A2BR Forward: 147 22907046c1 

















































































































 Reverse:   









































































PCR amplification was performed using standard Taq polymerase (New England 
Biolab, UK) protocol as summarised in the Table 2.4. 
 
Table 2.4  
Thermocycler set up used for amplification 
Step Temperature Time 
Denaturation 95°C 5 min 
Amplification–36 cycles 95°C 30 s 
 60°C 60 s 
 72°C 60 s 
Final extension 72°C 10 min 
Final step 4°C ♾ 
 
All PCR products were run on a 2% agarose gel. The gel was visualised in the 
presence of ethidium bromide and imaged using a G Box iChemi gel documentation 
system. Density of each band was analysed with GeneTools analysis software 
(Syngene, UK). 
 
2.2.6 Mutagenesis of PAR4-A120  
PAR4T120 in pcDNA3.1 served as a template for the point-mutation to switch the 
threonine to alanine residue at position 120. Single point mutagenesis was performed 
using QuikChange Lightning Site-Directed Mutagenesis Kit in accordance with the 
manufacturer’s instruction. Table 2.5 and 2.6 display the oligonucleotides and the 
components used, respectively, for generating PAR4-A120 variant. Oligonucleotides 
for mutagenesis were designed using the online QuikChange Primer Design 
programme (https://www.agilent.com/store/primerDesignProgram.jsp).  
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Table 2.5  
Oligonucleotides that were designed to generate PAR4 variant that express alanine 
at position 120  
Oligonucleotides Sequence (5’ à 3’) 
Forward 344TGATGAACCTCGCG(G)CTGCTGACCTCCTG372 
Reverse 372CAGGAGGTCAGCAG(C)CGCGAGGTTCATCA344 
The start and end nucleotide positions within PAR4 sequence that bind with 
oligonucleotide are indicated by superscript. Whereas points mutations are indicated 
by sequence in bracket. 
 
Table 2.6  
Summary of component reaction for mutagenesis 
Component Volume  
10x reaction buffer 5 μl 
DNA template (plasmid/construct) 100 ng 
Forward oligonucleotides (10 mM) 1 μl 
Reverse oligonucleotides (10 mM) 1 μl 
dNTP mix (10 mM) 1 μl 
QuikSolution reagent 1.5 μl 
ddH2O Add to 50 μl 
QuikChange Lightning Enzyme  1 μl 
  
Successful mutagenesis was determined by Sanger sequencing (Department of 
Biochemistry, University of Cambridge, UK).  
 
2.2.7 Cloning of Nanoluciferase (NLuc)-tagged PAR4 
PAR4 A120 and T120 variants served as the template for generating C-terminally 
Nano luciferase (Nluc) tagged receptors. Oligonucleotides were designed to introduce 
5’ and 3’ XbaI and EcoRI restriction sites, respectively to the template. DNA fragments 
were ligated into MCS-Nluc in pcDNA3.1(-)-zeo plasmid.  
Briefly, PAR4 templates were amplified by PCR using oligonucleotides that have been 
designed (Table 2.7). PCR was performed using Phusion DNA polymerase, as 
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Table 2.7  
Oligonucleotides that were designed to introduce restriction sites on PAR4 constructs 
Oligonucleotide Restriction 
enzyme 
Sequence (5’ à 3’) 
Forward XbaI GGGGTâCTAGAATGTGGGGGGC 
ACTGC 
Reverse EcoRI GGGGGâAATTCCTGGAGCAAAG 
AGGAGTGGG 
Start codon was indicated by bold letter (ATG). Stop codon was omitted to be able put 
the construct in pcDNA3.1-Nluc construct 
 
Table 2.8 
List of components used for PCR amplification 
Component 50 μl reaction Final Concentration 
Nuclease-free water 30 μl 1X 
5x Phusion HF buffer 10 μl 200 µM 
10 mM dNTPs 1 μl 0.5 µM 
10 μM forward 
oligonucleotide 
2.5 μl 0.5 µM 
10 μM reverse 
oligonucleotide 
2.5 μl < 250 ng 
DNA template (1pg-10 ng) 1 μl  
DMSO 2.5 μl 3% 
Phusion DNA polymerase 0.5 μl 1.0 units/50 µl PCR 
 
Table 2.9  
Thermocycler set up for molecular cloning 
Step Temperature Time 
Denaturation 98°C 30 s 
Amplification – 30 cycles 98°C 30 s 
 40°C/50°C/60°C 30 s 
 72°C 30 s per kb 
Final extension 72°C 10 minutes 
Final step 4°C ∞ 
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The elongation cycle parameters were performed for 45 s for the insert PAR4 of 1158 
kb. PCR amplicons were run on a 2% agarose gel for > 45 minutes at 120V. 
Appropriate bands were cut and extracted using QIAquick gel extraction kit (Qiagen, 
UK). The yield value of the samples was determined using a NanoDropTM Lite 
spectrophotometer. Approximately 1μg of each vector and insert fragments were 
digested with XbaI and EcoRI. The mixture was incubated at 37°C for 1 hour. 
Afterwards, samples were electrophoresed on a 2% agarose gel for 45 minutes at 
120V before correct band size was extracted.  
DNA fragments were inserted into plasmid vector with 1:3 ratio 
(NEBioCalculatorTM) and ligated by T4 DNA ligase. The ligation mixture was incubated 
for at least 1 hour at room temperature. As a control, vector alone was used to verify 
that the vector was completely digested. The resulting recombinant plasmids were then 
transformed into competent E. coli on antibiotic selective LB agar plates.  
Approximately 3 colonies from each plate showing bacterial growth were 
isolated and suspended in 10 μl sterile water. The cells were lysed by pipetting up and 
down and samples were amplified using for PCR (components were described in table 
2.9) to verify the colonies contained an insert of the correct size.  
  The amplified fragment (using the set up described in Table 2.10 and the PCR 
set up in Table 2.4) was then run on a 2% agarose gel at 120V for about 30 minutes 
or until well separated. If a band of correct size was visualised, the remaining cell 
suspension was used for bacterial transformation. To determine if the sequence was 
correct, the purified plasmid was sent for Sanger sequencing.  
 
Table 2.10 
Component for PCR colonies 
Component 10 µl Reaction 
Nuclease-free water 7.5 µl 
10x Taq buffer 1 µl 
10 mM dNTPs 0.2 µl 
100 μM forward oligonucleotide 0.1 µl 
100 μM reverse oligonucleotide 0.1 µl 
DNA template (1pg-10 ng) 1 µl 
Taq DNA polymerase 0.1 µl 
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2.2.8 Transient transfection of HEK-293S/ HEK-293T cells 
Transient transfection of HEK-293S or HEK-293T cells, as appropriate, was performed 
48 hours before assaying using either FuGENE®HD (Promega, UK) or 
polyethylenimine (PEI, with MW 25kDa, Polyscience Inc, UK). PEI was prepared into 
a stock of 1 mg/ml following the manufacturer’s instruction. Approximately 100 mg of 
PEI was dissolved at 90 ml of water (to a concentration of 1.11 mg/ml) and pH of 
solution was adjusted to reach pH 2.0 by adding 12 M hydrochloric acid (HCl). The 
solution was mixed continuously for approximately 3 hours until the solution became 
clear prior to the addition of 10 M sodium hydroxide until reaching pH 7.0. PEI solution 
was then aliquoted in microcentrifuge tubes and stored at -20 °C. Detailed methods 
are as following. 
 
2.2.8.1 Fugene method 
Cells were grown 24 hours before transfection to reach ~60-70% confluency. DNA and 
FuGENE®HD were mixed in serum free DMEM/F12 at a 1:3 w/v ratio (Table 2.11) and 
incubated for 10 minutes before addition to cells: 
 
Table 2.11 
Components used for FuGENE®HD transfection method 
Format Component Volume (in μl) or 
amount (in μg) 
24 well plate DNA 
FuGENE® HD 
Serum free media 
0.25 μg 
0.75 μl 
Add to 25 μl 
 
2.2.8.2 PEI method 1 
PEI is a stable cationic polymer that condenses DNA and generates a positive charge 
around the particle. DNA-PEI complexes are then endocytosed by cells. Unless 
described, transient transfection of HEK-293T or HEK-293-S cells in this study using 
PEI was performed using this method.  The protocol outlined in this study uses a 1:6 
of DNA to PEI (w/v) as described on table 2.12. DNA and PEI was diluted separately 
in NaCl 150 mM solution and incubated for 5 minutes at room temperature. Afterwards, 
PEI mixture was added into DNA solution, gently mixed by pipetting up and down, then 
were incubated for further 10 minutes. The overnight culture medium was replenished 
with fresh complete medium before adding DNA-PEI complexes slowly to the cells.   
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Table 2.12 
Components used for PEI transfection method in several different formats 
Format Mixture 1 Mixture 2 
96-well plate DNA 100 ng 
NaCl 150 mM Add to 4 μl  
 
PEI 0.6 μl 
NaCl 150 mM Add to 4 μl  
 
24-well plate DNA 250 ng 
NaCl 150 mM Add to 40 μl  
 
PEI 1.5 μl 
NaCl 150 mM Add to 40 μl  
 
6-well plate DNA 2 μg  
NaCl 150 mM Add to 80 μl  
 
PEI 12 μl 
NaCl 150 mM Add to 80 μl  
 
 
2.2.8.3 PEI method 2 
This method was utilized for transfection on COS-7 applying ratio of DNA to PEI 1:3 
(w/v). The following format was used to describe PEI transfection protocol for each well 
in 24 well-plate. DNA and PEI solution were mixed into un-supplemented growth 
medium as described (in table 2.12 or 2.13) for 15 minutes at room temperature. The 
DNA-PEI solution was then added to the cells dropwise.  
 
Table 2.13  
Component used for transfection using PEI in 24 well plate 
Format Component Volume (in μl) or 
amount (in μg) 
24-well plate DNA 1 
DNA 2 
PEI 




Add to 25 μl 
 
2.2.9 cAMP accumulation assay  
Cells were grown to confluency in appropriate growth medium. Cells were then 
trypsinised for 1 minute, re-suspended in stimulation buffer (PBS with 0.1% bovine 
serum albumin (BSA)) and plated onto 384-well optiplates (Perkin Elmer, UK) at a 
density of 2000 cells/well (for C6 and ST14A cells) or 1500 cells/well (for U87 and 
HEK-293S cells). To determine the efficacy of individual PDE inhibitors, cells were co-
stimulated, immediately after seeding, with three different concentrations of 
compounds (which spanned 100-fold either side of the individual IC50 value in vitro) 
and pEC20 values of forskolin (1.6 µM for C6 cells, 50 nM for ST14A cells, 0.15 µM for 
U87 cells, 0.2 µM for T98 cells and 0.35 µM for HEK-293S cells) for 30 minutes. 
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Stimulating cells with the pEC20 of forskolin, enables a larger range to observe any 
effect of the PDE inhibitors on cAMP production.  
To generate full dose response curves, compounds were added to cells in the 
range of 0.1 pM – 100 µM for 30 minutes. Detection of cAMP was assessed using 
LANCE cAMP detection kit (Perkin Elmer, UK) and end-point measurement was 
performed using a Mithras LB940 microplate reader (Berthold Technologies, 
Germany). The detection was applied based on time-resolved fluorescence resonance 
energy transfer (TR-FRET), using europium-streptavidin/biotin-cAMP to detect free 
cAMP from the cells. The principle of the assay is illustrated in Figure 2.1. 
 
 
Figure 2.1 Principle of LANCE ® cAMP assay kit. The assay is homogenous time-
resolved fluorescence energy transfer (TR-FRET) immunoassay which is based on the 
competition between cAMP tracer complex (europium-labelled cAMP) with cAMP 
generated by the cells. Biotin-bound cAMP will form a tight complex with europium-
streptavidin. If the tracer complex binds to AlexaFluor®647 conjugated-anti cAMP 
antibody, energy form the dye is transmitted to cAMP tracer resulting in emission at 
665 nm. This binding will be replaced in the presence of produced cAMP from the cells, 
thereby reducing the FRET ratio. 
 
To determine the role of individual of G proteins subtypes on cAMP production, 
C6 cells were grown in complete MEM medium in the presence of either pertussis toxin 
(PTx) or cholera toxin (CTx) for 16 hours (as a pre-treatment). Subsequently, cells 
were dissociated using trypsin for 1 minute after which, complete medium was added 
to inactivate trypsin. Cells were washed, resuspended in PBS containing 0.1% BSA, 
and plated onto 384-well optiplates at a density of 8000 cells/well. Total accumulation 
of cAMP was determined using the same protocol as described above. Data were 
either normalised to the maximal level of cAMP accumulation from cells in response to 
100 μM forskolin stimulation or were interpolated to the cAMP standard curve and 
expressed as the concentration cAMP per 106 cells.  
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2.2.10 Quantification of intracellular and extracellular cAMP concentrations 
C6 cells were trypsinised and resuspended in PBS containing 0.1% BSA. 150,000 cells 
were then treated with various concentrations of PU23, a multidrug resistance protein-
4 (MRP4) inhibitor (10 μM, 3.16 μM, and 1 μM, diluted in PBS containing 0.1% BSA) 
for 30 minutes. After treatment, cells were washed with PBS containing 0.1% BSA and 
stimulated with the pEC50 concentration of forskolin (3.16 μM), trequinsin (4.7 μM) or 
the PDE inhibitor cocktail (26 μM) for 1 or 2 hours, in the presence or absence of each 
concentration of MRP inhibitors. After stimulation, cells were centrifuged at 5000 rpm 
for 4 minutes to separate supernatant and cell pellet. LANCE cAMP detection kit was 
used to determine extracellular cAMP levels (supernatant) and intracellular cAMP 
levels (cell pellet). The concentration of cAMP was determined by interpolating the TR-
FRET values to the cAMP standard curve.  
 
2.2.11 cGMP accumulation assay 
Confluent C6 cells were trypsinised and resuspended in PBS containing 0.1% BSA. 
Cells were plated onto a 384-well plate at a density of 500,000 cells/well and 
immediately stimulated with compounds for 30 minutes.  After stimulation, 5 µl of 
cGMP-labelled with d2 reagent (d2-cGMP) analogue and 5 µl of anti-cGMP antibody 
conjugated with europium cryptate (mAb-cryptate) were added to each well and 
incubated for 1 hour at room temperature as per the manufacturer’s instruction (Cisbio, 
France). The principle of the assay is illustrated in Figure 2.2. The d2-cGMP 
fluorophore was excited at a wavelength of 337 nm and emission was detected at 665 
nm and 620 nm. Fluorescence was measured using a Mithras LB940 microplate 
reader. Delta F% values were calculated using the 665 nm/620 nm ratio and all data 
were interpolated to a standard curve which covered a range cGMP concentration 
between 0.5 to 500 nM. 
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Figure 2.2 Principle of Cisbio Bioassays’ cGMP assay kit. The assay is 
homogenous time-resolved fluorescence energy transfer (HT-FRET) immunoassay 
based on the competition between cGMP acceptor complex (d2-cGMP) with cGMP 
generated by the cells. If the tracer complex binds to anti-cGMP conjugated with 
europium cryptate antibody (as donor), energy form the dye is transmitted to cGMP 
acceptor resulting in emission at 665 nm. This binding will be replaced in the presence 
of produced cGMP from the cells, thereby reducing the FRET fluorescence intensity. 
 
2.2.12 Quantifying the extent of cell proliferation  
To determine compounds effect on cell growth, CCK-8 kit (cell counting kit-8) was 
utilised. The assay is based on the ability of alive cells to convert WST salt which is 
exist in the kit to WST-8 formazan dye. The amount of WST-8 formazan formed is 
directly proportional to the number of viable cells and can be detected by measuring 
the absorbance at 450 nm (Figure 2.3). Cell proliferation was calculated as a 
percentage of number of cells treated with vehicle alone.  
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Figure 2.3 Principle of CCK-8 (cell counting kit-8) assay. Cell proliferation assay 
using CCK-8 is based on colorimetric method allowing determination of cell viability. 
WST-8, tetrazolium salt as the main component in CCK-8 kit, will be reduced by the 
activity of dehydrogenase in viable cells generating WST-8, which is soluble in tissue 
culture medium. The amount of formazan WST-8 dye is proportional to the number of 
viable cells and can be detected by measuring the absorbance at 450 nm.  
 
All cells in this study were seeded at a density of 2,500 cells/well in a clear flat bottom 
96-well plate (Corning). After 24 hours, cells were exposed to test compounds or 
vehicle, in appropriate growth medium supplemented with serum, and were incubated 
for 72 hours. The optimum conditions for this assay were determined and displayed in 
Figure 2.4 and 2.5. Initial optimisation was initially performed in U87 cells and similar 
conditions were further applied to a range of cell lines for validation (Figure 2.6).  
 
 
Figure 2.4 The effect of un-supplemented and complete growth media upon U87 
cell growth. Proliferation of U87 cells after incubation in serum free media (open 
symbols) or complete growth medium (closed symbols) after 24, 48 or 72 hours. Cells 
were initially seeded at the same cell density of 10,000 cells/well. Data are expressed 
as the raw absorbance values measured at 450 nm, with intensity proportional to the 
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Figure 2.5 Influence of cell density and treatment period on U87 cell growth. 
Proliferation of U87 cells seeded at varying cell densities up to 12500 cells per well 
after 24-, 48- or 72-hour incubation in complete growth medium. Data are expressed 
as the raw absorbance values measured at 450 nm, with intensity proportional to the 
number of cells/proliferating cells. Simple linear regression was utilized to fit the curve 




Figure 2.6 Cell proliferation assay in several of cell lines. Selected conditions that 
were determined on U87 cells were applicable for other cell lines. Cells were initially 
seeded at the density of 2500 cells/well and treated by cisplatin for 72 hours. Cisplatin, 
as a cytotoxic reference compound, displayed anti-proliferative effect in a dose-
dependent manner in all cell lines: (A) U87, T98, and HEK293S; C6 and ST14A (B); 
LK2, H520, and H1792 (C) cells. Data are expressed as percentage of cell survival 
compared to vehicle-treated group (PBS 1%) in complete media. Data were fitted into 
non-linear regression of 6-14 individual data. 
 
To further investigate whether downstream pathways of cAMP influenced cell 
proliferation, cells were cotreated with selective inhibitors that target cAMP/cGMP 
sensors including PKA, PKG, and Epac1/2. Cells were seeded as previously described 
and treated with either forskolin or trequinsin in the presence of the following inhibitors: 
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KT5720 to inhibit PKA, KT5823 to inhibit PKG, ESI-09 as non-selective Epac1/2 
inhibitor, CE3F4 as a selective Epac1 inhibitor, and HJC0350 as a selective Epac2 
inhibitor. In order to investigate the effect of blockade of cAMP export on cell 
proliferation, cells were treated with forskolin, trequinsin or PDE inhibitor cocktail in the 
presence, or absence, of various concentrations of PU23 (10 μM, 3.16 μM, and 1 μM). 
After 72 hours incubation, 5 µL of Cell Counting Kit – 8 (CCK-8, Sigma, UK) was added 
to each well and the cells were incubated for an additional 2-3 hours at 37°C in the 
dark. The absorbance of each well was measured using a Mithras LB940 microplate 
reader with an excitation of 450 nm. 
 
2.2.13 Quantifying Caspase-3/-7 activity 
C6 cells were seeded into clear bottom black 96-well plates (Corning) and treated with 
forskolin (1-100 µM), trequinsin (1-100 µM) or staurosporine (1 µM, a pan caspase 
activator) in complete MEM media. 1% DMSO was used as vehicle control. Cells were 
exposed to test compounds for 72 hours, plates were treated with 2 µM of the 
CellEventTMCaspase-3/7 green detection reagent (Life Technologies, UK) for 60 
minutes at 37°C in the dark. Caspase activity was detected by cleavage of the 
tetrapeptide substrate DEVD (aspartic acid-glutamic acid-valine-aspartic acid), which 
is conjugated to a nucleic acid binding dye (illustrated in Figure 2.7). Intracellular 
caspase-3/7 activities were imaged using a BD Pathway 855 Bioimager (BD 
Biosciences, USA). To normalise the number of cells with caspase activated, cells 
were also labelled with Hoechst 33342 (Cambridge Bioscience, UK). Activated 
caspase-3/7 cleaves substrate and produce green fluorescence which was visualised 
using FITC/Alexa FluorTM 488 filter setting. To determine the total number of cells 
Hoechst 33342 was added and measured on the was measured on the BD Pathway 
855 using 350 nm excitation and 461 nm emission filters. The cell number was 
quantified automatically using Fiji (Schindelin et al., 2012) by applying classic 
watershed plugin on the captured image. 
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Figure 2.7 Principle of CellEventTM Caspase-3/7 assay kit. The kit consists of 4 
amino acid (DEVD) conjugated to a high-affinity nucleic acid binding dye. DEVD 
conjugated dye is non-fluorescent intrinsically. Cell with activated caspase-3/7 such as 
in apoptotic cells, will cleave DEVD peptide releasing DNA-binding dye and allowing 
dye to bind DNA. Upon binding with DNA, the dye will emit fluorescence light (~530 
nm) that can be detected using appropriate filter.  
 
2.2.14 Cell cycle analysis 
Cell cycle analysis using fluorescence-activated cell sorting (FACS) provides 
information on the distribution of cells in interphase stages of the cell cycle (G0/G1, S, 
and G2/M). C6 cells were seeded in 24-well plates and cultured for 24 hours. Cells 
were exposed to selected treatments including forskolin, trequinsin, and a combination 
of individual PDE2,3,7 inhibitor for 72 hours. Subsequently, cells were harvested and 
resuspended in PBS containing 0.1% Triton X-100, 10 µg/ml RNase A, and 5 µg/ml 
propidium iodide (PI) before incubation at 37°C for 15 minutes. Samples were analysed 
using a BD Accuri C6 flow cytometer (BD Biosciences) and cell cycle analysis was 
performed using BD C6 software.  
The samples will be plotted in a graph with forward scatter area (FCS-A) and 
side scatter area (SSC-A) as the axes. For analysis, gating on the single cell population 
to exclude debris and aggregates, as depicted in Figure 2.8A. The single cells have 
been gated and by combining with signal recorded from FL2-A (from channel 2), 
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histogram plot was shown (Figure 2.8B) for further analysis. Area M1, M2, and M3 
(Figure 2.8B) represent each of cell cycle of G0/G1, S, and G2/M phase, respectively. 
 
Figure 2.8. Representative figures of cytogram for cell cycle analysis. (A) Gating 
the alived cells and exclude debris or doublets. (B) Representative histogram of cell 
treated with vehicle control (DMSO 1%) from channel 2 (FL2-A). This filter channel 
records signal from propidium iodide. Each phase of cell cycle was counted based on 
M1 area (G0/G1 phase), M2 (S), and M3 (G2/M). 
 
2.2.15 Quantification of ligand affinity through BRET-based ligand binding assay 
106 cells/well of HEK293T cells were seeded into 6 well-plate for 24 h in DMEM/F12 
medium supplemented with 10% FBS and 1% antibiotic/antimycotic at 37oC. Cells 
were then transfected with 1.5 μg Nluc-A2AR construct (a gift from Dr. Stephen Briddon, 
and Professor Steven Hill, University of Nottingham, UK) per well using PEI method, 
with the ratio of DNA:PEI was 1:6 in 150 mM NaCl, as described in the method section. 
After 24h, cells were harvested and re-seeded into PLL-coated white 96-well plates 
(Greiner, UK) at a density of 50,000 cells/well. Cells were then cultured overnight. On 
the day of the assay, culture medium was replaced by 80 μl BRET buffer (PBS 
supplemented with 0.9 mM CaCl2, 0.5 mM MgCl2, and 1% BSA (w/v)). The assay was 
initiated by adding 10 μl of furimazine (Promega, UK) to a final concentration of 0.4 
μM, diluted in BRET buffer. Furimazine is a substrate of Nanoluciferase (NLuc) and 
the principle of the assay is depicted in Figure 2.9. The plate was incubated at room 
temperature in the dark for 5 minutes. 
 In association-dissociation kinetic experiments, 40 nM of CA200645 was added 
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injected to a final concentration of 10 μM to displace all bound CA200645. For 
competition association assays, following furimazine incubation, 300 nM CA200645 
was added simultaneously in the presence of unlabelled “cold” ligand in a range of 10 
pM to 100 μM. BRET signal was recorded for 50 minutes (for kinetic experiments) or 
20 minutes (for competition assays), on a Mithras LB940 to allow signal from 
CA200645 and Nluc. The BRET ratio refers to the ratio of the emission from CA200645 
using long pass filter (640-685 nm) over the Nluc fluorescence at 460 nm. ΔBRET 
ligand-induced was used to generate both association-dissociation kinetics and 
competition binding curves of unlabelled “cold” ligand. To generate dose-response 
relationship, the BRET ratio was substracted by the signal from vehicle only group.  
 
 
Figure 2.9 Principle of BRET-based ligand binding assay. The A2AR N-terminally 
tagged Nluc and a probe CA200645 (red circle) – an adenosine receptor antagonist, 
were utilised to quantify ligand binding at the A2AR. BRET relies on the transfer of 
energy between a bioluminescent donor (NLuc) and a fluorescent ligand, CA200645, 
where the proximity between these substances is within ~10nm. Before the binding of 
fluorescent probe to the Nluc-A2AR, there is no BRET signal detected. The binding of 
the probe to the Nluc-A2AR leads to production of BRET signal – representing the 
association phase. The presence of unlabelled “cold” ligand (black circle) displaces 
bound CA200645 which lead to the dissociation phase where the BRET signal is 
diminished. 
 
2.2.16 Quantification of RAMP cell surface expression using FACS 
COS-7 cells were seeded in 24-well plates and cultured for 24h in complete growth 
medium. For initial screening, FACS analysis were performed in COS-7 expressing 
different GPCRs (PAR4A120, or PAR4T120) and FLAG tagged RAMP at the same 
ratio of 1:1 (section 2.2.8, Table 2.13). FLAG is polypeptide protein tag served as 
epitope in recombinant technology that consist of 8 amino acids: DYKDDDDK.  
 Cells were grown for further 48 hours before being harvested using cell 
dissociation buffer. Subsequently, cells were washed once with PBS followed by 3 
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washes in FACS buffer (PBS with 1% BSA and 0.03% sodium azide) and resuspended 
in 50 μl FACS buffer containing allophycocyanin (APC)-conjugated anti-FLAG antibody 
(BioLegend1:80 dilution). Cells were incubated in the dark at room temperature on 
rotating mixer for 1h. Before being analysed, cells were washed twice in FACS buffer 
and resuspended in 50 μl FACS buffer. Samples were analysed using a BD Accuri C6 
flow cytometer. The percentage of events with an increased APC intensity was 
normalised to that of vector as 0% and HA-CLR RAMP2 co-expressed cells as 100%. 
APC antibody is cell-impermeable thus the signals that were recorded come from the 
antibody attached to cell surface. 
 
2.2.17 Quantification of intracellular calcium signaling  
HEK-293T cells were seeded in a 6-well plate at a density of 106 cells/well. 24 hours 
later, cells were transiently transfected with PAR4 (A120 or T120) and co-expressed 
with RAMP/vector with the ratio of 1:1 (PAR4:RAMP) using PEI (section 2.2.8, table 
2.12). After a further 24 hours, cells were harvested and seeded onto poly-L-lysine 
(PLL) coated black, clear bottomed, 96-well plates, at a density of 105 cells/well, and 
were grown overnight. On the day of the assay, cells were washed with calcium 
containing Hank’s Balance Salt Solution (HBSS) and incubated with 10 μM Fluo-4 AM 
DirectTM calcium assay kits (Invitrogen), for 1 hour in the dark at room temperature. 
Fluo-4 AM is an indicator that exhibits increase in fluorescence upon binding to Ca2+. 
Fluo-4 bound calcium will emit green fluorescence light that can be detected using 
appropriate filter in flow cytometer or microscope. Afterwards, cells were washed twice 
using HBSS containing calcium to remove residual dye. A dilution series of ligands 
including α-thrombin, trypsin, AYPGKF-NH2 (PAR4 selective agonist peptide) were 
injected robotically using a BD Pathway 855 Bioimaging Systems. The excitation 
wavelength of the Ca2+-bound fluo-4 was at 494 nm and emission wavelength at 516 
nm. The intensity of fluorescence was determined immediately after injection of ligands 
and responses were recorded every second for 80 s. After correcting for background 
fluorescence using Fiji (Is Just) Image J, peak intensity was measured for generating 
dose-response curves. The results were normalized to the maximum intensity 
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2.2.18 Quantification of ligand-mediated β-arrestin recruitment through 
bioluminescent resonance energy transfer (BRET)-based assay 
HEK-293T cells were seeded in 6-well plates at density of 106 cells/well and grown 
overnight. Cells were transfected with the following components: PAR4T/A120-NLuc 
(0.167μg); RAMP (0.167μg); β-arrestin1-YFP (yellow flurescent protein) or β-arrestin-
2-YFP (0.83μg) and vector (6.67 μg). The ratio of DNA:PEI used for this transfection 
was 1:6 in 150 mM NaCl. Cells that were transfected with Gastric Inhibitory Polypeptide 
Receptor (GIPR), β-arrestin-2-YFP, and G protein-coupled receptor kinase 5 (GRK5) 
were used as positive control. The amount of DNA for each transfection was 
maintained. Cells were grown overnight, harvested and seeded at a density of 105 
cells/well into PLL-coated white 96-well plates (Greiner, UK) in MEM serum-reduced 
media (supplemented with 2% FBS (v/v), 1% antibiotic/antimycotic, 2mM L-glutamine) 
and cultured for a further 24h.  
On the day of the assay, culture medium was discarded and replaced by 80 μl 
BRET buffer which consist of PBS supplemented with CaCl2, MgCl2, and 1% BSA 
(w/v). For PAR4-Nluc expressed cells, the assay was started by adding 10 μl of 
furimazine (Promega, UK) (diluted in PBS supplemented with CaCl2, MgCl2, and 1% 
BSA (w/v) to a final concentration of 4 μM) and the plate was incubated in the dark at 
room temperature for 5 minutes before adding 10 μl of ligand (AYPGKF-NH2). The 
principle of the assay is illustrated in Figure 2.10. 
Thrombin and trypsin were used as the non-selective ligand for PAR1 and 
PAR2, respectively, TFLLR-NH2 as selective PAR1 agonist, and SLIGKV-NH2 as 
selective PAR2 agonist. BRET signal was recorded for 20 minutes on a Mithras LB940 
plate reader allowing sequential integration of signal detected from YFP and Nluc or 
Rluc, as appropriate. The BRET ratio corresponds to the ratio of light emission from 
acceptor (YFP, 530nm) over donor (Nluc 460 nm or Rluc 485 nm). Ligand-induced 
ΔBRET was used to construct the concentration response curve at 13 minutes time 
point for AYPGKF-NH2, 
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Figure 2.10 Principle of BRET-based β-arrestin recruitment assay. BRET relies on 
the transfer of energy between a bioluminescent donor (NLuc) and a fluorescent 
acceptor (YFP) where the proximity between these proteins is within ~10nm. Light 
emission from acceptor, YFP, is detected at 520 nm, whereas bioluminescent 
transmitted energy is recorded at 460 nm.  
 
2.2.19 Data Analysis 
All data analysis was performed in GraphPad Prism 8.4 (SanDiego, US). To quantify 
gene expression through RT-PCR, the densitometry results of each gene of interest 
were normalised to GAPDH signal.  
For cAMP accumulation, cell proliferation assays, intracellular calcium 
mobilisation assay, and BRET-based β-arrestin recruitment assays, data were fitted to 
obtain concentration–response curves using the three-parameter logistic equation 
using GraphPad Prism 8 (GraphPad Software, San Diego) to obtain values of Emax 
/Imax, pEC50/pIC50, baseline, and span.  
" = $%&&%' +	 (+%, − $%&&%')(1 + 10("#$%&!"'()) 
(1) 
 
Where Y is pharmacological response; top (Emax) and bottom (baseline) values are 
upper and lower plateau of sigmoidal dose-response curve. The equation (1) was also 
used to determine % response (Y) corresponds to effect of forskolin (at the 
concentration giving 20% of Emax, pEC20) in the presence of PDE inhibitor in 
optimisation experiment. Span is the range between Emax and baseline values and is 
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expressed as %. X is concentration in logarithmic scale. By assuming Hill slope to be 
1, log EC20 can be determined using the formula below:  
log 45* = log45+, + 6
1
7899	:9%,;< × 9%> 6
?
100 − ?< 
(2) 
 
Statistical differences were analysed using one-way ANOVA followed by Dunnett’s 
post-hoc (for comparisons amongst more than two groups) or independent Student’s 
t-test (for comparison between two groups). To determine the correlation of cAMP 
levels and cell proliferation of each PDE inhibitor in all cell lines, Pearson’s correlation 
coefficient (r) was calculated with 95% confidence interval. To compare the ability of 
compounds to suppress glioma/glioblastoma cell proliferation, a selection criterion was 
calculated, whereby the term for affinity (pIC50) was multiplied by the term for efficacy 











Where, SEMA and SEMB are the standard error of measurement A and B with mean 
of D- and D/, D-/ is the composite mean and n is the number of repeats. 




PHOSPHODIESTERASE INHIBITION AS A THERAPEUTIC TARGET:  
STUDY IN A MODEL OF GLIOMA 
 
3.1 Introduction 
Glioma, a type of brain tumour that originates from astrocytes, has been a challenge 
due to its pathological progressiveness. Glioblastoma multiforme (GBM), the most 
common type of glioma, is reported to be the deadliest, with a 5-year survival rate of 
5% (Schwartzbaum et al., 2006; Delgado-López and Corrales-García, 2016). 
Abnormalities in several signalling pathways have been reported to be involved 
in glioma-genesis, these include alterations to the following cascades: 
phosphatidylinositol-3 kinase/ phosphatase and tensin/ protein kinase B/ mammalian 
target of rapamycin (PI3K/PTEN/Akt/mTOR) cascade that often deletes or suppresses 
phosphatase and tensin (PTEN) suppressor gene (Rekers, Sminia and Peters, 2011; 
X. Li et al., 2016) ; the retinoblastoma pathway (pRB) (Burns et al., 1998), the Ras/ 
mitogen-activated protein kinase (RAS/MAPK) pathway (Rekers, Sminia and Peters, 
2011); signal transducer and activator of transcription 3 (STAT3) (Jahani-As et al., 
2016); zinc transporter 4 (ZIP4) (Lin et al., 2013; Kang et al., 2015); and adenylyl 
cyclase (AC) pathway (Mao et al., 2012). Aberrant signalling in the AC system results 
in cAMP suppression approximately 4-fold lower compared to normal healthy brain 
cells: 25.8 pmol/mg protein versus 98.8 pmol/mg protein  (Furman and Shulman, 1977; 
Mao et al., 2012).  
Targeting cAMP using forskolin has been shown to beneficially impact in a 
broad range of relevant anti-cancer effects (Illiano et al., 2018) which involve  improving 
sensitivity towards chemotherapeutic agents, blocking cell motility and migration 
(Naviglio et al., 2010; Quinn et al., 2017), and suppressing cell growth (Sawa et al., 
2017). While cAMP-analogues such as 8-bromo-cAMP, 8-chloro-cAMP, monobutyryl 
cAMP and dibutyryl cAMP also showed promising results, the use of these compounds 
were not recommended due to toxicity (Hirsh et al., 2004). Hence, there is an urgency 
to develop relatively safe and effective compounds that elevate cAMP levels.  
As mentioned previously, PDEs hydrolyse cAMP into adenosine 5’-
monophosphate (AMP) to control the functional level of cAMP (Figure 3.1) (K Omori 
and Kotera, 2007b). However, several PDEs including PDE1, PDE4, PDE5, and PDE7 
Chapter 3                                                                                     PDE inhibition in glioma cells 
 86 
have been found to be upregulated in a range of tumours to alter the basal level of 
cAMP. This evidence is supported by other reports that lower cAMP levels are 
associated with malignancy (Savai et al., 2010b; Sengupta et al., 2011; Brooks et al., 
2014; Cesarini et al., 2017). Therefore, increasing the level of cAMP through PDE 
inhibition to compensate for overexpression of PDEs may be a viable approach for 
cancer therapy (Chen et al., 2007).  
 
 
Figure 3.1. Illustration of regulation process of intracellular level of cAMP. 
Intracellular concentration of cAMP is tightly controlled by its production: through 
activation of GPCR or direct stimulation at adenylyl cyclase (AC); its degradation 
through phosphodiesterase (PDE) activities; as well as cGMP levels through dual-
substrate PDEs.  
 
In this study, C6 cells were used as model for glioma and as the tool to characterise 
pharmacological role of PDEs. C6 cells is glioma cells derived from rat origin that is 
continuously exposed to N-Nitroso-N-methylurea (Benda et al., 1968). This cell line is 
reported to be genetically close to GBM and resembles numerous properties including 
morphological and development of tumor in vivo, and the angiogenesis during tumor 
development (Giakoumettis, Kritis and Foroglou, 2018). Indeed, the C6 rat glioma 
model is considered the most common model that has been studied to investigate 
growth, aggressiveness, and invasion of high-grade glioma (Auer, Maestro and 
Anderson, 1981; Nagano et al., 1993; Giakoumettis, Kritis and Foroglou, 2018). For 
comparison, ST14A cells, a medium spiny neurons-like cell line derived from rat 
embryonic striatum, was used as a model of healthy neurons (Ehrlich et al., 2001). 
Considering that intracellular concentration of cAMP is not only controlled by its 
synthesis through AC, but also is influenced by other affecters including GPCR and G 
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proteins, PDEs, and cGMP which all of them contribute to regulating spatiotemporal 
action of this secondary messenger (Figure 3.1). Therefore, in this study, the role of 
each PDE isoenzymes through cAMP pathway were investigated as well as impact on 
cell growth. The study also would include upstream proteins that involve in cAMP 
production as well as another secondary messenger – cGMP. 
 
3.2  Elevation of cAMP through β-adrenoceptor, G protein, and adenylyl cyclase 
exhibit differential range of anti-proliferative effects in C6 glioma cells 
It has been suggested that elevation in cyclic nucleotides can lead to changes in cell 
growth. Using the rat C6 cells as a model for glioma, the role of intracellular cyclic 
nucleotides in modulating cell growth was investigated. Firstly, the ability of an AC 
activator (forskolin) and guanylyl cyclase (GC) activators (YC-1 and BAY 41-8543) to 
stimulate cAMP or cGMP production was assessed.  
 There was a dose-dependent elevation in cAMP levels in C6 cells upon 
stimulation with forskolin, YC-1, and BAY 41-8543 for 30 minutes (Figure 3.2A) with 
the rank order of potency (pEC50): forskolin (5.75 ± 0.24) > BAY 41-8543 (5.38 ± 1.00) 
>YC-1 (5.11 ± 0.81). This time point was taken based on the routines in the laboratory 
and has been proven to be able providing sufficient window of observation for most of 
the compounds. Whilst very small amount of cAMP was detected in vehicle treated 
group (DMSO 1%), the maximal cAMP level in response to GC activators 
approximately 30-fold lower compared to that of forskolin (p<0.001, Figure 3.2B).  
Although there was an increase in cGMP accumulation upon stimulation with 
the nitric oxide donor, SNAP and GC activator (p<0.001, Figure 3.2C), in general, 
cGMP production was ~1000-fold lower in C6 cells than cAMP production. Treatment 
with forskolin dose-dependently suppressed proliferation of C6 cells (pIC50 5.34 ± 
0.09), whilst YC-1 and BAY 41-8543 only reduced cell proliferation at 100 μM (Figure 
3.2D). These results suggest that cell growth is predominantly affected by cAMP 
signalling compared to cGMP. A previous report by Zaccolo and Movsesian (Zaccolo 
and Movsesian, 2007), details that crosstalk between cAMP and cGMP occurs through 
PDEs. Taking this into account, accumulation of cGMP levels may allosterically 
regulate dual-substrate PDEs modulating the concentration of cAMP and suppressing 
cell proliferation. This also may explain the findings that GC activator-mediated cAMP 
accumulation and cell growth suppression that has been mentioned previously.   
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Figure 3.2 Elevation of cAMP, but not cGMP, mediates cell growth suppression. 
A. cAMP levels following 30 minutes treatment with adenylyl cyclase activator 
(forskolin) or guanylyl cyclase activators (YC-1 and BAY 41-8543). cAMP levels 
following 30 minutes treatment with adenylyl cyclase activator (forskolin) or guanylyl 
cyclase activators (YC-1 and BAY 41-8543). B-C. Comparison of accumulation of 
cAMP and cGMP in C6 cells in response to forskolin (100 µM), BAY 41-8543 (100 µM), 
YC-1 (100 µM), or SNAP (100 µM). D. Survival of C6 cells following 72 hours treatment 
with forskolin, BAY 41-8543 or YC-1. Data are expressed as percentage survival 
relative to vehicle alone and are the mean±SEM of 6-9 individual experiments. 
Statistical significance was determined using a one-way analysis of variance followed 
by Dunnett’s post hoc test (***, p<0.001). 
 
Since GPCRs can also stimulate the production of cAMP, here, we tested the 
effects of isoprenaline, a non-selective β-adrenoceptor agonist on cAMP production 
and cell proliferation. Although isoprenaline (pEC50: 8.62 ± 0.13) was more potent 
compared to forskolin (pEC50: 6.11 ± 0.12) in cAMP accumulation assay, the anti-
proliferative effect was significantly lower than that of forskolin (pIC50 isoprenaline 4.55 
± 0.25; pIC50 forskolin 5.84 ± 0.13, p< 0.01) (Figure 3.3A and B). Furthermore, direct 
targeting of G proteins using PTx (pertussis toxin) or CTx (cholera toxin), show that G 
protein-mediated cAMP elevation only moderately suppresses cell growth (~20% 
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suppression, Figure 3.3C and D), with the potency of each would be 0.14 ± 0.38 and 
0.66 ± 0.15 ng/ml, for PTx and CTx, respectively.  
It can be concluded that either transiently activation of GPCRs or directly 
modifying heterotrimeric G proteins display sub-optimally anti-proliferative effects 
compared to forskolin treatment. Taken together, these data suggest that elevation of 
cAMP, through direct AC activation, triggers cell growth suppression with a possible 
involvement of cGMP signalling. 
 
Figure 3.3 Forskolin stimulation has a greater effect on suppression of C6 cell 
growth than activation of β-adrenoceptor or Gα G protein subunits. A. 
Comparison of accumulation of cAMP in C6 cells in response to forskolin and 
isoprenaline. B. Survival of C6 cells following 72 hours treatment with forskolin, 
isoprenaline. C. Concentration of cAMP in C6 cells after 16 hours pre-treatment with 
PTx or CTx in comparison to untreated cells. D. Survival of C6 cells after treatment 
with PTx and CTx. Data are expressed as percentage survival relative to vehicle alone 
and are the mean ± SEM of 6-9 individual experiments. Statistical significance was 
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determined using a one-way analysis of variance followed by Dunnett’s post hoc test 
(**, p<0.01). 
 
3.3 Determination of PDE expression profile in glioma cells 
The concentration of intracellular cAMP is tightly regulated by the action of AC and 
PDEs. However, given the fact that AC is more abundantly expressed in various 
tissues leading to lack of selectivity, therefore, determination of AC roles was ruled out. 
It was next necessary to profile PDE expression in C6 cells as model for glioma, in 
comparison with ST14A cells.   
 To do this, reverse transcription polymerase chain reaction (rt-PCR) was 
conducted to identify expression levels of genes of interests. GAPDH, glyceraldehyde 
3-phosphate dehydrogenase, is one of housekeeping gene that is commonly used as 
the reference to normalise other genes of interests (Karge, Schaefer and Ordovas, 
1998). Despite the reports that GAPDH as housekeeping gene will be affected by the 
experimental setting (Barber et al., 2005), using the same tissue GAPDH remains valid 
as denominator for gene expression studies. To validate there was no contamination 
from genomic DNA (gDNA), the similar PCR reaction was performed without including 
reverse transcriptase.   
Since PDE6 isoenzymes are specifically expressed in the eyes, amplification of 
these isoforms was precluded. As shown in Figure 3.4, the overall expression of PDEs 
at the mRNA level was greater in C6 compared to ST14A cells. While expression of 
PDE1C, PDE4B, PDE4D, PDE7A, and PDE7B were statistically upregulated in C6 
cells, discrepancy amongst remaining isoforms was minor. It is worth noting that 
amongst all PDEs, the highest expression was detected on PDE1C, PDE4B, and 
PDE4D in C6 cells.  
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Figure 3.4 Expression profile of PDE isoenzymes in C6 and ST14A cells. A. 
Representative gel documentation showing amplified PDEs genes from C6 and ST14A 
cell line. (*) on the gel showed correct band size. B. Semi-quantitative mRNA levels in 
C6 cells and ST14A cells. Expression of each gene of interest was normalised relative 
to GAPDH. Data are expressed as the mean ± SEM from 5-7 individual repeats. Data 
were determined as statistically different (*, p<0.05; **, p<0.01; ***, p<0.001) compared 
to individual isoenzyme between both cell lines using Student’s t-test analysis. 
 
3.4 Pharmacological characterization of PDE inhibitors on modulating cAMP 
concentration 
Since the expression profiles obtained from rt-PCR were only semi-quantitative, it was 
next required to determine the role of each PDE isoforms through functional assays. 
Small molecule selective PDE inhibitors were used to probe the involvement of each 
PDE isoenzymes in modulating intracellular concentration of cAMP and its impact on 
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3.4.1 Development of a screening method to profile the efficacy of small 
molecule PDE inhibitors in modulating cAMP signalling 
Before characterising the role of each PDE isoenzymes, preliminary studies were 
conducted to establish an appropriate rapid and high throughput but robust screening 
method to test the activity of each compound in modulating the total concentration of 
cAMP.  
 Illustrated in Figure 3.5, if cells were co-stimulated with a concentration 
equivalent to the pEC50 value of forskolin, the window of observation would be too 
narrow to detect elevation of cAMP because of reaching the plateau of the maximal 
response (Figure 3.5). Instead, using a concentration equivalent to the pEC20 provides 
a wider range of observation of elevated cAMP in the presence of different PDE 
inhibitor (Figure 3.5). The effect of PDE inhibitor treatment on the forskolin response 
was determined by comparing the response at the pEC20 concentration of forskolin in 
the absence of PDE inhibitor (Figure 3.5). 
 
Figure 3.5 Comparison in using pEC20 and pEC50 of forskolin to provide sufficient 
window of observation for developing screening method. The graph represents 
the dose-response curve of forskolin without any PDE inhibitor upon stimulation for 30 
minutes. This graph shows that if cells were co-stimulated with pEC20 forskolin and 
compounds that synergistically increase cAMP levels, the range of response will be 
wider compared to that of pEC50 forskolin.  
 
To validate this approach, the following PDE inhibitors: rolipram (PDE4; was used at 
concentration of 25 μM), IBMX (non-selective; 50 μM), trequinsin (PDE2,3,7; 12.5 μM), 
and RO20-1724 (PDE4; 10 μM) were co-stimulated with forskolin for 30 minutes. 
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These PDE inhibitors were selected as the inhibitors that are commonly used in our 
laboratory. As mentioned previously, 30-minute time point was chosen based on 
similar protocols used to study GPCR-mediated cAMP production (Knight et al., 
2016a). The response of forskolin in the presence of PDE inhibitors was quantified 
(formula (1) in section 2.19) at corresponding pEC20. Data are summarised in Figure 
3.6 and Table 3.1. Meanwhile the pharmacological parameters for each dose-response 
curve are summarised in Table 3.2 and 3.3 for C6 and ST14A cells, respectively.  
As displayed in Figure 3.6 and Table 3.1, co-stimulation with selected PDE 
inhibitors resulted in raising cAMP accumulation in correspondence with forskolin 
alone. Not only did PDE inhibitors increase the potency of forskolin, but they also 
elevated the baseline level especially in ST14A cells. Whilst IBMX and trequinsin 
elevated the basal cAMP >15% in C6 cells, (Table 3.2), the baseline was rised to 20-
40% in ST14A cells in the presence of all PDE inhibitor with RO20-1724 increased only 
8% (Table 3.3). In both cells, rolipram showed the highest efficacy (increased cAMP 
levels up to 78%), followed by IBMX/trequinsin (in a range of 70-76%), and RO20-1724 
(~57%). By co-stimulating cells with small amount of forskolin, it is evident that this 
approach is a viable method to quantify the differential effects of each PDE inhibitor in 
accumulating cAMP. This method is beneficial to provide bigger range of observation 
and avoid misinterpretation due to reaching the plateau of maximal response of the 
system. Thus, the effect of each PDE isoenzymes using this approach was next 
determined. By applying formula (2) based on the dose-response curve of forskolin in 
each cell lines, pEC20 of forskolin was calculated to be 5.83 ± 0.04 for C6 cells and 
7.34 ± 0.09 for ST14A cells.  
 
Table 3.1  
The response of C6 and ST14A cells when were stimulated with forskolin and 
selected PDE inhibitors corresponding to pEC20 forskolin. 
 
Group % Response (relative to forskolin) 
C6 ST14A 
Forskolin       20.09 ± 0.58            18.34 ± 0.90               
Forskolin + Rolipram 78.49 ± 2.80*** 78.70 ± 4.49*** 
Forskolin + IBMX 72.83 ± 2.90*** 76.13 ± 3.37*** 
Forskolin + trequinsin 74.86 ± 3.76*** 70.92 ± 2.67*** 
Forskolin + RO20-1724 58.15 ± 1.50*** 57.00 ± 1.27***  
Percentage of response of each compound was equal to total cAMP levels. Values are 
expressed as mean ± SEM. Statistical significance was determined by comparing the 
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value of 6-8 data sets to that of forskolin by using one-way ANOVA followed by 





Figure 3.6 PDE inhibitors increased the concentration of cAMP in the presence 
of forskolin in C6 and ST14A cells. Representative dose-response curve of forskolin 
in the absence/presence of selected PDE inhibitors in C6 cells (A) and ST14A cells 
(B). Black and red lines are displayed to visualize interpolation of pEC20. Scatter plot 
of individual data as a comparison to the corresponding pEC20 of forskolin were 
displayed on the bottom panel for each cell line. Values are expressed as mean ± SEM 
of 6-10 individual data set. Statistical significance was determined by comparing the 
value of n data sets to that of forskolin by using one-way ANOVA and Dunnet’s post-
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Table 3.2 
Pharmacological parameters of forskolin in the presence of different PDE inhibitors in C6 cells 
Group Basal (%) Emax (%) pEC50 Span (%) 
Forskolin           0.04 ± 0.17 100.00 ± 0.90          5.23 ± 0.04         100.1 ± 0.9 
Forskolin + rolipram           3.81 ± 1.40 101.70 ± 2.76 6.35 ± 0.06***           97.9 ± 2.3 
Forskolin + IBMX 15.78 ± 3.55*** 102.40 ± 2.63 6.15 ± 0.08*** 86.7 ± 3.7*** 
Forskolin + trequinsin 18.61 ± 1.45*** 100.10 ± 2.54 6.21 ± 0.09*** 81.5 ± 2.4*** 
Forskolin + RO20-1724           2.08 ± 1.38   94.21 ± 1.53 6.06 ± 0.07***           92.1 ± 1.7 
The values are generated after curve fitting using three logistic equation by Prism 8.4. The response was normalised to 100 μM forskolin 
upon stimulation for 30 minutes. The values are represented as mean ± SEM of 9-10 individual data set. Statistical difference was 
determined using one-way ANOVA followed by Dunnett’s post-hoc analysis (*, p<0.05; **, p<0.01; ***, p<0.001). 
 
Table 3.3 
Pharmacological parameters of forskolin in the presence of different PDE inhibitors in ST14A cells 
Group Basal (%) Emax (%) pEC50 Span (%) 
Forskolin          -0.16 ± 0.71 99.97 ± 0.25          6.77 ± 0.08         100.1 ± 0.6 
Forskolin + rolipram 20.92 ± 4.64*** 99.46 ± 0.72 7.49 ± 0.10*** 78.6 ± 4.3*** 
Forskolin + IBMX 31.79 ± 3.03*** 99.67 ± 0.72 7.32 ± 0.07*** 67.4 ± 2.7*** 
Forskolin + trequinsin 38.97 ± 4.31*** 101.2 ± 1.46 7.33 ± 0.09*** 62.3 ± 3.7*** 
Forskolin + RO20-1724           8.61 ± 2.12 99.35 ± 0.66          7.26 ± 0.08**            89.9 ± 1.7 
The values are generated after curve fitting using three logistic equation by Prism 8.4. The response was normalised to 100 μM forskolin 
upon stimulation for 30 minutes. The values are represented as mean ± SEM of 9-10 individual data set. Statistical difference was 
determined using one-way ANOVA followed by Dunnett’s post-hoc analysis (*, p<0.05; **, p<0.01; ***, p<0.001).
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3.4.2 Elevation of intracellular cAMP positively correlates with cell growth 
suppression 
Having established the screening method, selected small molecules that have been 
reported to inhibit PDE isoenzymes (provided by IOTA Pharmaceutical Ltd) were 
assayed to determine which PDEs are involved in cAMP signalling and cell 
proliferation. Selective PDE inhibitors against each isoform were initially blind-
screened and subsequently decoded after data analysis. Four concentrations were 
used spanning 100-fold of the established in vitro estimates of the IC50 concentration 
(Table 3.4).  
 
Table 3.4  
Established in vitro pIC50 values of each PDE inhibitors used in this study 
Compounds Target PDE(X) In vitro pIC50 
Vinpocetine  1 21 μM 
EHNA 2 4 μM 
Cilostamide  3 0.1 μM 
Amrinone 3 50 μM 
Milrinone  3 0.33 μM 
Trequinsin 2,3,7 250 pM (for PDE3) 
5 μM (for PDE5) 
12.5 μM 
Rolipram  4 1 μM 
Ibudilast  4 1 μM 
Piclamilast  4 1 nM 
Roflumilast  4 0.6 nM 
Sildenafil  5 5 nM 
Tadalafil  5 5 nM 
Caffeine  1,4,5 10 μM 
Zaprinast  5,6,9,11 2.6 μM 
TC3.6 7 1 μM 
BRL-50481 7 180 nM 
BC 11-38 8 0.28 μM 
BAY-736691 9 55 nM 
PF-0449613 9 14 nM 
PF 2545920 10A 0.37 nM 
PF 04671536 11 2 nM 
IBMX  Non-selective 20 μM 
 
Both cell lines were stimulated with the pEC20 equivalent concentrations of 
forskolin as described previously (section 3.4.1). The individual dose-response curve 
in cAMP assays is displayed in Figure 3.7 and 3.8 for both cell lines. Whereas the 
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pharmacological results are shown in Table 3.5. From this series of experiments, some 
compounds were found to be able to elevate total cAMP concentration in a forskolin-
mediated cAMP production in C6 cells: vinpocetine, EHNA, cilostamide, amrinone, 
trequinsin, rolipram, ibudilast, piclamilast, roflumilast, BRL-50481, and IBMX. While 
there was a marginal increased in cells stimulated with sildenafil, tadalafil, and 
zaprinast; the remaining PDE inhibitors did not show any effects. Fewer compounds 
elevated cAMP production in ST14A cells compared to C6 cells, those compounds 
include: amrinone, milrinone, trequinsin, rolipram, ibudilast, piclamilast, roflumilast, and 
IBMX. Interestingly, sildenafil, tadalafil, and PF0449613 suppressed the production of 
cAMP in ST14A cells, whilst forskolin-mediated cAMP production remains unaffected 
in the presence of the rest of the compounds.  
 Subsequently, the compounds were tested for their ability to modulate cell 
proliferation (Figure 3.9 to 3.10, Table 3.5). In general, compounds that elevate cAMP 
production were found to exhibit anti-proliferative effects, especially in C6 cells. 
However, these patterns were not entirely followed in ST14A cells (summarised in 
Table 3.6).  
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Figure 3.7 Effect of a panel of established PDE inhibitors on forskolin-mediated cAMP production in C6 cells. Dose-response curve 
of each PDE inhibitors in the presence of small amount of forskolin after 30 minutes stimulation. Responses were normalised to 100 μM 
forskolin. Each data point is expressed as mean ± SEM of 6-9 individual data set. Compounds that elevate cAMP concentration are red 
colour coded, whereas all of which suppress cAMP level are displayed in blue. Compounds that show no effect are shown as black curves. 
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Figure 3.8 Effect of a panel of established PDE inhibitors on forskolin-mediated cAMP production in ST14A cells. Dose-response 
curve of each PDE inhibitors in the presence of small amount of forskolin after 30 minutes stimulation. Responses were normalised to 100 
μM forskolin. Each data point is expressed as mean ± SEM of 6-9 individual data set. Compounds that elevate cAMP concentration are 
red colour coded, whereas all of which suppress cAMP level are displayed in blue. Compounds that show no effect are shown as black 
curves. 
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Table 3.5  
Potency values for cAMP production (pEC50) and for cell growth inhibition (pIC50) of each PDE inhibitor in C6 and ST14A cells.  
  C6 ST14A 
Compounds Target 
PDE(X) ¥ 
pEC50a Span (cAMP)b 
(%) 
pIC50 c Span 
(proliferation)d 
(%) 
pEC50 a Span (cAMP) b 
(%) 
pIC50 c Span 
(proliferation)d 
(%) 
Vinpocetine  1 15.10 ± 0.08*** 27.9 ± 1.1*** 5.83 ± 0.13* 45.3 ± 3.1*** 4.16 ± 0.04***  13.2 ± 2.2*** N/A N/A 
EHNA 2 15.06 ± 0.07*** 24.3 ± 1.8***    5.04 ± 0.25 36.3 ± 3.3*** N/A  N/A    6.57 ± 0.08*** 20.9 ± 1.2*** 
Cilostamide  3 17.19 ± 0.09*** 15.2 ± 1.4*** N/A N/A N/A N/A   8.39 ± 0.15*** 10.6 ± 1.9*** 
Amrinone 3 13.68 ± 0.08*** 108.9 ± 4.8***   4.11 ± 0.04*** 86.4 ± 2.3***  3.84 ± 0.02***   89.7 ± 1.1**   3.91 ± 0.11*** 54.4 ± 6.2*** 
Milrinone  3 N/A N/A   8.06 ± 0.13*** 34.5 ± 4.7***  7.05 ± 0.18***   27.5 ± 2.4 N/A N/A 
Trequinsin 2,3,7 15.65 ± 0.08*** 50.6 ± 2.0*** 4.87 ± 0.07* 96.9 ± 0.9***  6.21 ± 0.06***   80.3 ± 1.9   4.62 ± 0.04*** 75.8 ± 0.8*** 
Rolipram  4 16.96 ± 0.04*** 60.5 ± 3.7***   6.78 ± 0.20*** 23.4 ± 2.9***  7.41 ± 0.04***   59.3 ± 4.1**  7.23 ± 0.05*** 15.6 ± 1.3*** 
Ibudilast  4 16.03 ± 0.11*** 64.2 ± 3.5***   7.05 ± 0.17*** 31.8 ± 1.3***  6.15 ± 0.12***  48.6 ± 2.2*** N/A N/A 
Piclamilast  4 18.72 ± 0.04*** 41.3 ± 2.9*** N/A N/A  9.02 ± 0.14***  35.2 ± 1.9*** N/A N/A 
Roflumilast  4 10.47 ± 0.03*** 54.6 ± 3.1*** 10.57 ± 0.22*** 14.7 ± 1.7*** 10.48 ± 0.08***   28.8 ± 0.8*** 10.92 ± 0.09*** a7.2 ± 1.6*** 
Sildenafil  5 N/A N/A   8.56 ± 0.16*** -6.8 ± 3.5***#  8.79 ± 0.20***   -4.6 ± 0.9***#   9.67 ± 0.11*** 12.7 ± 2.0*** 
Tadalafil  5 N/A N/A N/A N/A   7.88 ± 0.04*** -23.2 ± 1.4***#   8.81 ± 0.43***  -2.7 ±1.6***# 
Caffeine  1,4,5 N/A N/A N/A N/A N/A N/A   6.65 ± 0.06*** a9.0 ± 1.0*** 
Zaprinast  5,6,9,11 5.61 ± 0.11*** 14.3 ± 1.1***   6.03 ± 0.30*** 49.7 ± 4.6*** N/A N/A    5.86 ± 0.09*** 46.7 ± 1.5*** 
TC3.6 7 N/A N/A   7.53 ± 0.26*** 15.3 ± 2.5*** N/A  N/A   5.69 ± 0.05*** 21.2 ± 1.5*** 
BRL-50481 7 a6.41 ± 0.09*** 31.3 ± 1.7***   6.70 ± 0.15 
*** 
33.1 ± 2.7*** N/A  N/A    7.73 ± 0.24*** a4.5 ± 1.7*** 
BC 11-38 8 N/A N/A N/A N/A N/A N/A N/A N/A 
BAY-736691 9 N/A N/A N/A N/A N/A N/A N/A N/A 
PF-0449613 9 N/A N/A N/A N/A 7.55 ± 0.12*** -23.5 ± 1.8***#   8.05 ± 0.08*** a6.4 ± 0.7*** 
PF 2545920 10A N/A N/A  9.46 ± 0.06*** -8.9 ± 3.1#*** N/A N/A 10.78 ± 0.11*** 11.9 ± 4.1*** 
PF 04671536 11 N/A N/A N/A N/A N/A N/A N/A N/A 
IBMX  Non-
selective a4.30 ± 0.06
*** 42.8 ± 1.5*** 6.12 ± 0.06*** 54.2 ± 3.2***  4.56 ± 0.06***   57.5 ± 3.5    4.20 ± 0.09    47.9 ± 2.7 
Forskolin AC activator a5.43 ± 0.08*** 64.9 ± 3.5*** 5.12 ± 0.06*** 84.7 ± 1.4***    6.43 ± 0.12   74.1 ± 3.1    6.44 ± 0.02      45.1 ± 1.2 
Cisplatin DNA 
crosslinker 
N/A N/A 6.02 ± 0.09*** 96.9 ± 2.6  N/A N/A    5.92 ± 
0.09*** 
   86.5 ± 2.3*** 
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Data are the mean ± SEM of 6-9 individual data sets.  
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b the range between basal and Emax on cAMP accumulation assay 
c The negative logarithm of the inhibitor concentration required to inhibit a half-maximal response 
d The range between survival in vehicle control and inhibitory maximal in cell proliferation assay 
N/A – not applicable; compounds did not have any effect on cAMP production or cell growth inhibition.  
¥, unless mentioned, targets refer to particular PDE isoform.  
#, showing negative responses, either suppressing cAMP accumulation or being pro-proliferative. 
Data were determined as statistically different (*, p<0.05; ***, p<0.001) compared to forskolin using one-way ANOVA followed by Dunnett’s 
post-hoc analysis. 
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Figure 3.9 Effect of a panel of established PDE inhibitors, forskolin, and cisplatin on modulating C6 cell growth. Cell survival was 
determined in C6 cells following 72 hours incubation with each PDE inhibitor. Cisplatin was used as cytotoxic reference compound exhibiting 
anti-proliferative action. Data are expressed as percentage of cell proliferation relative to vehicle (complete medium containing 1% DMSO) 
from 6-9 data sets. Data are expressed as mean ± SEM. Compounds that suppress cell growth are red colour coded, whereas all of which 
pro-proliferative are displayed in blue. Compounds that show no effect is shown as black curves. 
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Figure 3.10 Effect of a panel of established PDE inhibitors, forskolin, and cisplatin on modulating ST14A cell growth. Cell survival 
was determined in C6 cells following 72 hours incubation with each PDE inhibitor. Cisplatin was used as cytotoxic reference compound 
exhibiting anti-proliferative action. Data are expressed as percentage of cell proliferation relative to vehicle (complete medium containing 
1% DMSO) from 6-9 data sets. Data are expressed as mean ± SEM. Compounds that suppress cell growth are red colour coded, whereas 
all of which pro-proliferative are displayed in blue. Compounds that show no effect is shown as black curves. 




































































M. N. O. P.
Q. R. S. T.
U. V. W.


































































































































































































Summary of the pharmacological effects of each PDE inhibitor on cAMP production 
and cell proliferation 
Compound Target C6 ST14A 
cAMP Proliferation cAMP Proliferation 
Vinpocetine 1 ­ ¯¯ ­ - 
EHNA 2 ­ ¯¯ - ¯ 
Cilostamide 3 ­ - - ¯ 
Amrinone 3 ­­­ ¯¯¯ ­­­ ¯¯¯ 
Milrinone 3 - ¯¯ ­ - 
Trequinsin 2,3,7 ­­­ ¯¯¯ ­­­ ¯¯¯ 
Rolipram 4 ­­­ ¯ ­­­ ¯ 
Ibudilast 4 ­­­ ¯¯ ­­ - 
Piclamilast 4 ­­ - ­­ - 
Roflumilast 4 ­­­ ¯ ­ ¯ 
Sildenafil 5 - ­ ¯ ¯ 
Tadalafil 5 - ­ ¯ ­ 
Caffeine 1,4,5 Bell-shape - - ¯ 
Zaprinast 5,6,9,11 ­ ¯¯ - ¯¯ 
TC3.6 7 - ¯ - ¯ 
BRL-50481 7 ­­ ¯¯ - ¯ 
BC 11-38 8 - - - - 
BAY-736691 9 - - - - 
PF-0449613 9 - - ¯ ¯ 
PF 2545920 10A - ­ - ¯ 
PF 04671536 11 - - - - 
IBMX Non-
selective 
­­ ¯¯¯ ­ ¯¯ 
­ = increase 10-30%, ­­ = increase 31-50%, ­­­= increase >50%, ¯: suppress 10-
30%, ¯¯: suppress 31-50%, ¯¯¯: suppress >50% 
 
 To determine whether there was any correlation between cAMP production and 
cell proliferation, the potency of each PDE inhibitor for cAMP production against the 
potency for the suppression of cell growth was plotted (Figure 3.11). Calculation of the 
Pearson’s correlation indicated there was a significant association between elevation 
of cAMP and anti-proliferative effect in both C6 cells (r = 0.83 (95% confidence interval 
0.46–0.95)) and ST14A cells (r = 0.97 (95% confidence interval (0.73–0.99)). Thus, 
these data suggest that increasing in intracellular concentration of cAMP prevents cell 
proliferation. 





Figure 3.11 Elevation of intracellular cAMP is positively correlated with cell 
growth suppression. Correlation (with 95% confidence interval) of log potencies of 
each PDE inhibitor in C6 (A) and ST14A cells (B) was determined by calculating 
Pearson’s correlation coefficient (r). Data are expressed as mean SEM of 4-8 individual 
repeats. 
 
In addition, to easily compare the PDE inhibitors and determine which would be 
suitable for further investigation, “selection criteria” was calculated by multiplying the 
terms of efficacy (span) and affinity (potency) for each of the compounds.  
A.































95% CI = 0.46 - 0.95
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95% CI = 0.73 - 0.99
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Figure 3.12 Illustration of how selection criteria are calculated. Displayed is 
cisplatin anti-proliferation curve on C6 cells, the selection criteria of cisplatin can be 
quantified by multiplying the terms of efficacy (span) and affinity (potency). 
 
These criteria are expressed as arbitrary units with 200 set as the lower threshold. All 
compounds that exceeded this number were considered worthy of further study. In this 
calculation, cisplatin, a non-selective cytotoxic agent, was used as a reference 
compound to validate this approach. Cisplatin exhibited a potent anti-proliferative effect 
in both cell lines (Figure 3.13 and Table 3.5), displaying the highest selection criteria 
values (582.1 in C6 cells and 511.1 in ST14A cells). This proves that this calculation 
may be beneficial in determining how efficacious the compounds are at inhibiting cell 
growth.  
According to selection criteria, the following compounds surpassed the 
threshold in C6 cells: vinpocetine (PDE1 inhibitor), amrinone, milrinone (both PDE3 
inhibitors), ibudilast (PDE4 inhibitor), trequinsin, IBMX and zaprinast (multiple PDE 
isoform inhibitors), BRL50481 (PDE7 inhibitor) and forskolin. A comparison of the PDE 
isoenzymes targeted by these inhibitors with the mRNA expression levels in C6 cells 
showed a good correlation (Figure 3.4). Following on from this, we set a selection 
criteria value of 350 as more rigorous threshold. Some compounds including forskolin, 
trequinsin, amrinone, and IBMX also passed this more stringent threshold. With the 
exception of amrinone, the aforementioned compounds are suggested to target other 
components out of cAMP synthesis and degradation pathways, thereby explaining 
their superior potency and efficacy. 
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Figure 3.13 Selection criteria of each PDE inhibitor including forskolin and 
cisplatin. Compound selection criteria from C6 (A) and ST14A cells (B) was calculated 
based on potency and efficacy in proliferation assay. The dashed lines represent 
threshold value of 200 (less stringent criteria) and the dotted lines a higher criteria 
value of 350. Individual data point was obtained from Figures 3.9 – 3.10 
 
While IBMX acts as non-selective PDE inhibitor, it also antagonises the action of the 
adenosine A1 receptor (Morgan, Murray and Challiss, 1993). Similarly, zaprinast - a 
non-selective PDE5,6,9,11 inhibitor, has also been reported to be a GPR35 agonist 
(Taniguchi, Tonai-Kachi and Shinjo, 2006). For this reason, IBMX and zaprinast were 
excluded from future investigations. In ST14A cells, all tested compounds showed 
lower selection criteria values, which was correlated well with the lower PDE 
expression compared to C6 cells (Figure 3.4). Taken together, compounds that are 
considerably efficacious in rat glioma models demonstrate reliance on the expression 
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3.5 Combinatorial effect of individual PDE2, PDE3, and PDE7 inhibitor was 
similar to that of, a multitarget PDE inhibitor trequinsin 
Trequinsin has been showing to be the most potent compound at increasing cAMP 
levels and suppressing cell growth in C6 and ST14A cells. Upon 72 h treatment with 
forskolin, cell density was lower, but in terms of cell morphology, there was no 
significant difference to that of vehicle control (Figure 3.14). There was a substantial 
feature that was observed under the microscope. The remaining cells were considered 
metabolically active demonstrated by limited absorbance in cell proliferation assay, but 
cells underwent significant morphological changes compared to either vehicle control 
or forskolin. However, this effect was not observed in trequinsin with lower 
concentration nor PDE inhibitor cocktail.  
  
 
Figure 3.14 Trequinsin may have potential toxic effect compared to forskolin at 
the same concentration. The figures are representative of C6 cells upon 72 h 
treatment with DMSO 1% as vehicle control, forskolin 100 μM, trequinsin 100 μM, and 
trequinsin trequinsin. Whilst the cell density was suppressed in forskolin treated group, 
Vehicle control (DMSO 1%) Forskolin 100μM
Trequinsin 100μM Trequinsin 10μM
100 μm 100 μm
100 μm100 μm
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morphological changes as well as cell condensation were observed in trequinsin 100 
μM group but not in trequinsin lower concentration. 
 
Although trequinsin is commonly known to inhibit mainly PDE3, another report 
suggests it also inhibits PDE2 and PDE 7 in hydrolysing cAMP (Rickles et al., 2010). 
However, there has not been any comprehensive study probing the mechanism of 
action of trequinsin. Therefore, in this study, further investigation was performed to 
address this particular aspect by using individual PDE2, PDE3, and PDE7 inhibitors – 
EHNA, amrinone, and BRL-50481.   
 
 
Figure 3.15 The effect of trequinsin on cAMP production and cell proliferation 
can be mimicked by combining PDE2, 3, and 7 inhibitors. cAMP accumulation was 
determined in C6 cells following 30-minute stimulation with EHNA, Amrinone, or BRL-
50481 alone (A), in pairs (B), or in combination (C). Data are expressed relative to 100 
µM forskolin. Cell survival was determined in C6 cells following 72 hours incubation 
with EHNA, Amrinone or BRL-50481 alone (D), in pairs (E), or combined (F). Data are 
expressed as percentage of cell proliferation relative to vehicle from 6-9 data sets. The 
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effect of trequinsin alone is displayed on each graph for comparison.  All data are the 
mean ± SEM of 6–9 individual repeats. 
 
In this experiment, C6 cells were stimulated with PDE inhibitors alone, in pairs, 
and combination of all three (PDE inhibitor cocktail). It is evident that none of the 
individual treatments displayed better activity than trequinsin in both cAMP signalling 
and cell proliferation, with all showing reduced potency and/or efficacy (detailed in 
Table 3.7). Although BRL-50481 was more potent in ligand-mediated cAMP 
accumulation (pEC50 6.20 ± 0.34), its span parameter was far less amongst the 
compound tested (13.86 ± 0.74 %). A similar pattern was also shown in cell 
proliferation. Despite having a similar maximal cAMP response to trequinsin, amrinone 
was only able to suppress cell proliferation by ~50% relative to trequinsin. Interestingly, 
although treatment in pairs did not equal the activity of trequinsin, the activity of 
compounds was improved compared to the individual treatments, indicated by a larger 
magnitude of cell growth suppression. When the individual PDE2, PDE3, and PDE7 
inhibitors were used in combination, surprisingly, the effect was comparable to that of 
trequinsin (Figure 3.14). It is clearer to see the improvement of efficacy/potency by 
comparing the selection criteria values from each treatment (Table 3.7). While the 
combination in pairs showed larger numbers compared to individual compounds, the 
PDE inhibitor cocktail (containing all three blockers) displayed a similar value to that of 
trequinsin. Taken together, these indicate that activity of trequinsin can be mimicked 




C6- proliferation assay-combinatorial effect of PDE2, 3, 7 inhibitors  
Compound cAMP accumulation assay  Proliferation Assay Selection 
criteria* pEC50 Span (%) pIC50 Span (%) 
Trequinsin 5.33 ± 0.11 46.3 ± 1.9 4.52 ± 0.11   91.21 ± 8.3 411.94 ± 38.52 
EHNA 4.91 ± 0.10 26.2 ± 0.9 4.20 ± 0.21   57.21 ± 10.5 240.44 ± 45.57 
Amrinone 4.58 ± 0.04 53.9 ± 1.6 3.94 ± 0.15   87.79 ± 13.6 346.01 ± 55.26 
BRL-50481 6.20 ± 0.34 13.9 ± 0.7 4.79 ± 0.17   47.02 ± 4.5 225.39 ± 22.73 
EHNA + 
amrinone 4.58 ± 0.03 62.5 ± 2.2 4.19 ± 0.17   85.97 ± 12.3 361.56 ± 53.66 
EHNA + 
BRL-50481 5.05 ± 0.20 27.2 ± 1.4 4.07 ± 0.13   77.77 ± 9.7 316.34 ± 40.85 
Amrinone + 




4.58 ± 0.07 64.9 ± 1.8 4.52 ± 0.14   84.64 ± 8.7 382.12 ± 41.10 
Data are expressed as mean ± SEM from 7-10 individual data.  
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* Compound selection criteria was calculated based on potency and efficacy in 
proliferation assay (data obtained from Figure 3.14). 
 
3.6 Targeting both adenylyl cyclase and phosphodiesterase enhances anti-
proliferative effect 
According to previous data, growth-inhibitory actions in C6 glioma cells were mediated 
by activation of AC that directly synthesises cAMP or through prevention of cAMP 
degradation by inhibition of PDEs. Therefore, this study was extended to investigate if 
concomitant targeting of AC and PDEs may synergistically suppress cell proliferation. 
To do this, cells were exposed simultaneously to forskolin and trequinsin. The 
combinatorial effect was evaluated through measurement of cAMP accumulation and 
cell proliferation.  
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Figure 3.16 Forskolin and trequinsin act synergistically to increase cAMP 
accumulation and suppress cell growth. A. Concentration-dependent effect of 
trequinsin upon cAMP accumulation in C6 cells following 30 min stimulation with 
forskolin. Data are expressed relative to 100 µM forskolin in the absence of trequinsin. 
B. Concentration-dependent inhibitory effect of trequinsin on C6 cell growth following 
72-hour incubation with forskolin. Data are expressed as percentage cell survival 
relative to vehicle. C. pIC50 values for individual cell survival curves for each treatment 
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as statistically different (ns, not significant; ***, p<0.001) compared to forskolin using 
one-way ANOVA followed by Dunnett’s post-hoc analysis. TRQ – trequinsin.  
 
In general, the effects of the co-treatment of forskolin and trequinsin was similarly on 
both cAMP assay and cell proliferation (Figure 3.16). Regarding cAMP accumulation 
assay, the baseline level was increased in a dose-dependent manner (Figure 3.16A). 
It is worth noting that the assay was conducted as end-point measurement. Therefore, 
an increase in basal levels may occurred due to accumulation of cAMP that was not 
degraded by trequinsin. Not only did combination elevate accumulation of cAMP levels 
(Figure 3.16A), it also dose-dependently increased the anti-proliferative effect (Figure 
3.16B and C). The addition of trequinsin synergistically potentiated forskolin-mediated 
cell growth suppression, with the potency (pIC50) of forskolin with 10 μM trequinsin was 
enhanced to 6.87 ± 0.13 compared to 5.75 ± 0.07 for forskolin only. Of note, co-
treatment of forskolin with trequinsin also elevated baseline level in cAMP 
accumulation assay. Trequinsin as multiple PDE inhibitor prevents the breakdown of 
produced cAMP. As mentioned previously, this assay was performed as end-point 
experiment, so that the elevated basal level was most likely due to accumulation of 
cAMP over 30-minute stimulation. In addition, cell growth was also suppressed in the 
combination of forskolin and trequinsin 10 µM. The observable effect at the lowest 
concentration of forskolin was possibly a result of trequinsin activity alone. Taken 
together, these data proved that targeting both AC and PDEs exhibiting synergistically 
increases cAMP signalling and enhances the magnitude of growth suppression.  
 
3.7 Blockade of cAMP export enhances the anti-proliferative effect of forskolin, 
trequinsin, and the PDE inhibitor cocktail 
The spatiotemporal signalling of cAMP is also controlled by an ATP-binding cassette 
(ABC) transporter, such as multidrug resistant protein 4 (MRP4). These proteins act 
as drug efflux transporters that are responsible for the transport of cAMP into the 
extracellular environment. As previously mentioned, brain tumour tissues have 
significantly lower concentration of cAMP (about 25%) compared to normal healthy 
brain tissue. Interestingly, C6 cells were reported to overexpress multidrug resistant 
protein 4 (MRP4), which may contribute to the lower content of cAMP. Thus, the study 
was extended to investigate if retaining cAMP within the intracellular compartment by 
pre-treating cells with PU23, an MRP4 inhibitor, will modulate cAMP levels and thus 
cell growth.  
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 To determine the effect of cAMP efflux pump, the PDE inhibitor cocktail was 
also appended. Since there is potential toxic consequence by trequinsin, it was 
necessary to investigate if there are any differences between trequinsin and 
combination of PDE inhibitor on cAMP in extra- and intra-cellular regions.  
The concentration of cAMP was monitored for 1h and 2h time-point in forskolin, 
whereas trequinsin and PDE inhibitor cocktail was evaluated for over 2h to increase 
window of observation. Upon 1h or 2h stimulation, pre-treatment with PU23 resulted in 
a dose-dependent reduction of extracellular cAMP levels compared to forskolin/ 
trequinsin/ PDE inhibitor cocktail alone (Table 3.8). Forskolin induced cAMP production 
up to 3 μM, with less than 1 μM of cAMP were detected extracellularly (Figure 3.17A).  
Without inhibiting cAMP efflux pump, cAMP was transported into extracellular 
compartment, whereas it was degraded intracellularly by the absence of PDE inhibitor 
(Figure 3.17B). The co-treatment of PU23 and forskolin marginally affected cAMP 
levels within the cells after 1h stimulation, interestingly, PU23 dose dependently 
reduced concentration of extracellular cAMP (Figure 3.17A). The clearer responses 
were observed over 2 h stimulation by forskolin where PU23 not only reduced the 
cAMP from being expelled, but also retained it in the intracellular compartment (Figure 
3.17B). In general, intracellular levels of cAMP were slightly higher in PU23-treated 
cells in both trequinsin and PDE-inhibitor cocktail group (Figure 3.17 and Table 3.8).  
When it comes to cell growth, co-treatment with PU23 also mediated dose-
dependently anti-proliferative effect. These results suggest that in normal 
circumstances without PDE inhibitors, blockade of cAMP efflux transporter maintains 
higher levels of intracellular cAMP.  
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Figure 3.17 Inhibiting MRP4 transporter elevates intracellular levels of cAMP in 
C6 cells. Extracellular and intracellular cAMP levels from C6 cells following stimulation 
with; forskolin for 1h (A) and 2h (B); trequinsin for 2h (C); or PDE inhibitor cocktail for 
2h (D), in the presence and absence of a range of concentrations of the MRP4 inhibitor, 
PU23. All data are the mean ± SEM of 4-8 individual repeats. FSK – forskolin, TRQ – 
trequinsin. Additional repeats for this experiment were performed together with Dr. Ho 
Yang Yeung (University of Cambridge). 
 
Table 3.8 
Concentration of intra- and extra-cellular of cAMP in cells treated with forskolin, 
trequinsin, or PDE inhibitor cocktail in the absence or in the presence of PU23, an 
MRP4 inhibitor 
Group cAMP concentration (nM per 106 cells) 
Intracellular Extracellular 
Forskolin – 1h   
Without inhibitor         3058.00 ± 90.49 900.50 ± 84.75 
+PU23 10 μM 2232.00 ± 112.40           181.70 ± 8.08 
+PU23 3.16 μM         1918.00 ± 89.75 368.40 ± 46.61 
+PU23 1 μM 3057.00 ± 240.60 648.50 ± 30.88 
Untreated 102.20 ± 16.22             34.92 ± 3.79 
   
Forskolin – 2h   
Without inhibitor             65.72 ± 12.04   425.3 ± 37.68 
+PU23 10 μM 701.20 ± 97.98 343.30 ± 45.37 
+PU23 3.16 μM 565.10 ± 12.61 473.60 ± 61.49 
+PU23 1 μM             93.30 ± 9.45 573.50 ± 84.97 
Untreated               8.36 ± 0.00 N.R. 
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Group cAMP concentration (nM per 106 cells) 
Intracellular Extracellular 
Trequinsin – 2h   
Without inhibitor 238.20 ± 30.57 128.90 ± 17.35 
+PU23 10 μM 244.10 ± 24.07             37.84 ± 12.40 
+PU23 3.16 μM 313.10 ± 20.79             58.81 ± 7.56 
+PU23 1 μM 325.50 ± 15.51   93.33 ± 18.02 
Untreated 21.15 ± 1.58 34.45 ± 2.47 
   
PDE inhibitor 
cocktail – 2h 
  
Without inhibitor 190.40 ± 21.46 154.50 ± 18.11 
+PU23 10 μM           237.90 ± 7.97 71.66 ± 9.39 
+PU23 3.16 μM 222.60 ± 14.48 111.10 ± 12.50 
+PU23 1 μM 214.40 ± 21.12 147.60 ± 13.72 
Untreated 49.83 ± 9.59 28.42 ± 7.68 
N.R. – no results because the values were undetectable 
Data are expressed as mean ± SEM of 4-8 individual data. Concentration of cAMP in 
both extracellular and intracellular have been recalculated to the standard curve and 
is expressed in nM unit per 106 cells.  
 
Combination with forskolin, trequinsin, or the PDE inhibitor cocktail potentiated 
anti-proliferative effects compared to each compound alone (Figure 3.18). Forskolin, 
in the absence of PU23 dose-dependently suppressed cell growth displaying potency 
of 5.39 ± 0.88. It was only PU23 10 μM that potentiated forskolin-mediated 
antiproliferative effect. While there was no significant effect on potency/span values 
while forskolin is combined with PU23 1 μM, the span of inhibitory effect is significantly 
reduced from 95.12 ± 3.55 % to 36.27 ± 1.43 % and 60.74 ± 3.83 % in combination 
with PU23 10μM and 3 μM, respectively (Table 3.8). The similar pattern was also 
observed in trequinsin- and PDE inhibitor cocktail- treated cells. While co-treatment 
with PU23 1 μM barely affected anti-proliferative effect of the compounds, the presence 
of MRP4 inhibitor both 10 μM and 3 μM increased potency of trequinsin and 
combination of PDE inhibitor (table 3.8). In conclusion, efforts to increase intracellular 
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Figure 3.18 Elevation of intracellular cAMP by inhibiting its efflux is correlated 
with cell growth suppression in C6 cells. Survival of C6 cells following 72-hour 
treatment with forskolin (A), trequinsin (B), or PDE inhibitor cocktail (C) in the absence 
and presence of increasing concentrations of PU23, an MRP4 inhibitor. Data are 
expressed as percentage cell survival relative to vehicle. All data are the mean ± SEM 
of 4-8 individual repeats. FSK – forskolin, TRQ – trequinsin.  
 
Table 3.9 
Pharmacological parameter of forskolin, trequinsin, PDE inhibitor cocktail on 








Forskolin      
No inhibitor   7.18 ± 3.38 102.30 ± 1.63 5.40 ± 0.08    95.1 ± 3.6 8 
PU23 10μM 13.33 ± 0.97   49.60 ± 1.15 6.05 ± 0.07*** 36.3 ± 1.4*** 7 
PU23 3μM 11.75 ± 3.63   72.49 ± 1.88 5.39 ± 0.13 60.7 ± 3.8*** 7 
PU23 1μM 13.22 ± 4.10   98.65 ± 2.22 5.45 ±0.11    85.4 ± 4.4 8       
Trequinsin      
No inhibitor 10.60 ± 1.05   89.4 ± 2.01  4.07 ± 0.30     89.4 ± 1.0 3 
PU23 10μM   7.35 ± 1.56 50.54 ± 2.21 4.97 ± 0.10**  50.5 ± 1.2** 6 
PU23 3μM   7.80 ± 1.67 67.51 ± 6.49  4.70 ± 0.29*     67.5 ± 8.1 7 
PU23 1μM 12.21 ± 0.86 78.67 ± 2.62  4.03 ± 0.36     78.7 ± 1.4 3       
PDE inhibitor cocktail      
No inhibitor 20.43 ± 6.60 90.33 ± 1.50 4.65 ± 0.14    69.9 ± 6.5 4 
PU23 10μM 24.05 ± 3.26 51.70 ± 2.35 5.87 ± 0.29* 27.6 ± 3.8*** 4 
PU23 3μM 21.56 ± 5.60 64.29 ± 2.10 4.98 ± 0.28 42.7 ± 5.7*** 4 
PU23 1μM 15.14 ± 8.64 87.42 ± 2.05 4.66 ± 0.18    72.3 ± 8.5 4 
Data are expressed as the mean ± SEM of n individual data 
Data were determined as statistically different (*, p<0.05; **, p<0.01; ***, p<0.001) 
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3.8 Anti-proliferative effects of forskolin and PDE inhibitors are predominantly 
mediated through the cAMP/PKA signalling pathway  
To delineate which downstream pathways are involved in cAMP-mediated cell growth 
suppression, small molecule inhibitors of cAMP and cGMP downstream effectors was 
utilised, including inhibitors against PKA, Epac, GC activation and PKG. KT5720 was 
selected to inhibit PKA, ESI-09 to non-selectively block both Epac subtypes, CE3F4 




Figure 3.19 Forskolin, trequinsin, or PDE inhibitor cocktail-mediated anti-
proliferative effect was partially rescued by PKA inhibitor, but not EPAC or PKG 
inhibitor. Cell survival was determined in C6 cells following 72 hours incubation with 
forskolin (A), trequinsin (B), or a combination of PDE2,3,7 inhibitors (C) in the presence 
of either KT5720 (10 µM), ESI-09 (10 µM), CE3F4 (10 µM), HJC0350 (10 µM), KT5823 
(10 µM), BAY41-8543 (10 µM). Data are represented as dose response curve relative 
to control vehicle. KT5720 – PKA inhibitor, ESI-09 - non-selective Epac1/2 inhibitor, 
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CE3F4 – Epac1 inhibitor, HJC0350 - Epac2 inhibitor, KT5823 PKG inhibitor, BAY41-
8543 – GC activator. 
 
Individual dose-response curves for cell proliferation (Figure 3.19) showed that 
co-treatment with KT5720 attenuated the anti-proliferative effect of forskolin, indicated 
by reduction in potency from 4.95 ± 0.09 to 4.53 ± 0.08 (Table 3.9, p<0.01). The similar 
pattern was also displayed in trequinsin- and PDE inhibitor cocktail- treated cells. 
Whilst the potency (pIC50) of trequinsin was 4.80 ± 0.03, co-treatment with KT5720 
reduced trequinsin-mediated anti-proliferation potency to 4.60 ± 0.03 (Table 3.9, 
p<0.001). The presence of PKA inhibitor also attenuated antiproliferative effect of the 
inhibitor cocktail to pIC50: 4.49 ± 0.03 compared to the compound alone 4.74 ± 0.09 
(Table 3.9, p<0.05). 
Dual or selective inhibition of Epac did not significantly affect the cell growth 
response, with the exception of when ESI-09 or CE3F4 with trequinsin (Figure 3.19B) 
indicated by smaller spans, although no difference was observed in its potency (Table 
3.9 and Figure 3.20). Interestingly, concurrent treatment with KT5823, a PKG inhibitor 
enhanced cell growth suppression compared to all individual treatments indicated by 
smaller span, but no potentiation on pIC50 on forskolin and trequinsin-treated cells were 
observed (Table 3.9, p<0.01 in forskolin group, p<0.001 in both trequinsin and 
combination of PDE inhibitors). Whereas BAY 41-8543 increased potency in forskolin-
treated cells (p<0.01), but not other groups. The suppression of cell growth in 
combination with KT5823 suggest that it may not purely inhibit the activity of PKG. The 
effect of GC inhibition on the forskolin response indicates a possible involvement of 
GC/cGMP pathway in cell proliferation. All data suggest that suppression in cell growth 
is mainly mediated through the cAMP/PKA-dependent pathway.  
 
Table 3.10 
Pharmacological parameters of forskolin, trequinsin, and PDE inhibitor cocktail in the 
absence and presence inhibitors targeting downstream effectors of cAMP and cGMP 
signalling  
Group pIC50 Span (%) n 
Forskolin    
No inhibitor         4.95 ± 0.09            83.6 ± 3.3 16 
+ KT5720         4.53 ± 0.08**            75.4 ± 3.7 20 
+ ESI-09         5.31 ± 0.12            74.1 ± 3.9 8 
+ CE3F4         5.42 ± 0.12**            70.0 ± 3.1 7 
+ HJC0350         4.82 ± 0.06            90.4 ± 4.6 8 
+ KT5823  5.66 ± 0.12*** 58.6 ± 4.9** 7 
+ BAY 41-8543         5.43 ± 0.10**            74.9 ± 2.8 7 
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Group pIC50 Span (%) n 
    
Trequinsin    
No inhibitor         4.80 ± 0.03          101.3 ± 2.8 9 
+ KT5720  4.60 ± 0.03***          103.0 ± 2.5 9 
+ ESI-09         4.81 ± 0.02   76.9 ± 1.0*** 7 
+ CE3F4         4.89 ± 0.04   75.8 ± 2.6*** 9 
+ HJC0350         4.87 ± 0.04            96.9 ± 1.2 9 
+ KT5823  5.48 ± 0.03***   50.2 ± 1.4*** 9 
+ BAY 41-8543         4.72 ± 0.03            90.0 ± 0.0 7 
    
PDE inhibitor 
cocktail 
   
No inhibitor          4.74 ± 0.09           87.4 ± 2.7 9 
+ KT5720  4.49 ± 0.03*           73.4 ± 2.0* 9 
+ ESI-09          4.65 ± 0.04           80.8 ± 2.5 8 
+ CE3F4          4.51 ± 0.05           83.3 ± 3.9 9 
+ HJC0350          4.68 ± 0.10           75.0 ± 6.4 8 
+ KT5823          4.82 ± 0.04 62.3 ± 2.9*** 8 
+ BAY 41-8543          4.66 ± 0.04           85.4 ± 3.3 6 
Values are generated from n individual data after curve fitting from Figure. 3.21 and 
are expressed as mean ± SEM. Data were determined as statistically different (*, p< 
0.05; **, p<0.01; ***, p<0.001) compared to in the absence of compounds using one-
way ANOVA followed by Dunnett’s post-hoc analysis. 







Figure 3.20 The effect of downstream effectors of cAMP and cGMP on forskolin and trequinsin-mediated cell growth suppression 
of C6 cells. Cell survival was determined in C6 cells following 72 hours incubation with forskolin (A), trequinsin (B), or a combination of 
PDE2,3,7 inhibitors (C) in the presence either KT5720 (10 µM), ESI-09 (10 µM), CE3F4 (10 µM), HJC0350 (10 µM), KT5823 (10 µM), or 
BAY41-8543 (10 µM). Data are represented as individual pIC50 values for anti-proliferation curves for each treatment condition (Fig, 3.20). 
Data were determined as statistically different (ns, not significant; *, p< 0.05; **, p<0.01; ***, p<0.001) compared to in the absence of 
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3.9 Trequinsin, but not forskolin or the PDE inhibitor cocktail, has cAMP-
independent actions leading to apoptosis  
Having confirmed strong association between cAMP signalling and anti-proliferative 
effect, we sought to determine the mechanism of how forskolin, trequinsin, and the 
PDE inhibitor cocktail inhibit cell growth. To do this, the effects of the compounds on 
apoptosis and cell death were explored.  
 Apoptosis is a cell death programme that is activated if there are any 
abnormalities within cells. Caspase activity, especially caspase-3 and -7, has been 
reported to be a biomarker to detect early apoptosis. To detect activation of caspase-
3 and -7, treated cells were labelled with CellEventTM Caspase-3/-7 and the number of 
cells that positively emitted fluorescence (green) was counted using the appropriate 
filter (Figure 3.21). Cells were also stained with nuclei-dye Hoechst 3342 to determine 
total cell number (cells in blue), and propidium iodide (PI) to label non-viable cells (in 
red) (Figure 3.21).  
 
 
Figure 3.21 Representative figure of C6 cells after 72 hours treatment and were 
subsequently loaded with 2 μM CellEvent TM caspase-3/-7. Representative figures 
of C6 cells were displayed after being treated with Staurosporine 1 μM in comparison 
with complete media. Images were taken using BD Pathway 855 Biomiaging Systems 
utilising 3 different filters to visualise total cell number (using Hoescht filter), activated 
caspase-3/-7 (using FITC filter), and dead cells (using propidium iodide (PI) filter). 
Arrows pointed to cells that were labelled as positive caspase-3/7 (green) or non-viable 
cells (red). The number of activated caspase-3/-7 or dead cells were counted and 
subsequently normalised to total cell number. Percentage of cell population for each 
treatment was summarised in Figure 3.22 as the mean ± SEM.  


















Chapter 3                                                                                      PDE inhibition in glioma cells 
 127 
 
 Staurosporine, a pan-caspase activator was used as the reference compound. 
As displayed in Figure 3.21, cells that were cultured in complete media showed many 
cells with a minimal number of dead cells and/or with activated caspase-3/-7. In 
contrast, cells that were treated with staurosporine were far less numerous, indicating 
cell death and significant caspase-3/-7 activation. This finding is also supported by PI 
staining showing that all cells with activated caspase-3/-7 were dead. Using the same 
method, the cell population with activated caspase-3/-7 and dead cells were quantified 
in similar method for all treated groups and the summary was in Figure 3.22. While 
treatment with forskolin or the PDE inhibitor cocktail resulted in <10% of the population 
with activated caspase, only trequinsin 100 μM-treated cells showed a comparable 
response to that of staurosporine (Figure 3.22). These data indicate that trequinsin at 
a high dose may have non-specific actions leading to cell death, which is not observed 
for forskolin or the combination of PDE inhibitors.  
 
 
Figure 3.22 Population of dead cells and activity of caspase-3/7 in C6 cells after 
72 h treatment. Percentage of dead cells determined by staining with propidium iodide 
and the percentage of cells with activated caspase-3/7, visualised by CellEventTM 
caspase-3/7. All values are normalised to total cell number in each well. Staurosporine 
1 µM was used as a control for apoptotic cell death and cause 100% dead cells. All 
data are the mean ± SEM of 4-5 individual data. FSK – forskolin, TRQ – trequinsin, 
STR – staurosporine. 
 
3.10 Elevated intracellular cAMP induces growth arrest at the G2/M phase of the 
cell cycle 
In the previous section, it has been shown that elevation of cAMP by forskolin or PDE 
inhibitor cocktail did not lead to apoptosis, in contrast to trequinsin at a higher dose 
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forskolin-, PDE inhibitor cocktail-, and trequinsin low dose- treated cells may relate to 
the compounds effect on the cell cycle. 
In normal cell cycle, about 60% of cell population were distributed in G0/G1 
phase, where approximately 35% were evenly distributed between G2/M and S phase, 
and a very little amount of aneuploids. Interestingly, forskolin and PDE inhibitor cocktail 
altered cell cycle distribution thus cells were arrested at G2/M phase up to ~70%. 
Whereas about 70% of cells became aneuploid in trequinsin-treated group. There was 
dose-dependent improvement on cell cycle distribution while lower concentration of 
compounds was used (Figure 3.23). 
Further confirmation by FACS analysis, corroborated the findings from the 
previous section, whereby the dead cells population was dominantly observed in cells 
treated with 100 μM trequinsin. The population of alive cells treated with trequinsin at 
a high dose were arrested in G2/M phase and remaining cells were found to be in 
aneuploid. Cells were predominantly arrested in G2/M phase, further suggesting non-
apoptotic effect of forskolin and the PDE inhibitor cocktail. These results were also 
aligned with results in previous section (Figure 3.22). We concluded that both forskolin 
and the combination of PDE2, PDE3, and PDE7 inhibitor alter cell cycle by a similar 
mechanism. However, it is possible that the apoptotic effect of 100 μM trequinsin is 
independently related to the cAMP pathway.  
 
 
Chapter 3                                                                                      PDE inhibition in glioma cells 
 129 
 
Figure 3.23 Cell cycle analysis by flow cytometry after PI staining. Representative 
histograms of cell cycle distribution of C6 cells were displayed with selected treatment 
(A). Histograms of cells following treatment with forskolin (B), trequinsin (C), or 
PDE2,3,7 inhibitor cocktail (D) for 72 h. The percentage of cell distribution for each 
treatment include G1, S, G2/M, and dead cell population (n= 4-8 individual data). All 
data are the mean ± SEM. FSK – forskolin, TRQ – trequinsin, STR – staurosporine. 
 
3.11 Discussion 
As a secondary messenger, both cAMP and cGMP control a plethora of both 
physiological and pathological responses (Sutherland, 1972) which also include 
reparative processes and cell proliferation. However, the incongruity of cAMP effect on 
cell growth have been reported which seems to be depending on cell types and the 
machinery of the selected cells (Cullen et al., 2004; Lerner and Epstein, 2006; Sawa 
et al., 2017). External and internal factors including stimulus, intracellular effector of 
cAMP, and compartmentalisations appear to be the reason of divergent effect of cAMP 
(Insel et al., 2012). As mentioned early on, cAMP concentration in brain tumpurs is 4-
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hypothesised that increasing intracellular concentration of cAMP may have beneficial 
effect in preventing cell growth.  
 
3.11.1 C6 cells as a suitable model to investigate role of PDE isoenzymes in 
glioblastoma  
Although C6 cells were originally derived from rats, their genotypic and phenotypic 
features resemble human glioblastoma (Grobben, De Deyn and Slegers, 2002). 
Therefore, most of the studies have used C6 cells to study tumour characteristic before 
moving forward to use human tissues. In terms of practicality to further investigate it in 
animal models, C6 cells have been widely explored as in vivo models to provide better 
resemblance with humans.   
 As previously mentioned, a reduction in cAMP concentration is found in brain 
tumour tissues. Besides, from the clinical studies collected from TCGA (details in 
chapter 1), PDE expression in brain tissues from glioblastoma patients was either 
upregulated or mutated. This data base may explain one factor that contributes to a 
lower level of cAMP in glioblastoma tissue. Having confirmed by rt-PCR (Figure 3.3), 
C6 cells showed higher expression of PDE at mRNA level than ST14A, rat medium 
spiny neurons as a comparison. This observation justifies that C6 cells can be used for 
further experimental validation to look over PDE roles in glioblastoma models. 
 
3.11.2 Elevation of intracellular cAMP through PDE inhibition or AC stimulation 
elicited a more potent anti-proliferative effect compared to modulating at 
GPCR levels or G proteins 
In this study, direct activation on AC or inhibition on PDE activity has been proven to 
exhibit to increase cAMP accumulation and suppress glioma cell proliferation. Other 
strategies to modulate G protein-mediated AC activation through. Although activation 
of Gs-coupled β-ARs by isoprenaline or modulation of G protein activity by PTx or CTx 
could elevate cAMP levels, none of them significantly demonstrated better efficacy in 
suppressing glioma cell growth. Targeting receptor or G proteins in this particular study 
seems to trigger transient activation of cAMP effectors, receptor desensitisation, or 
spatial localisation of cAMP within the cells that prevent further growth signalling. Not 
only does sustained stimulation using GPCR agonists cause receptor desensitisation, 
but it also may results in receptor downregulation because of changes in transcription 
levels (Hausdorff, Caron and Lefkowitz, 1990). It is also worth noting the chemical 
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instability of isoprenaline in aqueous solution may account for this effect; therefore, 
antioxidant addition may be beneficial to prevent degradation of isoprenaline. 
 
3.11.3 The efficacy of PDE inhibitors demonstrates reliance on PDE expression 
profile 
ST14A cells appeared to be more responsive than C6 cells by stimulation of forskolin 
indicated by smaller pEC20 value (section 3.4.1). Since ST14A cells are considered 
normal and healthy cells, they have lower basal levels of cAMP; therefore, cells appear 
to be more responsive when stimulated by AC activator. Given that ST14A cells also 
expressed less PDE isoforms than C6 cells, ST14A cells may not possess sufficient 
tuning mechanism to control stimulation by cAMP. It is also worth noting there is a 
possibility that AC expression is higher in ST14A cells. However, this notion needs to 
be confirmed further. 
This study is the first to dissect the pharmacological roles of PDEs in C6 glioma 
cells. As displayed in Figure 3.3, both C6 and ST14A expressed most PDE 
isoenzymes. As for PDE6, because these enzymes are specifically expressed in the 
eyes and involved in phototransduction (Zhang et al., 2015), the role of PDE6 was 
exclude. However, specific inhibition on cAMP or cGMP PDEs showed minimal effects 
on cell proliferation, except ibudilast (cAMP-specific PDE4 inhibitor). While inhibition of 
PDE1, PDE2, PDE3, PDE4 and PDE7 increased cAMP accumulation in par with a 
more significant cell growth suppression. Apart from PDE4 and PDE7, PDEs 
mentioned earlier are known as dual-substrate PDE hydrolysing both cAMP and 
cGMP. This PDE category provides a function for crosstalk between both second 
messengers and possess distinct tuning mechanism (Surapisitchat et al., 2007; 
Francis et al., 2010).  
 
3.11.4 Trequinsin as multiple PDE inhibitor may have the potential effect that is 
independent of cAMP/PKA and can be counteracted by combining 
individual PDE2, PDE3, and PDE7 inhibitor 
Although trequinsin is firstly known as a PDE3 inhibitor, for the first time, this study has 
revealed the possible mechanism of action of trequinsin through multiple inhibitions of 
PDE2, PDE3, and PDE7. While there is a possibility of toxic effect by trequinsin, the 
combination of individual PDE2, PDE3, and PDE7 inhibitor exhibited similar affinity and 
efficacy in cAMP and cell proliferation assays to that of trequinsin. These effects, 
however, were less profound in either individual treatment or as in pair. Not only did 
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the PDE inhibitor cocktail showed similar efficacy, but also without significant toxic 
effect in C6 glioma cells. Trequinsin, especially at higher concentration, caused 
caspase activation leading to apoptosis. Although the cell number with activated 
caspase-3/7 in cocktail-treated cells is higher than that of forskolin, this effect was far 
less than trequinsin, the observable effect is likely due to available PDEs become 
caspase substrate (Lerner and Epstein, 2006) 
 Using several pharmacological tools, it appears that the observed effect of 
forskolin is mediated through cAMP/PKA pathways. This also applies to trequinsin and 
PDE inhibitor cocktails. cAMP has been known to preferentially bind to PKA over 
Epac1/2 with the affinity towards PKA to be 5 – 24.6 nM and 4μM/1.2 μM towards 
Epac1/2 (Bubis, Saraswat and Taylor, 1988; Ringheim and Taylor, 1990; de Rooij et 
al., 1998). Taken together, both stimulation at AC and inhibition of PDE induce the 
elevation of cAMP intracellularly, therefore PKA pathway may be prominently activated 
with the minor involvement of Epac1/2 leading to cell growth suppression. Anti-
proliferative effect of cAMP also has been reported to involve complex mechanism 
between PKA, MAPK/ERK, and CDK2 (Vadiveloo et al., 1997; Favot et al., 2003). 
Cotreatment with PKG inhibitor, surprisingly, potentiated anti-proliferative effect of 
forskolin, trequinsin, and PDE inhibitor cocktail. Since some of PDEs act as dual 
substrate enzymes, it is possible that the effect was likely generated from cross-talk 
between secondary messengers.   
 Although PDE2 and PDE3 are known as dual substrate enzymes, the 
mechanism of regulation is distinct depending on cGMP concentration. Whilst 
hydrolysis rate of cAMP is allosterically modulated by cGMP at PDE2 (affinity 1-5 µM), 
cGMP has a higher affinity to the catalytic site of PDE3 (180 nM) and elicited 
competitive binding at the same binding pocket of PDE3 with cAMP. (K Omori and 
Kotera, 2007b; T Keravis and Lugnier, 2012). Since C6 cells have weaker liability to 
produce cGMP, a moderate elevation on cGMP levels is likely to compete with cAMP 
to bind to the same catalytic sites, leading to slower degradation of cAMP by these 
particular PDEs. These events may predominantly activate PKA due to the net 
elevation of cAMP within the intracellular compartment. Subsequently, sustained 
elevation of intracellular cAMP through PDE inhibition may provide an adequate signal 
to promote anti-proliferative effect.  
 Whilst co-treatment using PKG inhibitor or GC activator enhances forskolin- and 
trequinsin-mediated cell growth suppression, no significant effect was observed in 
cocktail-treated cells.  Despite there is a possibility that KT5823, a PKG inhibitor, does 
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not selectively inhibit PKG, the cellular compartmentalisation should be taken into 
account to explain the functional effect of PDE inhibitor cocktails. An increase in cGMP 
concentration may occur in particular regions leading to local activation of PKA, 
possibly via anchoring proteins (AKAP) that is specifically distributed into the different 
intracellular compartment (T Keravis and Lugnier, 2012). Indeed, this notion needs 
further investigation.  
 
3.11.5 Forskolin and PDE inhibitor induces cell growth arrest 
Whilst high doses of trequinsin caused caspase-3/7-dependent apoptosis, neither 
forskolin nor the PDE inhibitor cocktail showed substantial death upon 72 h treatment. 
In the case of trequinsin 100μM, it is possible that rapid and large elevation of cAMP 
causes cell failure to go through the normal cell cycle and unable to exit mitotic point. 
Although there have been no studies on the mechanism of trequinsin-mediated 
apoptosis and aneuploidy, it is suggested that PDE inhibitor may activate protein 
phosphatase 2A (PP2A) and Bim/BAD expression through phosphorylation of PKA 
which in the end activate caspase and promote apoptosis (Lerner and Epstein, 2006). 
Cells treated by forskolin and combination of PDE2, PDE3, and PDE7 were trapped 
prominently in G2/M, demonstrating the possibility of failure to synthesise essential 
proteins for replication. 
 
3.11.6 Modulation to increase cAMP concentration leads to negative regulation 
on cell growth 
Although trequinsin may pose potential toxic effects, its ability to inhibit multiple PDEs 
is considerably better, displayed as the most potent PDE inhibitor to modulate both 
cAMP accumulation and cell growth suppression. To minimise the compound toxicity, 
the synergistic combination can be applied without compromising the efficacy and 
selectivity. In the previous section, it has been proven that the combination of forskolin 
and trequinsin can increase cAMP levels and display negative effect on cell 
proliferation. The combinatorial effect was shown to be better than forskolin alone, 
therefore the dose of each compound could be reduced.  
Another effort to increase intracellular cAMP was conducted by targeting cAMP 
efflux transporter, namely MRP4. It is evident that this pump protein controls cAMP 
signalling and by blocking its activity, cAMP remains trapped within intracellular 
regions. The cAMP concentration was enhanced in all treated cells with forskolin, 
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trequinsin, and PDE inhibitor cocktail. The augmentation of cAMP has also potentiated 
the anti-proliferative action of each group. 
 
3.11.7 Conclusion 
This study has been conducted using pharmacological tools to explore potential roles 
of cAMP in inhibiting glioma cell growth. Forskolin elevated concentration of cAMP 
intracellularly which led to activation of PKA and altered cell cycle distribution. Whereas 
trequinsin as potent multiple PDE inhibitors not only elicited anti-proliferative effect 
through cAMP/PKA pathways, but also activated caspase-3/7 and induced cell death.  
Taken together, it is evident that trequinsin possess toxic effect that is independent 
from cAMP/PKA signaling. Combination of PDE2, PDE3, and PDE7 inhibitor has 
shown to be an alternative to trequinsin. The efficacy of PDE inhibitor cocktail is 
equipotent to that of trequinsin in glioma cells without having substantial toxic effect. In 
addition, synergistic mechanism is also found to potentiate cell growth suppression by 
concomitant targeting at AC and PDEs, therefore provides other strategies to minimise 
the adverse effect of trequinsin.  
 
3.12 Summary 
It has been reported that many signalling pathways are involved in malignancy leading 
to brain tumours. One of the abnormalities that was of interest on this study was the 
influence of the concentration of intracellular cAMP. Having reported to be associated 
with severity of malignancy, cancer cells have specific mechanism to maintain lower 
levels of cAMP. Here, we report findings to show that there is an association between 
increasing intracellular cAMP and suppression of cell proliferation.  
 Concentration of cAMP is tightly controlled by homeostasis between its 
synthesis and degradation. As a secondary messenger, cAMP also undergoes cross-
talk mechanism with cGMP through sequestration of non-specific PDEs. Firstly, the 
investigation has been made covering direct activation on AC and activation on beta-
adrenergic receptor and heterotrimeric G proteins. Secondly, we also look at the 
functionality of each PDE isoenzymes using small molecule inhibitors to tease out 
which PDEs are involved. This study also covered the possible mechanism between 
cAMP and cGMP in regulating cAMP levels as well as cell growth.  
 Although we have shown that GPCR or G protein-mediated cAMP elevation 
suppresses C6 cell growth, PDE inhibition and direct activation on AC demonstrate 
greater anti-proliferative effects. Forskolin supresses cell growth in a PKA-dependent 
Chapter 3                                                                                      PDE inhibition in glioma cells 
 135 
manner by inducing cell arrest at G2/M phase. In contrast, trequinsin (a non-selective 
PDE2, PDE3, and PDE7 inhibitor), not only inhibited cell growth via PKA, but also 
stimulated caspase-3/-7 independently of the cAMP/PKA pathway. Treatment with 
trequinsin was also shown to induce C6 cells to be aneuploidy phenotype. 
Interestingly, a cocktail of individual PDE2, PDE3, and PDE7 inhibitors suppressed cell 
growth in similar mechanism to forskolin. In addition, the PDE inhibitor cocktail activity 
is similar to that of trequinsin but without significant toxicity. Finally, we demonstrate 
that concomitant targeting of both AC and PDEs synergistically elevate intracellular 
concentration of cAMP and enhance anti-proliferative effects. In conclusion, targeting 












Glioblastoma multiform (GBM) is the most common and fatal type of primary 
brain tumour that originates from astrocytes. Whilst its annual incidence is about 3.2 
cases per 100,000 population (Cesarini et al., 2017) or about 15% of all brain tumour 
cases, the recurrence rate is considerably high reaching 85%. In the UK, approximately 
2200 cases of GBM are reported each year (Public Health England, 2014). Patients 
with glioblastoma have poor prognosis, with the overall median survival being 6 
months. The major barrier to improving prognostic factors is the chemoresistance of 
these tumours. In addition, the understanding of the complexity of signal transduction 
in tumour cells, as well as interaction within tumour microenvironment remain limited, 
it has become a challenge to find potential targets to optimally halt tumour progression. 
As has been mentioned in the previous chapter, targeting cyclic nucleotide 
pathways through PDE inhibition or activating AC may be beneficial to counter 
abnormality in cell growth, a common feature in cancer. Using human cell lines, this 
study was extended to determine if the findings can be translated to human cells. The 
importance of secondary messenger will be investigated further in this chapter.  
It has been suggested that glioblastoma cells maintain lower cAMP 
concentrations (Daniel, Filiz and Mantamadiotis, 2016). In five types of cancer 
including glioblastoma, lung adenocarcinoma, bladder urothelial carcinoma, uterine 
endometrial carcinoma, as well as stomach and esophageal carcinoma, concentration 
of cAMP is suppressed highlighting its association with malignancy (Daniel, Filiz and 
Mantamadiotis, 2016). From 4 clinical studies, approximately 12% of all glioblastoma 
samples have been found to have PDEs upregulated at the mRNA level (cBioportal). 
 Due to the convoluted machinery cancer cells possess, it is also necessary to 
look at other potential targets/pathways. Dynamic signal transduction between calcium 
(Ca2+) and cAMP was initially reported in 1970 (Rasmussen, 1970), but it was not until 
2009 that the existence of store-operated cAMP signalling (SOcAMPS), was linked to 
store-depleted mechanism (store operated calcium entry, SOCE) of AC signalling that 
leads to elevation of intracellular cAMP (Lefkimmiatis et al., 2009). The illustration of 
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this dynamic is depicted in Figure 4.1. Despite this evidence, the dynamic role between 
these two pathways has not been fully resolved. Dr. Rahman’s previous work utilising 
computational methods to repurpose available drugs was used to investigate their 
action in modulating calcium signalling (Rahman, 2020). Here, the study was extended 
to validate the pharmacological role of compounds in cell proliferation that were 
previously characterised to influence SOCE mechanism.  
 
Figure 4.1. Illustration of calcium signalling and possible interplay between store 
operated calcium entry (SOCE) mechanism and the cyclic nucleotide pathway. 
SOCE is mediated through the formation of Orai-STIM1 macromolecular complex 
facilitating calcium influx. STIM1, but not Orai, is believed to be a modulator to influence 
AC activity leading to cAMP synthesis. Lefkimmiatis indicated the possibility of 
SOcAMPS representing cross-talk between calcium and cAMP signalling event 
(Lefkimmiatis et al., 2009). IP3R: inositol-1,4,5-trisphosphate receptor, STIM1: stromal 
interaction molecule 1, IP3: inositol-1,4,5-triphosphate, PLC: phospholipase C, GPCR: 
G protein-coupled receptor, AC: adenylyl cyclase, ER: endoplasmic reticulum, SR: 
sarcoplasmic reticulum. (Figure was adapted from (Berridge, Lipp and Bootman, 2000; 
Putney, 2009), with some modification). 
 
4.2  Pharmacological characterisation of PDEs in model glioblastoma cells  
4.2.1  Human glioblastoma cells express various PDEs at mRNA levels  
To characterise the role of PDEs in human glioblastoma models, U87 and T98 cells 
were used. Both cell lines were originally isolated from male glioblastoma patients67. 
Before validating the functions of PDE isoenzymes in GBM cell model, the expression 
levels of each PDEs were quantified using rt-PCR. The gene expression was 
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housekeeping gene, GAPDH. Representative gel documentation is displayed in Figure 
4.2 for U87 (A), T98 (B), and HEK293S (C) cells. With the exception of PDE1B, 
PDE1C, PDE5A, PDE8A, PDE9A, and PDE10A, there was no significant difference 
observed between glioblastoma cell lines (U87 and T98 cells) and control (HEK293S). 
PDE5A expression was distinctively higher in T98 cells compared to other cell lines.  
Despite expected tissue specificity of PDE6 which is expressed in the eye, low levels 
of most PDE6 isoforms were observed in HEK293S cells with PDE6B, PDE6D, and 
PDE6G also expressed T98 and U87 cells. Meanwhile, PDE6H was marginally 
expressed in human glioblastoma models but not detected in HEK293S cells.  
 
 
     
Figure 4.2 Expression profile of PDEs in human glioblastoma cell lines (U87 and 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 4                                                 Role of second messengers in human glioblastoma 
 139 
amplified PDE genes from U87 (A), T98 (B), and HEK293S (C) cell lines. Semi-
quantitative expression profile of PDE isoenzymes in U87, T98, and HEK293S cells at 
mRNA levels (D). Expression of each gene of interest was normalised relative to 
GAPDH. Data are expressed as the mean ± SEM from 4-6 individual repeats. Data 
were determined as statistically different (*, p<0.05; **, p<0.01; ***, p<0.001) compared 
to individual isoenzyme among these cell lines using one-way ANOVA following by 
Dunnett’s post-hoc analysis.  
 
4.2.2  Development of a method to characterise the role of PDEs in accumulating 
cAMP signalling 
Using human glioblastoma cells: U87 and T98 cells, further investigation was 
performed by utilising functional assays to probe the pharmacological role of PDE 
isoforms. Similar to the previous chapter using rat C6 glioma cells, it was necessary to 
validate if the findings can be translated to human cells. To do this, the study began by 
validating the activity of PDE inhibitors in modulating cAMP levels. The full dose-
response curve of forskolin was determined in the absence and in the presence of PDE 
inhibitors. Initially, several, commonly used PDE inhibitors, which include rolipram, 
IBMX, trequinsin, and RO20-1724 were selected. Representative dose response curve 
of forskolin with/without PDE inhibitors are displayed in Figure 4.3 with the 
pharmacological values represented in Table 4.1. 
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Figure 4.3. PDE inhibition increased the concentration of cAMP in the presence 
of forskolin across glioblastoma cell lines. Representative cAMP dose-response 
curves following 30 minutes stimulation with forskolin in the absence or presence of 
selected PDE inhibitors in U87 (A), T98 (C), and HEK293S (E) cells. Black and red 
dashed lines are displayed to visualize interpolation of pEC20. Data are expressed 
relative to the maximal response produced by 100 μM forskolin in the absence of PDE 
inhibitor. Individual data are displayed as a scatter plot as a comparison to the 
corresponding pEC20 of forskolin alone in U87 (B), T98 (D), and HEK293S (F) cells. 
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significance was determined by comparing the value of n data sets to that of forskolin 
using a one-way ANOVA and Dunnett’s post-hoc analysis. (**, p<0.01; ***, p<0.001). 
 
Based upon the pharmacological parameters that are displayed in Table 4.1, 
co-stimulation of forskolin with selected PDE inhibitors not only improved the potency, 
but also in some groups increased the baseline level. The classical approach by 
looking at pEC50 and span may not be optimal for these experiments to screen of 
compounds since the window of observation is restricted. Instead, using pEC20 
approach, it will be more practical to evaluate the compounds over a bigger range to 
understand if they are able to elevate cAMP level (as described in chapter 3).  
 
Table 4.1  
Pharmacological parameters of forskolin in the presence of selected PDE inhibitors 
 
Treatment  pEC50 Span (%) n 
U87    
Forskolin 6.23 ± 0.13 100.1 ± 0.5 8 
Forskolin + rolipram 6.60 ± 0.08*   89.2 ± 2.9 8 
Forskolin + IBMX 6.36 ± 0.06   84.4 ± 5.3** 6 
Forskolin + trequinsin 6.85 ± 0.11***   79.0 ± 3.4*** 8 
Forskolin + RO20-1724 6.49 ± 0.08   92.8 ± 3.1 5 
T98    
Forskolin 6.11 ± 0.05 100.0 ± 2.2 4 
Forskolin + rolipram 6.92 ± 0.06   91.2 ± 2.2 4 
Forskolin + IBMX 6.99 ± 0.04   88.1 ± 1.6 4 
Forskolin + trequinsin 6.80 ± 0.05   79.5 ± 1.6 4 
Forskolin + RO20-1724 7.00 ± 0.07   94.8 ± 2.9 4 
HEK293S    
Forskolin 5.94 ± 0.19 100.6 ± 2.5 9 
Forskolin + rolipram 7.03 ± 0.19***   96.7 ± 3.7 9 
Forskolin + IBMX 6.71 ± 0.16**   76.2 ± 8.8 9 
Forskolin + trequinsin 6.40 ± 0.14   87.8 ± 8.1 7 
Forskolin + RO20-1724 6.35 ± 0.12   99.1 ± 7.1 7 
The values are expressed as mean ± SEM from n individual data. Statistical 
significance was determined by comparing the value of n data sets to that of forskolin 
using a one-way ANOVA and Dunnett’s post-hoc analysis. (*, p<0.1; **, p<0.01; ***, 
p<0.001).  
 
Using formula (1) that was explained in chapter 2, the cAMP accumulation can be 
quantified upon stimulation with forskolin in the presence of PDE inhibitor (Table 4.2). 
From the curve fitting, it was found that the pEC20 value of forskolin for the cell lines 
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were 6.84 ± 0.13 in U87 cells, 6.86 ± 0.13 in T98 cells, and 6.46 ± 0.26 in HEK293S 
cells. 
As displayed in Table 4.2, all PDE inhibitors differentially increased total cAMP 
levels. In U87 cells, the highest potentiation was observed in cells co-treated with 
trequinsin, followed by IBMX, whereas rolipram efficacy was comparable to that of 
RO20-1724 (Figure 4.3.A,B). Both rolipram and RO20-1724 are selective PDE4 
inhibitors even though they preferentially inhibited different PDE4 isoforms. 
Interestingly, all PDE inhibitors increased forskolin-mediated cAMP production to the 
same extent in T98 cells (C-D). In HEK293S cells, cAMP production increased to ~80% 
in the presence of rolipram, IBMX and trequinsin, whilst co-treatment with RO20-1724 
only increased cAMP levels up to 30% (Figure 4.3. E-F). These data suggest that co-
stimulating cells with a small amount of forskolin provides a suitable range for 
screening the ability of PDE inhibitors to modulate cAMP levels. T98 cells in particular, 
appeared to have less control to modulate cAMP concentration compared to the 
remaining cells. This seemed to be correlated with a few numbers of PDE isoenzymes 
that were expressed in T98 cells (Figure 4.2). Having established this method, further 
investigation was performed to explore the role of each isoform.  
 
Table 4.2 
Percentage response of each cell line in the presence of PDE inhibitors at the pEC20 
concentration of forskolin alone 
 
Group treatment % Response (Relative to forskolin) 
U87 T98 HEK293S 
Forskolin 19.55 ± 1.20 20.96 ± 4.19 18.34 ± 0.90  
Forskolin + rolipram 44.10 ± 4.22*** 62.89 ± 3.29*** 78.70 ± 4.49*** 
Forskolin + IBMX 56.15 ± 4.50*** 69.23 ± 1.86*** 76.13 ± 3.37*** 
Forskolin + trequinsin 68.16 ± 2.60*** 64.31 ± 1.01*** 70.92 ± 2.68*** 
Forskolin + RO20-1724 42.14 ± 5.31*** 68.67 ± 0.59*** 31.54 ± 5.76 
Statistical significance was determined by comparing the value of n data sets to that of 
forskolin using a one-way ANOVA and Dunnett’s post-hoc analysis. (***, p<0.001). 
 
4.2.3 Pharmacological role of PDEs in cAMP and cell proliferation 
By applying the modified cAMP assay that has been mentioned in the previous section, 
activity of PDE inhibitors was assessed. A similar approach was carried out to that of 
performed in rat C6 cells in the chapter 3.  
Aside from forskolin, some compounds were found to increase cAMP 
production in all three cell lines including amrinone, trequinsin, rolipram, ibudilast, 
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piclamilast, roflumilast, and IBMX (Figure 4.4 to 4.6). BRL-50481 and BAY 73-6691, 
on the other hand, appeared to be active in U87 and HEK293S cells only (Figure 4.5 
and 4.6), whilst sildenafil increased forskolin-mediated cAMP accumulation in T98 and 
HEK293S cells (Figure 4.5 and 4.6). Surprisingly, sildenafil, a selective PDE5A (a 
cGMP specific PDE) inhibitor, was able to increase cAMP in T98 cells because the 
cells expressed higher levels of PDE5A (Figure 4.2D). EHNA, caffeine, and PF-
04449613 were able to modulate cAMP levels in only U87 cells (Figure 4.4), whereas 
vinpocetine, milrinone, TC3.6, BC 11-38, PF-2545920, and PF 04671536 elevated 
total cAMP concentration in HEK293S cells (Figure 4.6).  
Thereafter, PDE inhibitors were also tested for their ability to modulate cell 
proliferation (Figure 4.7 to 4. 9). As expected, most of the compounds that elevated 
cAMP levels suppressed cell growth. Having displayed the characterisation of each 
PDE inhibitors from Figure 4.4 to 4.9 pharmacological parameters for the ability of the 
compounds to modulate both cAMP levels and cell growth are shown in Table 4.3 and 
4.4. The summary of effects of each PDE inhibitor in both assays are displayed in 
Table 4.5 
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Table 4.3  
Potency values for cAMP production (pEC50) and span of each PDE inhibitor in U87, T98, and HEK-293S cells.  
Compounds Target PDE(X) 
¥ 
U87  T98 HEK-293S 
pEC50a Span (cAMP)b 
(%) 
pEC50a Span (cAMP)b 
(%) 
pEC50a Span (cAMP)b  
(%) 
Vinpocetine  1 N/A N/A N/A N/A 4.36 ± 0.26 31.11 ± 4.71 
EHNA 2 6.15 ± 0.33  21.3 ± 5.3 N/A N/A 4.73 ± 0.63 4.19 ± 1.31 
Cilostamide  3 N/A N/A N/A N/A N/A N/A 
Amrinone 3 4.07 ± 0.09  69.1 ± 2.7 3.80 ± 0.15 77.8 ± 7.6 4.13 ± 0.11 62.73 ± 3.88 
Milrinone  3 N/A N/A N/A N/A 5.78 ± 0.25 26.16 ± 5.04 
Trequinsin 2,3,7 5.20 ± 0.18  66.4 ± 6.2 5.78 ± 0.18 40.6 ± 3.8 4.77 ± 0.21 52.14 ± 6.34 
Rolipram  4 5.75 ± 0.39  25.5 ± 5.9 7.53 ± 0.38 26.9 ± 4.8 5.47 ± 0.32 29.40 ± 6.18 
Ibudilast  4 5.50 ± 0.31  12.9 ± 1.9 6.32 ± 0.29 38.6 ± 5.5 5.72 ± 0.41 11.07 ± 2.68 
Piclamilast  4 10.09 ± 0.91  13.0 ± 6.8 10.00 ± 0.71 22.0 ± 8.8 9.26 ± 0.25 16.17 ± 2.01 
Roflumilast  4 10.98 ± 0.51  22.3 ± 9.4 10.66 ± 0.99   25.8 ± 17.3 8.53 ± 0.26 16.69 ± 2.19 
Sildenafil  5 7.56 ± 0.56 -12.7 ± 4.6 8.22 ± 0.84 10.6 ± 5.1 8.08 ± 0.25 31.08 ± 4.46 
Tadalafil  5 9.92 ± 1.38 9.1 ± 9.0 N/A N/A N/A N/A 
Caffeine  1,4,5 5.91 ± 0.37 16.5 ± 3.4 N/A N/A 6.61 ± 0.52 7.34 ± 1.83 
Zaprinast  5,6,9,11 N/A N/A N/A N/A 4.81 ± 0.68 3.77 ± 1.35 
TC3.6 7 N/A N/A N/A N/A 5.38 ± 0.57 10.59 ± 2.92 
BRL-50481 7 5.89 ± 1.18 13.4 ± 14.7 6.09 ± 2.07 -14.4 ± 21.4 6.52 ± 0.26 17.32 ± 2.57 
BC 11-38 8 N/A N/A N/A N/A 7.47 ± 2.29 9.32 ± 11.21 
BAY-736691 9 6.91 ± 0.54  9.6 ± 3.1 9.06 ± 1.70 3.3 ± 3.0 7.15 ± 0.22 16.26 ± 2.09 
PF-0449613 9 7.86 ± 0.28       23.2 ± 3.7 N/A N/A N/A N/A 
PF 2545920 10A 8.78 ± 0.78 -5.6 ± 5.7 N/A N/A 8.42 ± 0.71 38.64 ± 31.26  
PF 04671536 11 9.67 ± 1.66 -5.9 ± 5.3 N/A N/A 9.35 ± 1.05 23.94 ± 11.25 
IBMX  Non-selective 3.75 ± 0.59  7.3 ± 2.4 4.66 ± 0.24       28.5 ± 3.9 4.52 ± 0.24 12.14 ± 2.71 
Forskolin AC activator 5.40 ± 0.15       66.3 ± 5.6 N/D N/D 4.73 ± 0.31 37.69 ± 7.72 
Cisplatin DNA 
crosslinker 
N/D N/D N/D N/D N/D N/D 
Data are the mean ± SEM of 6-9 individual data sets.  
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b The range between basal and Emax on cAMP accumulation assay. 
N/A – not applicable; compounds did not have any effect on cAMP. 
N/D – not determined.  
¥, unless mentioned, targets refer to particular PDE isoform.  
#, showing negative responses, either suppressing cAMP accumulation or being pro-proliferative. 
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Figure 4.4 Effect of a panel of established PDE inhibitors on forskolin-mediated cAMP production in U87 cells. Dose-response 
curve of each PDE inhibitors in the presence of small amount of forskolin after 30 minutes stimulation. Responses were normalised to 100 
μM forskolin. Each data point is expressed as mean ± SEM of 6-9 individual data set. Compounds that elevate cAMP concentration are 
red colour coded, whereas those suppress cAMP level are displayed in blue. Compounds that show no effect are shown as black curves. 
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Figure 4.5 Effect of a panel of established PDE inhibitors on forskolin-mediated cAMP production in T98 cells. Dose-response 
curve of each PDE inhibitors in the presence of small amount of forskolin after 30 minutes stimulation. Responses were normalised to 100 
μM forskolin. Each data point is expressed as mean ± SEM of 6-9 individual data set. Compounds that elevate cAMP concentration are 
red colour coded, whereas those suppress cAMP level are displayed in blue. Compounds that show no effect are shown as black curves. 
Note: the experiment to test BC 11-38 and PF04671536 cannot be accomplished due to covid-19 restriction.  
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Figure 4.6 Effect of a panel of established PDE inhibitors on forskolin-mediated cAMP production in HEK293S cells. Dose-
response curve of each PDE inhibitors in the presence of small amount of forskolin after 30 minutes stimulation. Responses were 
normalised to 100 μM forskolin. Each data point is expressed as mean ± SEM of 6-9 individual data set. Compounds that elevate cAMP 
concentration are red colour coded, whereas those suppress cAMP level are displayed in blue. Compounds that show no effect are shown 
as black curves. 
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Table 4.4 
Potency values for cell growth inhibition (pIC50) and span of each PDE inhibitor in U87, T98, and HEK-293S cells  
 
Compounds Target PDE(X) 
¥ 










Vinpocetine  1 4.70 ± 0.36 30.4 ± 6.2 6.00 ± 0.41 27.7 ± 6.7 4.10 ± 0.71 25.0 ± 11.7 
EHNA 2 6.72 ± 0.31 25.5 ± 4.0 4.95 ± 0.22 33.3 ± 4.7 5.13 ± 0.22        57.4 ± 7.3 
Cilostamide  3 8.23 ± 0.54 27.5 ± 7.6 6.41 ± 0.95   17.9 ± 11.6 7.02 ± 0.87       -16.9 ± 8.3 
Amrinone 3 4.36 ± 0.23 60.2 ± 7.6 4.13 ± 0.25 57.6 ± 8.5 3.90 ± 0.11        77.2 ± 0.9 
Milrinone  3 8.06 ± 0.24 31.4 ± 3.6 8.00 ± 0.22 46.0 ± 4.8 N/A  N/A 
Trequinsin 2,3,7 4.86 ± 0.14 84.6 ± 2.1  4.69 ± 0.13 77.8 ± 3.3 4.79 ± 0.06        84.4 ± 1.8 
Rolipram  4 7.50 ± 0.39 26.8 ± 4.9 7.50 ± 0.42   57.9 ± 11.4 7.28 ± 0.93 9.9 ± 5.4 
Ibudilast  4 7.55 ± 0.27 32.8 ± 4.1 7.57 ± 0.69   39.0 ± 18.1 6.16 ± 0.30        12.6 ± 2.0 
Piclamilast  4 10.30 ± 0.19 31.7 ± 3.9 10.43 ± 0.34 33.2 ± 5.3 N/A N/A 
Roflumilast  4 10.81 ± 0.21 26.1 ± 2.6 10.53 ± 0.31 27.2 ± 3.9 N/A N/A 
Sildenafil  5 9.28 ± 0.84 20.5 ± 9.6 9.58 ± 0.56  18.4 ± 8.4 N/A N/A 
Tadalafil  5 7.29 ± 2.56 29.2 ± 8.5 N/A N/A 8.58 ± 0.68      -15.8 ± 5.4 
Caffeine  1,4,5 6.44 ± 0.13 38.9 ± 2.3 N/A N/A 6.22 ± 0.37       15.9 ± 3.5 
Zaprinast  5,6,9,11 N/A N/A 5.24 ± 0.21 78.9 ± 8.4 4.64 ± 0.17       24.8 ± 5.7  
TC3.6 7 N/A N/A 7.52 ± 0.45 22.7 ± 4.8 N/A N/A 
BRL-50481 7 8.27 ± 0.49 12.9 ± 3.1 7.43 ± 0.36 22.9 ± 3.8 N/A N/A 
BC 11-38 8 8.15 ± 0.72  15.2 ± 3.4  N/A N/A 7.30 ± 0.62      -18.2 ± 5.5 
BAY-736691 9 8.69 ± 0.13 43.1 ± 2.5 8.82 ± 0.25 36.8 ± 4.4 8.82 ± 0.57       24.8 ± 6.7 
PF-0449613 9 9.42 ± 0.27 30.8 ± 4.0 9.41 ± 0.32 27.9 ± 4.2 7.79 ± 0.56       11.6 ± 3.73 
PF 2545920 10A N/A  N/A N/A N/A 10.57 ± 0.38      -22.2 ± 4.9 
PF 04671536 11 8.27 ± 1.47 -19.6 ± 17.6 N/A N/A 10.15 ± 0.72      -24.1 ± 10.6  
IBMX  Non-selective N/A N/A 4.14 ± 0.45 30.9 ± 9.1 N/A N/A 
Forskolin AC activator N/A N/A 6.42 ± 0.25 23.6 ± 2.7 N/A N/A 
Cisplatin DNA 
crosslinker 
5.73 ± 0.29 44.1 ± 5.9 5.52 ± 0.33 41.3 ± 6.5 5.38 ± 0.32       71.2 ± 11.9 
Data are the mean ± SEM of 6-9 individual data sets.  
a The negative logarithm of the inhibitor concentration required to inhibit a half-maximal response 
b The range between survival in vehicle control and inhibitory maximal in cell proliferation assay 
N/A – not applicable; compounds did not have any effect on cAMP production or cell growth inhibition.  
¥, unless mentioned, targets refer to particular PDE isoform.  
#, showing negative responses, either suppressing cAMP accumulation or being pro-proliferative. 
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Data were determined as statistically different (*, p<0.05; ***, p<0.001) compared to forskolin using one-way ANOVA followed by Dunnett’s 
post-hoc analysis.
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Figure 4.7 Effect of a panel of established PDE inhibitors, forskolin, and cisplatin on modulating U87 cell growth. Cell survival was 
determined in U87 cells following 72 hours incubation with each PDE inhibitor. Cisplatin was used as cytotoxic reference compound 
exhibiting anti-proliferative action. Data are expressed as percentage of cell proliferation relative to vehicle (complete medium containing 
1% DMSO) from 6-9 data sets. Data are expressed as mean ± SEM. Compounds that suppress cell growth are red colour coded, whereas 
those pro-proliferative are displayed in blue. Compounds that show no effect are shown as black curves.  
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Figure 4.8 Effect of a panel of established PDE inhibitors, forskolin, and cisplatin on modulating T98 cell growth. Cell survival was 
determined in U87 cells following 72 hours incubation with each PDE inhibitor. Cisplatin was used as cytotoxic reference compound 
exhibiting anti-proliferative action. Data are expressed as percentage of cell proliferation relative to vehicle (complete medium containing 
1% DMSO) from 6-9 data sets. Data are expressed as mean ± SEM. Compounds that suppress cell growth are red colour coded, whereas 
those pro-proliferative are displayed in blue. Compounds that show no effect are shown as black curves. 
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Figure 4.9 Effect of a panel of established PDE inhibitors, forskolin, and cisplatin on modulating HEK293S cell growth. Cell survival 
was determined in HEK293S cells following 72 hours incubation with each PDE inhibitor. Cisplatin was used as cytotoxic reference 
compound exhibiting anti-proliferative action. Data are expressed as percentage of cell proliferation relative to vehicle (complete medium 
containing 1% DMSO) from 6-9 data sets. Data are expressed as mean ± SEM. Compounds that suppress cell growth are red colour 
coded, whereas those pro-proliferative are displayed in blue. Compounds that show no effect are shown as black curves.
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Table 4.5 
Summary of the pharmacological effects of each PDE inhibitor on cAMP production 
and cell proliferation  







Vinpocetine 1 N.R. ¯¯ ¯ ¯ ­ ¯ 
EHNA 2 ­ ¯ N.R. ¯ N.R. ¯ 
Cilostamide 3 N.R. ¯ N.R. ¯ N.R ­ 
Amrinone 3 ­­­ ¯¯¯ ­­­ ¯¯¯ ­­­ ¯¯¯ 
Milrinone 3 N.R. ¯¯ N.R. ¯¯ ­ ­ 
Trequinsin 2,3,7 ­­­ ¯¯¯ ­­ ¯¯¯ ­­­ ¯¯¯ 
Rolipram 4 ­ ¯ ­ ¯¯¯ ­ ­ 
Ibudilast 4 ­ ¯¯ ­­ ¯¯ ­ ¯ 
Piclamilast 4 ­ ¯¯ ­ ¯¯ ­ N.R. 
Roflumilast 4 ­ ¯ ­ ¯ ­ N.R. 
Sildenafil 5 ¯ ¯ ­ ¯ ­ ­ 
Tadalafil 5 ­ ¯ N.R. ¯¯ N.R. ­ 
Caffeine 1,4,5 ­ ¯¯ N.R. ¯¯ N.R. ¯ 
Zaprinast 5,6,9,11 N.R. N.R. N.R. ¯¯¯ N.R. ¯ 
TC3.6 7 N.R. N.R. N.R. ¯ ­ ¯ 
BRL-50481 7 ­ ¯ N.R. ¯ ­ N.R. 
BC 11-38 8 N.R. ¯ - N.R. N.R. ­ 
BAY-736691 9 ­ ¯¯ N.R. ¯¯ ­ ¯ 
PF-0449613 9 ­ ¯¯ N.R. ¯ ¯ ¯ 
PF 2545920 10A ¯ N.R. N.R. ¯ ­ ­ 
PF 
04671536 
11 N.R. ­ - N.R. ­ ­ 
IBMX Non-
selective 
­ N.R. ­ ¯¯ ­ N.R. 
N.R. No response 
­ = increase 10-30%, ­­ = increase 31-50%, ­­­= increase >50%, ¯: suppress 10-
30%, ¯¯: suppress 31-50%, ¯¯¯: suppress >50% 
 
4.3 Elevation of cAMP by targeting PDEs positively correlated with cell growth 
suppression 
Subsequently, Pearson’s correlation coefficient was calculated to determine if there 
was a correlation between these two pathways (Figure 4.10). Indeed, there was a 
strong association between cAMP production and cell growth inhibition in all human 
cells tested, with Pearson’s corelation (r) of 0.87 in U87 cells (95% confidence interval 
= 0.58 – 0.96), 0.96 in T98 cells (95% confidence interval = 0.81 – 0.99), and 0.88 in 
HEK293S cells (95% confidence interval = 0.39 - 0.98). Nevertheless, most of the 
compounds were found to be more efficacious in glioblastoma cells lines: U87 and T98 
cells in comparison to HEK293S cells. As displayed in Figure 4.10C, the slope of 
correlation was steeper in HEK293S cells compared to any other cell line (Figure 
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4.10C). The small range in changes of cAMP within the cells drives a more potent anti-
proliferative effect. This demonstrates that HEK293S cells possess a mechanism to 
control cAMP levels compared to U87 or T98 cells, which is very likely generated by 
the presence of various PDEs. Based on the cAMP accumulation assay, forskolin 
showed lower potency in HEK293S cell (Figure 4.3). Taken together, all results 
corroborated that HEK293S cells have a particular mechanism to keep maintaining 
lower cAMP by expressing more PDEs, as displayed in Figure 4.2. 
  
 
Similar to chapter 3, selection criteria were applied to quantify how efficacious 
the compounds were at inhibiting cell proliferation. The top and bottom thresholds were 
again set to 350 and 200, respectively. Interestingly, cisplatin exhibited much less 
potent anti-proliferative effects in T98 cells compared to U87 or HEK293S cells (Figure 
4.11). Although the data is not as robust as that obtained in rat C6 glioma cells, there 
are more compounds that reach the threshold in human glioblastoma cell lines. The 
efficacy of PDE inhibitors were generally less profound in HEK293S cells, with only 
EHNA, amrinone and trequinsin reaching the selection criteria threshold. This suggests 
that the majority of compounds display selectivity towards glioblastoma cell lines.  
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Figure 4.10 Elevation of intracellular
cAMP positively correlates with cell
growth suppression in U87 cells, T98
cells and HEK-293S cells. Correlation (with
95% confidence interval) of log potencies of
each PDE inhibitor on U87 cells (A), T98
cells (B) or HEK-293S cells (C) was
determined by calculating Pearson’s
correlation coefficient (r). Data are
expressed as mean ± SEM of 4-8 individual
repeats.




Figure 4.11 Selection criteria of PDE inhibitor in U87, T98, and HEK293S cells. 
Compound selection criteria was calculated based on potency and efficacy in 
proliferation assay. The dashed lines represent threshold value of 200 (less stringent 
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obtained from Figures 4.7 – 4.9. Data are expressed as mean ± SEM of 3-8 individual 
repeats.  
 
4.4 The combinatorial effect of PDE2, PDE3, and PDE7 inhibitors mimicks the 
effect of trequinsin 
As shown above, trequinsin scored the highest in selection criteria for both GBM model 
cell lines. With regards to the combinatorial effect of individual PDE2 (EHNA), PDE3 
(amrinone), and PDE7 (BRL-50481) inhibitor in rat glioma cells (Chapter 3), in this 
chapter the study was extended to investigate whether this has potential to be 
translated to human glioblastoma cell lines. To do this, the similar approach describe 
din chapter 3 was adopted for probing mechanism of action of trequinsin, by using 
PDE2, PDE3, and PDE7 inhibitor. 
 All cell lines were stimulated with PDE inhibitors alone, in pairs, and as PDE 
inhibitor cocktail. Whilst no individual compound was as efficacious as trequinsin in 
these cell lines, both potency and Emax was improved when PDE inhibitors were 
combined in pairs compared to their individual effects (Figure 4.12, Table 4.6). Whilst 
PDE inhibitor cocktails appeared to be less potent than trequinsin in U87 cells, the 













Figure 4.12. The combinatorial effect of PDE2, PDE3, and PDE7 inhibitor was 
similar to that of trequinsin in modulating cAMP production. cAMP accumulation 
was determined in C6 cells following 30-minute stimulation with EHNA (PDE2 
inhibitor), amrinone (PDE3 inhibitor), or BRL-50481 (PDE7 inhibitor) alone (left panel), 
in pairs (middle), or in combination (right panel). The effects were observed across 
human glioblastoma U87 (A), T98 (B), and HEK293S (C) cells. Data are expressed 
relative to 100 µM forskolin and are the mean ± SEM of 6-9 data sets. The effect of 
trequinsin alone is displayed on each graph for comparison.   
  
While PDE2, PDE3, and PDE7 inhibitors were combined either in pairs or as 
cocktails, there was a marginal effect observed in cell growth on U87 cells (Figure 
4.13A, Table 4.7). However, with the exception of 100 μM trequinsin, the curve 
between the PDE inhibitor cocktail and trequinsin overlapped. As mentioned in the 
previous chapter, the observed effect of 100 μM trequinsin was most likely generated 
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by its activity towards caspase-3/-7 (chapter 3). When the PDE inhibitors where 
combined in pairs and added to T98 cells, the anti-proliferative effect was enhanced 
compared to the individual compounds as indicated by potency (pIC50) or span values 
(Figure 4.13B, Table 4.7). Equivalent suppression by the PDE inhibitor cocktail 
(combined three inhibitors) to that of trequinsin was observed in T98 cells. The 
improvement generated by the combination of these PDEs is clearer when the 
selection criteria was applied (Table 4.7). Using this approach, it is evident that T98 
cells appeared to be less resistant to the PDE inhibitor cocktail than U87 cells. 
Meanwhile in HEK293S cells, combination of PDE2, PDE3, and PDE7 inhibitors 
exhibited a greater reduction in comparison to individual compounds but did not 
exceed the activity of trequinsin alone. It is most likely that the trequinsin-mediated 
antiproliferative effect in HEK293S cells results from caspase-3/-7 activation, as 
described in chapter 3. Taken together, these data suggest that trequinsin activity can 
be mimicked by combining PDE2, PDE3, and PDE 7 inhibition and may only be 











Figure 4.13 Anti-proliferative effect of trequinsin can be mimicked by combining 
individual PDE2, PDE3, and PDE7 inhibitor. Cell survival was determined in these 
cells following 72 hours incubation with EHNA, amrinone or BRL-50481 alone, in pairs, 
or in combination. Data are expressed as percentage of cell proliferation relative to 
vehicle. The curve of trequinsin alone is displayed on each graph for comparison.  All 
data are the mean ± SEM of 6–9 data. 
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Combinatorial effect of individual PDE2, PDE3, and PDE7 inhibitor in glioblastoma cell lines U87 and T98 cells in comparison to 
HEK293S cells 
 
Compound cAMP accumulation assay   Proliferation Assay  Selection criteria 
pEC50a Spanb (%) n pIC50c Spand (%) n 
U87        
Trequinsin§ 5.06 ± 0.09 81.8 ± 4.3 6 4.46 ± 0.05 89.0 ± 0.3 9       396.50 ± 4.79 
EHNA 5.35 ± 0.20 31.5 ± 3.2 6 6.58 ± 0.07 31.5 ± 1.1 9       207.18 ± 7.86 
Amrinone 4.64 ± 0.14 60.5 ± 5.4 6 7.12 ± 0.22 34.9 ± 6.8 9 248.87 ± 48.68 
BRL-50481 5.31 ± 0.22 17.7 ± 2.0 6 6.99 ± 0.30 35.1 ± 8.4 9 245.51 ± 59.70 
EHNA + amrinone 4.51 ± 0.11 86.7 ± 6.5 6 6.19 ± 0.16 24.9 ± 2.2 9 153.99 ± 14.13 
EHNA + BRL-50481 4.74 ± 0.19 43.5 ± 5.4 6 6.71 ± 0.13 23.9 ± 1.9 9 160.38 ± 13.39 
Amrinone + BRL-50481 4.48 ± 0.16 66.4 ± 7.4 6 6.93 ± 0.18 18.9 ± 2.4 9 131.35 ± 17.22 
EHNA + amrinone + BRL-50481 4.52 ± 0.14 78.6 ± 7.8 6 6.84 ± 0.14 31.9 ± 3.2 9 218.76 ± 22.59 
        
T98        
Trequinsin§ 4.69 ± 0.20 58.9 ± 7.6 6 4.41 ± 0.06 81.8 ± 3.4 9 360.32 ± 15.92 
EHNA 4.63 ± 0.23 36.9 ± 5.7 6 4.65 ± 0.10 55.2 ± 5.9 9 257.03 ± 28.33 
Amrinone 4.56 ± 0.08 56.7 ± 4.6 6 4.41 ± 0.09 43.7 ± 1.1 6       192.85 ± 6.31 
BRL-50481§ 5.62 ± 0.46 14.7 ± 3.1 6 4.58 ± 0.18 24.9 ± 4.6 6 113.81 ± 21.41 
EHNA + amrinone§ 4.63 ± 0.09 56.8 ± 6.7 6 4.08 ± 0.03 68.1 ± 2.6 6 277.60 ± 10.87 
EHNA + BRL-50481§ 4.89 ± 0.17 35.7 ± 3.7 6 3.88 ± 0.05 53.4 ± 3.1 6  206.85 ± 12.19 
Amrinone + BRL-50481 4.38 ± 0.29   64.7 ± 14.5 6 4.69 ± 0.18 68.5 ± 11.8 6 321.40 ± 56.96 
EHNA + amrinone + BRL-50481§ 4.70 ± 0.12 57.4 ± 6.8 3 4.40 ± 0.07 74.9 ± 4.7 9 330.17 ± 21.25 
        
HEK293S        
Trequinsin§ 5.19 ± 0.14 47.2 ± 3.7 6 5.10 ± 0.05 81.4 ± 2.0 5 415.29 ± 11.15 
EHNA 5.00 ± 0.16 25.9 ± 2.4 6 5.00 ± 0.17 39.3 ± 3.6 9 196.76 ± 19.02 
Amrinone 4.81 ± 0.08 50.9 ± 2.6 6 N/A  N/A 6 N/A  
BRL-50481 5.20 ± 0.26 13.7 ± 1.8 5 N/A N/A 8 N/A 
EHNA + amrinone 4.58 ± 0.14 65.6 ± 6.0 6 4.54 ± 0.19 50.2 ± 6.7 6 228.01 ± 31.77 
EHNA + BRL-50481§ 4.88 ± 0.18 39.9 ± 4.5 6 4.77 ± 0.10 50.3 ± 4.6 6 239.63 ± 22.43 
Amrinone + BRL-50481 4.61 ± 0.20 55.9 ± 7.4 6 4.14 ± 0.33 55.4 ± 19.1 6 229.49 ± 81.53 
EHNA + amrinone + BRL-50481§ 4.55 ± 0.16 69.9 ± 7.6 6 4.94 ± 0.10 52.5 ± 6.3 9 259.69 ± 31.71 
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§ The curve was fit by constraining top value to 100 and bottom minimum value observed from proliferation assay 
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b the range between basal and Emax on cAMP accumulation assay 
c The negative logarithm of the inhibitor concentration required to inhibit a half-maximal response 
d The range between survival in vehicle control and inhibitory maximal in cell proliferation assay 
N/A – not applicable; compounds did not have any effect on cAMP production or cell growth inhibition.  
* selection criteria were calculated based on pIC50 and span on proliferation assay from Figure 4.13 
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4.5 Concomitant targeting AC and PDEs only affects short-term cAMP 
production, but is insufficient to modulate cell proliferation in human 
glioblastoma cells 
Although forskolin alone significantly suppressed rat glioma cell lines (described in 
chapter 3), it only reduced cell growth by ~15% on human glioblastoma cells. Forskolin 
acts through AC activation that subsequently increases the production of cAMP. 
Trequinsin has been shown to inhibit multiple PDEs, including PDE2, PDE3, and 
PDE7, leading to improved activity modulating both cAMP production and cell growth. 
Therefore, this study was performed to investigate if increasing cAMP levels by 
concomitant targeting of both AC and PDEs will improve anti-proliferative effects 
compared to individual treatments. To do this, glioblastoma cells were co-treated with 
forskolin and trequinsin. 
Upon 30-minute stimulation with forskolin, cAMP accumulation was differentially 
increased in a dose-dependent manner by trequinsin (Figure 4.14A). Interestingly, the 
baseline levels were also dose-dependently increased in all cell lines with U87 cells 
displaying the most sensitivity towards forskolin and trequinsin combinations. The most 
prominent effect was shown in U87 cells, followed by T98 and HEK293S cells, 
respectively. Interestingly, there was no potentiation of cell growth suppression when 
forskolin was co-treated with trequinsinin any of the cell lines tested (Figure 4.14B). In 
U87 cells, the relative cell number tended to increase compared to forskolin alone 
suggesting that the co-treatment was pro-proliferative. In T98 cells, only the 
combination of forskolin and 10 μM trequinsin enhanced anti-proliferation which was 
not observed at lower concentrations of trequinsin. There was no significant effect of 
trequinsin co-treatment at any concentration on forskolin-mediated anti-proliferation in 
HEK293S cells. Titration of forskolin with 100 μM trequinsin in all tested cell lines 
completely abolished cell growth (Figure 4.14C). Given that trequinsin at 100 μM also 
activates caspase-3/-7, the effect observed in these combinations indicate a cAMP-
independent mechanism that causes apoptosis.  
 




Figure 4.14 Co-treatment of forskolin and trequinsin mediated elevation of cAMP 
levels but showed marginal effect in cell proliferation across human 
glioblastoma cell lines. (A) dose-dependent effect of trequinsin upon cAMP 
accumulation following 30-minute stimulation with forskolin or trequinsin alone ( ) in 
U87, T98, and HEK293S cells. Response are normalised to 100 μM forskolin. Each 
data point is expressed as mean ± SEM of 4-6 data. (B) Cell survival of U87, T98, and 
HEK293S cells after being exposed to forskolin and combination of forskolin trequinsin 
(1nM – 10 μM), and (C) with trequinsin 100 μM. Combination of forskolin and trequinsin 
100μM diminished cell growth in all test cell lines.  
 
The minimal effect of co-treatment in all tested cells, indicates that the 
concomitant targeting of AC and multiple PDE inhibition by trequinsin is insufficient to 
translate into observable pharmacological effects. Since the expression of PDEs at 
mRNA levels in human cells: U87, T98, and HEK293S cells are higher (Figure 4.3) 
compared to C6 rat glioma cells (Figure 3.4), it is possible that these cell lines may 
restore cAMP levels to the resting state after intracellular cAMP was increased by 
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forskolin and trequinsin. Thus, in longer exposure, elevation in cAMP will be tuned 
down by the activity of many PDEs. This also suggests cells may have other 
mechanisms to fine-tune any modulation occurred within the intracellular compartment, 
possibly through cAMP efflux transporter. 
 
4.6 The pharmacological effect of cAMP efflux transporter in glioblastoma: MRP4  
Having confirmed that glioblastoma cells were less responsive to the combination of 
forskolin and PDE inhibitor treatment, a different pathway that may contribute to cAMP 
regulation was investigated. Concentration of cAMP is also maintained by its transport 
into the extracellular compartment by the ABC efflux transporter, MRP4. ABC efflux 
transporters are highly expressed in human glioblastoma and have been reported to 
contribute to chemoresistance (Declèves et al., 2002; Rama et al., 2014; Tivnan et al., 
2015; Hill et al., 2016) 
In the previous chapter it was validated that PU23 effectively blocks MRP4 to 
transfer cAMP out of cells and retain cAMP within intracellular compartment. 
Therefore, this study would be focused on the effect of MRP4 inhibition on cell 
proliferation. In U87 cells, whilst treatment with forskolin resulted in cell growth 
suppression of only approximately 15%, cotreatment with PU23 enhanced suppression 
in cell growth in a dose-dependent manner (Figure 4.15). In T98 cells, the potentiation 
of the forskolin-mediated anti-proliferative effect was only observed upon cotreatment 
with 10 μM PU23. The findings in both cells further suggest that cAMP is anti-
proliferative in glioblastoma cell lines. Although the role of PDEs may be less 
pronounced in human glioblastoma U87 and T98 cells compared to rat C6 cells, all 
these data suggest that cAMP mediates an anti-proliferative effect.  
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Figure 4.15 PU23, an MRP4 inhibitor, potentiate anti-proliferative effect of 
forskolin on human glioblastoma U87 and T98 cells. Cell survival was determined 
upon 72-hour treatment with forskolin in the absence and presence of increasing 
concentrations of PU23, an MRP4 inhibitor. Data are expressed as percentage cell 
survival relative to vehicle. All data are the mean ± SEM of 3-6 individual data.  
 
4.7  Modulation of calcium signalling through SOCE mechanism exhibited 
negative effect on glioma/glioblastoma cell proliferation 
Although targeting cAMP signalling can suppress cell growth, it appears that targeting 
PDEs and cAMP signalling may not optimally control abnormalities in glioblastoma cell 
growth. Hence, another secondary messenger may also be involved.  
Calcium is a universal intracellular messenger that controls the vast majority of 
proteins and contributes to physiological changes at the tissue and cellular level, 
including fertilisation, cell death, cell differentiation and proliferation, B cell activation, 
mast cell degranulation and insulin secretion (Hoth and Penner, 1992; Berridge, Lipp 
and Bootman, 2000; Feske, 2007; Rorsman, Braun and Zhang, 2012; Rahman and 
Rahman, 2017). In collaboration with Dr. Rahman (Department of Pharmacology, 
University of Cambridge), the functional significance of calcium signalling in cell growth 
was examined. Specifically, the transient receptor potential cation channels (TRPC) 
channel was targeted using small molecule inhibitors; Pyr6, teriflunomide, brequinar 
sodium, and vidoflunimus. All the compounds tested in this study were already 
approved by FDA for various indications with the main mechanism to inhibit 
dihydroorotate dehydrogenase (DHODH) as well as inhibiting SOCE activity (Rahman 
and Rahman, 2017).  































































































Chapter 4                                                 Role of second messengers in human glioblastoma 
 172 
In this experiment, repurposed compounds were validated on glioma and 
glioblastoma cells: C6, U87, and T98 cells utilising cell proliferation assay (Figure 4.16, 
Table 4.8). Although cisplatin dose-dependently suppressed C6 cells, it appeared to 
be less profound in T98 cells (Figure 4.16A and C). On the contrary, anti-proliferative 
effect of cisplatin on U87 cells was negligible (Figure 4.16E). This observation was in 
agreement with previous studies highlighting the resistance of human glioblastoma 
U87 cells.  
 
 
Figure 4.16 Some compounds that inhibit SOCE displayed anti-proliferative 
action in glioma and glioblastoma cell lines. Cell survival was determined after 72 
h treatment by selected compounds in C6 (A,B), T98 (C,D), and U87 (E,F) cells 
normalisation to vehicle control. Data are expressed as the mean ± SEM of 3-10 data.  
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All tested compounds exhibited anti-proliferative effects on both C6 and T98 
cells (Figure 4.16 A-D), except teriflunomide on T98 cells. These compounds were 
more apparent in C6 cells, with the rank order of potency: brequinar Na > teriflunamide 
> vidoflunimus > Pyr6 (Table 4.8). With the exception of teriflunamide, the rank order 
of potency of SOCE inhibitor in T98 cells was also the same. Similar to what was 
observed in cisplatin-treated cells, teriflunomide exhibited minimal anti-proliferative 
effects in U87 cells (Figure 4.16.E). Despite variable repeats, only vidoflunimus was 
able to reduce U87 cell growth (Figure 4.16.F). Again, U87 cells were resistance to 
these treatments.  







The summary of pharmacological parameters of SOCE inhibitors in modulating cell growth 
 
Compound C6  T98  U87  
pIC50 Span n pIC50 Span n pIC50 Span n 
Cisplatin 5.91 ± 0.06 93.00 ± 0.58 6 5.81 ± 0.32 41.47 ± 5.85 10   4.82 ± 1.87   26.62 ± 0.61 4 
Trequinsin 4.78 ± 0.07*** 90.76 ± 0.99 8 4.99 ± 0.06 82.20 ± 3.04*** 9 N/A 87.52 ± 0.28***$ 9 
Teriflunamide 6.09 ± 0.14 69.88 ± 1.35*** 6       N/D         N/D 8 9.78 ± 0.43***   13.17 ± 3.04** 4 
Pyr6 4.50 ± 0.06*** 65.74 ± 3.77*** 6 5.59 ± 0.12 47.21 ± 1.98 6        N/D           N/D 3 
Vidoflunimus 5.27 ± 0.41*** 61.16 ± 1.41*** 6 4.49 ± 0.13*** 42.22 ± 2.24 8 9.17 ± 0.51*** 46.31±16.24** 2# 
Brequinar Na 6.01 ± 0.05 62.84 ± 1.67*** 6 6.50 ± 0.13* 39.82 ± 3.11 6        N/D           N/D 2# 
When necessary, the curve was constrained to 100 for top plateau and inhibition maximum from each treatment  
N/D, not determined 
N/A, not applicable 
Statistical significance was determined by comparing the value of n data sets to that of forskolin using a one-way ANOVA and Dunnett’s 
post-hoc analysis. (**, p<0.01; ***, p<0.001). 
$ the parameter was calculated based in top and bottom value for the selected experiment 
# cannot be investigated further due to Covid-19 pandemic 
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4.8 Discussion 
4.8.1 Human glioblastoma cell lines are more aggressive model compared to 
rat C6 glioma cells  
Although C6 cells are considered to be a gold standard to study glioma, it is necessary 
to include the human glioblastoma model to see if PDE effects are translatable into 
human cells. Therefore, the study was extended using U87 and T98 cells. Despite the 
heterogeneity of human glioblastoma cell lines, Cheng and collagues reported that 
cyclic nucleotide signalling and PDE isoenzymes are well preserved in cultured cells 
providing a robust model to dissect PDE roles in human-derived cell lines (Cheng and 
Grande, 2007). 
In clinical findings, the only pathway that consistently appears in various cancer 
cells including glioblastoma and urothelial carcinoma, breast cancer, lung 
adenocarcinoma, stomach and oesophageal carcinoma (Daniel, Filiz and 
Mantamadiotis, 2016) is cAMP signalling. While glioma cells were reported to have 
cAMP suppressed, no information is available on non-cancerous cells such as 
HEK293S cells. Since HEK293S cells expressed many more PDEs compared to U87 
and T98 cells, it is possible that any modulation of cAMP levels will trigger PDE 
sequestration and tune down the second messenger. Considering that HEK293S cells 
are considered as “normal” cell lines, it is possible if the cAMP pathway controls other 
signalling events that may not directly correlate to cell growth. It is also worth noting 
that kidney epithelial cells may have different machinery where the elevation of cAMP 
by particular PDEs may promote cell proliferation. 
Although in human cell lines, each PDE inhibitor's span was not as high as that 
in C6 cells, almost all PDE inhibitors differentially suppressed human glioblastoma cell 
growth (Figure 4.7-4.8). The Pearson correlation calculation also showed that, 
regardless of a broad distribution of each data, a number of compounds were 
considered effective in U87 and T98 cells. 
 
4.8.2 Differential responses towards PDE inhibitors: U87 vs T98 cells 
Both human glioblastoma U87 and T98 cells have been widely used as glioblastoma 
models. Although many reports highlighted that both cells can be used as model for 
GBM, these cells may respond to chemotherapeutic agents differently due to biological 
varieties (Lee, 2016). 
The most significant feature observed between both glioblastoma models was 
the expression of PDE5A (Figure 4.3). PDE5A, a cGMP specific PDE, was highly 
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expressed in T98 cells compared to U87 and HEK293S cells. Despite this, there was 
a slight increase in cAMP upon stimulation with PDE5 inhibitors, sildenafil and tadalafil, 
on both T98 and U87 cells. Treatment of these compounds also positively correlated 
with PDE5 inhibitor-mediated anti-proliferative effect. Since many other PDEs were 
also expressed on human glioblastoma cell lines, elevation on cGMP by PDE5 
inhibition may promote activation of dual substrate PDEs by sequestering the signalling 
towards the cAMP pathway. However, this effect was not observed with zaprinast 
treatment, another PDE5, PDE6, and PDE9 inhibitors classified as cGMP specific 
PDEs. This inconsistency may occur because of the non-selective action of zaprinast, 
being an agonist towards GPR35 that is coupled with Gαi and Gα13 (Divorty et al., 
2015). While PDE5A was also present on HEK293S cells, the treatments with sildenafil 
and tadalafil enhanced HEK293S cell growth. The effect is likely due to PDEs general 
expression on HEK293S cells were more abundant than the glioblastoma models. 
Since HEK293S cells' origin was also different, this cell line may have different 
machinery by having PDEs to be coupled to different signalosomes. Indeed, this notion 
needs to be investigated further. 
This study found that cells that were sensitive towards forskolin appeared to be 
more responsive towards PDE treatments. In this particular case, despite forskolin 
increasing total cAMP levels, no effect was observed in HEK293S cell growth. This 
observation agrees with selection criteria, where most PDE inhibitors were deemed to 
not have an effect on HEK293S cells. Again, this indicates that probably PDEs may 
not directly control cell growth in cell originating from the kidney. Lack of PDE effect on 
non-cancerous HEK293S cells also demonstrates the selectivity of PDE inhibitor 
mediated-antiproliferative effect towards cancer cells.  
Further experiments targeting AC and PDEs concomitantly displayed distinct 
responses between U87 and T98 cells. It appears that in this study T98 cells are more 
sensitive compared to U87 cells. It has been reported that overexpression of PDE2A, 
PDE5A, and PDE10A dictate the sensitivity towards cAMP-elevating agents (Daniel, 
Filiz and Mantamadiotis, 2016). Although expression of PDE2 seems to be similar 
between both cells, in agreement with this finding, PDE5A and PDE10A were highly 
expressed in T98 cells than U87 cell lines. 
The ability of cells to translate their sensitivity towards cAMP to cell growth 
suppression has been reported to be associated to BIM expression, that was 
predominantly influenced by PDE expressions (Daniel, Filiz and Mantamadiotis, 2016). 
Upregulation of BIM negatively correlates with MAPK signalling that directly suppress 
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cell proliferation (Ciechomska et al., 2020). In addition, the dominance of RAF isoform 
is postulated to dictate the sensitivity of GBM cells towards cAMP elevating agents. 
Daniel and colleagues reported that in more sensitive cells, such as T98 cells, C-RAF 
is more dominant and plays a role in inhibiting MAPK signalling and upregulating 
expression of BIM (Daniel, Filiz and Mantamadiotis, 2016). In these sensitive cells, 
cAMP not only activates PKA but also further increases BIM expression. On the other 
hand, B-RAF dominance was found in more resistant cells. B-RAF existence will 
increase MAPK signalling and therefore suppress BIM expression.  
 
4.8.3 Elevation of cAMP by PDE inhibitor cocktail and concomitant targeting at 
AC and PDEs cannot optimally induce anti-proliferation in U87 cells 
As in the rat glioma model, the trequinsin effect can be mimicked by the combination 
of individual PDE2, PDE3, and PDE7 inhibitors in human cells. The effects were more 
apparent in short-term stimulation than in extended stimulation periods in a cell 
proliferation assay. Surprisingly, U87 cells were more prone to produce cAMP upon 
short-term stimulation by the compounds. The effects were indicated by the span 
(range between top and bottom responses in cAMP accumulation). Whilst there was 
no individual inhibitor that better than trequinsin, either potency and/or Emax of 
combination in pair was also improved. As expected, the PDE inhibitor cocktail curve 
was overlapped with trequinsin, suggesting that the combinatorial effect has a similar 
action with trequinsin in modulating total cAMP concentration.  
The resistance of U87 cells to cAMP-elevating agents is demonstrated by the 
fact that even at the highest concentration of trequinsin, it was only able to suppress 
cell growth by ~80% but only reduced 20% on lower concentrations (Figure 4.13). 
Except for response at 100 μM, the PDE inhibitor cocktail showed a similar effect to 
trequinsin on U87 cells. Although the study cannot provide further evidence on the 
toxic effect of trequinsin, the findings in rat glioma cells suggest that trequinsin 100 μM 
exerts its effect through activation of caspase-3/-7.  
Indeed, the equipotency of the PDE inhibitor cocktail was more evident in T98 
cells. The similar pattern was also observed in concomitant targeting of AC and PDEs, 
short-term stimulation giving rise to cAMP concentration cannot be directly translated 
into cell proliferation. Whilst there was clear potentiation by trequinsin in forskolin-
mediated cAMP production in all cells, the degree of antiproliferative effect was not as 
clear as that of rat glioma cells. In some reports, cAMP-elevating agents: forskolin, 
IBMX, and forskolin IBMX has a negative effect on cell growth on T98 cells, but the 
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effect was insignificant in more resistant cells such as U113 and U87 cells (Formolo et 
al., 2011). Therefore, differential responses from both cell lines strongly depend on 
each cell line's sensitivity. Due to the effect of Covid-19, the experiment cannot be 
performed to investigate whether anti-proliferation observed in human glioblastoma 
cell lines is due to cAMP/PKA pathways. 
Although anti-proliferative effects were insignificant in more resistant cell lines, 
the elevation of cAMP may also affect aggressiveness, invasive and migration ability, 
and induce cells into cell senescence. Xing et al. reported that activation on cAMP 
pathway through PKA/CREB/PGC1α induces metabolic reprogramming called the 
anti-Warburg effect (Xing et al., 2017). This indicates that elevating cAMP levels may 
not be only limited to control cell proliferation, but also to modulate other cellular 
responses such as metabolic functions or other second messengers. The cAMP-
elevating agents induce U87 cell differentiation from glioblastoma phenotypes onto 
normal astrocytes that are more prone to cytotoxic agents. Besides, treatment of PDE 
inhibitor with xanthine-based backbones reduced the aggressiveness of glioblastoma 
cells by modulating calcium levels and Rho-associated protein kinase (ROCK), which 
may be independent of cell proliferation (Kang et al., 2010; Ying Chen et al., 2014).  
 Since elevating cAMP by targeting AC and/or PDEs may not optimally affecting 
cell proliferation, targeting other proteins such as MRPs and those involved in second 
messenger signalling might be worth investigating further.  
 
4.8.4 Inhibiting MRP4 efflux transporter improves forskolin- and trequinsin-
mediated antiproliferative effect  
As mentioned in chapter 3, MRP4, an ABC-cassette efflux transporter, plays an 
essential role in maintaining the intracellular concentration of cAMP. MRP4 inhibition 
potentiated the effects of forskolin and trequinsin on glioblastoma cell growth (Figure 
4.15), which was not significantly observed in the previous sections.  
Although this study did not specify the MRP4 efflux transporter's expression 
level on both U87 and T98 cell lines, other studies have highlighted MRP4 upregulation 
in human glioblastoma taken from patients (Rama et al., 2014). Another report also 
showed that both U87 and T98 cells express a series of MRP transmembrane proteins 
responsible for chemotherapeutics resistance (Mohri, Nitta and Yamashita, 2000). 
Together with MRP4 as a cAMP efflux pump, both glioblastoma cell model and from 
clinical specimens, have been reported to express MRP1, MRP3, MRP5 and P-
glycoproteins (Pgp) that also extrude cytotoxic drug from the cells (Mohri, Nitta and 
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Yamashita, 2000; Calatozzolo et al., 2005; Decleves et al., 2008; Tivnan et al., 2015). 
In agreement with this, the degree of anti-proliferative effect of cisplatin on 
glioblastoma cell lines in this study was lower than that of rat glioma and HEK293S 
cells. This effect implies the presence of efflux pump may reduce not only cAMP but 
also chemotherapeutics. Thereby these therapeutic agents have never reached 
effective exposure to modulate cell growth signalling. Taken together, the action of 
MRP4 and other transmembrane transporter contributes to the resistant phenotypes 
and sensitivity of glioblastoma cell models.  
Given the impacts of Covid-19, investigation on the effect of MRP4 blockage on 
cAMP production and on PDE inhibitor cocktail-mediated responses cannot be 
included. It would be of interest to dissect the role of MRP4 and presumably other MRP 
proteins in regulating cAMP levels and cell growth.  
 
4.8.5 Inhibiting SOCE as another approach to inhibiting human glioblastoma 
cell growth: is it a feasible target?  
Abnormalities in calcium signalling have been reported to be involved in various 
pathological conditions. A previous study from Rahman and colleagues found  a series 
of compounds were characterised to inhibit mainly SOCE, but not IP3R and voltage-
gated calcium entry (Rahman and Rahman, 2017). Two classes of compounds were 
identified to be able to inhibit SOCE, including PDE inhibitors (trequinsin, roflumilast, 
BAY 73-6691) and DHODH inhibitors (vidoflunimus, brequinar sodium, Pyr6, and 
teriflunomide). The mechanism of action of SOCE was further investigated to 
determine the particular protein target these compounds work on inhibition of TRPC-
mediated calcium entry and formation STIM1-Orai1 complexes. Whilst no specific 
action from almost all the compounds, only trequinsin and roflumilast inhibited TRPC, 
but not the STIM-Orai1 clustering formation. In contrast, vidoflunimus was found to be 
specific inhibiting STIM1-Orai puncta formation (Rahman, 2020). 
PDE inhibitors, roflumilast and trequinsin, were found to be able to inhibit SOCE 
and TRPC-channel besides their activity in elevating cAMP levels (Rahman, 2020; 
Safitri et al., 2020). However, none of these compounds affected STIM1-Orai1 complex 
formation (Rahman, 2020). Although the idea of crosstalk between calcium and cAMP 
signalling has been initiated, but the interconnected point between these pathways has 
not been completely elucidated. To date, the mechanism of interaction between both 
second messengers is postulated through cAMP induced SOCE formation (Willoughby 
et al., 2012) and SOcAMPS mechanism (Lefkimmiatis et al., 2009; Maiellaro et al., 
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2012) . The latter has been reported to be independent from calcium influx changes 
but requires calcium depletion in the ER leading to STIM1 clustering at the plasma 
membrane (Lefkimmiatis et al., 2009; M. Hofer, 2012; Spirli et al., 2012; Ahuja et al., 
2014). Since this particular part was not explored in the previous nor current studies, 
it would be interesting to unravel the crosstalk between cAMP and calcium signalling 
and how PDE inhibitors affect this regulation.   
The second classes, DHODH inhibitors, displayed differential responses in 
glioma/glioblastoma cell proliferation. As the most potent inhibitor for human DHODH 
(Sainas et al, 2017), brequinar sodium was effective in suppressing cell proliferation in 
C6 and T98 cells, but not U87 cells. Only did vidoflunimus exert anti-proliferative effect 
in a dose-dependent manner on more resistant model, U87 cells. In addition, 
vidoflunimus as a SOCE inhibitor also disrupted NFAT translocation to the nucleus 
(Rahman, 2020). Considering that NFAT is highly expressed in glioma cell (Urso et al., 
2019), it is assumed that the NFAT transcription factor plays a more critical role in U87 
cells than other glioblastoma models. Taken together, SOCE inhibition by DHODH 
inhibitors appeared to contribute to anti-proliferative actions. However, further 
validation is necessary to see if these compounds act through different mechanisms.  
 
4.9 Summary 
Using human glioblastoma cells that were reported to be more aggressive and more 
resistant to any treatment, we validated our finding that were previously validated in rat 
derived cells. We found that small compounds that are classified as PDE inhibitors 
were found to be active in human glioblastoma T98 and U87 cells, although the activity 
was not as prominent as in rat C6 cells. There was a strong correlation between cAMP 
production and cell growth suppression, suggesting that targeting cAMP signalling may 
become a feasible target to control cell growth. Applying the selection criteria, more 
PDE inhibitors were revealed as promising compounds for future studies compared to 
C6 cells.  
Similar to the previous study, trequinsin showed remarkable pharmacological 
activity in modulating cAMP levels which led to suppressing cell growth. Using three 
different cell lines, we proved that trequinsin inhibits multiple PDEs which include 
PDE2, PDE3, and PDE7. Although in HEK293S cells, the trequinsin effect was 
generated through a cAMP-independent mechanism via caspase-3/-7 activation. 
Unfortunately, concomitant targeting of both AC and PDEs, by combining forskolin and 
trequinsin only affected short-term cAMP production but failed to suppress cell growth. 
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However, the combination of forskolin and PU23, an MRP4 inhibitor, led to greater 
suppression compared to forskolin alone. Therefore, it is possible that overexpression 
of a cAMP efflux transporter in glioblastoma may attenuate any antiproliferative effect 
of PDE inhibition. 
Not only was this study performed to investigate cAMP signalling, but it revealed 
a potential role of SOCE/calcium pathways in modulating cell proliferation. Here, 
compounds that were previously characterised to inhibit DHODH and modulate SOCE, 
were examined using the cell proliferation assay. Although only vidoflunimus was 
found to be effective in the more aggressive U87 cell lines, almost all compounds, 
except teriflunomide, reduced cell growth after 72h treatment, in both C6 and T98 cells. 
 




IDENTIFYING DUAL-ACTION LIGANDS AGONISING A2AR AND 
INHIBITING PDE10A 
 
5.1  Introduction  
In the previous chapters, impaired cAMP signalling was shown to have an impact on 
cell growth and therefore targeting PDEs may offer therapeutic benefits to suppress 
tumour progression in glioma and glioblastoma models. Amongst the 24 types of PDE 
isoenzymes, PDE10A is often thought to play a significant role in maintaining various 
physiological functions within the brain, including controlling behavioural and motor 
functions (Fujishige, Kotera and Omori, 1999). Due to the abundance of PDE10A 
expression in the striatum, this particular enzyme has been shown to be involved in 
various neurological diseases such as psychosis, Huntington’s disease, and 
schizophrenia (Siuciak et al., 2006; Grauer et al., 2009; Niccolini et al., 2015). 
Recently, PDE10A also has been reported to be involved in caloric intake and therefore 
is proposed to be a potential target to type 2 diabetes mellitus treatment (Nawrocki et 
al., 2014). Furthermore, PDE10A has been shown to contribute to tumourigenesis in 
numerous types of cancers including colorectum, breast, brain, and lung (Lindsey et 
al., 2016; Zhu et al., 2017), although the mechanism of action is not well understood 
to date.  
PDE10A is a dual-substrate PDE that degrades both cAMP and cGMP 
(Soderling, Bayuga and Beavo, 1999). Although PDE10A has been shown to bind to 
both cyclic nucleotides, kinetic studies suggest that cGMP hydrolysis by PDE10A may 
be regulated by cAMP (Soderling, Bayuga and Beavo, 1999). Interestingly, compared 
to other cGMP-hydrolysing PDE families including PDE2, PDE5, and PDE6; PDE10A 
has a higher affinity towards cAMP (Soderling, Bayuga and Beavo, 1999), making this 
enzyme to be known as a cAMP-inhibited dual-substrate PDE (Kenji Omori and Kotera, 
2007). Given its unique property to modulate intracellular levels of cAMP, this study 
focused on concomitant targeting of PDE10A and other proteins that mediate cAMP 
synthesis at the receptor levels and their concomitant effect to modulate cell 
proliferation. To do this, the study was extended to include A2AR which is postulated to 
be a target that will increase intracellular cAMP levels upon activation (Sattin and Rall, 
1970; Londos and Wolff, 1977; Calker, Müller and Hamprecht, 1979).  
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A2AR is a subtype of the adenosine receptors (other subtypes include A1R, 
A2BR, and A3R) which is predominantly coupled to Gs and therefore activation of this 
receptor stimulates AC leading to cAMP production. Due to its localisation in the brain, 
A2AR plays an important role in modulating the release of all known neurotransmitters 
and neuromodulators, including neuropeptides and  neurotropic factors (Sebastiao and 
Ribeiro, 2009). The A2AR has been reported to be linked to CNS disorders such as 
epilepsy, hypoxia, ischemia, Parkinson’s, Alzheimer’s, and Huntington’s Diseases 
(Dale and Frenguelli, 2009; Fredholm, 2010; Knight et al., 2016b). In addition, A2AR 
can also be found in adipose tissues, cardiac tissues, and inflammatory cells 
(Sachdeva and Gupta, 2013). A2AR has been shown to be overexpressed in many 
cancer cells such as colorectal, non-small lung cancer (NSCLC). Therefore, it may play 
a role in tumour progression (Inoue et al., 2017).  
Whilst the previous chapter validated the approach of using ligand combinations 
to modulate cAMP levels through numerous proteins, in this chapter the study was 
conducted using a different approach, utilising a single ligand that synergistically 
modulates multiple targets. Here, structure-based virtual screening was performed by 
Dr. Kalash (University of Cambridge) to identify compounds that may simultaneously 
inhibit PDE10A and activate A2AR. Top hits were selected based on the optimum 
values of computing Matthews correlation coefficient (Kalash et al., 2017). In particular, 
six compounds with triazoloquinazoline backbones, which have been found initially to 
inhibit PDE10A (Kehler et al., 2011), were shown to bind to the orthosteric sites of the 
A2AR. These compounds were further reported to display differential extent of 
selectivity across all adenosine receptors in yeast and mammalian surrogate 
overexpression systems (Winfield, 2017). The structure of the compounds as well as 
their pharmacological parameters (pIC50) at PDE10A, determined previously through 
in vitro experiments (Winfield, 2017), are summarised in the table 5.1.  
While the use of overexpression system provides benefits for dissecting the 
molecular mechanism, using more physiologically relevant cells or tissues confers 
distinct advantages for translating the effect across physiologically relevant settings. 
The data presented in this chapter is part of a wider study to evaluate 
triazoloquinazoline-based compounds as dual-target ligands for the A2AR and 
PDE10A. Where appropriate, I will summarise the studies conducted by my co-authors 
(Dr. Kalash and Dr. Winfield) to enable full understanding of the story, while focussing, 
in depth, on my contributions to the project. Data related to the use of yeast as a screen 
platform and heterologous overexpression are cited as appropriate. Summary of 
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characterisation of triazoloquinazoline-based compounds at the A2AR prior to my 
contributions are displayed in Table 5.2-5.4 (details are available in Appendix 1). Dr. 
Kalash performed the in silico docking and taget identifications aspects of the project, 
Dr. Winfield characterised triazoloquinazolines, compound 1-6 for adenosine receptor 
subtype activity (using yeast assays and CHO-KI cell lines) while I determined the 
affinity constants for the triazoloquinazolines compounds at the A2AR and 
characterised their activity on on lung cancer cell lines. This study has now been 
published (Kalash et al., 2021) for which I am a joint-first author. Finally, in this chapter 
I describe how I have extended the investigation of the triazoloquinazolines into glioma 
and glioblastoma models that differentially express A2AR and PDE10A. 
 
Table 5.1 
The reference of triazoloquinazolines used in this study 
 
Structure Compound reference PDE10A 
pIC50a Kehler, 2011 Our reference 
 
46 Compound 1 9.87 ± 0.10 
 
5c Compound 2 6.71 ± 0.03 
 
5a Compound 3 7.01 ± 0.07 
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Structure Compound reference PDE10A 
pIC50a Kehler, 2011 Our reference 
 
44 Compound 4 8.47 ± 0.04 
 
40 Compound 5 7.49 ± 0.10 
 
45 Compound 6 8.62 ±0.12 
a The potency of selected compound to inhibit 50% of PDE10A activity. The experiment 
was performed by Dr. Winfield (Winfield, 2017).  





Potency (pEC50) and Emax values for NECA, CGS 21680 and trizaoloquinazoline stimulation of adenosine A1, A2A and A2B receptors in 
yeast expressing GPA1/Gαi1/2 or GPA1/Gαs and CHO-K1-A3R cells. 
 A1R - GPA1/Gαi1/2 A2AR - GPA1/Gαs A2BR - GPA1/Gαs CHO-K1-A3R 
pEC50a Emaxb pEC50a Emaxb pEC50a Emaxb pEC50a Rangec 
NECA 5.87 ± 0.1 100.40 ± 3.2*** 6.27 ± 0.2*** 91.14 ± 4.8*** 4.15 ± 0.1* 99.76 ± 13.2*** 9.50 ± 0.2*** -44.19 ± 2.7*** 
CGS21680 ND ND 4.80 ± 0.2** 107.2 ± 12.2* ND ND 7.58 ± 0.2*** -52.87 ± 2.4*** 
Compound 1 NR NR 5.29 ± 0.2*** 69.01 ± 1.9*** NR NR NR NR 
Compound 2 NR NR 5.91 ± 0.2*** 54.33 ± 5.1*** NR NR NR NR 
Compound 3 NR NR 5.79 ± 0.2*** 60.16 ± 5.5*** NR NR NR NR 
Compound 4 5.44 ± 0.3 060.88 ± 9.0*** 6.14 ± 0.5*** 38.78 ± 5.3*** 4.79 ± 0.2* 17.62 ± 2.5*** 9.43 ± 0.1*** -17.04 ± 0.9*** 
Compound 5 4.95 ± 0.6     22.7 ± 8.1*** 8.33 ± 0.9***   9.96 ± 4.0*** 4.64 ± 0.3* 08.66 ± 2.2*** NR NR 
Compound 6 NR NR NR NR NR NR NR NR 
 
Data ± SEM of 4-6 individual replicates 
a Negative logarithm of agonist concentration producing half-maximal response 
b Maximal response observed upon agonist stimulation, as a percentage of that observed upon stimulation with 100 μM NECA 
c Range of response, as a percentage of that observed upon stimulation with 100 μM forskolin 
ND – Not determined – full dose-response curve not feasible 
NR – No response 
Statistical difference between each agonist and NECA was calculated using a one-way ANOVA with Dunnett’s post-test (*, p < 0.05, **, p 
< 0.01, ***, p < 0.001) 










Potency (pEC50) and range of responses for cAMP production upon CGS 21680 and triazoloquinazoline stimulated cAMP accumulation 
in CHO-K1-A2AR and CHO-K1 cells. 
 CHO-K1-A2AR CHO-K1 CHO-K1-A2AR vs CHO-K1  
pEC50a Rangeb n pEC50a Rangeb n Δ pEC50c Δ Ranged 
CGS21680    8.78 ± 0.2    86.33 ± 7.2 9 ND ND 4 - - 
Compound 1    7.32 ± 0.2 61.14 ± 5.2*** 8 6.49 ± 0.3 20.19 ± 2.7 4 0.83 ± 0.5 40.95 ± 7.80 
Compound 2 6.29 ± 0.5***    30.50 ± 8.1 6 4.85 ± 0.2 39.46 ± 3.9 4 1.44 ± 0.6  -8.96 ± 10.6 
Compound 3    7.26 ± 0.3**    28.95 ± 6.3 6 5.90 ± 0.3 18.32 ± 2.3 4 1.21 ± 0.5 10.63 ± 8.70 
Compound 4    7.55 ± 0.2    37.71 ± 2.9** 5 6.62 ± 0.2 18.75 ± 1.7 4 0.93 ± 0.6 18.96 ± 3.60 
Compound 5    7.70 ± 0.4**    27.42 ± 4.4 6 6.30 ± 0.2 19.49 ± 1.7 4 1.28 ± 2.4 7.93 ± 6.1 
Compound 6    6.52 ± 0.4    33.87 ± 5.3 6 6.35 ± 0.3 31.42 ± 4.6 4 0.17 ± 0.8 2.45 ± 9.9 
 
Data ± SEM of n individual replicates 
a Negative logarithm of agonist concentration producing half-maximal response 
b Percentage range of response observed upon agonist stimulation, relative to that obtained with CGS21680 stimulation in each cell type. 
c Change in pEC50 between CHO-K1 and CHO-K1-A2AR cells (Δ pEC50 = pEC50(CHO-K1-A2AR) - pEC50(CHO-K1)) 
d Change in range between CHO-K1 and CHO-K1-A2AR cells (Δ Range = Range (CHO-K1-A2AR) - Range (CHO-K1)) 
ND – Not determined, full dose-response curve not feasible 
Statistical difference, between CHO-K1-A2AR cells and CHO-K1 cells, was calculated using pair-wise t-tests, for each agonist (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001) 
Data was taken from the previous study performed by Dr. Winfield (University of Cambridge) 
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Table 5.4 
The summary of triazoloquinazolines-based compound according to previous 
characterisation on yeast and heterologous overexpression system 
Compound  Summary of previous characterisation  
Compound 1 PDE10 inhibitor, selective A2AR agonist 
Compound 2 PDE10 inhibitor, selective A2AR agonist 
Compound 3 PDE10A inhibitor, selective A2AR agonist 
Compound 4 PDE10A inhibitor, non-selective AR agonist 
Compound 5 PDE10 inhibitor, A2AR and A2BR agonist 
Compound 6 PDE10 inhibitor, no effect on AR 
 
5.2  Triazoloquinazolines displayed differential binding affinities at A2AR 
The initial findings from the computational study by Kalash suggested that 
triazoloquinazolines (compound 1-6) bound to A2AR with the involvement of His252 and 
Val84 residues leading to conformational changes (Kalash et al., 2017). Here, the 
finding from the in-silico study were to be confirmed in the overexpression 
heterologous mammalian systems to specifically characterise their binding at the A2AR.  
To do so, the ligand binding studies were conducted to determine the binding 
properties of triazoloquinazoline at the A2AR. Traditionally, competitive radioligand 
binding assays are performed (Kenakin, 1988; Bylund and Toews, 1993). In this study, 
however, radioligands were substituted with fluorescent ligands, and any effects on the 
ligand binding properties were evaluated using Nano-BRET technology (Stoddart et 
al., 2015). Aside from its practicality and cost efficiency, Nano-BRET assays offer 
several advantages including utilising the robust and sensitive methods, a lower 
chance to cause steric hindrance, and allowing the ligand-receptor interaction to be 
tracked in real-time in live cells (Xu, Piston and Johnson, 1999; Stoddart et al., 2015; 
Dale et al., 2019). Therefore, BRET-based ligand binding assays have potential for 
profiling applications.  
CA200645 was selected to be the probe in this ligand binding assay. The 
compound is a xanthine amine congener (XAC)-based fluorescent antagonist and 
shows differential affinity towards adenosine receptor families CA200645 has been 
routinely used to characterise ligand properties towards A1R and A3R (Stoddart et al., 
2012; Barkan et al., 2019; Soave et al., 2020), and the results have shown that this 
compound displays high binding affinity towards A1R and A3R subtypes. Despite 
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having lower affinities towards the remaining adenosine receptors, CA200645 can still 
be used to determine binding properties at A2AR and A2BR.  
Before establishing the binding affinity of triazoloquinazoline-based 
compounds, the affinity constant, KD (dissociation constant of CA200645) was 
calculated in HEK293T cells transiently transfected with human A2AR N-terminally 
tagged with Nluc. Firstly, the saturation assays were performed to determine the KD 
parameter, during which a series of concentrations of CA200645 were applied to the 
cells. The BRET signal reached steady state 10 minutes after the addition of 
CA200645 (Figure 5.1A), and hence the 10-minute time point was used to generate a 
saturation curve (Figure 5.1C). In addition, cells were also co-treated with both 
CA200645 at a range of concentrations and a selective A2AR antagonist ZM241385 at 
10μM was used to determine the non-specific binding at A2AR (Figure 5.1B). From the 
saturation curve (Figure 5.1C), the KD was calculated to be about 200nM, yet an 
apparent equilibrium state was not achieved. Therefore, there is a possibility that the 
KD reported here may be overestimated. Many reports have highlighted that kinetic 
studies offer a better accuracy in obtaining the true KD value (Sullivan et al., 2006; 
Hulme and Trevethick, 2010). To further the true KD parameter, kinetic studies were 
next performed to act as a comparison to the constant determined by the saturation 
binding assays.  
 
 
Figure 5.1 Representative traces of BRET signal in ligand binding saturation 
assay of CA200645 in the absence or presence of ZM241385. HEK-293T cells 
transiently transfected with Nluc-A2AR were stimulated with increasing concentrations 
of fluorescent A2AR ligand CA200645 for 30 minutes in the absence (A) or presence of 
selective A2AR antagonist ZM241385 (B).  Data were background subtracted to the 
vehicle and are expressed as ligand-induced ΔBRET. The ΔBRET signal at t=10 
minute was taken to generate saturation curve shown in (C). The representative 
saturation curves were fitted using one-site binding in GraphPad Prism 8.4.  
 
Similar to the saturation binding assays, CA200645 was applied to HEK293T 
cells transiently transfected with Nluc-A2AR until reaching plateau. Subsequently, 
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CGS21680, a selective agonist of A2AR, was injected to displace binding of CA200645 
from Nluc-A2AR (Figure 5.2A). In spite of the unusual association binding curve, steady 
state was reached after 5 minutes. Surprisingly, following the fitting of the data set to 
the association-dissociation binding kinetic model, a KD of 65 nM was obtained (Figure 
5.2B). This value calculated using a kinetic binding approach was approximately 3-fold 
lower than that obtained with the use of saturation binding to reach equilibrium. 
Therefore, the KD obtained from the kinetic binding assay was used for the competition 
assays to determine binding properties of triazoloquinazolines.  
 
 
Figure 5.2 Determination of dissociation constant of CA200645 using BRET-
based kinetic binding studies. Kinetic binding curve of CA200645 expressed 
HEK293T cells transiently expressing Nluc-A2AR. After 19 minutes of association with 
40 nM CA200645, CGS21680 was injected to give a final concentration of 10 μM in 
order to displace the fluorescent probe. The curve was fit into “association then 
dissociation” regression built in Prism 8.4.3 by constraining maximal specific binding 
(Bmax) to 0.1 and non-specific binding (NS) to 0.01.  
 
Characterisation of the binding properties of selected triazoloquinazolines-
based compounds was then performed by applying CA200645 together with a series 
of concentration of test compounds in the HEK293T cells transiently expressing Nluc 
A2AR. Taken into the account the background noise that may affect the signal, a 
concentration above the calculated KD (300nM) was chosen to ensure that the number 
of occupied receptors is sufficient to give window of observation from displacement.  
 To confirm if this approach was suitable for evaluating the binding properties of 
the test compounds, the following reference compounds were included: CGS21680, 
NECA, and isoprenaline. As noted, CGS21680 is an A2AR selective agonist, whereas 
association dissociation
CA200645 40nM + CGS21680 10 μM
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NECA is a non-selective adenosine receptor agonist (Jarvis et al., 1989; Monopoli et 
al., 1994). Isoprenaline, which is a beta-adrenoceptor agonist, was also included as a 
negative control to show that the compounds selectively bind A2AR. The representative 
traces of BRET signal are displayed in Figure 5.3 which were recorded over 20 minutes 
after co-treatment with CA200645 and the reference compounds. As displayed in 
Figure 5.3A and B, there was a dose-dependent decrease in BRET signal, suggesting 
CA200645 was displaced by CGS21680 and NECA, respectively. While these two 
compounds were shown to bind to the A2AR, isoprenaline failed to compete with the 
binding of fluorescent probe (Figure 5.3C). Using this assay, the affinity constants (pKi) 
obtained in this study was 6.39 ± 0.04 for CGS21680 and 6.36 ± 0.09 for NECA (Figure 
5.3D, Table 5.5). However, these values were slightly lower that those previously 






Figure 5.3 BRET signal traces from competition binding assays of reference 
compounds at A2AR. Representative ligand induced ΔBRET traces in competition 
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binding method to determine binding properties of CGS21680 (A), isoprenaline (B), 
and NECA (C). After 5 minutes curve seems to be reached plateau in for almost all 
reference compounds. Ten-minute time point was taken to generate competition curve 
(D).  
 
Having validated the ligand binding approach to determine the pKi values of the 
reference compounds, the binding affinities of triazoloquinazolines were determined. 
As shown in Figure 5.4A, all triazoloquinazolines were able to displace the binding of 
CA200645 at A2AR in a dose-dependent manner. The association constants were 
determined by fitting the data set to “one-site Ki” equation where KD and the 
concentration of hot ligand were set to be at 65 nM and 300 nM, respectively. The 
summary of pKi from each test compound is displayed in bar charts (Figure 5.4B) and 
Table 5.5. The rank order of affinities for the triazoloquinazoline compounds at the 
A2AR was as follows: compound 4> compound 2> compound 6> compound 1= 
compound 3> compound 5 (note: under condition tested, compound 5 was unable to 
fully displace CA200645, with the maximum inhibition up to 37% compared to 
CGS21680) (Figure 5.4). Interestingly, compound 6 also bound to the A2AR from this 
assay. Given the fact that previous validation compound 6 did not display any effect in 
a yeast assay (Table 5.2, Appendix 1), therefore it is probable that compound 6 may 
act as an antagonist to the A2AR. However, further validation is necessary to confirm 
this hypothesis.  
 
 
Figure 5.4. Triazoloquinazolines were confirmed to bind at the A2AR. (A) 
Displacement curve of CA200645 (300nM) by triazoloquinazolines. The curves were 
generated by fitting the data to the “one-site Ki” equation where KD and concentration 
A. B.
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of hot ligand were set to 65 nM and 300 nM, respectively. Data points are the mean ± 
SEM from 3-27 repeats performed in duplicate. (B) The summary of binding affinities 
(pKi) of tested ligands. pKi values were calculated from inhibition of CA200645 binding 
at equilibrium to Nluc-A2AR-expressed HEK293T cells. # Cmpd 5 did not fully displace 
binding of CA200645 under condition tested. Statistical significance (***, p<0.001) 
compared to CGS21680 was determined by one-way ANOVA with Dunnett’s post-test 
 
Table 5.5  
Binding affinities of triazoloquinazolines at the human A2AR using fluorescent probes 
CA200645 
Compound pKia pKi ref b n 
CGS21680     6.39 ± 0.04 6.7 – 8.1 27 
NECA     6.36 ± 0.09 6.9 – 8.7 6 
Isoprenaline           N/R N/A 4 
Compound 1     5.26 ± 0.17*** N/A 7 
Compound 2     6.01 ± 0.09 N/A 4 
Compound 3 5.27 ± 0.13*** N/A 8 
Compound 4     6.70 ± 0.15 N/A 6 
Compound 5 N/A N/A 3 
Compound 6 5.55 ± 0.03*** N/A 5 
apKi values were calculated from the inhibition of equilibrium fluorescent probe 
CA200645 binding to HEK293T cells expressing Nluc-A2AR. 
bpKi reference values were accessed from 
https://www.guidetopharmacology.org/GRAC/LigandListForward?type=Synthetic-
organic&database=all#C  
N/A – not available 
N/R – no results 
Statistical significance (***, p<0.001) compared to CGS21680 was determined by one-
way ANOVA with Dunnett’s post-hoc analysis. 
  
To conclude, based on previous characterisation using yeast and heterologous 
overexpression system, it is confirmed that all compounds inhibit PDE10. While 
compound 1-3 are found to be selective A2AR agonist, compound 4 elicited activity on 
all adenosine receptor subtypes and compound 5 also stimulated A2BR-mediated 
responses. According to ligand binding data, it suggests that compound 6 may act as 
an antagonist to the A2AR.   
 
5.3  Non-small lung cancer cell lines as the appropriate model to validate 
multi-target ligand against A2AR/PDE10A 
To validate that triazoloquinazoline compounds have synergistic mechanisms to 
activate A2AR and inhibit PDE10A simultaneously, NSCLC cell lines were used as they 
show differential cumulative expression of A2AR and PDE10A (Figure 5.5). These cells 
can be further categorised as LUSC (lung squamous cell carcinoma) and LUAD (lung 
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adenocarcinoma). In this study, four types of cells were used: LK2 and H520 cells 
(LUSC), as well as H1792 and H1563 cells (LUAD). Despite the differences between 
these cell lines in molecular machinery, their endogenous expression of adenosine 
receptors and PDE10A warranted their use in the subsequent pharmacological 
characterisation studies. 
 In order to evaluate the expression levels of adenosine receptor subtypes and 
PDE10A in these four cell lines, rt-PCR was performed. As shown in Figure 5.5A, the 
aforementioned cell lines expressed, to different extent, the 4 adenosine receptors 
subtypes and PDE10A. While all cell lines expressed almost all adenosine receptors, 
there was no detectable band for A2AR and A3R in LK2 cells and very low levels of A3R 
expression in H1563 cells (Figure 5.5B). The expression of PDE10A amongst these 
cells were also diverse with LK2 expressing the lowest, followed by H1792 cells, and 
H1563 cells. However, PDE10A was not detected in H520 cell lines. Interestingly, 
these systems had cumulative expression of both targets A2AR and PDE10A, with the 
cumulative expression as follows: LK2< H520< H1792< H1563 (Figure 5.5B). These 
results indicated that using these cells lines that endogenously express proteins of 
interests may serve as useful cell systems for validation of compounds at 
physiologically relevant settings.  
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Figure 5.5 Non-small lung carcinoma (NSCLC) cell lines differentially expressed 
different levels of adenosine receptors and PDE10A. (A) Representative gel picture 
of amplified adenosine receptors and PDE10A genes. (B) Semi-quantitative 
expression profile of adenosine receptors and PDE10A in at mRNA levels. Expression 
of each gene of interest was normalised relative to GAPDH and was determined in 
LK2, H520, H1792, and H1563 cell lines. C) Comparison of cumulative A2AR plus 
PDE10A expression amongst NSCLC cells. Data are expressed as the mean ± SEM 
from 4-6 individual repeats.  
 
5.4 Synergistic activities of dual mechanism of PDE10A inhibition and A2AR 
agonism on ligand-mediated cAMP accumulation leading to cell growth 
suppression in human lung cancer cell lines 
5.4.1 Triazoloquinazolines promoted cAMP production in human NSCLC cells 
Having determined the individual expressions of adenosine receptor subtypes and 
PDE10A in the designated NSCLS cell lines, compound 1-6 were further validated in 
these physiologically relevant cell lines. In this experiment, CGS21680 was also 
included, which acted as the reference compound to compare cAMP responses with 
the test compounds. Since the expression of A2AR varied amongst the four cell lines, 
different extents of cAMP accumulation were observed upon stimulation with 
CGS21680 (Figure 5.6A). Here, the LK2 cells showed the weakest cAMP accumulation 
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potency (pEC50 4.84 ± 0.38) and efficacy relative to forskolin (pEC50 6.85 ± 1.62) 
responses upon CGS21680 stimulation (Table 5.6). The potencies were increased in 
H1563 (pEC50 5.34 ± 0.21), H520 (pEC50 5.46 ± 0.11), and H1792 (pEC50 5.52 ± 0.17) 
cell lines, which results aligned well with the previously determined A2AR expression 
profile (Figure 5.2, Table 5.6).  
Compound 1 displayed the negligible activity in LK2 cells, which was improved 
when applied to H520 and H1792 cells, with the pEC50 of 5.49 ± 0.24 and 6.09 ± 0.22, 
respectively. The most potent activity of compound 1 was observed in H1563 cells 
(pEC50 6.44 ± 0.11) which express the highest levels of cumulative A2AR and PDE10A 
expression (Figure 5.5B). In general, compound 1 activity was enhanced in the cells 
that expressed higher cumulative expression levels of A2AR and PDE10A (Figure 
5.5C). As for compound 5, its efficacy exerted a similar pattern to compound 1, which 
was in agreement with the previous characterisation in yeast and overexpression 
mammalian systems (Winfield, 2017). Interestingly, compound 2 (Figure 5.6C) showed 
consistent effects regardless of cell types suggesting the effect was most likely due to 
action independent of A2AR and/or PDE10A. Furthermore, compound 3 elevated 
similar cAMP responses in both LK2 and H1563 cells with potency values in the 
micromolar range (Figure 5.6D, Table 5.6). There was also an increase of efficacy 
upon stimulation with compound 3 in H520 (Emax 22.36 ± 1.53) and H1792 (Emax 24.17 
± 1.83) cells compared to other cell lines. As expected, the results demonstrated here 
were consistent with the previous study highlighting the action of compound 3 towards 
A2AR, which were both H520 and H1792 cells expressed to the similar extent on A2AR 
expression (Figure 5.5).  
Due to additional action towards A2BR, compound 4 promoted a higher cAMP 
production in cells that showed higher level of A2BR. This is verified by its increased 
activity in H1792 cells (pEC50 of 7.47 ± 0.31) that expressed more A2BR than LK2 cells 
(4.74 ± 0.61) (Figure 5.6E). Although compound 6 showed affinity at the A2AR in the 
previous ligand binding experiment, there was only a slight increase of cAMP 
accumulation upon stimulation with compound 6 in NSCLC cell lines (Figure 5.6G, 
details in Table 5.6). It is possible that cAMP elevation by compound 6 was generated 
by rolipram (a PDE4 inhibitor) which was present in the stimulation buffer. 
Corroborated with the previous study using the yeast system expressing A2AR, here 
compound 6 also did not show any pharmacological action. These indicate that 
compound 6 may act as an antagonist at the A2AR, as described in Table 5.4 and 
Appendix 1.  
Chapter 5                                       Dual target ligand at A2AR/PDE10A 
 197 
 
Figure 5.6 Multitarget ligand mediated cAMP accumulation on NSCLC cell lines. 
Accumulation of cAMP was determined following 30 minutes stimulation with 
compound 1-6 (B to G) in LK2, H520, H1792, and H1563 cells in the presence of 
rolipram. CGS21680 (A) is a selective A2AR compound and is used as a reference 
compound for cAMP accumulation assay. Data are expressed relative to the maximal 
response produced by 100 μM forskolin. Values are expressed as mean ± SEM of 4-
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5.4.2 Triazoloquinazolines mediated anti-proliferative effects on human NSCLC 
cell lines 
Having established that triazoloquinazolines were able to modulate cAMP levels to 
different extents in NSCLC cell lines, cell proliferation assays were performed to 
investigate if these compounds influence cell growth. Here, forskolin, a pan-AC 
activator, was used as a reference compound to determine the effect of cAMP 
activation on cell growth. Upon treating the four cell lines with forskolin for 72 h, 
forskolin supressed cell growth by approximately 25% (Figure 5.7A). Next, these cell 
lines were treated with CGS21680. Interestingly, cell growth on selected cells was 
unaffected by selective agonism of A2AR induced by CGS21680 (Figure 5.7B). This 
suggests that short-lived CGS21680-mediated cAMP accumulation did not lead to anti-
proliferation, which may be explained by receptor desensitisation, as similar effect was 
also observed in glioma cells (chapter 3) where stimulation at receptor levels were 
inadequate to alter cell proliferation.  
These four cell lines were treated with compound 1-6 for 72h in order to 
compare their effect on cell proliferation with the reference compound, forskolin. Here, 
change to higher potencies and larger suppressions of compound 1 and 5 was 
observed on NSCLC cell lines (Figure 5.7C and G, Table 5.6). These observations 
aligned with the previous results in the cAMP accumulation assay (chapter 5.3.1), 
whereby potent cAMP responses induced by compound 1 and 5 were presumably 
mediated through the synergistic agonism of A2AR and inhibition of PDE10A. As 
expected, the activity of compound 2 across lung carcinoma cell lines remained 
constant, suggesting the anti-proliferative or cytotoxic effects were independent of the 
dual targets (Figure 5.7D). Furthermore, compound 3, previously established as a 
selective A2AR receptor agonist (Table 5.4), induced a similar extent of anti-proliferative 
effects on all cell lines (Figure 5.7E). As for compound 4, its effect aligned with its ability 
to elevate cAMP levels in the presence of A2ABR, with greater suppression on cell 
growth observed in cells expressing higher A2BR (H1792 cells) (Figure 5.7F). Finally, 
although there were slight increases in cell proliferation at high concentration, 
compound 6 did not significantly affect cell growth on any human lung cancer cell lines 
(Figure 5.7G). To determine the extent to which the compounds inhibit cell growth, 
again, a proliferation factor, which was similar to the selection criteria in chapter 3 and 
4, was applied by multiplying potency (pIC50) and span from individual anti-proliferation 
curves (from Figure 5.7). 
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Figure 5.7 Differential anti-proliferative effect in NSCLC cell lines after 
triazoloquinazolines treatment. Dose-response curves of forskolin (A), CGS21680 
(B), compound 1 to 6 (C-H) on LK2, H520, H1792, and H1563 cells. Cell survival was 
determined upon 72h treatment. Data are expressed as percentage survival relative to 
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5.5 Multi-target ligands simultaneously displayed better efficacy across 
human lung cancer cell lines corresponding to cumulative expression of 
A2AR and PDE10A  
To determine if the modulation of cAMP concentration had any association with anti-
proliferative effect, Pearson’s correlation coefficient was calculated by correlating the 
potency of each compound in both cAMP accumulation and cell proliferation pathways. 
As displayed in Figure 5.8A, strong correlation was observed between potency of 
compound in elevating cAMP levels and potency in inhibiting cell growth (r = 0.801 
with 95% confidence interval of 0.85 – 0.91). Since potency was not the only 
measurement to determine how good the compounds were in inhibiting cell growth, 
the magnitude of anti-proliferative effect was also taken into account. Therefore, 
proliferation factors were calculated based on pIC50 and Imax from individual dose-
response curves (Figure 5.8B). As expected, this approach confirmed that only 
compound 1 and 5 exhibited progressive improvement parallel to the cumulative 
expression of A2AR and PDE10A (Figure 5.2). Whilst compound 3 and 4 also elicited 
improved efficacies, compound 2 remained the same irrespective of cell types. Taken 
together, it was corroborated that compound 1 and 5 work through dual actions: 
agonism at A2AR and inhibition of PDE10A, whereas compound 3 appeared to be a 
non-selective adenosine receptor agonist with some action towards PDE10A, and 
compound 4 was more pronounced when A2BR was present in the cells. It was only 
compound 2 that modulated both cAMP and inhibit cell growth independent of A2AR-
PDE10A expression suggesting the probability of an off-target mechanism leading to 

















Figure 5.8 Multi-target ligands simultaneously displayed better efficacies across 
cell lines corresponding to the cumulative expression of A2AR and PDE10A. A. 
Correlation plot of log potencies of each ligand in all NSCLC cell lines. Correlation plot 
(with 95% confidence interval) was determined by calculating Pearson’s correlation 
coefficient (r). Data are expressed as mean ± SEM of 4-8 individual repeats. B. 
Proliferation factor of each ligand across NSCLC cell lines. Proliferation factor was 
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Table 5.6  
Summary of pharmacological activities of triazoloquinazolines across human NSCLC cells 
 
Compound cAMP  Cell proliferation   
pEC50 Span (%) n pIC50 Span (%) Proliferation 
Factor 
n 
LK2        
Forskolin 6.23 ± 0.08 89.0 ± 4.7 6 3.47 ± 0.19      19.7 ± 4.8    69.12 ± 19.84 6 
CGS21680 4.84 ± 0.38 6.9 ± 1.6*** 8 N/A            N/A            N/A 4 
Compound 1 N/A N/A 4 N/A            N/A            N/A 6 
Compound 2 4.42 ± 0.28 31.8 ± 6.6*** 5 4.81 ± 0.15 78.9 ± 6.9*** 380.57 ± 45.22*** 5 
Compound 3 5.96 ± 0.21 14.1 ± 1.4*** 4 N/A         43.5 ± 16.5     43.51 ± 16.52 6 
Compound 4 5.08 ± 0.32 15.6 ± 2.4*** 6 N/A        -4.1 ± 4.9    -12.19 ± 14.48* 9 
Compound 5 N/A N/A 6 N/A             N/A            N/A 6 
Compound 6 N/A N/A 7 N/A             N/A            N/A 6 
        
H520        
Forskolin   7.02 ± 0.07 99.3 ± 3.2 8 4.13 ± 0.43      31.2 ± 4.6    130.38 ± 32.48 5 
CGS21680 5.46 ± 0.11*** 20.3 ± 1.1*** 6 N/A 1.9 ± 4.3**        4.72 ± 17.13 4 
Compound 1 5.49 ± 0.24*** 26.9 ± 3.1*** 6 N/A      16.0 ± 9.4      53.96 ± 33.97 6 
Compound 2 4.91 ± 0.31*** 44.8 ± 8.6*** 6 4.34 ± 0.37      70.2 ± 16.1    309.40 ± 95.00* 5 
Compound 3 5.87 ± 0.15*** 22.4 ± 1.5*** 6 4.16 ± 0.07      40.2 ± 5.9    167.77 ± 27.33 4 
Compound 4   6.39 ± 0.17 20.5 ± 2.1*** 4 3.78 ± 0.28      25.0 ± 3.6      95.05 ± 17.22 6 
Compound 5 5.45 ± 0.22*** 16.3 ± 1.5*** 3 N/A      17.9 ± 2.3      57.00 ± 12.99 6 
Compound 6 4.74 ± 0.65*** 12.4 ± 4.5*** 4 N/A            N/A              N/A 6 
        
H1792        
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Compound cAMP  Cell proliferation   
pEC50 Span (%) n pIC50 Span (%) Proliferation 
Factor 
n 
Forskolin 6.98 ± 0.11 84.8 ± 4.7 8 3.73 ± 0.10      25.9 ± 2.6    96.97 ± 11.75 7 
CGS21680 5.52 ± 0.17*** 27.8 ± 2.2*** 8 N/A N/A N/A 4 
Compound 1 6.09 ± 0.22*** 31.8 ± 3.3*** 7     4.00 ± 0.23      35.9 ± 6.7  144.86 ± 32.40 6 
Compound 2 4.78 ± 0.36*** 28.4 ± 6.4*** 6   4.79 ± 0.18*** 86.2 ± 1.4***  413.37 ± 20.56*** 6 
Compound 3 6.39 ± 0.17 24.2 ± 1.8*** 5     3.92 ± 0.08      29.4 ± 6.9  115.63 ± 29.13 6 
Compound 4 7.47 ± 0.31 20.5 ± 2.6*** 6     4.51 ± 0.23*      56.0 ± 1.7**  252.83 ± 20.64*** 4 
Compound 5 5.61 ± 0.27*** 27.1 ± 3.4*** 5     3.74 ± 0.11      31.5 ± 4.9  118.17 ± 21.47 6 
Compound 6 4.72 ± 0.16*** 24.7 ± 2.5*** 6 N/A            N/A            N/A 6 
        
H1563        
Forskolin  6.54 ± 0.08      99.4 ± 3.3 6 3.83 ± 0.06      29.9 ± 2.1  114.44 ± 9.70 4 
CGS21680  5.34 ± 0.21* 15.6 ± 1.6*** 7 3.66 ± 0.22*      18.9 ± 4.3    69.77 ± 18.94** 6 
Compound 1  6.44 ± 0.11 29.4 ± 1.3*** 7 4.37 ± 0.06      55.3 ± 2.9  241.55 ± 12.73*** 4 
Compound 2   4.60 ± 0.22 30.5 ± 4.6*** 6 4.62 ± 0.10      71.9 ± 9.5  332.70 ± 44.98 4 
Compound 3 6.46 ± 0.17*** 12.5 ± 0.9*** 6 4.24 ± 0.22      50.7 ± 42.4  207.52 ± 22.83 4 
Compound 4   6.86 ± 0.20 10.7 ± 0.9*** 5 3.98 ± 0.21      29.9 ± 5.8  119.88 ± 29.21 4 
Compound 5   6.82 ± 0.20 14.9 ± 1.0*** 7 4.34 ± 0.02      51.0 ± 1.0  221.22 ± 5.65* 4 
Compound 6   5.22 ± 0.18** 15.1 ± 1.5*** 8 N/A N/A            N/A 4 
N/A – not applicable 
Negative values in represented mean selected compound promoted cell growth 
Statistical significance was calculated using one way ANOVA compared to forskolin followed by Dunnet’s post-hoc analysis (*p<0.05, **, 
p<0.01, ***, p<0.001) 
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The study on NSCLC cell lines as the relevant model to validate the dual-target 
mechanism has proved the ability of triazoloquinazolines in elevating the concentration 
of cAMP, which leads to anti-proliferative effects. As expected, triazoloquinazolines 
actions on cell growth were aligned with their ability to modulate cAMP levels with both 
actions dependent on cumulative expressions of A2AR and PDE10A. 
 
5.6 Targeting A2AR/PDE10A elevated cAMP levels but did not optimally 
suppressed glioma/glioblastoma model 
5.6.1 Expression profile of A2AR and PDE10A in glioma/glioblastoma cell 
models 
As mentioned previously, targeting particular PDEs or another second messenger 
such as those proteins that are involved in SOCE mechanism (chapter 4) have resulted 
in anti-proliferation to some extent in glioma and glioblastoma cells. Since the 
synergism of targeting A2AR and PDE10A sufficiently suppressing NSCLC cell lines, 
the study was extended to identify whether targeting PDE10A and A2AR from multi-
target ligand will have similar effects in inhibiting brain-derived cancer cells. To do this, 
C6 cells were used as glioma model that is derived from rat origins, U87 and T98 cells 
as human glioblastoma model, and HEK293S cells as non-cancerous human normal 
cells.  
 Firstly, the expression profile of all subtypes of adenosine receptors and 
PDE10A at the mRNA level was determined by rt-PCR. Displayed in Figure 5.9A, all 
cell lines expressed most of the adenosine receptor subtypes with differential 
expression of PDE10A. The rat C6 glioma cells displayed similar levels of expression 
of adenosine receptors and PDE10A (with expression of A1R the highest). U87 and 
T98 cells also expressed A1R, A2AR, and A2BR, with the latter receptor showing the 
highest expression among the ARs. A3R expression was very low in T98 cells and 
undetectable in U87 cells. Regarding the PDE10A expression, U87 cells showed a 
higher intensity band than that of T98 cells. Similar to U87 cell line, there was no 
detectable band for A3R whilst other genes of interests were present in HEK293S cells. 
To conclude, the cumulative expression of both targets (A2AR and PDE10A) appeared 
to be similar between rat C6 and human T98 cells, whereas U87 cells was similar to 
that of HEK293S cells expressing higher concordance targets (Figure 5.9C).   
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Figure 5.9 Glioma and glioblastoma cell lines differentially expressed all 
subtypes of adenosine receptors and PDE10A. (A) Representative of gels and 
expression profiles of gene of interests from glioma and glioblastoma cell lines: C6, 
U87, T98, and HEK293S cells. (B) Expression profile of adenosine receptors (ARs) 
and PDE10A from glioma/glioblastoma cell lines including HEK293S cells as 
comparison. C) Comparison of cumulative A2AR plus PDE10A expression amongst 
glioma, glioblastoma and HEK293 cell lines. Relative expression was calculated based 
on GAPDH band and are expressed as the mean ± SEM from 3-6 individual repeats.  
 
5.6.2 Triazoloquinazolines mediated cAMP accumulation in glioma and 
glioblastoma cells 
Having confirmed the expression levels of the genes of interests in the previous 
section, the functional assays were applied to determine compounds activity in 
modulating total cAMP accumulation in C6, U87, and T98 glioma/glioblastoma cell 
lines, as well as HEK293S cells as a control. To do this, cells were stimulated for 30 
minutes with the selected compounds in buffer containing rolipram (PDE4 inhibitor) to 
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 CGS21680 was tested to confirm A2AR activation in promoting cAMP synthesis. 
As depicted in Figure 5.10A, there was a dose-dependent increase upon stimulation 
with CGS21680 in all cell lines, with the largest effect was observed in U87 cells, which 
expressed the highest A2AR levels (Figure 5.10B) amongst all cell lines, followed by 
HEK293S cells. The efficacies of CGS21680 appeared to be similar in C6 and T98 
cells.  
 The similar approach was applied by applying triazoloquinazolines to all cell 
lines. However, the effect of compounds on cAMP production were minimal in U87 
cells regardless of the abundant expression of both targets. Interestingly, the basal 
responses were lower in U87 cells compared to remaining cells suggesting intrinsic 
activity of the compounds in U87 cells, with the exception of compound 4 (Figure 5.10). 
The efficacies of compound 1 and 4 were the most profound in T98 cells, 
followed by C6 cells (Figure 5.10B and E). While compound 1 was equipotent in C6 
and HEK293S cells, compound 4 was only active in C6 glioma and human 
glioblastoma T98 cells. Interestingly, no difference in cAMP accumulation in all cells 
was observed when they were stimulated by compound 2 or compound 3 (Figure 5.10 
C and D). Compound 5, that was previously shown to be a dual ligand at A2AR/PDE10A 
was more potent in T98 and HEK293S cells, while it showed less potent responses in 
C6 and U87 cells (Figure 5.10F). Whilst compound 6 did not elicit any activities in yeast 
and CHO-K1 cell systems (Data were displayed in Table 5.2-5.3, summarised in Table 
5.4), there was a dose-dependent increase in cAMP accumulation in the rat and human 
glioblastoma models. Since rolipram was added in the stimulation buffer, it is possible 
that the effect was generated from the activity of PDE4 inhibition.  




Figure 5.10 Different effects of multi-target ligands on cAMP accumulation in 
glioma and glioblastoma cell lines. CGS21680 (A) is a selective A2AR compound 
and used as a reference compound for cAMP accumulation assay. The accumulation 
of cAMP was determined following 30 minutes stimulation with compound 1-6 (B to G) 
in C6, U87, T98, and HEK293S cells in the presence of rolipram Data are expressed 
relative to the maximal response produced by 100 μM forskolin. Values are expressed 
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5.6.3 Multi-target ligands suppressed cell proliferation on C6 cells but elicited 
differential responses across human glioblastoma cells  
After confirming the efficacies of triazoloquinazolines in stimulating cAMP production, 
the investigation was further performed to determine whether modulation at cAMP 
levels can be translated to cell proliferation. In this study, both rat and human 
glioma/glioblastoma cells were selected and further exposed to the test compounds 
for 72 hours before adding CCK-8 reagent.  
 Overall, C6 cells were more reactive upon treatment with the 
triazoloquinazolines class of compounds compared to human glioblastoma cells or 
HEK293S cells. Forskolin, a pan AC activator, stimulates cAMP synthesis independent 
of any receptors, thus it can be used as a reference compound to show the association 
between cAMP and cell proliferation. Here, forskolin decreased C6 cell growth (Figure 
5.11A). Whereas human glioblastoma cells were more resistant towards forskolin 
(indicated by only ~20% suppression), forskolin did not sufficiently show an anti-
proliferative effect on HEK293S cells (Figure 5.11A).  
Interestingly, selective activation of A2AR by CGS21680 appeared to be pro-
proliferative in human glioblastoma cells (Figure 5.11B). Although CGS21680 was able 
to increase cAMP accumulation on these cell lines (Figure 5.11A), stimulation at A2AR 
alone was insufficient to inhibit cell growth. Similar observations were also found when 
glioma cells were treated with a beta-adrenergic agonist (Chapter 3). It is possible that 
the signalling through GPCRs was desensitised throughout the treatment period and 
therefore no anti-proliferative effects were observed. 
 Compound 1 and 3 dose-dependently suppressed C6 and T98 cell growth. 
However, no effect was detected on U87 and HEK293S cells (Figure 5.11C and E). It 
is possible that the elevation of cAMP mediated by A2AR agonism and inhibition of 
PDE10A were more noticeable on C6 and T98 cells because these cells expressed 
fewer PDE families compared to U87 or HEK293S cells (chapter 3 and 4). It is also 
worth noting that PDE10A is a dual substrate PDE, therefore any elevation in cAMP 
concentration will eventually affect cGMP signalling and activate various alternative 
signalling cascades leading to distinctive physiological/cellular responses beyond 
proliferation. Thus, cells with complex machinery such as U87 and HEK293S cells 
were more likely to be resistant to triazoloquinazolines. 
 In previous studies in lung cancer cells, compound 2 was suggested to have 
non-specific effects independent of A2AR agonism/PDE10A inhibition. Although U87 
cell line is considered more resistant, compound 2 dose-dependently suppressed cell 
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proliferation. These results indicate, again, that compound 2 may have off-target toxic 
effects leading to cell growth suppression.  
While the human glioblastoma models (U87 and T98 cells) did not respond to 
compound 3, this compound reduced cell proliferation in HEK293S cells (Figure 
5.11E). These effects were expected since HEK293S cells expressed the highest 
levels of adenosine receptors and PDE10A at the mRNA level (Figure 5.9B). With the 
exception of U87 cells, compound 4 induced anti-proliferative effects in all cells (Figure 
5.11F). As noted earlier, the compound 4 effect was more pronounced in cells 
expressing A2BR, thereby the cell growth suppression occurred was most likely due to 
the non-selective action towards A2BR.  
While the efficacy of compound 5 was greater in human lung cancer cell lines 
expressing higher levels of A2AR and PDE10A, in this experiment the anti-proliferative 
effect of compound 5 can only be seen in C6 and T98 cells, and the anti-proliferative 
effect induced by compound 5 was comparable to that of compound 1 (Figure 5.11G). 
Despite the differences in the origins of human and rat cells, the similar effects of 
compound 5 on the rat C6 and human T98 cells lines were likely due to the similar 
cumulative expression of A2AR/PDE10A (Figure 5.12B). In this study compound 6 was 
able to inhibit cell proliferation on C6 cells but no other cell types. Although compound 
6 may be an antagonist at the A2AR, the anti-proliferative effects that were displayed 
in Figure 5.11H were most likely due to PDE10A inhibition only (Table 5.1). Likewise, 
comparing with selective PDE10 inhibitor that was used in the previous chapters, 
inhibition at PDE10A alone was not able to exhibit substantial cell growth suppression. 
 
 




Figure 5.11 Multi-target ligands did not show any particular pattern in inhibiting 
cell proliferation across cell lines tested. Dose-response curves of 
glioma/glioblastoma cell growth upon 72h treatment with forskolin (A), CGS21680 (B), 
triazoloquinazolines compound 1-6 (C-H) on glioma/glioblastoma cell lines after 72 h 
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5.7 Elevation of cAMP levels by triazoloquinazolines failed to be translated 
into cell proliferation in glioma and glioblastoma cells 
Similar to the approach in lung cancer cell lines, Pearson’s correlation was calculated 
to determine the efficacies of compounds in glioma/glioblastoma cell models. There 
was a weak association between cAMP and cell proliferation pathways in C6 and T98 
cells (r = 0.42, 95% confidence interval -0.14. – 0.78, Figure 5.12A), but not with U87 
and HEK293S cells. It is interesting to note that even though cAMP augmentation 
within the intracellular compartment by inhibiting PDEs has a strong correlation with 
cell growth (chapter 3 and 4), concomitant targeting of PDE10A/A2AR only showed 
weak correlation in glioma/glioblastoma cell model: C6 and T98 cells. Both U87 and 
HEK293S cells, on the other hand, expressed more abundant PDE isoenzymes 
(Chapter 4). This suggests both cell lines have more control to maintain cAMP levels 
and to prevent this dynamic to alter further signalling cascades. Proliferation factors on 
glioblastoma models were also shown in Figure 5.12B. With the exception of 
CGS21680, a broad range of proliferation factor values were observed in all 
compounds tested. Overall, U87 cells had very low proliferation factors compared to 
the other cell lines, except in the presence of compound 2. While some compounds 
differentially suppressed cell growth in all cell lines, there was no specific pattern 
indicating improvement in efficacy regardless of the cumulative expression of 
A2AR/PDE10A, unlike the observation in lung cancer cell lines. The pharmacological 
effects of triazoloquinazoline compounds on both cAMP and proliferation pathways in 
the glioblastoma models were summarised in terms of pharmacological parameters, 
potencies and spans, as well as proliferation factors (Table 5.4).  
Since multiple downstream signalling cascades are involved between cAMP 
pathways as initial signalling events and cell growth as a final biological response, it is 
worth noting that elevation of cAMP by triazoloquinazolines may influence particular 

















Figure 5.12 There is no correlation between the elevation of cAMP level and cell 
growth upon stimulation with triazoloquinazolines on rat and human 
glioblastoma cells. (A). Pearson’s correlation plot of triazoloquinazolines across 
glioma/glioblastoma cell lines. There was association between both cAMP and cell 
growth pathways in C6 and T98 cells. (B) Proliferation factor of triazoloquinazolines, 
forskolin, and CGS21680 across glioma and glioblastoma cell lines as well as 
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Table 5.7 
Summary of pharmacological activities of triazoloquinazolines across glioma and glioblastoma cells 
 
Compound cAMP  Cell proliferation   
pEC50 Span (%) n pIC50 Span (%) Proliferation Factor n 
C6        
Forskolin   6.59 ± 0.07      97.3 ± 2.9 16   5.30 ± 0.11    76.6 ± 1.7         407.11 ± 16.42 4 
CGS21680   4.59 ± 0.45* 36.2 ± 10.6*** 7         N/A            N/A                   N/A 5 
Compound 1   5.86 ± 0.39      11.9 ± 2.2*** 10   4.92 ± 0.09    81.7 ± 2.5         403.13 ± 17.68 9 
Compound 2 4.83 ± 0.16***      30.6 ± 3.0*** 9   5.31 ± 0.10    73.6 ± 2.0         391.80 ± 16.81 9 
Compound 3   6.53 ± 0.66*        8.8 ± 2.4*** 10   4.89 ± 0.03    75.5 ± 1.9         368.95 ± 9.19 9 
Compound 4   6.22 ± 0.52        7.8 ± 1.7*** 10   4.84 ± 0.10*    78.5 ± 1.4         380.15 ± 10.72 9 
Compound 5   4.60 ± 0.35***      22.4 ± 5.2*** 8   4.89 ± 0.07    82.2 ± 1.9         402.24 ± 10.52 6 
Compound 6   5.25 ± 0.23**      19.8 ± 2.3*** 8 4.52 ± 0.28*** 54.1 ± 4.4*** 249.28 ± 37.92*** 6 
        
U87        
Forskolin    6.93 ± 0.08       96.6 ± 3.3 16 N/A N/A N/A 6 
CGS21680    6.87 ± 0.21       47.0 ± 4.2*** 9 N/A N/A N/A 4 
Compound 1    5.34 ± 0.40*       20.7 ± 4.0*** 6 N/A N/A N/A 8 
Compound 2 4.46 ± 0.19*** 21.9 ± 2.2*** 4 4.46 ± 0.23 49.8 ± 3.2 221.53 ± 16.27 7 
Compound 3   4.81 ± 0.75       11.5 ± 6.3*** 8 N/A 11.5 ± 9.3 49.46 ± 41.17 7 
Compound 4         N/A             N/A 6 N/A N/A N/A 7 
Compound 5   4.90 ± 0.49       16.2 ± 4.9*** 5 4.83 ± 0.54 8.6 ± 3.3 82.04 ± 18.40 8 
Compound 6   4.68 ± 0.48       10.3 ± 2.7*** 4 N/A N/A N/A 7 
        
T98        
Forskolin  6.52 ± 0.07       99.0 ± 2.9 6 6.06 ± 0.58 18.2 ± 6.6 137.38 ± 30.64 3 
CGS21680 4.62 ± 0.15** 48. 6 ± 4.8*** 8 N/A N/A N/A 3 
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Compound cAMP  Cell proliferation   
pEC50 Span (%) n pIC50 Span (%) Proliferation Factor n 
Compound 1    6.26 ± 0.27      16.4 ± 2.0*** 4   4.69 ± 0.11* 61.9 ± 3.9*** 292.30 ± 24.16* 6 
Compound 2    4.35 ± 0.52* 32.5 ± 13.6*** 8   4.35 ± 0.12** 61.7 ± 4.4*** 270.27 ± 24.09* 5 
Compound 3    5.89 ± 0.51        9.3 ± 2.3*** 4 N/A        3.1 ± 5.4            38.28 ± 15.90 6 
Compound 4    5.53 ± 0.26      19.8 ± 2.5*** 6    5.06 ± 0.23      48.8 ± 4.2*          248.17 ± 29.80 3 
Compound 5    6.13 ± 0.27      15.0 ± 1.9*** 4    4.31 ± 0.08** 59.9 ± 1.5**          258.06 ± 9.75 3 
Compound 6    4.93 ± 0.34      23.8 ± 4.9*** 5    4.43 ± 0.76*      32.9 ± 16.4          171.04 ± 110.43 3 
        
HEK293S        
Forskolin    6.29 ± 0.06     99.9 ± 2.5 8    4.17 ± 0.45 44.2 ± 4.0        187.22 ± 23.66 5 
CGS21680    5.79 ± 0.24     24.3 ± 2.7*** 8          N/A N/A                  N/A 5 
Compound 1    6.35 ± 0.33     12.5 ± 1.8*** 10           N/A N/A                  N/A 9 
Compound 2 4.50 ± 0.27**     36.5 ± 6.9*** 13    4.51 ± 0.03 72.5 ± 1.5         327.13 ± 7.68*** 9 
Compound 3    6.20 ± 0.41     10.2 ± 1.9*** 8 4.79 ± 0.12** 62.7 ± 3.4 303.70 ± 23.27*** 9 
Compound 4    6.68 ± 0.31     12.9 ± 1.6*** 12    4.11 ± 0.10 34.8 ± 3.2         144.67 ± 14.55 9 
Compound 5    6.94 ± 0.51       8.9 ± 1.9*** 7    4.02 ± 0.04 41.3 ± 4.2         166.17 ± 17.73 6 
Compound 6    6.39 ± 0.61     10.3 ± 2.7*** 8          N/A N/A                   N/A 6 
Statistical significance was calculated using one way ANOVA compared to forskolin followed by Dunnet’s post-hoc analysis (*p<0.05, **, 
p<0.01, ***, p<0.001) 
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5.8  Discussion 
5.8.1  Validation using functional assays proving triazoloquinazolines as dual-
target ligands working on A2AR and PDE10A 
In the collaborative study with Dr. Kalash, using a computer-aided design of multi-
target ligand identified a series of compounds that elevate cAMP levels. The study was 
accomplished by docking triazoloquinazolines, which are known as PDE10A inhibitors 
(Kehler et al., 2011), into the orthosteric site of the active form of A2AR crystal (Lebon 
et al., 2011). This work was then further validated using MD simulations to identify Val84 
as the conformational descriptor for activation of A2AR (Lebon et al., 2011, 2015; 
Carpenter and Lebon, 2017). Although it was found that triazoloquinazolines showed 
binding through computational studies on the orthosteric site of A2AR, this needed 
validation through functional assay.  
To validate that a series of triazoloquinazolines binds to A2AR, it was necessary 
to assess ligand-binding. As an alternative to using the classical radioactive ligand 
binding approach, the Nano-BRET ligand binding assay offers many advantages due 
to its practicalities and allowing real-time detection of interactions in living cells without 
compromising the membrane integrity (Kenakin, 1988; Briddon et al., 2004). Since 
CA200645 has been shown to be membrane impermeable and thus label only surface 
receptors, this compound was used as a probe. Although CA200645 exhibits a higher 
affinity against A1R and A3R, this probe also binds to some extent to A2AR and A2BR. 
Given the fact of limitation of CA200645 and until this study was performed, a very 
limited number of probes were available to serve as a suitable tool for detecting ligand 
- A2AR interactions using BRET or imaging. It was not until Comeo reported the new 
fluorescent ligand that has better affinity to leverage binding profiling at the A2AR 
(Comeo et al., 2020). The preferences of CA200645 towards A1R and A3R then may 
explain lower pKi values for the reference compounds in this study. The calculated pKi 
for both NECA and CSG21680 were low compared to previously published values. 
Aside from different the protocols used to obtain pKi, the discrepancy of KD and pKi 
may also come from the influence of endogenous expression of A1R and/or A3R, which 
are expressed in kidney-derived cells (Figure 5.9), and presumably are also expressed 
in HEK293T cells. 
In agreement with Kehler (Kehler et al., 2011), a series of triazoloquinazolines 
were revalidated to be PDE10A inhibitors through PDE in vitro assay (Table 5.1, 
appendix 1). Furthermore, all triazoloquinazolines were shown to bind to the A2AR in 
vitro (Figure 5.4). Based upon previous characterisation on the yeast and CHO-K1 
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cells, compound 5 activity was considered effective when both A2AR and PDE10A were 
expressed. Of all triazoloquinazolines, surprisingly, compound 5 exerted the weakest 
binding property. Based on previous study using yeast and heterologous expression 
system, stimulation by compound 5 elicited pharmacological responses through A2BR 
(Table 5.2 and Table 5.3). In addition, compound 5 also showed better activity on 
human lung cancer cell lines (Figure 5.10), where both A2AR and PDE10A were 
expressed. This phenomenon may be explained by the functional group in compound 
5. The pyridine moiety in compound 5 is considerably more polar than in the other 
triazoloquinazolines (Table 5.1). Therefore, this functional group may affect the 
permeability of compound 5. Even though compound 5 has a considerably low binding 
affinity at the A2AR (Figure 5.4), this compound may more easily cross the plasma 
membrane, further enhancing its action towards PDE10A.  
Taken together, it was evident that compound 1-6 are all PDE10 inhibitors and 
synergistically bind to the orthosteric site of the A2AR. Although previous computational 
studies also highlighted the role of Val84 as a conformational descriptor for A2AR 
activation and the His252 residue that contributed to triazoloquinazolines activity 
towards A2AR, indeed, these notions require further validation using mutagenesis 
studies. 
 
5.8.2  Differential effects of triazoloquinazolines in various cancer models 
In the previous chapters, concomitant targeting of two essential proteins involved in 
regulating cAMP concentration in the intracellular compartment has been explored. As 
mentioned, the elevation of cAMP is beneficial in circumventing tumour progression in 
the glioma model. Using ligand combinations is a common approach to target multiple 
affecters to produce similar biological effects providing some advantages, including the 
use of lower concentration, which leads to less toxicity and better tolerability (Lehár et 
al., 2009). In this chapter, an alternative approach was applied to discover compounds 
that simultaneously act as a PDE10A inhibitor and A2AR agonist. It was hypothesised 
that concomitant targeting will potentiate cAMP signalling cascades by enhancing its 
production and inhibiting its degradation through PDE10A. 
Triazoloquinazolines have been proven to inhibit PDE10A activity (Table 5.1, 
appendix 1). Although PDE10A was firstly postulated to be involved in neurological 
functions mainly such as motoric and cognitive functions, PDE10A has grown to be a 
potential cancer target. The inhibition of PDE10A has been reported to be beneficial in 
the colorectal, oral, lung, and prostate cancer (De Alexandre et al., 2015; Lee et al., 
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2015, 2016; Titulaer, Irani and Lassmann, 2019). As a dual-substrate enzyme, 
PDE10A is commonly known as a cAMP-inhibited cGMP PDE and it is believed that 
an increase in cAMP concentration would potentiate cGMP-mediated signalling 
pathways (Fujishige, Kotera and Omori, 1999). Although it is evident from this study 
that there is a strong association between elevation on cAMP and cell growth 
suppression in NSCLC cells, other reports highlighted opposing mechanisms. Instead 
of influencing cAMP levels, PDE10A has been reported to mediate cell growth 
suppression by increasing cGMP in human cancer cell lines (HT29, SW480, and 
HCT116) which further phosphorylate PKG and β-catenin (Mehta and Patel, 2019; 
Zagórska, 2020). However, the work presented in this chapter demonstrated 
triazoloquinazoline-mediated cAMP accumulation, yet it did not investigate changes in 
cGMP concentration. It would be of interest to investigate the cGMP signalling cascade 
by triazoloquinazolines in future studies. 
As modulation of cAMP by triazoloquinazolines lead to diverse effects on cell 
proliferation, it is also worth noting there is a gap between upstream cAMP levels and 
the cell growth axis. From the previous studies, triazoloquinazolines were found be 
biased towards ERK1/2 signalling in an A2AR-dependent manner (Winfield, 2017). As 
a member of the MAPK family that mainly control cell proliferation and programmed 
cell death, it is assumed that the effect of triazoloquinazoline may involve ERK1/2 
activation. Activation of ERK1/2 can result in phosphorylation of transcription factor 
leading to cell growth or activation of cyclin families that further induce growth 
arrest (Mebratu and Tesfaigzi, 2009; Thérèse Keravis and Lugnier, 2012a). However, 
since cascades connecting cAMP and cell proliferation have not been fully elucidated, 
it is necessary to identify the key target genes/proteins between upstream and 
downstream signalling, which may also depend on spatiotemporal of the intracellular 
responses.  
The importance of A2AR signalling has been an intriguing topic in cancer. The 
underlying mechanism of A2AR in cancer has not been fully elucidated as the role of 
A2AR has been mainly studied in immune cells and more complex organisation 
involving tumour microenvironment (TME). In a model involving TME and immune 
cells, A2AR acts as an immune checkpoint. Therefore, the blockade of A2AR functions 
as an immunosuppressive axis through immune cells, such as T cells, NK cells, NKT 
cells, and dendritic cells (Ohta et al., 2006, 2012; Kalhan et al., 2012; Steingold and 
Hatfield, 2020). However, only a few reports showcased the A2AR signalling cascade 
in cancer cells (Inoue et al., 2017) and are not without contradicting results. Activation 
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on A2AR has been shown to decrease cell survival by inducing apoptosis in PC12 cell 
lines (Trincavelli et al., 2003). On the contrary, antagonistic action induced apoptotic 
programmed cell death in H1975, PC9, and A540 lung cancer cells (Kuzumaki et al., 
2012; Beavis et al., 2013; Mediavilla-Varela et al., 2013). Since then, studies have 
suggested that A2AR inhibition is more beneficial to affect immune cells but not on 
tumour expressing A2AR (Beavis et al., 2013).  
Different cellular machinery may underlie diverse effects in triazoloquinazoline-
mediated anti-proliferative effects among cancer models. For instance, the expression 
level of A2AR is different depending on cell types, which contribute to its G protein 
coupling preferences, receptor oligomerisation, and desensitisation (Cieslak et 
al.,2008; Fredholm, 2014, Carpenter and Lebon 2017). This has been implicated in 
affecting the agonist binding affinity, which gives distinct signalling profiles (Snyder and 
Rajagopal, 2020). The recent finding also highlighted that A2AR was found to have 
different isoforms in different tissues (Marti-Solano et al., 2020). Taken together, it is 
possible that A2AR couples to different signalosomes exhibiting diverse signalling. The 
effect may not be limited to cell proliferation in this case but may activate different 
signalling pathways, which requires further investigation. 
Similar to A2AR, each PDE can have different splice variants and the expression 
patterns can vary in tissues, in particular, subcellular localisation (Beavo, 1995; 
Fujishige et al., 1999). Different splice variants of PDE10A dictated different kinases 
and associated proteins (O’Connell et al., 1996; Degerman, Belfrage and Manganiello, 
1997). These associations appeared to be cell-dependent (O’Connell et al., 1996). In 
mouse striatum, for instance, PDE10A was tethered to more complex signalosomes 
involving PKA, AKAP150, and PSD95 that altogether influenced the signalling of 
NMDA receptors (Russwurm, Koesling and Russwurm, 2015). Different cell types may 
also influence which receptor population and PDE10A would be colocalised 
(Hennenberg et al., 2016). Although the impact of PDE10A signalosomes in cancer 
are not fully elucidated, PDE10A from different cell types or origins may form a 
particular macromolecular complex that controls specific cellular functions.  
Despite the fact that triazoloquinazolines were more effective in human lung 
cancer cells than glioblastoma models, application of triazoloquinazolines may be 
useful as an alternative approach to cancer therapy. It would be interesting if 
triazoloquinazolines can be deployed into a translational tangent. Again, further 
investigation is required to circumvent any adverse indiscriminate toxic effects on 
normal cells or possible off-target actions from these compounds. 





From this study and previous characterisation, it was confirmed that all 
triazoloquinazolines elicited concomitant inhibition of PDE10A and stimulation of A2AR. 
All compounds were also shown to differentially bind to the A2AR based on the BRET-
based ligand binding experiments.  
Triazoloquinazolines inhibited lung cancer cell growth and these effects had 
strong correlation with the elevated total cAMP levels. While it was confirmed that 
compound 1 and 5 selectively targeted A2AR/PDE10A, compound 2 may have off-
target effects leading to potential toxicity. Not only did compound 3 inhibit PDE10A but 
also non-selectively targeted ARs, whilst compound 4 was more efficacious in the 
presence of A2BR. Regardless of the cumulative expression of both targets, compound 
6 did not have any effect on the human lung cancer cells.  
Interestingly, in spite of the apparent anti-proliferative effect of these 
triazoloquinazoline-based compounds on the lung cancer cells, a similar effect was not 
observed in the glioblastoma models, even though there was a slight increase in cAMP 
accumulation. Glioblastoma cell lines may have better mechanism to lowering cAMP 
concentration by overexpressing cAMP efflux transporters. It is possible that this 
compound-induced differential effect in the lung cancers vs glioma/glioblastoma were 
due to differences in cell-type dependent molecular machinery. Almost all compounds 
were less effective on human glioblastoma cells suggesting there is another 
mechanism or interacting partners that are significantly different from those of human 
lung cancer cell lines. While the individual components in the downstream signalling 
cascades between these two pathways (cAMP and cell proliferation) is not fully 
elucidated within this study, cells from different origins may have different distributions 
of isoenzymes, mutation, or couple to different protein targets that contributed to 
different responses. Therefore, although there was no significant effect through A2AR 
and PDE10A targeting, the elevation of cAMP may affect other signalling cascades 
that are not covered in this study.  
To conclude, increasing cAMP by a synergistic mechanism between agonism 
at A2AR and inhibition of PDE10A appeared to show potential benefits in preventing 
cell growth in human lung cancer cells. Although there was a short-term increased in 
total cAMP levels, the same mechanisms failed to promote significant anti-proliferative 
effects in more resistant glioblastoma cell model such as U87 cell line. For the future 
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studies, computational techniques may be applied to improve the physicochemical 
properties of triazoloquinazolines. 




RECEPTOR ACTIVITY MODIFYING PROTEIN (RAMP) MODULATION 
OF PROTEASE-ACTIVATED RECEPTOR 4 (PAR4) AND CALCITONIN-
LIKE RECEPTOR (CLR) SIGNALLING  
 
6.1 Introduction 
RAMPs are single transmembrane proteins that were first found to associate with 
calcitonin receptor-like receptor (CLR) (McLatchie et al., 1998). Although firstly 
identified as chaperones for CLR, since then RAMPs have been shown to allosterically 
modulate CLR pharmacology. In addition, they also provide direct ligand contact points 
leading to alteration of ligand binding, G protein-coupling, and receptor internalisation 
(Simms et al., 2009; Woolley et al., 2017; Garelja et al., 2018). Interestingly, RAMPs 
have also been reported to interact with a broader range of receptors, not only limited 
to class B GPCRs but also class A and C (Poyner et al., 2002; Hay et al., 2016; 
Barbash et al., 2017; Mackie et al., 2019). Recent studies have shown that these 
accessory proteins interact with chemokine receptors leading to control important 
physiological responses (Mackie et al., 2019).  
Protease-activated receptor 4 (PAR4), together with other PAR isotypes (PAR1-
3), are class A GPCRs distributed in various tissues such as adipose, breast, and 
lung8. Although PAR4 is expressed by many tissues, this receptor is enriched in blood 
and endothelial cells, showing a pivotal role in platelet activation (Coughlin, 1999). Like 
other PAR family members, PAR4 is known to be activated by endogenous serine 
protease thrombin with a putative cleavage site at R47/G48 revealing tethered ligand 
GYPGQV (details in Chapter 1). Peptide agonists for PAR4 are currently limited, 
although the low potency synthetic peptide AYPGKF-NH2 has been widely used as an 
agonist to activate PAR4 without proteolysis (Faruqi et al., 2000; Hollenberg and 
Saifeddine, 2001). Interest in targeting PAR4 has been increasing over other PARs 
due to less bleeding liability (Ramachandran et al., 2017)  
Single nucleotide polymorphism (SNP) rs773902 was identified in the coding 
sequence of PAR4 gene F2RL3 leading to amino acid substitution at residue 120 from 
alanine to threonine. Interestingly, clinical findings on the PAR4 polymorphism at 
 
8 https://www.proteinatlas.org/ENSG00000127533-F2RL3 
Chapter 6                                                        RAMP modulation on PAR4 and CLR signalling 
 222 
residue 120 has been shown to account for the differential degrees of platelet 
aggregation by thrombin, PAR4 agonist peptide (PAR4-AP), or antagonists. These 
variants will be referred as PAR4-A120 and PAR4-T120. PAR4-T120 isoform appears 
to show hyper-reactivity to thrombin-mediated responses compared to the A120 form 
(Tourdot et al., 2015). Taking blood samples from a population with homozygous 
genotypes, platelet expressing Thr120/Thr120 needs less thrombin to promote platelet 
aggregation compared to Ala120/Ala120 variants. This Thr120/Thr120 is believed to 
occur in race-dependent responses which is more commonly found in black ancestry 
than in Caucasian people. Another study conducted within the Japanese population 
found that there were less people with Thr120/Thr120 variant (Morikawa et al., 2018). 
Whilst the residue substitution has led to different responsivity towards thrombin, 
PAR4-agonist peptide, or antagonist, there is no evident that this variant alters the 
number of receptors expressed on platelets (Li et al., 2020) 
Biased signalling is now widely accepted as an approach to modify receptor 
signalling and has shown therapeutic benefits (Foley, 2018). However, little is known 
about biased signalling of PAR4, thereby this particular field remains to be explored 
(Zhao, Metcalf and Bunnett, 2014). The distinct signalling events may affect various 
signalling events, including receptor phosphorylation by GRKs, pleiotropy to activate 
numerous G proteins, and act as “barcodes” to recruit β-arrestin leading to different 
functional responses (Zhao, Metcalf and Bunnett, 2014).  
Although many studies highlight that PAR4 forms heterodimers with P2Y12R, 
little is known about RAMP modulation on PAR4 signalling. RAMPs have been shown 
to be expressed in platelets but, to date,  there were no known canonical RAMP-
interacting GPCRs partner also expressed (Rowley et al., 2011). Therefore, it is 
hypothesised that PARs may interact with RAMP. To understand and confirm this 
hypothesis, the study focused on dissecting the PAR4 signalling profile using a 
heterologous overexpression system. Understanding this mechanism would give some 
insight into providing a potential target for drug development. 
Firstly, this chapter presents data that dissects the functional impact of the 
PAR4 polymorphism and determines if RAMPs act as accessory proteins to PAR4 so 
modulating its signalling profile. Unfortunately, due to the impact of the COVID-19 
pandemic, and subsequent restricted access to the laboratory most of the results in 
this chapter can only be considered preliminary. 
Secondly, this chapter also displays the role of RAMP in CLR pharmacology in 
various cell lines. The RAMPs and CLR forms new receptors that activate specific 
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signalling by different peptide ligands: CGRP, adrenomedullin (AM), and AM2. As part 
of collaborative work with Dr. Clark (University of Cambridge), the results presented in 
this chapter will focus on the impact of CLR-RAMP interaction on the canonical cAMP 
pathway and its impact on cell growth. The study was performed using various human 
cell lines, including human glioblastoma, human umbilical vein endothelial cells 
(HUVECs), and human cardiomyocytes (hCMs). The investigation of CLR-RAMP 
interaction on primary human cardiovascular cells on upstream signalling cascades 
have been extensively studied and are available as a pre-print (currently under review 
at Communication Biology) to which I am a co-author (Clark et al., 2021) . 
 
6.2 PAR4 is coupled to Gαq to promote intracellular calcium release 
To understand the clinical impact of the polymorphism of PAR4, both PAR4-A120 and 
PAR4-T120 variants were used. To compare and investigate whether protease and 
agonist peptide may contribute to biased signalling, α-thrombin as the endogenous 
ligand for PAR4 and AYPGKF-NH2, as agonist/activating peptide were included as 
pharmacological tools to dissect the signalling profile of PAR4. 
It has been widely known that PAR4 couples to Gαq and Gα12/13 after being 
activated. Since dissociation of Gαq subunit will lead to activation of phospholipase C 
(PLC), which promotes intracellular calcium mobilisation from the endoplasmic 
reticulum (ER) to cytoplasm, it is possible to observe calcium release. To do this, 
HEK293T cells transiently expressing either PAR4-A120 or PAR4-T120 were labelled 
using calcium indicator, Fluo-4 AM. To quantify the intracellular calcium release level 
from ER to cytoplasm, the change of fluorescence intensity was monitored for 
approximately 2.5 minutes. Representative images captured for this experiment are 
displayed in Figure 6.2A and B. By taking the peak of each treatment Figure 6.1B, the 
dose-response curve can be generated, as shown in Figure 6.1C. 
 




Figure 6.1 Representative figures of intracellular calcium release on HEK293T 
cells expressing PAR4-A120 upon stimulation with thrombin. ((A) The sequence 
of the image captured at the peak of calcium release after PAR4-A120 expressed 
HEK293T cell were treated by the ligands. (B) The traces of intracellular calcium 
mobilisation in response to various concentrations of thrombin after normalisation to 
10 μM ionomycin. (C) Dose-response curve of thrombin at PAR4 was generated by 
taking peak intensity from the traces displayed in Figure B and was fit into three 
parameter non-linear regression built-in Prism 8.4. 
 
In this study, both endogenous ligand and agonist peptide were tested against both 
PAR4 variants. Thrombin dose-dependently promoted intracellular calcium 
mobilisation on both PAR4 variants. Interestingly, the Emax of thrombin in PAR4-T120 
expressing cells was slightly higher (Figure 6.2A and Table 6.1) even though it was 
less potent than its counterpart. AYPGKF-NH2, on the other hand, was far less potent, 
and the dose-response curve did not reach a plateau. This is in agreement with what 
has been published in many studies (Faruqi et al., 2000; Ma, Hollenberg and Wallace, 
2001; Thibeault et al., 2020). However, whilst we saw a discrepancy in thrombin-
mediated calcium release, there was no difference in all pharmacological parameters 
upon stimulation with PAR4-AP (Figure 6.3B and Table 6.1). 
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Figure 6.2 Both thrombin and PAR4-agonist peptide promote intracellular 
calcium release. Dose-response curve of thrombin (A) and AYPGKF-NH2 (PAR4-
agonist peptide) (B) in stimulating calcium mobilisation on HEK293T cells transiently 
expressing both PAR4 variants. PAR4-T120 variant appeared to be more responsive 
towards thrombin, but no difference was found in AYPGKP-NH2 treated cells. Each 
data point is presented as the mean ± SEM of 2 – 15 individual data. 
 
Table 6.1 
Pharmacological parameters of thrombin and PAR4-agonist peptide on PAR4-A120 
and PAR4-T120 variants 
Receptor Ligand i[Ca2+] n 
pEC50 Emax (%) 
PAR4-A120 Thrombin 
 
9.30 ± 0.09      52.89 ± 3.34 4 
PAR4-T120 8.90 ± 0.32      81.45 ± 4.80 5 
PAR4-A120 AYPGKF-NH2 4.89 ± 0.41      33.07 ± 6.09 5 
PAR4-T120 5.34 ± 0.32      43.74 ± 15.47 3 
 
Calcium data was displayed after normalisation to that of 10μM ionomycin. Data are 
represented as mean ± SEM of 3-5 individual data. Data were determined as 
statistically different compared to receptor only using one-way ANOVA followed by 
Dunnett’s post-hoc analysis.  
 
6.3 PAR4 recruits β-arrestin  
Upon PAR4 activation, like many other GPCRs, it will couple to various regulatory 
proteins, which mainly engage to G proteins. Beside, recruitment of β-arrestin has 
been reported to occur following PAR4 activation (Lin et al., 2019; Vanderboor et al., 
2020) or after dimerization of PAR4 and P2Y12R (Li et al., 2011; Khan et al., 2014; 
Smith et al., 2016).  As mentioned before, when necessary, both thrombin and agonist 
peptide of PAR4 were included in this study. However, using the BRET-based β-
arrestin recruitment assay, it was not possible to detect a BRET signal upon stimulation 
with thrombin. It is also possible that endogenous expression of thrombin-activated 
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PAR1 and PAR2, which are known to express in HEK293 cells (Atwood et al., 2011) 
may affect detection of β-arrestin recruitment to PAR4 in response to thrombin. 
Regardless of this fact, the recruitment of β-arrestins was still detected when cells were 
stimulated with AYPGKF-NH2. The BRET signal was vehicle subtracted and plotted as 
net BRET ratio (Figure 6.3A, using β-arrestin1 recruitment to PAR4-A120 variant as 
an example). There was a dose-dependent increase in the max ligand-induced change 
in BRET. Taking 13 minutes time point, the dose-response curve can be generated 
with the EC50 of 6.08 ± 0.59 (Figure 6.3B). 
 
 
Figure 6.3 The representative of BRET signal on β-arrestin recruitment assay. 
(A) Kinetics of BRET signal recorded from HEK293T cells transiently expressing PAR4 
in response to various concentrations of PAR4-AP. (B) The dose-response curve was 
generated by taking the max ligand-induced BRET signal from A. The graph was taken 
from an experiment conducted on PAR4-A120 using the β-arrestin1 sensor. 
 
Using the same approach, further investigation was conducted to assess the signalling 
of PAR4 polymorphism in recruiting β-arrestins. Surprisingly, PAR4-A120 showed a 
distinct β-arrestin recruitment profile compared to PAR4-T120 (Figure 6.4, Table 6.2). 
Despite different concentration intervals between experiments, it is clear that PAR4 
variants elicited different β-arrestin recruitment response profiles. PAR4-T120 variant 
recruited β-arrestin1/2 more potently, but lower in Emax, in response to PAR4-AP 
compared to PAR4-A120 variants (Figure 6.5A and B). This polymorphism in PAR4 
therefore appears to dictate a distinct signalling profile, especially in recruiting β-
arrestins.  
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Figure 6.4 PAR4 both variants differentially recruited β-arrestin upon stimulation 
with AYPGKF-NH2. HEK293T cells were cotransfected with PAR4-A120 or T120 and 
β-arrestin1/2 at ratio of 1:1. Recruitment of β-arrestin was measured after subtracting 
with vehicle control and is expressed as ΔBRET-ligand induced. Concentration-
response curves for β-arrestin1/2 recruitment after 13 minutes stimulation with PAR4-
AP on PAR4-A120 (A) and PAR4-T120 (B) variants. Data are expressed as the mean 
± SEM from 3-5 individual data. HL Jia-Qi performed the experiment of BRET-based 
β-arrestin assay using PAR4-T120 variant. 
 
Table 6.2 




Ligand β-arr1  β-arr2 
pEC50 Emax (%) n pEC50 Emax  (%) n 
A120 AYPGKF-
NH2 
 6.08 ± 0.59  27.13 ± 4.43 9   6.20 ± 0.33 26.69±2.99 15 
T120  7.37 ± 0.15  27.86 ± 1.94 3   6.86 ± 0.45   9.12±0.75 3 
Calcium data was displayed after normalisation to that of 10μM ionomycin. Data are 
represented as mean ± SEM of 3-15 individual data. Data were determined as 
statistically different compared to receptor only using one-way ANOVA followed by 
Dunnett’s post-hoc analysis.  
 
6.4 RAMPs are promoted to plasma membrane in the presence of PAR4-A120 
and PAR4-T120 
Having investigated the signalling profile of both PAR4 variants, the study was 
expanded to investigate if RAMPs could interact with PAR4 and alter their signalling. 
To determine the interaction between RAMPs and PAR4, it was necessary to 
investigate whether the presence of PAR4 promote cell surface expression of RAMPs. 
RAMPs are poorly trafficked to the plasma membrane in mammalian cells. Forming 
heterodimers between RAMPs and a GPCR enhanced RAMP translocation to the cell 
surface (McLatchie et al., 1998). A couple of methods have been developed to 
investigate association of RAMP and GPCRs, which include co-immunoprecipitation 
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(Bouschet, Martin and Henley, 2005), suspension bead array (SBA) (Lorenzen et al., 
2019b), and BRET based assay (Héroux et al., 2007a; Harikumar et al., 2009; Lenhart 
et al., 2013). Bailey and colleague firstly developed a FACS method to observe RAMP-
GPCR interaction (Bailey et al., 2019) and recently, Mackie also observed RAMP-
GPCR interaction using FACS confirming functional localisation of RAMP with a series 
of GPCRs that were previously determined by BRET (Mackie et al., 2019).  
In this study, the FACS method was applied to determine the effect of co-
expression of PAR4 to RAMP cell surface expression. To do this, COS-7 cells, a 
fibroblast-like cell line derived from African monkey kidney tissue, were used as they 
do not endogenously express RAMPs (Bouschet, Martin and Henley, 2005). Thus 
COS-7 cells serve as a suitable system to investigate RAMP-receptor interactions. 
COS-7 cells were co-transfected with PAR4 and N-terminal FLAG-tagged RAMPs, at 
a ratio of 1:1 for 48 hours. Since the antibody used (anti-FLAG antibody conjugated 
with APC, details in chapter 2) in the FACS experiment was non-cell permeable, only 
RAMPs expressed at the plasma membrane would be detected. Therefore, APC 
intensity in the presence of PAR4 variants could be compared to control levels to 
indicate whether PAR4 co-expression promoted RAMP cell surface expression. 
 In the absence of receptor, there was a marginal cell-surface expression of 
RAMP1 and RAMP2 (Figure 6.5). The surface expression of RAMP1 and RAMP2 were 
significantly increased when co-expressed with PAR4-A120 or PAR4-T120. 
Interestingly, in the absence of the receptor, the plasma membrane expression of 
RAMP3 was considerably higher, suggesting it can traffic to the cell surface without 
interacting partners. Despite this observation, co-expression with PAR4-T120, but not 
PAR4-A120, further enhanced RAMP3 localisation to the plasma membrane. 
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Figure 6.5 The presence of PAR4 influence RAMPs cell surface expression.  
COS-7 cells were co-transfected with FLAG-RAMP1/2/3 and PAR4-A120/PAR4T120 
at a ratio of 1:1. Control vehicle cells was transfected with pcDNA3.1-zeo with the same 
amount of DNA and served as control. Cell surface expression of FLAG-RAMPs was 
determined by FACS. The expression was normalised to that of control (0%) and HA-
CLR+FLAG-RAMP2 (as 100%). Data are expressed as the mean ± SEM of 3-9 
individual data. Data were determined as statistically different (*, p< 0.05; **, p<0.01; 
***, p<0.001) compared to vector using one-way ANOVA followed by Dunnett’s post-
hoc analysis.  
 
6.5 RAMPs alter thrombin-mediated intracellular calcium mobilisation 
Having demonstrated a difference in the pharmacological action of both PAR4 variants 
and identified interactions with RAMPs, the study was extended to investigate if 
RAMPs affect PAR4 signalling.  
 While the PAR4-A120 variant was less responsive compared to PAR4-T120 
upon stimulation with thrombin (Figure 6.6A), the co-expression with RAMP1 increased 
the Emax of calcium release (from 52.89 ± 3.34 % to 68.23 ± 6.74 %, Figure 6.6B). 
RAMP2 and RAMP3 also enhanced calcium mobilisation equal to that of PAR4-A120 
in the presence of RAMP1 (70.47 ± 3.69 % and 72.44 ± 4.87 %, respectively, Figure 
6.6C and D). Interestingly, whilst RAMP increased Emax in PAR4-A120, the interaction 
resulted in Emax reduction on the PAR4-T120 variant (Table 6.3). RAMP1 appeared to 
equalise the signalling, whereas RAMP2/3 reversed the effects of both variants. No 
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Figure 6.6 The presence of RAMPs modulate intracellular calcium mobilisation 
at PAR4 upon stimulation with thrombin. HEK293T cells were transiently 
transfected with PAR4, RAMP1/2/3 or pcDNA3.1-zeo with the ratio of 1:1. The dose-
response curve of thrombin on both PAR4-A120 and PAR4-T120 variants in the 
absence of RAMP (A) and the presence of RAMP1 (B), RAMP2 (C), or RAMP3 (D) 
were determined after normalisation to 10 μM ionomycin. Each data point is the mean 
± SEM from n of 2 – 5 individual repeats 
 
Using the much less potent PAR4-AP (AYPGKF-NH2), there were no changes 
observed to calcium responses in the presence of RAMPs (Figure 6.7A-D). The values 
of each group's span and potency (Table 6.2) showed that these parameters remained 
the same regardless of RAMP co-expression. Due to the impact of Covid-19, it was 
not possible to perform further experiments to obtain more repeats on this particular 
section. 
 




























































































































































Figure 6.7 PAR4 agonist peptide-mediated calcium release remain unaffected in 
RAMPs co-expressed with PAR4 in HEK293T cells. (A) The dose-response curves 
of AYPGKF-NH2 on both PAR4-A120 and PAR4-T120 variants that were transiently 
transfected in HEK293T cells in the absence of RAMP (A) and co-expressed with 
RAMP1 (B), RAMP2 (C), and RAMP3 (D). Each data point is the mean ± SEM from  2 
– 4 individual repeats.  
 
6.6 RAMP alters β-arrestin recruitment to PAR4  
Next, the effect of RAMPs on recruitment of β-arrestin was investigated. As mentioned 
in the previous section, both variants of PAR4 were able to couple to β-arrestin1/2 
upon stimulation with AYPGKF-NH2 in a dose-dependent manner (Figure 6.4). As 
displayed in Figure 6.8A-D, there was no difference observed in β-arrestin1 
recruitment by PAR4-AP. Interestingly, ligand-mediated β-arrestin2 recruitment was 
slightly potentiated in the presence of RAMP1 and RAMP3, but not RAMP2. While the 
potencies of AYPGKF-NH2 were increased, the Emax for both PAR4s was reduced in 
the presence of RAMPs (Figure 6.8, Table 6.3). It was only with RAMP3 that AYPGKF-
NH2 became significantly more potent compared to PAR4-A120 alone (Table 6.3, 
A. B.
C. D.
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pEC50 from 6.20 ± 0.33 to 10.81 ± 1.72). The presence of RAMP3 appears to induce 
PAR4-AP to be more potent. Due to limited access during COVID-19, the effect 
observed on PAR4:RAMP3 interaction to modulate β-arrestin recruitment was 
considered preliminary only. It is necessary to obtain more repeats to validate the 
observed effects. 
 The presence of RAMPs also altered β-arrestin recruitment on the PAR4-T120 
variant. There was a reduction in PAR4-AP potencies in recruiting β-arrestin1, which 
was associated with a reduction in the Emax parameter in the presence of RAMP (Table 
6.1). In contrast, recruitment of β-arrestin2 upon stimulation with AYPGKF-NH2 was 
potentiated in cells expressing both RAMP and PAR4-T120. The Emax values for β-
arrestin2 recruitment were significantly increased compared to receptor alone (from 
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Figure 6.8 RAMPs differentially modulate β-arrestin recruitment on both PAR4 
polymorphisms upon stimulation with PAR4-agonist peptide. AYPGKF-NH2 
promote β-arrestins recruitment in HEK293T cells transiently expressing PAR4-A120 
in the absence of RAMP (A), RAMP1 (B), RAMP2 (C), or RAMP3 (D). The same 
peptide also recruits β-arrestin either in the absence of RAMP (E) or in the presence 
of RAMPs (F-H) on HEK293T cells transiently expressing PAR4-T120 variant. Each 
data point is the mean ± SEM from 3 – 15 individual repeats. HL Jia-Qi performed 
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Table 6.3 
Pharmacological parameters of PAR4-agonist peptide on PAR4-A120 and PAR4-T120 variants in the absence and presence of RAMPs 
 
Receptor Ligand i[Ca2+]  β-arr1  β-arr2  
pEC50 Emax  (%) n pEC50 Emax  (%) N pEC50 Emax  (%) n 
PAR4-A120 AYPGKF-
NH2 
4.89 ± 0.41 33.07 ± 6.09 5  6.08 ± 0.59  27.13 ± 4.43 9   6.20 ± 0.33 26.69 ± 2.99 15 
+RAMP1 5.21 ± 0.27 27.67 ± 4.79 4  5.99 ± 0.64  19.19 ± 2.60 9   6.94 ± 0.21 17.47 ± 1.65 11 
+RAMP2 5.31 ± 0.22 26.17 ± 2.23 3  6.20 ± 0.76  21.05 ± 6.89 9   5.59 ± 0.22 18.09 ± 1.30 8 
+RAMP3 5.36 ± 0.30 32.84 ± 9.82 4  7.54 ± 0.63  17.23 ± 3.56 9 10.81 ± 1.72*** 18.38 ± 0.90 3 
           
PAR4-T120 AYPGKF-
NH2 
5.34 ± 0.32 43.74 ± 15.47 3  7.37 ± 0.15  27.86 ± 1.94 3   6.86 ± 0.45   9.12 ± 0.75 3 
+RAMP1 5.53 ± 0.26 28.65 ± 6.55 3  6.63 ± 0.17  23.17 ± 0.75 3   7.18 ± 0.08 18.84 ± 2.96** 3 
+RAMP2 5.29 ± 0.19 27.00 ± 6.14 3  7.01 ± 0.25 18.16 ± 0.89*** 5   6.98 ± 0.32 20.51 ± 1.33** 3 
+RAMP3 5.51 ± 0.41 31.49 ± 3.99 3 5.31 ± 0.17***   9.54 ± 0.98*** 4   7.43 ± 0.16 23.41 ± 0.58*** 4 
Calcium data was displayed after normalisation to that of 10μM ionomycin, whereas for βarr1/2 data was corrected after subtracting with 
vehicle control. Emax in βarr1/2 is displayed in mBU unit. Data are represented as mean ± SEM of 3-15 individual data. Data were determined 
as statistically different (*, p< 0.05; **, p<0.01; ***, p<0.001) compared to receptor only using one-way ANOVA followed by Dunnett’s post-
hoc analysis.  
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6.7 Quantification of signalling bias at PAR4 in the presence of RAMPs 
Having confirmed RAMPs altered the signalling profile of PAR4, the study was then 
followed by quantification of signalling bias. Here, biased agonism is calculated 
through two methods including relative activity (RAi) of PAR4 in the presence of each 
RAMP and calculating bias factor (β). The later was used to allow comparison between 
pathways, which in this case, the β value was expressed relative to calcium – since 
calcium responses remained unaffected by RAMPs. By calculating the bias factor (β), 
it is possible to compare signalling between two pathways and receptor complexes 













RAi – relative activity of PAR4 in the presence of RAMP relative to PAR4 in  Ca2+ 
mobilisation assay as a reference 
Emax – % response maximum 
EC50 – concentration of PAR4-agonist peptide that gives 50% of the maximal response 
β – bias vector 
 
From the study presented in this chapter, it is only possible to calculate signalling bias 
using PAR4-AP as the ligand, but not with thrombin. As mentioned previously, 
thrombin-induced β-arrestin recruitment was undetectable. In PAR4A-120, not only did 
RAMP2 regulate receptor towards β-arrestin1 but also include β-arrestin2. Whereas 
RAMP1 drove the biased away from β-arrestin2 (Figure 6.9A). However, due to limited 
data for this particular section, it is not possible to show the biased of PAR4-A120 
variants by RAMP3.  
Interestingly, PAR4-T120 displayed different behaviour. Whilst there was an 
indication that PAR4-AP showed β-arrestin bias over the calcium pathway, RAMP3 
biased signalling towards β-arrestin2 and away from β-arrestin1 (Figure 6.9B). 
RAMPs, therefore, appear to govern functional selectivity on PAR4 signalling. The 
polymorphism of these receptors also dictated the signalling consequences of PAR4 
and RAMP interaction. 
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Figure 6.9 Quantification of biased signalling at PAR4 both variants by the 
presence of RAMPs. The radar plot of PAR4 variants in releasing intracellular calcium 
and recruiting arrestin1/2 on PAR4-A120 (A) and PAR4-T120 (B) variants. Biased plot 
was then recalculated relative to intracellular calcium mobilisation for both PAR4 
variants (C,D). N.A: not applicable. Bias of RAMP3 in PAR-A120 mediated responses 
cannot be calculated using the current data.  
 
6.8 Stimulation by CGRP-based peptide agonists elevated cAMP 
concentration and promoted glioblastoma U87 cell growth 
The role of RAMPs for functional CLR signalling has been well documented  
(McLatchie et al., 1998; Christopoulos et al., 1999; Husmann et al., 2003; Garelja et 
al., 2020; Hendrikse et al., 2020; Pioszak and Hay, 2020), although the mechanism is 
not fully elucidated. It is an absolute necessity for CLR to oligomerise with RAMP to 
traffic to the plasma membrane and to interact with their cognate ligand: CGRP, AM, 
and AM2 (intermedin). Targeting CGRP-R has been proved to be beneficial in treating 
migraine (Bhakta et al., 2021). Ubrogepant has been proven to be an affective CGRP 
antagonist (ubrogepant) to relieve migraine, whereas monoclonal antibodies against 
CGRP (eptinezumab, fremanezumab, galcanezumab) and CGRP-R (erenumab) have 
also been used in clinical settings. Ostrovskaya and colleagues reported that CLR was 
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RAMPs (Ostrovskaya et al., 2019). This study found that stimulation with CGRP, AM, 
and AM2 dose-dependently increased cAMP production with the rank order of potency 
CGRP> AM> AM2 (Figure 6.10, Table 6.4 Unlike the findings in the previous chapters 
where elevated cAMP levels induced anti-proliferative effects; CGRP-based peptide 
agonists also increased cAMP production; however, it did not lead to cell growth 
suppression. Instead, activation by CGRP, AM, or AM2 promoted cell proliferation to 
different extents (Figure 6.10, Table 6.4). In comparison, forskolin elevated cAMP 
concentration and suppressed cell proliferation. These results suggest that CLR has 
different pharmacological actions that drive different cellular responses. This finding 
led to the hypothesis that whether the stimulation of CLR would be applicable to 
degenerative disease models or cellular protection that require repairment in cell 
growth. CGRP, AM and AM2 are known as vasodilatory peptides with pleiotropic 
effects (Nuki et al., 1993; Cui et al., 2021) Given the fact that AM and RAMPs 
(especially RAMP2/3) are highly expressed in the heart910 (Tippins, 1986; Ishiyama et 
al., 1993), the study was then followed by investigating the role of RAMP in 
cardiovascular system. Thus, HUVECs and hCMs were used to investigate this 
objective particularly in corresponding to cell growth. 
 
 
Figure 6.10 Elevation on cAMP concentration by peptide ligands induced cell 
proliferation on U87 cells. Accumulation of cAMP was determined upon 30-minute 
stimulation by the selected agonist. The response was normalised to that of forskolin 
100 μM. Cell survival was calculated as the percentage response relative to vehicle 
control, determined upon 72h treatment. Each data point is expressed as mean ± SEM 





































































The value of potency (pEC50) and maximum responses (Emax) of agonist peptide on 
cAMP production and cell growth in U87 cells 
Ligand cAMP Cell Proliferation 
pEC50a Emaxb  (%) n pEC50a Emaxb  (%) n 
Forskolin 7.39 ± 0.09  98.62 ± 2.66 4 7.06 ± 1.14   84.50 ± 5.98 5 
CGRP 8.95 ± 0.29 19.43 ± 1.10*** 3 6.37 ± 0.44 119.73 ± 3.99 6 
AM 8.09 ± 0.36 14.84 ± 1.08*** 4 5.55 ± 0.32 124.36 ± 5.54* 6 
AM2 6.49 ± 0.95 11.82 ± 2.18*** 3 5.38 ± 0.69 132.32 ± 18.79* 6 
a The negative logarithm of the agonist concentration required to produce a half-
maximal response. 
b The maximal response to the agonist expressed as a percentage of the system 
maximal as defined for corresponding. 
Data are expressed as the mean ± SEM of 3-6 individual data. Data were determined 
as statistically different (*, p< 0.05; **, p<0.01; ***, p<0.001) compared to forskolin 
using one-way ANOVA followed by Dunnett’s post-hoc analysis.  
 
6.9 RAMP regulate cellular signalling and cell growth of HUVECs and hCMs 
Stimulation of hetero oligomers of CLR and RAMPs has been shown to promote cell 
proliferation of U87 cells. The study was then extended to explore the effect of 
stimulation of CLR and RAMP in human cardiovascular systems. To do this, HUVECs 
and hCMs were utilised.  
In the study performed by Dr. Clark, HUVECs and hCMs expressed CLR and 
different types of RAMP (Clark et al., 2021). Whilst HUVECs expressed RAMP2, 
RAMP1 amplicon was detected in hCMs (Appendix 4). The difference in RAMP 
expression appeared to contribute to a distinct signalling profile involving cAMP 
synthesis, calcium release, ERK1/2 activation, and NO release. 
Since HUVECs expressed RAMP2 and CLR, allowing both proteins to form the 
AM1-R (adenomedullin receptor). As expected, AM was the most potent ligand in the 
canonical cAMP pathway (Appendix 4). However, for ERK1/2 activation, CGRP was 
the most potent ligand to activate ERK1/2, aligning with the effects observed on cell 
growth (Figure 6.11, Table 6.5). In hCMs that expressed RAMP1 and CLR, the cognate 
peptide for this receptor (CGRP-R) showed the highest activity in promoting cAMP 
production (Appendix 4) but not in ERK1/2 activation. Again, the most active ligand, 
AM, in activating ERK1/2 elicited a similar activity in cell proliferation (Figure 6.11, 
Table 6.5). Investigation of other signalling events has been reported in more detail  
(Clark et al., 2021). Taken together, it is apparent that RAMPs regulate the 
pharmacological action of CLR in endogenous systems. 




Figure 6.11 Stimulation by CGRP family peptides induced cell proliferation to 
different extents on HUVECs and hCMs. The effects were observed in both cells 
appeared to be related to predominant RAMP expressed in corresponding cells 
(Appendix 2). Percent proliferation was defined relative to control vehicle upon 72h 
treatment. Each data point is expressed as mean ± SEM from 3-8 individual data.  
 
Table 6.5 
The value of potency (pEC50) and maximum responses (Emax) of agonist peptides on 
cell growth in HUVECs and hCMs 
Ligand HUVECs hCMs 
pEC50 a Emax b  (%) pEC50 a Emax b  (%) 
CGRP 8.00 ± 0.19* 140.39 ± 2.13 5.32 ± 0.80 108.80 ± 24.2 
AM 5.73 ± 0.68 106.90 ± 3.47 7.08 ± 0.23* 160.32 ± 6.82 
AM2 7.06 ± 0.90 103.74 ± 1.43 6.48 ± 0.58 114.68 ± 3.58 
a The negative logarithm of the agonist concentration required to produce a half-
maximal response. 
b The maximal response to the agonist expressed as a percentage of the system 
maximal as defined for corresponding assays.  
Data are expressed as the mean ± SEM of 3-8 individual data. Data were determined 
as statistically different (*, p< 0.05; **, p<0.01; ***, p<0.001) compared to AM for 




6.10.1 The novel interaction of PAR4 with RAMPs changes β-arrestin1/2 
recruitment  
Polymorphisms and variants of GPCRs have recently been found to dictate distinct 
signalling profiles. This may also explain why drugs targeting particular GPCRs fail in 
clinical trials due to differential expression of isoforms in tissue and cells (Marti-Solano 
et al., 2020; Snyder and Rajagopal, 2020). In the case of PAR4, there are two 
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polymorphisms reported which influence platelet aggregation; that influences residue 
120 in the second transmembrane domain to be alanine (A120) or threonine (T120); 
and the less common form of Phe296Val (Edelstein et al., 2014). Dimorphism at 
residue 120 has been reported to be associate with responsivity towards thrombin, 
where the T120 variant appears to be hyper-responsive compared to its counterpart 
leading to a higher risk of CV events. In agreement with this study, the PAR4-T120 
variant induced intracellular calcium mobilisation with higher magnitude upon 
stimulation with thrombin, but not with PAR4-AP (Figure 6.2). It is worth noting that 
using HEK293T cells may not be an ideal surrogate system to dissect PAR4 
pharmacology in modulating calcium release. As Atwood investigated, HEK293 cells 
endogenously express PAR1 and PAR2 (Atwood et al., 2011). It is widely known that 
PAR1 and PAR4 can be activated by thrombin (Xu et al., 1998; Adam et al., 2003) with 
different kinetics. Since Fluo4-AM acts as a general calcium sensor, the signal 
observed may need further investigation to validate if the signals come from cumulative 
activation from PAR1 and PAR4 receptor populations. Considering there was no 
manipulation of expression of other PARs, it was assumed that calcium release (Figure 
6.2) might reflect the activity of PAR4.  
It has been reported that different ways to activate PAR4 lead to distinct receptor 
signalling (Zhao, Metcalf and Bunnett, 2014), however, it was not possible to detect 
thrombin-mediated β-arrestin recruitment from this study. As an endogenous ligand for 
both PAR1 and PAR4, thrombin failed to generate BRET signals in our β-arrestin 
recruitment assay. Ayoub et al. demonstrated that thrombin very rapidly promoted β-
arrestin recruitment to PAR1 in COS-7 cells, with the signal rapidly returning to 
baseline (Ayoub et al., 2007). Given the higher expression of endogenous PAR1 in 
HEK293T and higher thrombin affinity towards PAR1, it is very likely that the PAR1 
population sequestered β-arrestin recruitment over PAR4. Again, this notion requires 
further validation. 
Upon PAR4 activation, like other GPCRs, G proteins or non-canonical β-
arrestin-mediated signalling pathways are engaged. Here, selective PAR4 stimulation 
recruited β-arrestin1/2. Indeed, further investigation of G protein activation will be of 
great interest to dissect PAR4 pharmacology, this can be achieved through utilisation 
of NanoBit or BRET-based G protein dissociation assay. It has been reported that 
activating PAR4 signalling, either by selective activation/inhibition of G protein coupling 
or β-arrestin signalling, showed a potential strategy to develop therapeutic agents to 
reduce platelet aggregation without bleeding liability. Previously, the signalling bias of 
Chapter 6                                                        RAMP modulation on PAR4 and CLR signalling 
 241 
PAR4 was studied by synthesising ligands that were selectively activating certain 
cascades (Bar-Shavit et al., 2016; Thibeault et al., 2019). The preliminary results 
presented in this chapter demonstrate that signalling bias can also be achieved by 
interaction with RAMPs. The advantages of signalling bias have been shown for 
various receptors to promote desired responses or circumvent potential adverse 
reactions, these have been demonstrated in μ-opioid receptors (Kliewer et al., 2020), 
GIPR ((Harris, 2019) restricted access), apelin receptor (Gargalovic et al., 2021), and 
ghrelin receptor (Nagi and Habib, 2021). 
Until now, PAR4 was only known to form dimers with the P2Y12 receptor with 
this interaction leading to different signalling events compared to individual receptors 
(Smith et al., 2017). Notably, this study confers PAR4 as a new interacting partner of 
RAMP. Through analysis by FACS, it enables the detection of RAMP and receptor 
interaction in a more functional setting (Bailey et al., 2019). Whilst this approach offers 
more advantages over other available methods, including suspension bead array 
(SBA) or BRET-based method (Lorenzen et al., 2019b; Mackie et al., 2019), 
observation using FACS may not be sufficient to rule out the possibility of endogenous 
GPCR in influencing RAMPs trafficking. Based on FACS analysis, there were 
significant increases in RAMP1 and RAMP2 cell surface expression when they were 
co-expressed with both PAR4 variants (Figure 6.5). However, it was observed that 
RAMP3 was also expressed in vehicle control that did not contain any receptor. This 
data suggests that either RAMP3 can traffic to the plasma membrane without 
interacting partner or there are effects from endogenous GPCRs that promote RAMP3 
expression to the plasma membrane. RAMP3, in particular, contains a type I PDZ-motif 
(DTLL) in its C-terminal, which has been reported to be responsible to maintain its cell 
surface expression ((Harris, 2019), restricted access). This also contributes to the 
interaction with PDZ domain-containing proteins such as Na+/H+ exchange regulatory 
factor (NHERF), N-ethylmaleimide-sensitive factor (NSF), which modulate GPCR 
signalling (Reczek, Berryman and Bretscher, 1997; Bomberger, Parameswaran, et al., 
2005; Bomberger, Spielman, et al., 2005; Serafin et al., 2020) 
 Based upon this study, AYPGKF-NH2 recruited β-arrestin after PAR4 activation, 
and this is in agreement with other reports highlighting the ability of PAR-AP to 
stimulated β-arrestin-mediated signalling (Ramachandran et al., 2017; Thibeault et al., 
2020; Vanderboor et al., 2020). The classical mechanism after receptor activation is 
that receptors couple to β-arrestin, undergo internalisation, thereby terminating 
receptor signalling and mediating receptor desensitisation  (Pierce, Premont and 
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Lefkowitz, 2002; Shenoy and Lefkowitz, 2005; Hanyaloglu and Von Zastrow, 2008). 
Aside from platelet aggregation, signal transduction mediated by β-arrestins has been 
shown in other studies to induce membrane blebbing that would be a potential target 
for preventing cellular migration, which is a common feature in cancer (Vanderboor et 
al., 2020). Since this study is limited to observing initial signalling events that involve 
canonical G protein-mediated signalling and non-canonical pathways through β-
arrestin, it would be of interest to investigate further if this dynamic will impact receptor 
internalisation, receptor trafficking and further downstream PAR4 signalling. 
 
6.10.2 RAMP regulate CLR pharmacology: the study on cell growth 
As the first receptor reported to interact with RAMPs, CLR-RAMP heteromers have 
been extensively studied (McLatchie et al., 1998; Christopoulos et al., 1999; Husmann 
et al., 2003; Garelja et al., 2020; Hendrikse et al., 2020; Pioszak and Hay, 2020). Whilst 
CLR pairs with RAMP1/2/3 forming new receptors that differentially bind to CGRP, AM, 
and AM2; development of drug discovery has shown that targeting CGRP is beneficial 
in various physiological functions. This includes its cardioprotective effect, pivotal role 
in migraine pathogenesis, bone formation and may be of value in cancer treatment 
(Kiriyama et al., 1997; Schönauer, Els-Heindl and Beck-Sickinger, 2017; Booe et al., 
2018; Ostrovskaya et al., 2019; Xu et al., 2020; Bhakta et al., 2021).  
As mentioned in the previous chapter, elevating intracellular cAMP through 
various targets suppressed suppression of glioma and human lung cancer cell lines. 
However, this was not sufficient in human glioblastoma U87 cells. Therefore, in this 
chapter, the study was performed to explore the possibility of other GPCRs in the GBM 
cell model.  Although CLR is pleiotropically coupled to different G proteins (including 
Gq/11/14 and Gi/o), it is widely known that this receptor predominantly recruited Gs, 
therefore, increasing cAMP production within cells (Wootten et al., 2018; Garelja et al., 
2020). Since CLR is predominantly coupled to Gs, it is not surprising that all peptides 
dose-dependently increase cAMP accumulation in U87 cells. The order of potency 
appears to be CGRP>AM>AM2, suggesting that U87 cells express functional CLR and 
RAMPs, with RAMP1 is most likely higher than other RAMP subtypes. Surprisingly, 
elevation of cAMP levels induced by these peptides did not suppress cell growth as 
expected from the previous chapters. Instead, the treatments promoted cell 
proliferation, with the order of potency was aligned with that of in cAMP pathway. 
Another study using CGRP-related peptides showed that elevation of cAMP 
differentially activates the ERK1/2 pathway, which correlates to cell growth control on 
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human cardiovascular cells (Clark et al., 2021). In comparison, elevation on cAMP 
levels induced by forskolin suppressed U87 cell growth. These contradictory results 
suggest that CLR-RAMP interaction may have specific mechanisms or different 
downstream targets that result in different outcomes. Some of the GPCRs from 
different tissues have been reported to have different ability to coupling to different 
regulatory proteins. These phenomena have been reviewed in more details (Snyder 
and Rajagopal, 2020). This possibility can be taken into account to demonstrate that 
CGRP, AM, and AM2 may activate particular cascades that result in distinct responses 
which presumably cell-type or tissue-dependent.  
In both HUVECs and hCMs, the most potent compounds in canonical cAMP 
pathway did not exhibit the same activity in cell growth (Appendix 2). These peptides, 
in fact, elicited differential actions on ERK1/2 activation in both primary cell lines, which 
was aligned with that of cell proliferation. Given that these peptides have not been 
validated for ERK1/2 phosphorylation U87 cells, it would be of interest to investigate 
this particular aspect for the future experiments.  
The study was expanded to use other systems where cell proliferation is 
measured to determine the different CLR-RAMP effects on cell growth. The extensive 
study from Dr. Clark has shown that interaction between RAMPs and CLR dictates 
different signalling profiles and, proved that signalling bias is naturally occurring in 
more physiologically relevant cells (Clark et al., 2021). HUVECs are reported to 
express RAMP2, whereas hCMs predominantly express RAMP1; CLR was present in 
both primary cells (Appendix 2). Notably, whilst AM was the most potent ligand in 
promoting cAMP production in HUVECs, this ligand did not exhibit similar activities in 
mediating Gq-mediated calcium mobilisation nor ERK1/2 phosphorylation. 
Interestingly, a similar pattern was observed between calcium release and NO 
production and ERK1/2 stimulation- cell growth axis. In comparison, CGRP was the 
most potent peptide in elevating cAMP levels and calcium release in hCMs, but in the 
case of ERK1/2 phosphorylation, the most remarkable effect was shown by AM. While 
all ligands: CGRP, AM, and AM2 were able to promote total cAMP production to 
different extends, their activation on ERK1/2 is believed to be independent of this 
canonical pathway in both cells. Rather, it is mediated through Gi/o activation for CGRP 
and AM2, and activation of Gq/11/14 and EPAC for AM (Clark et al., 2021). These unique 
findings govern the multifaceted signalling on CLR pharmacology which is driven by 
RAMPs. Taken together, RAMPs appear to serve as a key or cellular barcode that 
specifically activates particular signalling cascades.  
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HUVECs and hCMs, as previously mentioned, expressed different types of 
RAMPs: RAMP2 and RAMP1, respectively. Close analysis of the cAMP responses in 
U87 cells would suggest a potential biphasic fit for CGPR and AM but not AM2 (as 
shown below, Figure 6.12, Table 6.5). This may suggest that U87 cells express, at 
least RAMP1 and RAMP2. CLR-RAMPs complexes can bind to all CGRP, AM, and 
AM2 with differential affinities; thus, it suggests that cAMP production in U87 cells may 
be driven by more than a single receptor population, presumably from CGRP-R and 
AM1-R.  Although this requires further investigation, the observation obtained from 
HUVECs and hCMs may explain biphasic responses observed in cAMP accumulation 
on U87 cells.  
 
 
Figure 6.12. CGRP and AM, but not AM2, mediate biphasic responses on cAMP 
production in U87 cells. Accumulation of cAMP was determined upon 30-minute 
stimulation by the selected agonist. The response was normalised to that of forskolin 
100 μM. The biphasic curve fitting was generated using Prism 9.0 by constraining 
LogEC50-n1 to be <-7 and LogEC50-n2 set to <-5. 
 
Table 6.6 
The value of potency and Emax of CGRP and AM after stimulation in U87 cells in 
cAMP accumulation assay 
Ligand pEC50 (1) pEC50 (2) Emax  (%) n 
CGRP 9.29 ± 0.79 6.75 ± 0.75 21.59 ± 1.43 3 







































Signalling bias has been long known to affect GPCR pharmacology. This chapter 
provides preliminary evidence of RAMPs as an interacting partner of PAR4. Indeed, 
RAMPs were demonstrated to interact with both A120 and T120 variants of PAR4. The 
interaction of RAMPs and PAR4 changed cell surface expression of the RAMP, which 
was characterised by FACS. Interestingly, this interaction can be translated to a distinct 
signalling profiles, depending on which RAMP is expressed with PAR4. These 
preliminary results demonstrate that RAMPs serve as a cellular barcode that 
selectively activates particular signalling events. Due to restrictions during Covid-19, 
further experiments could not be performed. It would be of interest to dissect the impact 
of RAMP-PAR4 interactions on other upstream signalling events and physiological 
consequences in more relevant models. 
As the second part of this chapter, cAMP elevation by stimulating CLR-RAMP 
heteromers differentially stimulated cell growth, which is different from that observed 
in the previous chapters. In both glioblastoma and human primary cardiovascular cells, 
selective stimulation using CGRP, AM, and AM2 differentially activated canonical 
cAMP pathways to promote cell growth. Although this finding may not be directly 
translatable for cancer therapy, these experiments highlight the possibility of targeting 
RAMP-CLR to provide cellular protection such as cardioprotective actions or promoting 
tissue regeneration for the model that requires repairing in cell growth such as in 
degenerative diseases.  
Together, the preliminary results focusing on RAMP-PAR4 interaction may 
become a potential target to manipulate cellular responses and provide therapeutic 
benefit with minimal adverse reactions in cardiovascular events. Further studies on 
RAMP-CLR complexes in this study also demonstrated a role of RAMPs in dictating 
specific signalling profiles, leading to different cellular responses, such as cell growth.  
This may shed light on how to manipulate receptor signalling and minimise adverse 









GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
7.1  Discussion 
7.1.1 Targeting cAMP pathway and its therapeutic benefits in cancer 
Glioblastoma and lung cancer carcinoma are considered as fatal types of tumours and 
are a leading cause of death, respectively11 (Schwartzbaum et al., 2006; Delgado-
López and Corrales-García, 2016). Due to the nature of their resistance, their 
heterogeneity and plasticity, it has been challenging to find compounds that can inhibit 
tumour progression. Of all abnormalities that have been reported, alteration in cAMP 
signalling has been found in numerous cancers including GBM and lung cancers 
(Daniel, Filiz and Mantamadiotis, 2016). 
 As previously mentioned in the introduction, cAMP has been reported to have 
divergent effects on cell growth. Depending on cell types, cAMP may elicit pro-
proliferative or anti-proliferative actions. This has been demonstrated in several types 
of cells such as neuronal derived cells (dorsal root ganglion, spinal motor, 
dopaminergic neurons, cerebral granule and cholinergic neurons); endocrines 
(pancreatic β-cells), gastrointestinal cells, hepatocytes, and myeloid (Lerner and 
Epstein, 2006).  On the contrary, we and others have observed negative effects of 
cAMP on cell proliferation in glioblastoma and primary cardiomyocytes (Ding et al., 
2005; Kang et al., 2014). Not only were the effects shown by aforementioned cells but 
also was observed in other mesenchymal and epithelial cells including fibroblasts, 
ovarian granulosa cells, and thyroid cells (Zwain and Amato, 2001; Huston et al., 2006; 
Sawa et al., 2017). Due to the limited number of cells included in this study, elevation 
of intracellular cAMP levels may promote cell growth in other cell types.  
 In this thesis, we have performed an in-depth analysis to characterise the 
actions of this second messenger in modulating cancer cell growth. This study provides 
some insights on how cAMP is generated and retained within intracellular 
compartments lead to cell growth suppression in cancer cells. Moreover, our study was 
accomplished using multiple models of cancer: glioma and glioblastoma cell lines from 
two different species - rat (C6 cells) and human glioblastoma (U87 and T98 cells), and 
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extended, to include human primary HUVECs and hCMs (Chapter 6) to determine the 
effects of different GPCR agonists on cell proliferation.  
 Across all cells that have been tested, it was revealed that elevation of cAMP 
levels by forskolin displayed negative effects on cell growth. Interestingly, cells that 
responded to forskolin stimulation in cell growth, were also found to be suppressed by 
a number of PDE inhibitors, as demonstrated in Chapter 3 and 4. Following short-term 
stimulation (30 minutes), all compounds including forskolin, PDE inhibitors (particularly 
those that worked on cAMP and a few compounds that inhibited dual-substrate PDEs) 
as well as β2-AR agonist, A2AR agonist and CGRP-based peptides promoted the 
production of cAMP. However, only those that activate directly on AC and inhibit PDE 
were able to exhibit greater suppression on cell growth. The negative effect of cAMP 
was corroborated by blocking the MPR4 transporter - an efflux pump for cyclic 
nucleotides, to retain cAMP within the intracellular compartment. The treatment with 
MRP4 inhibitor further enhanced the anti-proliferative actions of cAMP-elevating 
agents (forskolin and PDE inhibitors). Interestingly, in the case of stimulation at the 
A2AR alone and CLR-RAMP complexes, long-term exposure did not exhibit anti-
proliferative effects (with the exception of H1563 cells). Instead, activation at these 
receptors was deemed to be pro-proliferative. Interestingly, dual-target ligands 
displayed antiproliferative actions through their dual activities as agonist at the A2AR 
and inhibitors of PDE10A (Chapter 6). These findings, in fact, open up further 
questions on whether the elevation of cAMP levels by different stimuli induce different 
cellular outcomes. The following sections will discuss the difference of these findings, 
discuss the limitation within the study, and recommend future research within the field.  
 
7.1.1.1  Different signalling profile between GPCR ligand-mediated and AC- 
/PDE-mediated cAMP responses  
Enzymes and GPCRs have different regulatory mechanisms. The concentration of a 
substrate mainly controls enzymes (AC and PDE), whereas agonist-occupied GPCRs 
typically undergo desensitisation or internalisation, although not all receptors 
encounter these processes. As demonstrated within this study, the elevation of cAMP 
levels by forskolin displayed anti-proliferative effects across all cell lines tested: rat and 
human glioblastoma (except U87 cells), human lung cancer cells, including primary 
cardiovascular cells HUVECs and hCMs. Stimulation at the GPCR level, or modulating 
the activity of Gαs or Gαi, promoted cAMP production, yet the cell growth suppression 
was considerably less profound compared to that of forskolin. This notion has been 
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clearly demonstrated through the effects of forskolin (direct activation of AC) and 
GPCR ligands (indirect activation), as shown in Chapter 3 using isoproterenol, PTx, 
and CTx; in Chapter 5, both NSCLC and GBM models were stimulated by the A2AR 
agonist: CGS21680; and Chapter 6 through stimulation of CLR-RAMP complexes by 
CGRP, AM, and AM2.  
Although the dose-dependent increase was observed in cAMP production, the 
potency and/or Imax of these ligands was weaker than that of forskolin in cell growth 
assay, with some of them being pro-proliferative (CGS21680 and CGR- related 
peptides). In agreement with other studies, prolonged exposure of β2-AR agonist-
induced receptor desensitisation or internalisation, mediated by GRKs and β-arrestins 
(Hausdorff, Caron and Lefkowitz, 1990; Shi et al., 2017). Some reports noted that A2AR 
was desensitised over more prolonged stimulation by CGS21680 in various cells 
(Ramkumar et al., 1991; Chern et al., 1993; Mundell, Benovic and Kelly, 1997; Mundell 
and Kelly, 1998), nevertheless, this mechanism remains poorly characterised. Notably, 
no palmitoylation identified at the C-terminal of A2AR, which is thought to be 
phosphorylation sites for GRKs or β-arrestin binding (Klaasse et al., 2008). In the case 
of CLR-RAMP complexes, it has been suggested that CLR is coupled to β-arrestin and 
undergoes internalisation (Hilairet et al., 2001).  
Although internalisation has been widely documented to terminate cellular 
signalling, more evidence has implicated the ability of GPCRs to maintain signal 
transduction from intracellular compartments (Calebiro et al., 2009; Ferrandon et al., 
2009). The complex of CLR-RAMPs and β-arrestin was found to transduce their own 
signalling to modulate cell growth despite being localised to endosomes (Kuwasako et 
al., 2000; Guidolin, 2010). In comparison, some GPCRs such as A2AR and GIPR-
RAMP heteromers have been shown to sustain their signal from the plasma membrane 
without undergoing internalisation (Carvalho et al., 2020; Harris et al., 2021). Indeed, 
the distinct regulation of GPCRs is appealing to investigate further. It will be interesting 
to determine how sustain and how strong a signal is required to be able to activate 
growth signalling cascade.  
 
7.1.1.2 Short-term vs prolonged exposure of cAMP and factors that may 
influence cell growth 
Although there is a discrepancy between cAMP production (30 minutes) and the cell 
proliferation assay (72h) utilised in this study, prolonged treatment was chosen to 
enhance the response that may not be detected for the short-term stimulation. Cell 
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growth can be determined after 24h, but longer exposure permits a better window for 
observation in terms of cell growth (see Chapter 2 optimisation of cell growth assay). 
In agreement with this, Vitali and colleagues also reported that either stimulatory or 
inhibitory effects on cell growth started 24h post-exposure, with the maximum effect at 
72h (Vitali et al., 2014). The more prolonged exposure may influence the expression 
of many proteins and most likely cause resistance. However, the latter requires a much 
more extended period of about 6-12 months, depending on cell types, to develop cell 
lines resistant to particular drugs. 
Among all PDEs characterised within this study, only those that mainly regulate 
cAMP could suppress cell growth, but a similar effect was not observed for cGMP-
specific PDE inhibitors. Instead of directly influencing cell growth, cGMP may act as 
an allosteric modulator that influences cAMP concentration through PDEs. Later, it was 
revealed that GC activators enhanced forskolin-mediated anti-proliferative effects 
indicating that dynamics in cGMP levels may control cAMP-mediated responses, 
possibly through dual-substrate PDEs. This finding opens up further questions: i) why 
did only PDEs that hydrolyse cAMP showed anti-proliferative effects but not others? ii) 
how does the change in cAMP concentration by different stimuli result in displaying 
different effects on cell growth? The following sections provide several viewpoints to 
explain the differential responses regarding the previous questions. 
 
A.  Spatiotemporal control by PDEs and association with other proteins within 
specific subcellular domain 
It has been suggested that PDEs are distributed in specific compartments within the 
cells. This microcellular domain is responsible for sculpting local pools of cAMP and 
dictating the activation of particular regulatory proteins to promote specific cellular 
responses. Of all PDEs, PDE4 is one of the most extensively studied to form 
macromolecule complexes that control the cAMP fine-tuning mechanism. In a report 
by Hoshi et al, the assembly of a signalosome containing PKA, PDE4, and AKAP79 
has disseminated different signals from two distinct receptors: bradykinin and 
muscarinic receptor onto two different effector systems (Hoshi, Langeberg and Scott, 
2005). Another signal complex comprising mAKAP, PKA, PDE4D3, EPAC, and 
MEKK/MEK/ERK5 controlled cAMP concentrations in the intracellular microdomain. 
The association of these proteins, in turn, dictate PKA, PDE4D3 enzymatic actions, 
and EPAC activity, providing the negative feedback loop to maintain physiological 
cAMP levels (Dodge-Kafka et al., 2005). Other mechanisms to control cAMP 
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concentration have also been reported by other studies highlighting the important role 
of PKA to activate PDE3, PDE4 and inhibit AC (AC5 and AC6) so maintaining cAMP 
homeostasis (Murthy, Zhou and Makhlouf, 2002; Khannpnavar et al., 2020). In 
addition, PDE10A has been shown to be tethered to a macromolecule complex 
involving PKA, AKAP150, and PSD95 that altogether influenced the signalling of N-
methyl-D-aspartate (NMDA) receptors (Russwurm, Koesling and Russwurm, 2015).  
The study presented in this thesis focused on producing total cellular cAMP and 
has not interrogated subcellular signalling. Given that PDEs control the spatiotemporal 
regulation of cAMP signalling in activating specific proteins, it would be of interest to 
investigate the role of prospective PDEs to identify the mechanism of PDE inhibitors in 
interfering with this signalling. 
 
B. Multiple proteins activated by cAMP are cell type-dependent 
In brain tumours, activation of PKA by cAMP induces the activation of the downstream 
transcription factor CREB to upregulate p27 and p21, both of which are cyclin-
dependent kinase (CDK) inhibitors (T Keravis and Lugnier, 2012). Both p27 and p21 
are known to mediate cell cycle arrest, therefore, inhibiting cell growth. In comparison, 
in lung cancer, PKA activation by cAMP-induced protein phosphatase 2A (PP2A) has 
been reported to recruit PDE4 to generate a macromolecular complex. The association 
of these proteins are reported to inhibit tumour suppressor genes such as ataxia 
telangiectasia mutated (ATM) gene encoding a serine-protein kinase that targets p53, 
breast cancer type 1 susceptibility protein (BRCA1), checkpoint kinase 2 (CHK2), H2A 
histone family member X (H2AX), and nibrin (NBS1); and NF-κB, as well as pro-
apoptotic proteins BCL2-interacting mediator of cell death (BIM) and BCL2 associated 
agonist of cell death (BAD) (H. Zhang et al., 2020).  
Aside from the differential proteins activated to control cell growth, the 
distribution of PKA isoforms has also been suggested to contribute to cell growth 
control. The expression ratio of RI and RII of the PKA subunits may determine the net 
effect between the pro- and anti-proliferative actions (Sapio et al., 2014). Furthermore, 
the activation of PKA-RIIβ, but not RIα isoform, appears to associate with cell growth 
suppression. Not only are they distributed into different domain within the cellular 
architecture, but also the patterns are different from each cell type (Cheadle et al., 
2008; Ilouz et al., 2017). Taken this into account, the types and distribution of PKA may 
be different between cell types and can be determined to better understand the effects 
of cAMP/PKA signalling. 
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Although many studies showed that the anti-proliferative actions could be driven 
by PKA or EPAC or both, in this study, the anti-proliferative effects of forskolin and 
PDE inhibitor in glioma cells were predominantly driven by PKA. In Chapter 3, we also 
showed that inhibition of EPAC enhanced the anti-proliferative effects of forskolin and 
PDE inhibitor. These suggest that there is a crosstalk between EPAC and PKA thereby 
driving the signalling through PKA leading to cell growth suppression. Interestingly, in 
A172 cells, another model of glioblastoma, the elevation of cAMP activated PKA and 
EPAC1/Rap1 signalling that together induces growth arrest and apoptosis (H. Zhang 
et al., 2020). Despite PKA and EPAC being cAMP effectors, each of these proteins 
can transduce its own signal. The activation of both proteins can be synergistic and 
antagonistic action in modulating cell growth.  
 
C. Crosstalk with MAPK signalling  
Amongst all regulatory pathways, the MAPK signalling cascade is widely known as a 
critical key player controlling cell growth, cell migration, proliferation, differentiation and 
apoptosis. The MAPK pathway is commonly known to be activated through stimulation 
of RTKs. Interestingly, evidence has emerged that suggests this cascade can be 
modulated through EPAC and PKA (Cheng et al., 2008; Borland, Smith and Yarwood, 
2009). Within the MAPK cascade, p38 and JNK are known to be activated in relation 
to stress responses, whereas ERK1/2 is primarily involved in cell growth following  
Ras-Raf activation (Yue and López, 2020). Interestingly, activation of these proteins 
can promote both cell growth and cell death.  
As part of the collaborative studies presented in this thesis, stimulation at the 
GPCR levels differentially modulates the ERK1/2 activation. Activation of CLR-RAMP 
complexes by CGRP-based peptides displayed activation of ERK1/2 and the pattern 
was aligned with the pro-proliferative effects following prolonged agonist exposure 
(Clark et al., 2021). In comparison, both CGS21680 and the triazoloquinazoline-based 
compounds were found to stimulate ERK1/2 phosphorylation upon short-term 
stimulation (Winfield, 2017), but both treatments displayed different final responses in 
cell growth. Stimulation at Gαi-coupled A1R by a series of newly synthesised agonists 
was also found to activate ERK1/2, even though its activation reduced cAMP 
concentration (Winfield, 2017). Given that ERK1/2 may trigger both anti- and pro-
proliferation, it requires further characterisation to understand better how this cascade 
works.  
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Many reviews marked the dual action of ERK1/2 phosphorylation, but the exact 
mechanism remains unsolved. It is suggested that the balance between intensity and 
duration between pro-and anti-apoptotic signals transmitted by ERK1/2 will determine 
the net effect of cell proliferation and growth inhibition (Zha et al., 1996). A recent 
review by Yue highlighted that ERK1/2 and proteins involved in MAPK cascade display 
bimodal actions with ultrasensitive responses (Yue and López, 2020). These 
properties mean that any changes in the upstream levels may produce extensive 
responses in the MAPK pathway and ERK1/2 signalling works like a “switch”. The 
changes need to exceed a certain threshold to activate apoptotic responses. This 
notion has been demonstrated in Xenopus oocytes, where the low and transient 
changes activated pro-proliferative actions, whereas intense and sustained signal-
induced apoptotic responses (Yue and López, 2020). It is also known that MAPK 
signalling requires a feedback loop to work, therefore once activated, the signal will be 
transmitted continuously until all cells showed synchronised responses. 
Furthermore, it has been suggested that not only the activation of ERK1/2 but 
also the translocation of ERK1/2 to the nucleus stipulates the pathway to be activated 
(Mebratu and Tesfaigzi, 2009). It has also been suggested that sustainability and the 
strength of the signal influences ERK1/2 phosphorylation to influence cell proliferation. 
There is currently limited understanding of how strong and how long the signal is 
transmitted by stimulating cells with forskolin and different GPCR ligands to finally 
influence cell growth. This particular aspect would be of interest to be investigated 
further. The real-time ERK kinase translocation reporters (KTRs) biosensor can be 
used as an alternative method to visualise ERK1/2 signalling by treating cells with 
different ligands (Yang et al., 2018).  
 
7.1.1.3 Physicochemical properties of tested compounds 
From what we have found from this study, it suggests that cAMP prevents cell growth 
across various cell lines tested except the resistant types of U87 cells. Aside from the 
different machinery that influences cellular responses, the stability of each compound 
used needs to be taken into account. For instance, isoprenaline was an agonist that 
eliciting a very potent activity in cAMP production compared to forskolin in glioma cells 
(Chapter 3). Due to the instability of isoprenaline in the aqueous solution, it is most 
likely that isoprenaline may be degraded during the proliferation assay. Thereby the 
ability of isoprenaline to suppress cell growth was less potent compared to forskolin. It 
may also occur that β2-ARs undergoes desensitisation followed by receptor recycling 
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after prolonged exposure. Thus, we can still observe, to some extent, the anti-
proliferation on glioma cells upon isoprenaline treatment, even though it was less 
potent than forskolin. However, some compounds may be degraded either because of 
their physicochemical properties or by cellular metabolic activity, leading to weaker 
actions or even elicited no effect on cell growth. Whilst some of the compound may still 
be active, little is known if the compounds tested here may generate inactive 
substances. Since there is limited information on the stability properties of each 
compound used within this study, it will be necessary to perform pharmacokinetics 
studies. 
 
7.1.1.4 Resistance cells were not responsive towards forskolin and PDE inhibitor 
Between the two cell lines of glioblastoma, U87 cells were found to be very resistant 
towards forskolin and PDE inhibitors. The possible explanation may come from the 
abundance of PDEs expressed within this cell line, as depicted in Chapter 4. Despite 
the fact that U87 cells are more sensitive for producing cAMP in short-term stimulation, 
this may trigger the activation of other PDEs to keep suppressing cAMP to the baseline 
level. Therefore, the anti-proliferative effect is negligible for prolonged exposure. Not 
only did U87 cells show resistance towards forskolin and PDE inhibitors, but also 
cisplatin – a reference cytotoxic drug.  
  A few essential proteins have been reported to contribute to the resistant nature 
of U87 cells. One of them is Raf kinase – a family of three serine/threonine-specific 
protein kinases in MAPK signalling. Raf has been reported to modulate the balance 
between pro-apoptotic and anti-apoptotic proteins (Häfner et al., 1994; Vossler et al., 
1997). Interestingly, the subtype Raf dominance is positively affected by PDE 
expression (Daniel, Filiz and Mantamadiotis, 2016). It has been reported that cells 
expressing the C-Raf isoform inhibit MAPK signalling through the cAMP/PKA pathway. 
The activation of PKA increases an anti-apoptotic protein BIM. Whereas in a more 
resistant type of cell, B-RAF is more dominant, so conferring the opposite effect in 
MAPK signalling and BIM expression (Daniel, Filiz and Mantamadiotis, 2016).  
It has been reported that U87 cells express MRP4, an efflux transporter that we 
and others have shown to be responsible for exporting cAMP into extracellular regions. 
Several proteins were also upregulated in U87 cells, such as ectonucleotide 
pyrophosphatase/ phosphodiesterase 1 (ENPP1) and CD73, encoded by the NT5E 
gene (Bageritz and Goidts, 2014; Wang and Matosevic, 2019). Both proteins are 
membrane-bound enzymes that mediate the conversion of extracellular cAMP into 
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AMP, ADP, ATP, and adenosine, which cells can subsequently use to modulate cell 
growth. Since multiple mechanisms possibly contribute to the resistance nature of U87 
cells, to disseminate the role of these proteins, application of selective inhibitors can 
be performed, such as dabrafenib, vemurafenib, or encorafenib (B-RAF inhibitor); 
ENPP1C (ENPP1C inhibitor), CP5244, AB680, and PB-12379 (CD73 inhibitor). 
Besides the upregulation of the proteins mentioned earlier, glioblastoma cells 
have also been shown to have metabolic reprogramming for rapid proliferation by 
utilising aerobic glycolysis – namely the Warburg effect, rather than oxidative 
phosphorylation that is generally found in normal cells. Interestingly, a study by Xing 
showed that treating resistant glioblastoma cells by forskolin or PDE inhibitor reversing 
glioblastoma phenotypes to astrocytes through the cAMP/PGC1α pathway (Xing et al., 
2017). Therefore, it has been suggested that reinstating normal oxidative 
phosphorylation may be beneficial to inhibit cancer cell growth and impair the 
metastatic ability (Schulz et al., 2006). For future studies, it is worth treating U87 cells 
with cisplatin after exposing cells to forskolin or PDE inhibitor to U87 cells to confirm 
the benefit of reversing the Warburg effect. 
 
7.1.1.5 Drug combination vs multi-target ligands 
Another aspect that can be highlighted is the advantage of drug combination to 
optimise therapeutic outcomes. Classically, drugs have been designed to target a 
single biological entity with high selectivity to evade unwanted off-target effects. 
However, drug design has faced remarkable challenges with the undesirable actions 
as the major drawback. This includes the possible toxicities of a single agent by non-
selective actions. The drug combination strategy has been applied to numerous 
diseases, including AIDS, atherosclerosis, cancer, antibiotic regimens and 
neurodegenerative disorders, all of which involve complex pathogenesis (Mokhtari et 
al., 2017; Ramsay et al., 2018; Tyers and Wright, 2019). The combination of A2AR 
agonists with particular PDE inhibitors has shown to be able to prevent uncontrollable 
cell growth in B-cell malignancies (Rickles et al., 2010). Based upon prospective 
approaches though PDE inhibition, the work presented in this thesis further explored 
two approaches to optimise enhancement in cAMP signalling: multiple targeting by 
drug combinations and developing multi-target ligands.  
Combination treatment is one of the most common strategies to improve drug 
efficacies. These have been demonstrated in detail in Chapters 3 and 4. Concomitant 
targeting of direct activation at AC and multiple PDE inhibition showed significant 
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advantages over the individual compounds. The improvement on efficacy by drug 
combinations may tackle the issues raised due to the compound toxicity, such as that 
of trequinsin. Taken together, targeting multiple proteins may be attained by using 
lower doses without compromising efficacy and with a better safety profile.  
The development of multi-target ligands was applied in Chapter 5. An approach, 
named the "multi-target lead discovery" can be considered a promising tool for 
identifying novel combinatorial effects of drugs (Overington, Al-Lazikani and Hopkins, 
2006). As previously mentioned, targeting receptors alone might be insufficient to be 
translated into cell growth. Similar to the stimulation on A2AR by CGS21680, an 
individual treatment by a PDE10 inhibitor caused a marginal effect on cell growth 
suppression. This study showed that the efficacy in inhibiting cell growth was enhanced 
by a multi-target ligand (Chapter 5). Despite showing notable anti-proliferative actions, 
triazoloquinazoline-based compounds exhibited low binding affinity at the A2AR, 
displaying pKi values in the micromolar range. This is not surprising because the vast 
majority of issues (>80%) in developing multi-target ligands arise from this particular 
aspect. Regardless of low affinities, these findings can be used as a starting point to 
improve binding affinities and develop better chemical entities for the future studies.  
Based on the therapeutic benefits of drug combination within this study, a 
couple of strategies may be prospective to inhibit cancer cell growth. Since cAMP has 
been shown to have a negative effect on cell proliferation, particularly in cancer models 
that were utilised in this study, it may be necessary to consider the following 
combination to enhance the intracellular concentration of cAMP. Aside from pairing 
with AC activator or A2AR agonist, the PDE inhibitor can be combined with other agents 
that increase cAMP action. These may include a combination with a Gαi-coupled 
GPCR antagonist, an MRP4 inhibitor, a PKA activator, and a GC activator. The latter 
is proposed given our findings in Chapter 3. The disturbance in cAMP and cGMP 
balance may sequester signalling to go through PKA, therefore, enhancing the 
antiproliferative effect mediated by cAMP/PKA. 
To conclude, either utilising drug combinations or developing multi-target 
ligands may be a practical strategy to design better drugs. However, the integrated 
rational characterisation at the chemical and biological aspects needs to be carried out 
carefully to develop effective small molecule candidates. 
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7.1.1.6 Potential use of cAMP elevating agent and further consideration for 
targeting cAMP pathway 
We have proven that elevating cAMP levels by targeting AC and/or multiple PDEs 
elicited beneficial effects to prevent tumour progression. Although it is considered to 
be prospective, many tissues express AC and PDEs to maintain cellular functions. 
Therefore, the systemic use of forskolin or PDE inhibitor may become a limiting factor. 
Given this constraint, some strategies should be developed to ensure localised 
forskolin and PDE inhibitors without exerting an adverse effect on healthy cells. 
Otherwise, another aspect that needs to be validated is the ability of compounds to 
cross the blood-brain barrier (BBB). Despite not being covered within this study, 
numerous models of the human BBB have been established and can be used for future 
studies, such as human immortalised endothelial hCMEC/D3 cell line, cord blood-
derived endothelial progenitor cells, or recent model utilising human pluripotent stem 
cells (hPSCs). 
 It is also worth noted that cAMP may promote cell growth depending on cell 
type. The application of cAMP elevating agent such as forskolin and PDE inhibitor, 
therefore, needs to be used deliberately to maximise the anti-proliferative effects by 
targeting cAMP pathways.  
 
7.1.2 Modulatory action of RAMPs in dictating PAR4 and CLR pharmacology 
The role of RAMPs in modulating GPCRs has been well appreciated, although, in the 
very beginning, it is first thought to be as a chaperone for CLR (McLatchie et al., 1998). 
Recent findings have shown that more receptors form an association with RAMPs, 
leading to distinctive signalling profiles. Serafin and colleagues culminated in an 
advancement discovery of 44 receptors as interacting partners of RAMPs, compared 
to 11 previously reported receptors (Serafin et al., 2020).  
 Aside from the receptors mentioned in the recent review by Serafin (Serafin et 
al., 2020), the study in this thesis has suggested that both PAR4 variants (PAR4-A120 
and PAR4-T120) can interact with RAMPs, leading to differential recruitment of β-
arrestins. Compared to other PAR families, different proteases induced signalling bias 
of PAR1 and PAR2, yet little is known about PAR4. Pharmacological substances such 
as peptides/peptidomimetics, blocking antibodies, small molecules, pepducins, 
parmodulins, or designer receptors exclusively activated by designer drugs 
(DREADDs) have been developed to modulate PAR family activities (Heuberger and 
Schuepbach, 2019), but it has not been validated in PAR4. Although it is considered 
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preliminary, the finding within this study opens up avenues of investigation on how the 
interactions with RAMPs change PAR4 pharmacology and its physiological 
consequences. Since PAR4 plays an essential role in blood clot formation and 
inflammatory processes (Faruqi et al., 2000; Heuberger and Schuepbach, 2019), 
signalling biased can be postulated to optimise therapeutic outcomes and reducing 
adverse reaction such as severe bleeding that was imposed by PAR1 antagonist or 
predominantly driven by Ca2+-mediated signalling upon PAR4 stimulation. 
 Further exploration on RAMP-CLR in native systems: glioblastoma model and 
primary human cardiovascular cells, corroborates that signalling bias driven by RAMPs 
may occur in physiological settings to provoke differential effects. Although there was 
a significant pattern observed between both systems, there was a clear connection 
between endogenous peptides used for the studies. Together with the study by Clark 
et al., it is apparent that each ligand promotes distinct signalling signatures and was 
aligned with what was observed in heterologous systems (Weston et al., 2016; Woolley 
et al., 2017; Clark et al., 2021) 
CGRP is known to be a potent vasodilator and is currently being used as a 
target for migraine therapy and has been suggested to be involved in cancer-related 
pain (Y. Zhang et al., 2020). AM and AM2 also display vasorelaxation effects and the 
expression of both peptides are upregulated by the hypoxia-inducible factor (HIF). AM, 
in particular, has been suggested to promote expression of anti-apoptotic factors and 
contributes to the tumour resistance to hypoxia, thereby promoting cell growth (Oehler 
et al., 2001). In spite of the indication that CLR and RAMPs are expressed in GBM cell 
lines, the role of CLR-RAMP complexes in cancer is not fully characterised. A number 
of studies highlighted that CGRP can both directly and indirectly influence cancer 
development by upregulating CLR and RAMP expression (Hoppener et al., 1987; 
Ostrovskaya et al., 2019; Y. Zhang et al., 2020). Kiriyama reported that activation of 
CGRP promoted secretion of IL-6 that has main function to induce nerve growth factor 
production in astrocytes as the response to cytokines and neuropeptides in glial cells 
(Kiriyama et al., 1997). Arguably, the expression of CLR and another family receptor, 
CTR, and their activation might not be correlated with the outcomes in patient-derived 
GBM cells (Ostrovskaya et al., 2019).  
Since the cells used for this study were native with endogenous expression of 
receptor of interests, there is also a possibility that another receptor - CTR, may 
interfere with the CGRP-mediated responses in glioblastoma. From the preliminary 
study, we found that U87 cells expressed CTR at mRNA levels (data not shown). While 
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CGRP shows a higher affinity to CLR-RAMP1 complexes, it also binds to CTR-RAMP1 
heterodimers showing a similar affinity to amylin (AMY). The binding of CGRP on 
different subsets of receptors has been reported to undergo a distinct receptor 
internalisation pattern (Gingell et al., 2020). However, there is not yet any evidence if 
the differences may have physiological consequences. Aside from what was reported 
by Clark and colleagues using cardiovascular cells, there is little other evidence to 
emphasise RAMPs modulatory effect on CLR in native physiological cells (Clark et al., 
2021). Given that the preliminary indications from this study, further characterisation is 
required to address the involvement of CLR-RAMP association in pathological 
circumstances.  
 
7.2  Future Directions 
Targeting multiple PDEs to promote anti-proliferative effects was explored in-depth 
within this study. Some PDE inhibitors have been shown to have potential in preventing 
cancer cell growth. To better understand these PDEs' mechanism in sculpting cAMP 
gradient in cellular microdomain, the investigation could be conducted using cAMP 
reporters, either PKA-based or EPAC-based sensor or modifying PDE of interest with 
fluorescence protein to aid cellular visualisation. Furthermore, co-immunoprecipitation 
studies may provide further insight into whether PDEs are tethered with other proteins 
and how this interaction regulates the spatiotemporal of cAMP within the cells. It is also 
worth noting that quantification on ERK1/2 phosphorylation throughout the proliferation 
period is required to connect a gap between upstream cAMP production and cell 
growth. As a translational tangent, the prospective compounds can be further 
characterised in vivo, such as applying it using the xenograft brain tumour model. For 
a series of considered prospective compounds for future studies, an appropriate BBB 
model and pharmacokinetic studies can be performed. 
PAR4 was discovered as a novel interacting partner of RAMPs from this study. 
However, this works only explored the upstream canonical Ca2+ mobilisation, but it 
remains unknown if the effect was mediated by Gαq or from Gβɣ dimers. The use of 
specific inhibitors could help to disseminate the involvement of G protein-mediated 
responses. Since this study is only preliminary, numerous aspects can be explored, 
including the pleiotropic coupling of PAR4 to other G proteins, receptor downstream 
signalling, and the mechanism of RAMP-PAR4 association. The presence of FRET-
based sensor, bioluminescence resonance energy transfer- (BRET) or enhanced 
bystander BRET- (ebBRET) based protocol, and functional complementation assay, 
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allow exploration to reveal PAR4 pharmacology in interacting with other regulatory 
proteins or G proteins (Zhao et al., 2014). Further elucidation on β-arrestin signalling 
and its consequences in receptor internalisation would also be of interest for future 
studies.  
The modulation of RAMPs on CLR pharmacology has been widely studied in 
heterologous expression systems. Based upon current data, it can be further explored 
if targeting these complexes may suppress cancer cell growth. The availability of 
antagonists or an antibody targeting CLR-RAMP heteromers may give aid to explore 
this hypothesis. Besides, pro-proliferative actions by CGRP and related peptides on 
cardiovascular cells can be seen as targets to regenerate endothelial functions. 
Therefore, it would be an attractive approach for treating ischemic heart disease or 
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Appendix Figure 1. Triazoloquinazolines differentially inhibit PDE10A activity in 
vitro. Concentration-response curves were displayed for compound 1-6 and 
CGS21680 at PDE10A. Data are expressed as the mean ± SEM of 6 individual data. 
This data was generated from previous study conducted by Dr. Winfield (University of 
Cambridge). 
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Appendix Figure 2. Triazoloquinazolines promote differential activations across 
all adenosine receptor subtypes. The selectivity characterisation to all adenosine 
receptors using yeast systems and CHO-K1 expressing A3R. To characterise 
selectivity of triazoloquinazolines, yeast systems were used as appropriate: A1R and 
GPA1/Gαi1/2, A2AR and GPA1/ Gαs, or the A2BR (with GPA1/Gαs expressed in yeast 
strains). The efficacy of the compounds (1–6) was measured against A3R in CHO-K1-
A3R cells. Each data point represents the mean of responses from 6 repeats after 
normalisation with either NECA (for A1R, A2AR, and A2BR) or forskolin 100 µM (for A3R. 
This data was generated from previous study conducted by Sabrina Carvalho 
(Department of Pharmacology, University of Cambridge). 
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Appendix Figure 3. Triazoloquinazoline-based compounds promote the production of 
cAMP in CHO-K1 stably expressing A2AR. Accumulation of cAMP was determined 
following 30 minutes stimulation with CGS21680 (A), compound 1-6 (B-G) in the 
presence of rolipram. Data are expressed relative to the maximal response produced 
by CGS21680 100 µM. Values are expressed as mean ± SEM of 4 – 9 individual 
repeats. This data was generated from previous study conducted by Dr. Winfield 
(University of Cambridge). 
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Appendix Figure 4. Anti-proliferative actions of forskolin and triazoloquinazolines 
(compound 1-5) was potentiated in CHO-K1 cells stably expressing A2AR. Percentage 
of cell number was determined upon 72h treatment. Data are expressed as relative 
cell number to the vehicle alone and are the mean ± SEM from 4 – 6 individual data.  
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A B S T R A C T
Supressed levels of intracellular cAMP have been associated with malignancy. Thus, elevating cAMP through
activation of adenylyl cyclase (AC) or by inhibition of phosphodiesterase (PDE) may be therapeutically bene-
!cial. Here, we demonstrate that elevated cAMP levels suppress growth in C6 cells (a model of glioma) through
treatment with forskolin, an AC activator, or a range of small molecule PDE inhibitors with di"ering selectivity
pro!les. Forskolin suppressed cell growth in a PKA-dependent manner by inducing a G2/M phase cell cycle
arrest. In contrast, trequinsin (a non-selective PDE2/3/7 inhibitor), not only inhibited cell growth via PKA, but
also stimulated (independent of PKA) caspase-3/-7 and induced an aneuploidy phenotype. Interestingly, a
cocktail of individual PDE 2,3,7 inhibitors suppressed cell growth in a manner analogous to forskolin but not
trequinsin. Finally, we demonstrate that concomitant targeting of both AC and PDEs synergistically elevated
intracellular cAMP levels thereby potentiating their antiproliferative actions.
1. Introduction
Glioma is a general term for brain tumours that originate from glial
cells in the central nervous system and which may progressively lead to
death if not treated early [1,2], with glioblastoma, the most common
type of glioma, showing particularly poor survival [3]. The develop-
ment of novel therapeutic approaches targeting glioma and glio-
blastoma are urgently required.
Defects in a number of signalling pathways have been reported in
glioma pathogenesis, including the phosphatidylinositol-3 kinases/
phosphatase and tensin/protein kinase B/mammalian target of rapa-
mycin (PI3K/PTEN/Akt/mTOR) cascade; the retinoblastoma pathway
(pRB); the Ras/mitogen-activated protein kinase (RAS/MAPK)
pathway; signal transducer and activator of transcription 3 (STAT3);
zinc transporter 4 (ZIP4); as well as the adenylyl cyclase (AC) system
[4].
Importantly, lower cAMP levels are observed in brain tumour tissue
(25.8 pmol/mg protein) compared to normal healthy tissue (98.8 pmol/
mg protein) [5]. Indeed forskolin, an AC activator that elevates cAMP
levels, has shown promising results in ameliorating cancer development
[6]. While high levels of intracellular cAMP may kill cancer cells, the
exact molecular mechanisms have not been clearly elucidated. Direct
elevation of cAMP using the cAMP analogues 8-bromo-cAMP, 8-chloro-
cAMP, monobutyryl cAMP and dibutyryl cAMP, however, cannot be
recommended due to the toxicity of these compounds [7]. Thus, there is
a need to develop safe and e"ective compounds that can increase cAMP
levels by pharmacological intervention.
Depending on the cell type where the malfunctions are observed,
cAMP may play a role in either promoting or suppressing cell pro-
liferation. This incongruity can be explained by two theories on the
cAMP signalling cascade. The !rst theory proposes that elevation of
intracellular cAMP is bene!cial for suppressing cell proliferation in
most mesenchymal and epithelial cell lines, such as glioblastoma [8],
thyroid cells [9], ovarian granulosa cells [10], !broblasts [11], and
primary cardiomyocytes [12]. In contrast, the second theory proposes
that cAMP promotes cell survival, which has been observed in myeloid
cells, pancreatic !-cells, hepatocytes, gastric and intestinal cells, spinal
motor, superior cervical ganglion sympathetic, dorsal root ganglion,
dopaminergic neurons, cerebral granule and septal cholinergic neurons
[13]. These two divergent roles of cAMP may be crucial in both phy-
siological maintenance and pathological conditions, but whether these
signalling cascades are interconnected remains unclear.
It has been well established that after synthesis by AC activation,
cAMP di"uses within cells and is hydrolyzed to 5!AMP by
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phosphodiesterases (PDEs). PDEs are a subfamily of ectonucleotidases
consisting of 11 isoforms (PDE1–11) in mammals and are encoded by
21 di!erent genes [14], which are distributed in many types of tissue
[15]. Each isoenzyme possesses di!erent a"nities for cAMP and/or
cGMP, kinetic characteristics, allosteric regulation by cAMP/cGMP and,
phosphorylative control by various protein kinases, that result in their
distinctive response to a stimulus [16,17]. To date, there are 3 classes of
PDEs subdivided according to their substrate speci#cities: cAMP-spe-
ci#c PDEs (PDE4, PDE7 and PDE8), cGMP-speci#c PDEs (PDE5, PDE6
and PDE9), and dual-substrate PDEs (PDE1, PDE2, PDE3, PDE10 and
PDE11) [18]. Through metabolizing both cAMP and cGMP, PDEs gen-
erate intracellular gradients and microdomains of these second mes-
sengers to regulate their spatio-temporal signalling [19]. PDEs prevent
non-speci#c activation, enabling both speci#city and selectivity to-
wards intracellular targets [20].
Overexpression of some PDEs, such as PDE1, PDE4, PDE5, and
PDE7, has been reported to alter patterns of cAMP in the brain [21–24].
Some evidence shows that particular PDE inhibitors, such as rolipram, a
selective PDE4 inhibitor, prevents leukaemia proliferation through an
elevation of cAMP and an induction of apoptosis. This suggests that
using speci#c PDE inhibitors is a viable approach for cancer therapy
[25]. Given that PDE inhibitors may o!er therapeutic e"cacy against
cancer, we investigated the role of each PDE upon cAMP accumulation
and cell proliferation in a glioma cell model using a range of pharma-
cological inhibitors. Our data indicates that tumour cell regression is
linearly correlated with elevation of cAMP. Among all PDE inhibitors
tested, trequinsin (a non-selective PDE2/3/7 inhibitor [26]) was found
to be the most potent at inhibiting cell proliferation. More importantly,
by using small molecule compounds we highlight that simultaneous
elevation of cAMP through activation of AC and inhibition of multiple
PDEs (speci#cally PDE2, PDE3 and PDE7) had synergistic anti-pro-
liferative e!ects on the glioma cells, predominantly by altering cell
cycle progression and inducing activation of caspase-3/7, providing a
novel treatment strategy for glioma.
2. Materials and methods
2.1. Cell lines
C6 glioma cells (a gift from Prof. Colin Taylor, University of
Cambridge) were cultured in Gibco® Minimum Essential Medium
(Thermo Fisher Scienti#c, UK) supplemented with 10% foetal bovine
serum (FBS, Sigma, UK), 2 mM L-glutamine (Sigma, UK), and 1% an-
tibiotic/antimycotic (Sigma, UK). ST14A cells (rat-derived striatal cells
(Tissue and Cell Biotechnologies, Italy) were grown in Gibco® DMEM/
F12 1:1 (1X) – Glutamax TM (Thermo Fisher Scienti#c, UK), supple-
mented with 10% FBS and 1% antibiotic/antimycotic. C6 cells were
maintained at 37 °C in humidi#ed 95% air and 5% CO2. ST14A cells
were grown at 33 °C in humidi#ed 95% air and 5% CO2 because pro-
pagation of ST14A cells at 37 °C has been shown to induce di!er-
entiation into glial cells [27]. Where appropriate cells were treated with
pertussis toxin (PTX, Thermo Fisher, UK) at a range concentration of
2 pg/ml to 200 ng/ml or cholera toxin (CTX, Sigma, UK), at a con-
centration of 3.5 pg/ml to 350 ng/ml. PTX uncouples receptor-medi-
ated G!i-dependent inhibition of cAMP production, meanwhile CTX
inhibits GTPase activity of G!s and causes permanent activation
[28,29].
2.2. Compounds
Forskolin (Sigma, UK) was diluted to a stock of 100 mM in DMSO
(Sigma, UK). Cholera toxin (CTX) was diluted in water to a stock of
35 "g/ml, whereas pertussis toxin (PTX) was diluted at a stock of
100 "g/ml. Isoprenaline hydrochloride (Sigma, UK) was dissolved in
water to a stock of 10 mM. Trequinsin, PF-2545920, vinpocetine, sil-
dena#l, rolipram, cilostamide, ca!eine, SQ22536, EHNA, amrinone,
zaprinast, TC3.6, ibudilast, milrinone, BAY 73-6691, BRL-50481, pi-
clamilast, IBMX, ro$umilast, tadala#l, PF-04449613 (all purchased
from Sigma, UK), BC 11-38, and PF 04671536 (both obtained from
Tocris, UK) were dissolved in DMSO to stock concentrations of either
100 mM or 10 mM. Guanylyl cyclase activators BAY 41-8543 and YC-1
were purchased from Tocris and diluted to a stock of 100 mM in DMSO.
Exchange protein directly regulated by cAMP (Epac) inhibitors ESI-09,
HJC0350, and CE3F4 (all purchased from Sigma, UK) were diluted to
10 mM stocks in DMSO. Protein kinase A (PKA) and protein kinase G
(PKG) inhibitors, KT5720 and KT5823, respectively (all obtained from
Cambridge Insight Biotechnology, UK) were diluted to stocks of
100 mM and 1 mM, respectively. MRP4 (multidrug resistant protein 4)
inhibitor, PU23 (Tocris, UK), was dissolved in DMSO to a stock of
50 mM.
2.3. Reverse transcription PCR
RNA was extracted from C6 and ST14A cells using RNAqueous®-
4PCR Total RNA Isolation Kit (Life Technologies, UK) according to
manufacturer’s instructions. In order to remove any contamination of
genomic DNA, all RNA samples were treated with DNAse I included in
the kit. The purity of RNA samples was quanti#ed using a NanoDropTM
Lite spectrophotometer (Thermo Scienti#c, UK) and only samples that
had a minimum yield of 100 ng/"L and A260/280 > 1.9 were used in
the experiments. Complementary DNA was synthesized using a
QuantiTect reverse transcription kit (Qiagen, UK). The oligonucleotides
(Sigma, UK) used for PCR were designed speci#cally for rat, including
GAPDH: forward 5!-TCCCTCAAGATTGTCAGCAA-3!, reverse 5!- AGAT
CCACAACGGATACATT-3! (309 bp); PDE1A: forward 5!-CGCCTGAAA
GGAATACTAAGA-3!, reverse 5!-TAGAAGCCAACCAGTCCCGGA-3!
(211 bp); PDE1B: forward 5!- CTGTCACCCCGCAGTCCTCCG-3!, reverse
5!-GAAGGTGGAGGCCAGCCAGTC-3! (309/306 bp); PDE1C forward
5!-CGCGGGCTGAGGAAATATAAG-3!, reverse 5!-GAAGGTGGAGGCCA
GCCAGTC-3! (237 bp); PDE2A: forward 5!-CCAAATCAGGGACCTCATA
TTCC-3!, reverse 5!-GGTGTCCCACAAGTTCACCAT-3! (86 bp); PDE3A:
forward 5!-CACAAGCCCAGAGTGAACC-3!, reverse 5!-TGGAGGCAAAC
TTCTTCTCAG-3! (123 bp); PDE3B: forward 5!-GTCGTTGCCTTGTATTT
CTCG-3!, reverse 5!-AACTCCATTTCCACCTCCAGA-3! (103 bp); PDE4A:
forward 5!-CGACAAGCACACAGCCTCT-3!, reverse 5!-CTCCCACAATGG
ATGAACAAT-3! (73 bp); PDE4B: forward 5!-CAGCTCATGACCCAGAT
AAGTGG-3!, reverse 5!-GTCTGCACAAGTGTACCATGTTGCG-3!
(787 bp); PDE4C: forward 5!-ATGGCCCAGATCACTGGGCTGCGG-3!,
reverse 5!-GCTGAGGTTCTGGAAGATGTCGCAG-3! (582 bp); PDE4D:
forward 5!-CCCTCTTGACTGTTATCATGCACACC-3!, reverse 5!-GATCC
TACATCATGTATTGCACTGGC-3! (262 bp); PDE5A: forward 5!-CCCTG
GCCTATTCAACAACGG-3!, reverse 5!-ACGTGGGTCAGGGCCTCATA-3!
(192 bp); PDE7A: forward 5!-GAAGAGGTTCCCACCCGTA-3!, reverse
5!-CTGATGTTTCTGGCGGAGA-3! (85 bp); PDE7B: forward 5!-GGCTCC
TTGCTCATTTGC-3!, 5!-GGAACTCATTCTGTCTGTTGATG-3! (99 bp);
PDE8A: forward 5!-TGGCAGCAATAAGGTTGAGA-3!, reverse 5!-CGAA
TGTTTCCTCCTGTCTTT-3! (97 bp); PDE8B: forward 5!-CTCGGTCCTTC
CTCTTCTCC-3!, 5!-AACTTCCCCGTGTTCTATTTGA-3! (147 bp); PDE9A:
forward 5!-GTGGGTGGACTGTTTACTGGA-3!, reverse 5!-TCGCTTTGGT
CACTTTGTCTC-3! (107 bp); PDE10A: forward 5!-GACTTGATTGGCAT
CCTTGAA-3!, reverse 5!-CCTGGTGTATTGCTACGGAAG-3! (115 bp);
and PDE11A: forward 5!-CCCAGGCGATAAATAAGGTTC-3!, reverse
5!-TGCCACAGAATGGAAGATACA-3! (87 bp).
All PCR products were run on a 2% agarose gel. The gel was vi-
sualised in the presence of ethidium bromide and imaged using a G Box
iChemi gel documentation system. Density of each band was analysed
with GeneTools analysis software (Syngene, UK). Correct band size was
compared to that of previous works.
2.4. cAMP accumulation assay
Cells were grown to con$uency in complete MEM growth medium.
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Cells were then trypsinised for 1 min, re-suspended in stimulation
bu!er (PBS with 0.1% BSA) and plated onto 384-well optiplates (Perkin
Elmer, UK) at a density of 2000 cells/well. To determine the e"cacy of
individual PDE inhibitors, cells were co-stimulated, immediately after
seeding, with three di!erent concentrations of compounds (which
spanned 100-fold either side of the individual IC50 value in vitro) and
pEC20 values of forskolin (1.6 !M for C6 cells and 50 nM for ST14A
cells) for 30 min. Stimulating cells with the pEC20 of forskolin, enables a
larger range to observe any e!ect of the PDE inhibitors on cAMP pro-
duction. To generate full dose response curves, compounds were added
to cells in the range of 0.1 pM – 100 µM for 30 min. Detection of cAMP
was assessed using LANCE cAMP detection kit (Perkin Elmer, UK) and
end-point measurement was performed using a Mithras LB940 micro-
plate reader (Berthold Technologies, Germany). The lysed cells were
excited at 340 nm wavelength with #uorescence from homogeneous
time-resolved FRET detected at 665 nm.
To determine the e!ects of G proteins on cAMP production, C6 cells
were grown in complete MEM medium in the presence of either PTX or
CTX for 16 h (as a pre-treatment). Subsequently, cells were dissociated
using trypsin for 1 min after which, complete medium was added to
inactivate trypsin. Cells were washed, resuspended in PBS containing
0.1% BSA, and plated onto 384-well optiplates at a density of 8000
cells/well. Total accumulation of cAMP was determined using the same
protocol as described above. Data were either normalised to the max-
imal level of cAMP accumulation from cells in response to 100 !M
forskolin stimulation or were interpolated to the cAMP standard curve
and expressed as the concentration cAMP per 106 cells. Where stated,
cAMP levels are quoted as pmoles per mg of protein mass, determined
using Bradford protein assay (Biorad, UK) following the manufacturer’s
instruction.
2.5. Determination of intracellular and extracellular cAMP levels
C6 cells were trypsinised and resuspended in PBS containing 0.1%
BSA. 150,000 cells were then treated with various concentrations of
PU23 (10 !M, 3.16 !M, and 1 !M, diluted in PBS containing 0.1% BSA)
for 30 min. After treatment, cells were washed with PBS containing
0.1% BSA and stimulated with the pEC50 concentration of forskolin
(3.16 !M), trequinsin (4.7 !M) or the PDE inhibitor cocktail (26 !M) for
1 or 2 h, in the presence or absence of each concentration of PU23.
After stimulation, cells were centrifuged at 1677 ! g for 4 min to se-
parate supernatant and cell pellet. LANCE cAMP detection kit (Perkin
Elmer, UK) was used to determine extracellular cAMP levels (super-
natant) and intracellular cAMP levels (cell pellet). The concentration of
cAMP was determined by interpolating the HTR-FRET values to the
cAMP standard curve. cAMP levels are expressed as the concentration
per 106 cells.
2.6. cGMP accumulation assay
Con#uent C6 cells were trypsinised and resuspended in PBS con-
taining 0.1% BSA. Cells were plated onto a 384-well plate at a density
of 500,000 cells/well and immediately stimulated with compounds for
30 min. After stimulation, 5 µl of d2-cGMP analogue and 5 µl mAb-
cryptate were added to each well and incubated for 1 h at room tem-
perature as per the manufacturer’s instruction (Cisbio, France). The d2-
cGMP #uorophore was excited at a wavelength of 337 nm and emission
was detected at 665 nm and 620 nm. Fluorescence was measured using
a Mithras LB940 microplate reader (Berthold Technologies, Germany).
Delta F% values were calculated using the 665 nm/620 nm ratio and all
data were interpolated to a standard curve which covered an average
cGMP range of 0.5–50 nM.
2.7. Cell proliferation assay
C6 cells were seeded at a density of 2500 cells/well in a clear #at
bottom 96-well plate (Corning). After 24 h, cells were exposed to test
compounds or vehicle, in complete MEM growth medium, and were
incubated for 72 h. To further investigate whether downstream path-
ways of cAMP in#uenced cell proliferation, cells were cotreated with
selective inhibitors that target cAMP/cGMP sensors including PKA,
PKG, and Epac. Cells were seeded as previously described and treated
with either forskolin, trequinsin, or PDE inhibitior cocktail in the pre-
sence of the following inhibitors: KT5720 to inhibit PKA, KT5823 to
inhibit PKG, ESI-09 as non-selective Epac inhibitor, CE3F4 as a selective
Epac1 inhibitor, and HJC0350 as a selective Epac2 inhibitor. In order to
investigate the e!ect of blockade of cAMP export on cell proliferation,
cells were treated with forskolin, trequinsin or PDE inhibitor cocktail in
the presence, or absence, of various concentrations of PU23 (10 !M,
3.16 !M, and 1 !M). After 72 h incubation, 5 !l of Cell Counting Kit – 8
(CCK-8, Sigma, UK) was added to each well and the cells were in-
cubated for an additional 2–3 h at 37 °C in the dark. The absorbance of
each well was measured using a Mithras LB940 microplate reader
(Berthold Technologies, Germany) with an excitation of 450 nm. The
amount of formazan formed is directly proportional to the number of
viable cells. Cell proliferation was calculated as a percentage of number
of cells treated with vehicle alone.
2.8. Caspase assay
C6 cells were seeded into clear bottom black 96-well plates
(Corning) and treated with forskolin (1–100 !M), trequinsin
(1–100 !M) or staurosporine (1 !M, a pan caspase activator) in com-
plete MEM media. 1% DMSO was used as vehicle control. Cells were
exposed to test compounds for 72 h, plates were treated with 2 !M of
the CellEvent™Caspase-3/7 green detection reagent (Life Technologies,
UK) for 60 min at 37 °C in the dark. Caspase activity was detected by
cleavage of the tetrapeptide substrate DEVD, which is conjugated to a
nucleic acid binding dye. Intracellular caspase-3/7 activities were im-
aged using a BD Pathway 855. To normalise the number of cells with
caspase activated, cells were also labelled with Hoechst 33342
(Cambridge Bioscience, UK). Activated caspase-3/7 cleaves substrate
and produce green #uorescence which was visualised using FITC/Alexa
FluorTM 488 $lter setting. The total number of cells stained with
Hoechst 33342 was measured using Hoechst $lter (350/461 nm).
2.9. Cell cycle analysis
Cell cycle analysis using #ow cytometry provides information on the
distribution of cells in interphase stages of the cell cycle (G0/G1, S, and
G2/M). C6 cells were seeded in to 24-well plates and cultured for 24 h.
Cells were exposed to selected treatments including forskolin, tre-
quinsin, and a combination of individual PDE2,3,7 inhibitor, for 72 h.
Subsequently, cells were harvested and resuspended in PBS containing
0.1% Triton X-100, 10 !g/ml RNase A, and 5 !g/ml propidium iodide
(PI) before incubation at 37 °C for 15 min. Samples were analysed using
a BD Accuri C6 #ow cytometer and cell cycle analysis was performed
using BD C6 software.
2.10. Statistical analysis
To quantify gene expression through RT-PCR, the densitometry re-
sults of each gene of interest were normalised to GAPDH signal. For
cAMP accumulation and cell proliferation assays, data were $tted to
obtain concentration–response curves using the three-parameter lo-
gistic equation using GraphPad Prism 8 (GraphPad Software, San
Diego) to obtain values of Emax/Imax, pEC50/pIC50, baseline, and span.
Statistical di!erences were analysed using one-way ANOVA followed
by Dunnett’s post-hoc (for comparisons amongst more than two groups)
or independent Student’s t-test (for comparison between two groups).
To determine the correlation of cAMP levels and cell proliferation of
each PDE inhibitor in both C6 and ST14A cells, Pearson’s correlation
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coe!cient (r) was calculated with 95% con"dence interval. To compare
the ability of compounds to suppress C6 cell proliferation a selection
criterion was applied, whereby the term for a!nity (pIC50) was mul-
tiplied by the term for e!cacy (span). Error for this composite measure
was propagated by applying the following equation.
! " ! "= #$ % &' + #$ % &' ( %Pooled SEM SEMx SEMx xAA BB AB
2 2
where SEMA and SEMB are the standard errors of the mean of mea-
surement A and B with mean of x̄A and x̄B, x̄AB is the composite mean.
3. Results
3.1. Elevation of cAMP levels reduces cell proliferation in a glioma cell line
We "rst sought to determine if changes in cAMP concentration
modulated glioma cell growth. When C6 cells, a rat-derived model for
glioma, were exposed to the pan-AC activator, forskolin, we observed a
dose-dependent increase in cAMP levels, up to 34,566 ± 9,346 nM per
106 cells which equates to 484.23 ± 134.11 pmol cAMP/mg protein
(lysed cells) (Fig. 1A, B), and reduced cell proliferation (Fig. 1D).
Given the fact that there is crosstalk between the cAMP and cGMP
pathways [30], we also evaluated the role of the cGMP pathway on cell
proliferation by treating cells with the small molecule guanylyl cyclase
activators, BAY 41-8543 and YC-1. Both compounds elevated cGMP
levels (Fig. 1C), however, cGMP production was ~1000! lower than
cAMP production in C6 cells, even in response to treatment with the
nitric oxide (NO) donor, S-Nitroso-N-acetyl-DL-penicillamine (SNAP)
(0.37 ± 0.04 pmol cGMP/mg protein). Surprisingly, both BAY 41-
8543 and YC-1 also dose-dependently increased cAMP levels (Fig. 1A)
but only ~20% relative to that of forskolin (Fig. 1A). BAY 41-8543 and
YC-1 also had a minimal e#ect on cell proliferation compared to for-
skolin, with a reduction in cell survival only observed at 100 µM
(Fig. 1D). These anti-proliferative e#ects may occur due to a mod-
ulatory e#ect between cAMP and cGMP. Accumulation of cGMP levels
may lead to allosteric regulation of dual-substrate PDEs leading to po-
tentiation of cAMP and suppression of cell growth. These results suggest
that that elevation cAMP pathway plays a more important role in re-
ducing cell proliferation.
Heterotrimeric G proteins are the primary e#ectors of G protein-
coupled receptors (GPCRs) with G!s activating AC and G!i/o inhibiting
AC [29]. Pertussis toxin (PTX) and cholera toxin (CTX) were utilised to
determine whether G protein-mediated cAMP production inhibits C6
Fig. 1. Elevation of cAMP, but not cGMP, mediates cell growth suppression. A. cAMP levels following 30 min treatment with adenylyl cyclase activator (forskolin) or
guanylyl cyclase activators (YC-1 and BAY 41–8543). B-C. Comparison of accumulation of cAMP and cGMP in C6 cells in response to forskolin (100 µM), BAY 41-
8543 (100 µM), YC-1 (100 µM), or SNAP (100 µM). Survival of C6 cells following 72 h treatment with forskolin, BAY 41-8543 or YC-1 (D) or PTX or CTX (E). F. cAMP
levels after 16 h pre-treatment with PTX or CTX in comparison to untreated cells. G. cAMP levels in C6 cells following 30 min stimulation with forskolin or the non-
selective beta-adrenergic agonist, isoprenaline. Data are expressed relative to 100 µM forskolin H. Cell survival of C6 cells following 72 h treatment with forskolin or
isoprenaline. Data are expressed as percentage survival relative to vehicle alone and are the mean ± SEM of 6–9 individual experiments. Statistical signi"cance was
determined using a one-way analysis of variance followed by Dunnett’s post hoc test (*, p < 0.05; ***, p < 0.001).
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cell growth. Treatment with CTX or PTX induced only a small elevation
in cAMP levels and only suppressed C6 cell growth by 20% in a dose-
dependent manner (Fig. 1D). Furthermore, despite potent stimulation
of cAMP accumulation upon treatment with the non-selective !-adre-
noceptor agonist, isoprenaline, suppression of cell growth was sig-
ni!cantly poorer than treatment with forskolin. This implies that GPCR-
mediated cAMP accumulation is insu"cient to maximally supress C6
cell growth and is likely a result of transient e#ector activation, re-
ceptor desensitisation or spatially localised signalling. Together, these
results suggest that increasing cAMP concentration, through direct
pharmacological activation of AC, plays a pivotal role in inhibiting cell
growth with a minimal involvement of cGMP.
3.2. Speci!c inhibition of PDEs indicates reliance on PDE expression levels
Given that intracellular concentrations of cAMP are modulated both
by its production and degradation, we next sought to investigate the
expression of PDEs in a glioma cell line. Reverse transcription PCR (rt-
PCR) was performed to determine the expression of each PDE iso-
enzyme in C6 cells, compared to ST14A cells, a rodent model for
healthy neurons. As shown in Fig. 2, the overall expression level of
PDEs was higher in C6 cells compared to ST14A cells. With the ex-
ception of PDE1C, there was little overall di#erence in the pro!les of
PDEs expressed between C6 cells and ST14A cells. PDE1C, PDE4D,
PDE7A, and PDE7B were the only PDEs to display signi!cant elevation
in C6 cells.
The rt-PCR expression pro!les showed a wide number of PDEs to be
expressed in glioma cells. However, this was only semi-quantitative,
thereby, not providing a clear indication as to which PDEs might be the
most important. Thus, we next investigated the role of PDEs in reg-
ulating cAMP levels and cell proliferation in C6 cells by applying small
molecule selective PDE inhibitors as tools to modify their action. The
small compounds were blindly screened and subsequently decoded
after data analysis (see methods). Both cell lines were stimulated with
the pEC20 concentration of forskolin to increase the range for detecting
an elevation of cAMP in the presence of selected PDE inhibitor. pEC50
values for cAMP production and pIC50 values for cell growth inhibition
for each compound are quoted in Table 1 and their pharmacological
actions are summarised in Table 2.
Plotting the potencies of each PDE inhibitor revealed a signi!cant
Fig. 2. Expression pro!le of PDE isoenzymes in C6 and ST14A cells. A. Representative gel documentation showing ampli!ed PDEs genes from C6 and ST14A cell line.
(*) on the gel showed correct band size. B. Semi-quantitative mRNA levels in C6 cells and ST14A cells. Expression of each gene of interest was normalised relative to
GAPDH. Data are expressed as the mean ± SEM from 5 to 7 individual repeats. Data were determined as statistically di#erent (*, p < 0.05; **, p < 0.01; ***,
p < 0.001) compared to individual isoenzyme between both cell lines using Student’s t-test analysis.
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(p < 0.001) positive correlation between elevation of cAMP levels and
inhibition of cell growth (Fig. 3A and 3B) for both C6 cells (r = 0.83
(95% con!dence interval 0.46–0.95)) and ST14A cells (r = 0.97 (95%
con!dence interval (0.73–0.99)). To provide a convenient and rapid
method for comparing each PDE inhibitor for e"ects on cell growth, the
terms for e#cacy and a#nity (potency and span values) were multi-
plied for both C6 and ST14A cells (arbitrary units – Fig. 3C and D). An
ideal compound would be one that shows high potency for inhibition of
growth and a large range. An arbitrary threshold of 200 was set to
determine compounds that might be worth further investigation. Cis-
platin, a widely used non-selective anti-proliferative agent, was used as
a reference to validate our method (with pIC50 of 6.02 and 5.92 in C6
and ST14A cells, respectively, Table 1). In both C6 and ST14A cells,
cisplatin showed the highest selection criteria value (582.1 in C6 cells
and 511.1 in ST14A cells), thus proving that this calculation may help
to determine how e"ective the compounds are at inhibiting cell pro-
liferation. From our initial screen only 9 compounds were deemed to
have passed the threshold: vinpocetine (PDE1 inhibitor), amrinone,
milrinone (both PDE3 inhibitors), ibudilast (PDE4 inhibitor), tre-
quinsin, IBMX and zaprinast (multiple PDE isoform inhibitors),
BRL50481 (PDE7 inhibitor), and forskolin. The selectivity of the in-
hibitors that were successful in the screen correlated well with PDE
expression levels in C6 cells (Fig. 2A and B). The compounds that
showed the highest values (> 350) were forskolin, trequinsin, amri-
none, and IBMX. Apart from amrinone, these compounds target mul-
tiple components in the cAMP synthesis/degradation pathway, thus
explaining their greater a#nity/e#cacy. IBMX and zaprinast were not
used in future studies due to selectivity issues. IBMX is an adenosine
receptor antagonist [31], whilst zaprinast is a GPR35 agonist [32]. Fi-
nally, it is worth noting that all compounds displayed lower a#nity/
e#cacy values in ST14A cells (Fig. 3D) and this is consistent with the
reduced PDE expression compared to C6 cells (Fig. 2B).
3.3. Cocktail of individual PDE2, PDE3, and PDE7 inhibitors exhibited a
similar e!ect to that of trequinsin, both upon elevating cAMP levels and
suppressing cell growth
Of all the compounds tested, trequinsin was the most potent at in-
creasing cAMP levels and suppressing cell growth. Trequinsin is known
to potently inhibit PDE3, but is suggested to also block the cAMP
binding site of PDE2 and PDE7 [26]. This, however, has not been
thoroughly investigated. Therefore, we probed the mechanism by
which trequinsin exerts its antiproliferative e"ects by combining se-
lective inhibitors against PDE2, PDE3, and PDE7 – by using EHNA,
amrinone, and BRL-50481, respectively. None of the selective PDE in-
hibitors were more potent at stimulating cAMP accumulation or in-
hibiting cell proliferation in C6 cells, as individual treatments, than
trequinsin (Fig. 4A and D). Although amrinone displayed a similar Emax
to that of trequinsin for cAMP accumulation, the Imax for cell growth
inhibition was ~50% relative to trequinsin (Fig. 4A and D, Table 3).
Subsequently, we investigated the combinatorial e"ect of individual
PDE2, 3, and 7 inhibitors. The combination of EHNA and amrinone
(PDE2 and PDE3 inhibitors), as well as EHNA and BRL-50481 (PDE2
and PDE7 inhibitors), enhanced the potency of e"ect compared to when
these drugs were used individually (Fig. 4B and E, Table 3). However,
the combination of BRL-50481 with amrinone (PDE3 and PDE7 in-
hibitors) was comparable to that of amrinone alone. Interestingly, when
all three selective inhibitors were combined, the potency and e#cacy
were similar to that of trequinsin (Fig. 4C and F, Table 3). Overall, this
suggests that simultaneous inhibition of PDE2, PDE3, and PDE7 can
mimic the antiproliferative e"ect of trequinsin.
3.4. Targeting both AC and PDEs enhances the anti-proliferative e!ect
Our data suggests that elevation of cAMP levels through either,
activation of AC, or inhibition of PDEs, positively correlates with re-
duced cell proliferation. Thus, we hypothesised that dual activation of
AC and inhibition of PDEs would induce larger suppression in cell
growth beyond that of a single target treatment. To test this, we de-
termined the combinatorial e"ect of forskolin and trequinsin on cAMP
accumulation and cell proliferation (Fig. 5).
There was a similar pattern of e"ects observed upon forskolin and
trequinsin co-treatment on both cAMP accumulation and cell pro-
liferation assays. The combination of forskolin and trequinsin sig-
ni!cantly enhanced cAMP accumulation and reduced C6 cell growth in
a dose-dependent manner compared to forskolin alone (Fig. 5A–C). The
potency of the forskolin-mediated anti-proliferative e"ect was en-
hanced approximately 10-fold in the presence of 10 !M trequinsin
(pIC50 of forskolin is 5.75, that of forskolin in combination with 10 !M
trequinsin is 6.87). These data demonstrate synergistic elevation of
cAMP by targeting AC and PDEs resulting in greater suppression of C6
cell growth. Indeed, the e"ect of the combination of 1 !M forskolin and
0.1 !M trequinsin was approximately equal to that of cisplatin (pIC50 of
6.09, Table 1).
3.5. Blockade of cAMP export enhances the anti-proliferative e!ect of
forskolin, trequinsin, and the PDE inhibitor cocktail
C6 cells are known to express MRP4 [33] a transporter known to
export intracellular cAMP. Having con!rmed that inhibiting PDEs, or
activating AC, elevates total cAMP levels and supresses proliferation of
C6 cells, we aimed to investigate if these e"ects could be enhanced by
preventing cellular export of cAMP.
Pre-treatment with PU23, a small molecule inhibitor of MRP4, re-
sulted in a dose-dependent reduction in extracellular cAMP levels post
stimulation with forskolin, trequinsin or the PDE inhibitor cocktail
(Fig. 6A, C and D). There was also a substantial elevation in in-
tracellular concentrations of cAMP in the presence of PU23 after 2 h
stimulation with forskolin (Fig. 6B). This suggests that in the absence of
Table 2
Summary of the pharmacological e"ects of each PDE inhibitor on cAMP pro-
duction and cell proliferation.
Compound Target C6 ST14A
cAMP Proliferation cAMP Proliferation
Vinpocetine 1 ! "" ! –
EHNA 2 ! "" – "
Cilostamide 3 ! – – "
Amrinone 3 !!! """ !!! """
Milrinone 3 – "" ! –
Trequinsin 2,3,7 !!! """ !!! """
Rolipram 4 !!! " !!! "
Ibudilast 4 !!! "" !! –
Piclamilast 4 !! – !! –
Ro$umilast 4 !!! " ! "
Sildena!l 5 – ! " "
Tadala!l 5 – ! " !
Ca"eine 1,4,5 Bell-shape – – "
Zaprinast 5,6,9,11 ! "" – ""
TC3.6 7 – " – "
BRL-50481 7 !! "" – "
BC 11–38 8 – – – –
BAY-736691 9 – – – –
PF-0449613 9 – – " "
PF 2,545,920 10A – ! – "
PF 04,671,536 11 – – – –
IBMX Non-selective !! """ ! ""
! = increase 10–30%, !! = increase 31–50%, !!! = increase > 50%, ":
suppress 10–30%, "": suppress 31–50%, """: suppress > 50%.
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PDE inhibitor, blockade of cAMP export maintains high intracellular
cAMP levels. Indeed, the combination of PU23 with forskolin, tre-
quinsin, or the PDE inhibitor cocktail enhanced the anti-proliferative
e!ect of each compound (Fig. 6E–G). Taken together, these data suggest
that suppression of C6 cell proliferation can be enhanced by blockade of
cAMP export.
3.6. The anti-proliferative e!ect of forskolin is mediated through a PKA-
dependent mechanism
Having con"rmed the e!ect of cAMP on C6 cell growth, we next
wanted to investigate the involvement of downstream e!ectors of
cAMP, such as PKA and Epac type I and II, as well as the cGMP e!ector,
PKG, and GC activation on proliferation of C6 cells (Fig. 7A). To do this,
we utilised a range of small molecule inhibitors: KT5720 (PKA), ESI-09
(non-selective Epac), CE3F4 (Epac1), HJC0350 (Epac2), and KT5823
(PKG), and the GC activator (BAY 41-8543). Co-treatment of 10 µM
KT5720 signi"cantly attenuated the anti-proliferative e!ects of for-
skolin (p < 0.01), trequinsin (p < 0.001) and the PDE inhibitor
cocktail (p < 0.05) on C6 cells (Fig. 7B–D). None of the selective or
non-selective Epac inhibitors had any e!ect on trequinsin-mediated cell
growth suppression, although there was an elevation of forskolin-
Fig. 3. Elevation of intracellular cAMP is positively correlated with cell growth suppression. A, B. Correlation (with 95% con"dence interval) of log potencies of each
PDE inhibitor in C6 (A) and ST14A cells (B) was determined by calculating Pearson’s correlation coe#cient (r). C, D. Compound selection criteria from C6 (C) and
ST14A cells (D) was calculated based on potency and e#cacy in proliferation assay. The dashed lines represent threshold value of 200 (less stringent criteria) and the
dotted lines a higher criteria value of 350. Individual data point was obtained from supplemental information (Figs. 1–4).
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mediated cell growth suppression with CE3F4 (p < 0.01) (Fig. 7B).
Interestingly, cotreatment with KT5823 signi!cantly enhanced the anti-
proliferative e"ects of forskolin and trequinsin (p < 0.001), whilst
BAY 41-8543 treatment also increased forskolin-mediated suppression
of cell proliferation (p < 0.01). This indicates an involvement of cGMP
signalling pathways in cell proliferation. It is possible that accumula-
tion of cGMP, in the presence of the PKG inhibitor or GC activator,
potentiates cAMP/PKA signalling pathways through the sequestration
of non-selective PDEs, thereby reducing cell growth. There was, how-
ever, no signi!cant e"ect of BAY 41-8543 treatment on the anti-
Fig. 4. The e"ect of selective PDE inhibitors, as individual, dual, or multiple treatments, on intracellular cAMP levels and cell proliferation in C6 glioma cells. A–C.
cAMP accumulation was determined in C6 cells following 30 min stimulation with EHNA, Amrinone or BRL-50481 alone (A), in pairs (B), or combined (C). Data are
expressed relative to 100 µM forskolin. D–F. Cell survival was determined in C6 cells following 72 h incubation with EHNA, Amrinone or BRL-50481 alone (D), in
pairs (E), or combined (F). Data are expressed as percentage of cell survival relative to vehicle from 6 to 9 data sets. The e"ect of trequinsin alone is displayed on each
graph for comparison. All data are the mean ± SEM of 6–9 individual repeats.
Table 3
C6- proliferation assay-combinatorial e"ect of PDE2, 3, 7 inhibitors.
Compound cAMP accumulation assay Proliferation Assay Selection criteria*
pEC50 Span pIC50 Span
Trequinsin 5.33 ± 0.11 46.31 ± 1.98 4.52 ± 0.11 91.21 ± 8.26 411.94 ± 38.52
EHNA 4.91 ± 0.10 26.19 ± 0.89 4.20 ± 0.21 57.21 ± 10.48 240.44 ± 45.57
Amrinone 4.58 ± 0.04 53.88 ± 1.63 3.94 ± 0.15 87.79 ± 13.62 346.01 ± 55.26
BRL-50481 6.20 ± 0.34 13.86 ± 0.74 4.79 ± 0.17 47.02 ± 4.45 225.39 ± 22.73
EHNA + amrinone 4.58 ± 0.03 62.51 ± 2.17 4.19 ± 0.17 85.97 ± 12.32 361.56 ± 53.66
EHNA + BRL-50481 5.05 ± 0.20 27.21 ± 1.40 4.07 ± 0.13 77.77 ± 9.73 316.34 ± 40.85
Amrinone + BRL-50481 4.65 ± 0.07 49.65 ± 2.95 3.77 ± 0.17 66.75 ± 11.94 248.98 ± 45.30
EHNA + amrinone + BRL-50481 4.58 ± 0.07 64.97 ± 1.82 4.52 ± 0.14 84.64 ± 8.69 382.12 ± 41.10
Data are expressed as mean ± SEM from 7 to 10 individual data.
*Compound selection criteria was calculated based on potency and e#cacy in proliferation assay (data obtained from Fig. 4).
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proliferative e!ects of trequinsin or the PDE inhibitor cocktail. This
may suggest that the actions observed for KT5823 are not purely due to
inhibition of PKG. These data highlight the importance of the home-
ostasis between cAMP and cGMP, as well as that the anti-proliferative
e!ects of forskolin, trequinsin and the PDE inhibitor cocktail are largely
mediated through a cAMP/PKA-dependent pathway.
3.7. Trequinsin, but not forskolin or the PDE inhibitor cocktail, has cAMP-
independent actions leading to apoptosis
In order to delineate the mechanism by which cAMP promotes cell
death or inhibits cell growth, we investigated if the anti-proliferative
e!ects on C6 cells were related to apoptosis. Early apoptotic events can
be detected through the protease activity of caspase-3 and caspase-7
that will eventually degrade proteins pivotal for cell survival. In this
study, we quanti"ed cells positive for caspase-3 and -7 activity in C6
cells using #uorescence microscopy after treatment with
CellEvent™Caspase-3/-7 green detection kit. Cells were co-stained with
Hoechst 33,342 and propidium iodide to label all nuclei and dead cells.
Staurosporine is a known pan caspase activator. Quantitative ana-
lysis revealed that staurosporine-treated cells were entirely positive for
active caspase-3/-7 (Fig. 8A). Consistent with these results, activated
caspase-3/-7 resulted in cell death which was con"rmed by propidium
iodide staining (Fig. 8A). Among all other treatments, only 100 µM
trequinsin exhibited comparable e!ects on cell death and caspase ac-
tivity to that of staurosporine. Treatment with forskolin or the PDE
2,3,7 inhibitor cocktail resulted in<10% caspase activity and cell
death (Fig. 7A). This suggests that 100 µM trequinsin may have toxic,
non-cAMP-dependent e!ects, on C6 cells.
3.8. Elevated intracellular cAMP induces growth arrest at the G2/M phase
of the cell cycle
Having demonstrated that elevation of cAMP inhibits cell pro-
liferation, without inducing extensive apoptotic events on cells treated
with forskolin, PDE inhibitor cocktail, or a low concentration of tre-
quinsin, we postulated that this e!ect arose due to cell growth arrest.
Thus, we investigated the individual stages of the cell cycle of C6 cells
post-treatment with forskolin, trequinsin or the PDE2,3,7 inhibitor
cocktail by using propidium iodide staining and #ow cytometry. Cell
cycle analysis showed that forskolin, trequinsin, and the PDE2,3,7 in-
hibitor cocktail altered the cell phase (Fig. 8B–E). While there was no
signi"cant di!erence between complete media and DMSO, forskolin or
PDE inhibitor cocktail treated cells arrested predominantly in G2/M
phase. This indicates that both forskolin and the PDE2,3,7 inhibitor
cocktail alter C6 cell cycle by a similar mechanism. In contrast, of the
proportion of cells that survived treatment with 100 µM trequinsin,
approximately 70% were aneuploid, with the remaining alive cells ar-
rested in G2/M phase. Interestingly, when lower concentrations of
trequinsin (< 100 µM) were considered, the cell phase pro"le more
closely matched that of 10 µM PDE2,3,7 inhibitor cocktail (Fig. 8B).
This data suggests that 100 µM trequinsin induces a toxic e!ect on the
C6 cells that is most likely independent of its action upon the cAMP
pathway.
4. Discussion
cAMP is a ubiquitous second messenger, which together with cGMP,
controls a myriad of physiological responses [34] including reparative
processes. Interestingly, cAMP signalling has been reported to have
di!erent e!ects on cell proliferation; either causing or arresting pro-
liferation, depending on the cell type investigated [9,13,35]. These
divergent e!ects of cAMP on the proliferative response are believed to
be controlled by several factors including stimulus, the nature of the
intracellular cAMP e!ectors within the cells, the strength of signal, and
subcellular compartmentalisation [36]. In brain tumours, suppression
Fig. 5. Forskolin and trequinsin act synergistically to increase cAMP accumu-
lation and suppress cell growth. A. Concentration-dependent e!ect of trequinsin
upon cAMP accumulation in C6 cells following 30 min stimulation with for-
skolin. Data are expressed relative to 100 µM forskolin in the absence of tre-
quinsin. B. Concentration-dependent inhibitory e!ect of trequinsin on C6 cell
growth following 72-hour incubation with forskolin. Data are expressed as
percentage cell survival relative to vehicle. C. pIC50 values for individual cell
survival curves for each treatment condition. All data are the mean ± SEM of
6–9 individual repeats. Data were determined as statistically di!erent (ns, not
signi"cant; ***, p < 0.001) compared to forskolin using one-way ANOVA
followed by Dunnett’s post-hoc analysis. TRQ – trequinsin.
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of cAMP is associated with gliomagenesis compared to non-tumour
controls [37,38]. As cAMP levels are suppressed 4-fold in brain tumours
compared to those in normal tissue [5], we hypothesised that aug-
menting production of cAMP may restore intracellular signalling and
have bene!cial antiproliferative e"ects.
Although PDEs have long been targets for pharmacological mod-
ulation, there have been no studies characterising PDE isoenzyme ex-
pression in glioma cells or the e"ect of PDE modulation. In the present
study, we demonstrate that direct pharmacological activation of AC and
inhibition of PDEs results in greater suppression of glioma cell pro-
liferation than G protein-mediated AC activation. Although activation
of Gs-coupled !-ARs by isoprenaline, or modulation of G protein ac-
tivity by PTX or CTX treatment increased cAMP production, neither
substantially suppressed glioma cell growth. This is possibly due to only
transient activation of cAMP e"ectors, receptor desensitisation, spa-
tially localised cAMP accumulation, or, the instability of isoprenaline in
aqueous solution. Prolonged stimulation with GPCR agonists not only
induces desensitisation through receptor internalisation, but may also
alter transcription levels resulting in receptor downregulation [39]. It is
worth noting that addition of antioxidant such as ascorbic acid or EDTA
may be useful to minimise the degradation of isoprenaline during the
treatment.
Evaluation of PDE mRNA expression level in C6 cells revealed that
almost all PDE isoenzymes are expressed. Interestingly, inhibitors of
cAMP-speci!c or cGMP-speci!c PDEs showed minimal e"ects on cell
growth, except for ibudilast (a cAMP-speci!c PDE4 inhibitor).
Inhibition of PDE1, PDE2, PDE3, PDE4, and PDE7 resulted in greater
modulation of cAMP levels and cell growth. These PDEs, with the ex-
ception of PDE4 and PDE7, hydrolyse both cAMP and cGMP. Dual
substrate PDEs provide a point for crosstalk between cGMP and cAMP
signalling pathways and have unique mechanisms of regulation
[40,41].
The most potent anti-proliferative e"ects were observed in tre-
quinsin-treated cells. Trequinsin is commonly known as an ultrapotent
PDE3 inhibitor, although it has also been shown to have activity against
PDE2 and PDE7 [26]. There have, however, been no studies into in-
hibition of PDE2 and PDE7 by trequinsin. A combination of inhibitors of
PDE2, PDE3, and PDE7, the PDE inhibitor cocktail, had a similar
magnitude of e"ect to that of trequinsin, whilst inhibition of single or
dual PDEs failed to mimic the e"ect. In order to enhance anti-
proliferative activity further, the selectivity of individual compounds
towards each PDE needs to be improved.
Through the use of several pharmacological tools we attributed
forskolin and trequinsin, and the PDE inhibitor cocktail mediated in-
hibition of cell growth to enhanced activation of PKA. Considering the
greater a#nity of cAMP for PKA than Epac1/2 (5–24.6 nM versus
4 µM/1.2 µM, respectively) [42–44], it is possible that elevated cAMP,
upon treatment with forskolin or PDE inhibitors will preferentially ac-
tivate PKA over Epac1/2. Taken together, there is a possibility that
stimulation of AC by forskolin or by PDE inhibitors will trigger massive
Fig.6. Elevation of intracellular cAMP by inhibiting its e$ux is correlated with cell growth suppression in C6 cells. A-D. Extracellular and intracellular cAMP levels
from C6 cells following stimulation with; forskolin for 1 h (A) and 2 h (B); trequinsin for 2 h (C); or PDE inhibitor cocktail for 2 h (D), in the presence and absence of a
range of concentrations of the MRP4 inhibitor, PU23. E–G. Survival of C6 cells following 72-hour treatment with forskolin (E), trequinsin (F), or PDE inhibitor
cocktail (G) in the absence and presence of increasing concentrations of PU23. Data are expressed as percentage cell survival relative to vehicle. All data are the
mean ± SEM of 4–8 individual repeats. FSK – forskolin, TRQ – trequinsin.
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production of cAMP and consequently the PKA pathway will be pre-
dominantly activated with minor involvement of Epac1/2. The in-
hibitory action of cAMP on cell growth has also been reported to in-
volve a complex mechanism between PKA, MAPK/ERK, and cyclin-
dependent kinase 2 [45,46].
Somewhat unexpectedly, this study demonstrated that PKG inhibi-
tion increased the anti-proliferative e!ects of forskolin- and trequinsin-
treated cells, whilst GC activation also potentiated forskolin-mediated
cell growth suppression. This is most likely due to cross talk between
the cGMP and cAMP pathways via dual substrate PDEs. For instance,
while cGMP binding to PDE2 allosterically enhances hydrolysis of
cAMP, cGMP competitively inhibits PDE3 to reduce the rate of cAMP
breakdown [17]. This control is, however, dependent on the con-
centration of cGMP, with allosteric regulation of PDE2 requiring higher
(1–5 µM) [47] cGMP levels than the a"nity of cGMP for the catalytic
site of PDE3 (180 nM) [17]. We have shown that C6 cells have a weaker
propensity to elevate cGMP levels than cAMP. Thus, a modest increase
in cGMP may compete with cAMP to occupy catalytic sites resulting in a
decrease in the hydrolysis rate of cAMP by dual substrate PDE isoforms,
thus activating the cAMP/PKA pathway triggering enhanced cell
growth suppression.
Surprisingly, there was no e!ect of PKG inhibition or GC activation
on the anti-proliferative e!ects of the PDE inhibitor cocktail. Whilst this
may suggest that the actions observed for KT5823 are not purely due to
inhibition of PKG, the functional e!ect of the PDE inhibitor cocktail
may be a!ected by compartmentalisation and local activation of PKA. A
small increase in cGMP may elevate cAMP levels only in distinct
subcellular regions in the presence of the PDE inhibitor cocktail to ac-
tivate PKA through anchoring proteins (AKAP) to di!erent intracellular
microstructures [47]. Although further investigation is required, these
phenomena can be taken into account in explaining the di!erential
responses observed upon PDE inhibitor cocktail treatment.
Although trequinsin has a comparable potency to that of forskolin
for elevating intracellular cAMP levels and supressing cell proliferation,
at high concentrations (100 !M) trequinsin induced substantial cell
death of C6 cells and ST14A cells. This implies that at such high con-
centrations trequinsin binds to other non-PDE proteins that results in
direct activation of caspase-3/7 to trigger cell death. Adequate activa-
tion of PKA will activate p53 and induce apoptosis [48] although we
observed only< 10% cell death. Nonetheless, the remaining cells were
aneuploidy with at least 4 N. It is likely that cells underwent faulty cell
division and were not able to exit the mitotic state due to rapid and
massive elevation of cAMP by 100 !M trequinsin. There are no studies
on the mechanism by which trequinsin causes aneuploidy and apop-
tosis, however, there are several reports that in other types of cancer
where cAMP levels are elevated by PDE inhibition, activation of PKA
resulted in activation of protein phosphatase 2A (PP2A) and Bim/BAD
expression [13] that eventually cleaves caspases to mediate apoptosis.
Despite this, the study demonstrates that multitarget enhancement
of cAMP signalling elevates anti-proliferative e!ects in a glioma cell
model. Increasing cAMP levels through activation of AC (forskolin) and
multiple PDE inhibition (by trequinsin) demonstrated synergistic cell
growth suppression. Similarly, whilst it has been suggested that cyclic
nucleotide e#ux pumps may not contribute to controlling cAMP
Fig. 7. The e!ect of downstream e!ectors of cAMP and cGMP on forskolin and trequinsin-mediated cell growth suppression of C6 cells. A. Schematic diagram
illustrating cAMP and cGMP synthesis, degradation and downstream e!ectors. B-D. Cell survival was determined in C6 cells following 72 h incubation with forskolin
(B), trequinsin (C), or a combination of PDE2,3,7 inhibitors (D) in the presence either KT5720 (10 !M) , ESI-09 (10 !M), CE3F4 (10 !M), HJC0350 (10 !M), KT5823
(10 !M), BAY41-8543 (10 !M). Data are represented as individual pIC50 values for anti-proliferation curves for each treatment condition. Data were determined as
statistically di!erent (ns, not signi$cant; *, p < 0.05; **, p < 0.01; ***, p < 0.001) compared to in the absence of compounds using one-way ANOVA followed by
Dunnett’s post-hoc analysis. KT5720 – PKA inhibitor, ESI-09 - non-selective Epac1/2 inhibitor, CE3F4 – Epac1 inhibitor, HJC0350 - Epac2 inhibitor, KT5823 PKG
inhibitor, BAY41-8543 – GC activator.
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signalling [49], our study shows that inhibiting export of cAMP sig-
ni!cantly enhances forskolin and multiple PDE inhibition mediated cell
growth suppression. Thus, the dose of each compound could be reduced
to potentially prevent any toxic side e"ects from trequinsin. Alter-
natively, combining individual selective inhibitors against PDE2,3,7
together showed similar e#cacy to that of trequinsin but without sig-
ni!cant toxicity in glioma cells. The inhibitor cocktail shows a higher
number of cells with active caspase-3/7 activity compared to forskolin,
possibly due to the availability of PDEs, which have been shown to be
caspase substrates [13]. Both forskolin and the inhibitor cocktail
trapped cells in G2/M phase, which may lead to the loss of essential
cellular components that are required for replication. Whilst this study
has demonstrated that targeting the cyclic nucleotide pathway can
suppress C6 cell growth, it should be noted that PDEs play an important
role in many systems throughout the body, including the cardiovascular
system, and thus targeting PDEs may cause o"-target e"ects.
In conclusion, we have used a chemical biology approach to de-
monstrate that cAMP inhibits growth of glioma cells. Anti-proliferative
e"ects of forskolin are mediated by elevating cAMP levels leading to
activation of PKA and arrest of cells in the G2/M phase of the cell cycle.
In comparison, multiple inhibition of PDEs by trequinsin not only in-
hibits cell growth via the cAMP/PKA cascade, but also triggers cell
death through caspase-3/-7 activation. Concomitant targeting of both
AC and PDEs synergistically elevates intracellular cAMP levels within
glioma cells. Due to possible side e"ects of trequinsin, a cocktail of
individual PDE2, PDE3, and PDE7 inhibitors can be used as an alter-
native to trequinsin to obtain similar functional e"ects without any
toxicity. This study o"ers insight to identify new therapeutic ap-
proaches which have potential bene!cial e"ects against glioma/glio-
blastoma.
Fig. 8. Population of dead cells and activity of cas-
pase-3/7 in C6 cells after 72 h treatment and cell
cycle analysis by $ow cytometry after PI staining. A.
Percentage of dead cells determined by staining with
propidium iodide and the percentage of cells with
activated caspase-3/7, visualised by CellEvent cas-
pase-3/7. All values are normalised to total cell
number in each well. Staurosporine 1 !M was used as
a control for apoptotic cell death and cause 100%
dead cells. B. Representative histograms of cell cycle
distribution of C6 cells with selected treatment. C–E.
Representative histograms of cells following treat-
ment with forskolin (C), trequinsin (D), or PDE2,3,7
inhibitor cocktail (E) for 72 h. The percentage of cell
distribution for each treatment including G1, S, G2/
M, and dead cell population (n = 4–8 individual
data). All data are the mean ± SEM of 5 individual
repeats. Data were determined as statistically dif-
ferent (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
compared to 1% DMSO using a one-way ANOVA
followed by Dunnett’s post hoc analysis. *p < 0.05,
**p < 0.005, ***p < 0.001. FSK – forskolin, TRQ –
trequinsin, STR – staurosporine.
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Structure!based identi"cation of!dual 
ligands at!the! A2AR and!PDE10A with!anti!
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Abstract 
Enhanced/prolonged cAMP signalling has been suggested as a suppressor of cancer proliferation. Interestingly, two 
key modulators that elevate cAMP, the  A2A receptor  (A2AR) and phosphodiesterase 10A (PDE10A), are di!erentially co-
expressed in various types of non-small lung cancer (NSCLC) cell-lines. Thus, finding dual-target compounds, which 
are simultaneously agonists at the  A2AR whilst also inhibiting PDE10A, could be a novel anti-proliferative approach. 
Using ligand- and structure-based modelling combined with MD simulations (which identified  Val84 displacement 
as a novel conformational descriptor of  A2AR activation), a series of known PDE10A inhibitors were shown to dock to 
the orthosteric site of the  A2AR. Subsequent in-vitro analysis confirmed that these compounds bind to the  A2AR and 
exhibit dual-activity at both the  A2AR and PDE10A. Furthermore, many of the compounds exhibited promising anti-
proliferative e!ects upon NSCLC cell-lines, which directly correlated with the expression of both PDE10A and the  A2AR. 
Thus, we propose a structure-based methodology, which has been validated in in-vitro binding and functional assays, 
and demonstrated a promising therapeutic value.
Keywords: Docking, MD simulations, Structure!based design, Virtual screening, A2AR, PDE10A, Anti!proliferative, Dual 
target, Triazoloquinazolines, NSCLC, Lung cancer
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Cyclic adenosine monophosphate (cAMP) is a second 
messenger that has a major role in transduction and cell 
signaling in several pathways and biological systems [1]. 
cAMP elevation may be achieved via the activation of the 
adenylate cyclases by Gs proteins, and the inhibition of 
cAMP-degrading phosphodiesterases [2], and has been 
shown to inhibit proliferation of several cancer cell types 
such as breast cancer, colon cancer, lung cancer, glioblas-
toma etc [3–6].
Two key modulators of intracellular cAMP are the 
adenosine  A2A receptor  (A2AR) and the phosphodies-
terase 10A (PDE10A), which are often co-expressed in 
di!erent amounts across NSCLC cell-lines. "e  A2AR 
is expressed in the two histologically distinct types of 
NSCLC cell-lines, lung adenocarcinoma and squamous 
carcinoma cell-lines [7, 8]. Likewise, PDE10A is overex-
pressed in lung adenocarcinoma, and its inhibition was 
found to suppress growth [9], demonstrating a correla-
tion between the levels of overexpression and survival 
[10]. "is makes these systems interesting avenues of 
investigation for relating the amount of co-expression 
of these two protein targets and their ability to elevate 
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We hypothesized that a novel approach would be to 
discover compounds, which act simultaneously as ago-
nists of the  A2AR that are also inhibitors of PDE10A. 
cAMP elevation could be achieved through the 
 A2AR-G!s-adenylate cyclase axis, while further promoted 
by the inhibition of its breakdown via PDE10A [7, 8]. A 
multi-target approach is a departure from standard drug 
discovery practice, where one target is often the driving 
force in compound optimization. A multi-target com-
pound could, through synergistic e"ects, be more e"ec-
tive in elevating cAMP. Indeed, dual PDE inhibition and 
 A2AR activation via compound combinations exhibited 
synergy (according to isobologram analysis) in cAMP 
elevation, and was observed to inhibit proliferation in 
other cancer cell types such as multiple myeloma and 
di"use large B-cell lymphoma [11]. #e use of multitar-
get ligands have$ also demonstrated beneficial e"ects on 
Alzheimer’s and Parkinson’s disease [12, 13]. #erefore, 
combining this approach in single dual-targeted com-
pounds at the  A2AR and PDE10A could be explored as a 
novel anti-proliferative strategy for adenocarcinoma and 
squamous carcinoma cell-lines.
For the purpose of designing PDE10A inhibitors and 
 A2AR agonists, many virtual screening protocols have 
been reported in the literature, implementing either 
ligand- or structure-based approaches Examples of 
ligand-based protocols include in silico target prediction, 
pharmacophore-based and fragment-based approaches 
and comparative molecular field analysis (CoMFA) 
[14–19]. Docking, as a structure-based approach, has 
also been employed for the design of either PDE10A 
inhibitors or  A2AR agonists [20]. In addition, molecular 
dynamics has been used extensively to investigate the 
conformational dynamics at the  A2A adenosine recep-
tor or PDE10A [20–27]. However, none of the reported 
protocols rationalizes or correctly predicts the functional 
activity of ligands against the targets of interest, in par-
ticular the  A2AR, which is addressed in this work.
Here, a novel structure-based methodology for identi-
fying ligands that activate the  A2AR while simultaneously 
inhibiting the PDE10A is devised. Given that PDE10A 
is an enzyme, compounds that target the active site 
would most likely confer inhibition. However, binding 
to the orthosteric site of the  A2AR may not guarantee the 
desired functional activity. For this reason, the structure-
based computational approach was focused on the more 
challenging goal, which involved identifying whether 
known PDE10A inhibitors are  A2AR agonists.
#e focus of this approach was on the key interact-
ing residues, which are reported in the literature to dis-
criminate between agonist and antagonist activity of 
 A2AR ligands [28–31]. It is postulated that the motion of 
the residue  Val84 in Transmembrane Helix 3, upon  A2AR 
ligand binding, might discriminate between agonist and 
antagonist activity, which has not previously been studied 
by any MD approaches [19–24, 32]. Hence, the motion of 
this residue has been investigated as a conformational 
descriptor for the characterization of receptor activation 
by  A2AR ligands.
Subsequently, the selected compounds were evaluated 
pharmacologically in$vitro using both binding and func-
tional assays. We then extended our studies to evaluate 
the compounds for their abilities to modulate cell prolif-
eration in lung squamous cell carcinoma and lung ade-
nocarcinoma cell-lines. #eir anti-proliferative e"ects 
were correlated with the co-expression of the  A2AR and 
PDE10A and (increased) cellular levels of cAMP.
Results
Method for!selecting triazoloquinazolines as!candidates 
for!dual ligand activity at! A2AR and!PDE10A
Triazoloquinazolines were identified by Kalash et$ al. as 
a compound series that showed the highest frequency of 
prediction as binders at the  A2AR and PDE10A by ligand- 
and structure-based approaches (Fig.$ 1a) [33]. For the 
purpose of finding dual-target ligands that elevate cAMP, 
the focus was on ligands that could simultaneously acti-
vate the  A2AR (agonists) and inhibit PDE10A.
From the ZINC database, six purchasable triazolo-
quinazolines (1–6) were shortlisted (compound 1–6 
Fig.$1a, see methods for details) [34], which were (Fig.$1b, 
c) previously shown to display inhibition of PDE10A 
(with a rank order of potency of 1 > 6 = 4 > 5 > 3 = 2) [34]. 
Importantly, for future reference, no significant activ-
ity of the  A2AR selective agonist CGS21680 at PDE10A 
was detected. Using a crystal structure of PDE10A (PDB 
ID: 4DDL) and ligand/protein docking, binding poses 
were found that appeared consistent (i.e. docking in 
approximately the same position) for all six compounds 
(Fig.$1d—illustration of predicted binding modes of rep-
resentative triazoloquinazolines 1 and 4). Importantly, 
this analysis highlighted that the interaction of Tyr683, 
a residue belonging to a ‘selectivity pocket’ of PDE10A, 
through a hydrogen bond with the thioether of the com-
pounds could explain their PDE10A subtype selectivity.
Following the initial shortlisting (based on PDE10A 
activity), compounds 1–6 were docked into the orthos-
teric site of the  A2AR protein crystal structure (PDB ID: 
2YDO). In this structure a relatively large displacement 
of the  Val84 residue was observed (when referenced to 
its average distance to  Leu249, a residue that is compara-
tively static in position relative to the structure as a whole 
(Additional file$ 1: Table$ S1). #e relative motion of this 
amino acid residue is essential for  A2AR activation, in 
order to avoid the steric clash that might otherwise result 
between the agonist and the receptor.
Appendix   
 339 
 
Page 3 of 17Kalash!et!al. J Cheminform           (2021) 13:17  
!e selection of the structure to be used as the dock-
ing model for the  A2AR was based on the  Val84-Leu249 
inter-residue distances found for the active/inactive 
forms of the  A2AR protein crystal structures reported 
in the protein data bank (PDB). Based on this criterion, 
the  A2AR crystal structure (PDB ID: 2YDO) was selected 
since it exhibited the largest inter-residue distance. It 
was hypothesized that this would allow ligand explora-
tion of a conformational space most likely to be occupied 
by  A2AR agonists when docked into the orthosteric site. 
Indeed, this enabled enrichment of  A2AR agonists over 
 A2AR antagonists and  A2AR inactives (refer to methods 
for details). !is is in agreement with a previous study 
by Rodríguez et" al. [26], where the  A2AR crystal struc-
ture (PDB ID: 2YDO) displayed the highest enrichment 
factor value (EF1 %) for docked agonists over the other 
active crystal structures of the  A2AR. !e 2YDO crystal 
structure enriched agonists 63.5-fold better than random 
and 2.9-fold better than antagonists (63.5 % versus 21.9 %) 
[26]. However, their docking approach failed to find any 
 A2AR agonists (which used three active structures: PDB 
IDs: 2YDO, 2YDV, and 3QAK). !e authors rationalized 
this as resulting from bias of the chosen chemical librar-
ies towards  A2AR antagonists over agonists.
!e evaluation of the six triazoloquinazolines 1–6 
(Fig."1a), as promising candidates for  A2AR agonism, was 
based on their docking scores. Compounds were selected 
based on their scores below the score threshold value of 
-7.33, which was determined as the optimum selection 
criteria for agonists based on computing the Matthews 
correlation coe#cient (see Methods for more details).
Compounds 1–6 were screened against PAINs (PAN 
Assay Interference Compounds) with regard to the 
recent analysis of the use of this approach by Tropsha 
using FAFDrug3 [35], and none of the compounds exhib-
ited any potential PAINs liability.
Analysis of!the!molecular docking studies 
of!the!representative triazoloquinazolines 1–4 shortlisted 
for!experimental validation
Docking studies predicted consistent molecular interac-
tions for the triazoloquinazolines, similar to those of the 
co-crystallized ligand bound to the  A2AR protein crys-
tal structure (PDB ID: 2YDO). Representative and dis-
tinct binding modes are illustrated in Fig."2. Compounds 
1–3, were predicted to be selective  A2AR ligands, which 
was attributed to interactions with  His250 [36, 37]. !is 
residue is located in the core region of the receptor and 
part of a sub-pocket formed by  Leu85,  Met177,  Trp246 
and  Leu249. Despite the fact that it is conserved among 
the  A1R and the  A2AR subtypes (as suggested by a recent 
study [38], due to the high conservation of amino acid 
residues in the adenosine receptor subtypes), subtype 
selectivity might not be attributed to the receptor-spe-
cific amino acid residues, but rather to conformational 
di$erences. Also, given that mutation experiments have 
failed so far to highlight any receptor-specific amino acid 
residues responsible for subtype selectivity, this would 
Fig. 1 The Structures of the identified PDE10A inhibitors with the potential to bind to the  A2AR, and their pharmacology at PDE10A. a Virtual 
screening protocol. b Chemical structures for the six compounds identified in the in silico screen, literature references, compound IDs (used here) 
and  pIC50 for PDE10A inhibition. c!Concentration-response curves generated for 1–6 and CGS21680 at PDE10A. Data is the mean of six individual 
replicates ± SEM. d Representative binding modes proposed for the triazoloquinazolines 1 and 4 docked to the PDE10A crystal structure (PDB ID: 
4DDL). Yellow spheres indicate lipophilic contacts. Aromatic interactions are illustrated by purple disks and hydrogen bond acceptors are shown 
as red arrows.  Tyr683 is part of the “selectivity pocket” of PDE10A [33], and its interaction through a hydrogen bond with the thioether of both 
compounds could explain their subtype selectivity
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add weight to the suggested hypothesis [37, 39]. Hence, 
the selectivity of  A2AR agonists could be attributed to 
the conformational preferences of the  His250 amino acid 
residue that contributes to shaping the orthosteric site 
to favor their selectivity [38]. Indeed, the interaction 
with this residue is only observed for the selective  A2AR 
co-crystallized agonists, CGS21680 (PDB ID: 4UHR) 
and UK432097 (PDB ID: 3QAK) but not for the non-
selective co-crystallized agonists NECA (PDB ID: 2YDV) 
and adenosine (PDB ID: 2YDO). !ese results appear to 
confirm that interactions with  His250 serve to improve 
binding to the lipophilic sub-pocket which suggests this 
is a driver for  A2AR sub-type selectivity. In terms of func-
tional activity however, the occurrence of this interaction 
cannot discriminate between agonists and antagonists 
[37, 39].
Compound 1 hydrogen bonds via the nitrogen of the 
quinazoline ring with  Asn253, and via the imidazo ring 
with  Glu169. !e triazole ring is "-stacked with  Phe168, 
and the phenyl group in quinazoline is "-stacked with 
 His250 (Fig.# 2). Compound 4 shows "-stacking with 
 Phe168. !e selective  A2AR agonist, compound 1# is pre-
dicted to bind deeper within the receptor core and to 
directly interact with  His250 and  Asn253, which is con-
sistent with the experimentally observed interactions 
between the co-crystallized ligands and the active  A2AR 
crystal structures (PDB IDs: 4UG2, 4UHR, 3QAK, 
2YDO and 2YDV). !e compounds were not predicted 
to display all the interactions exhibited by the agonist 
co-crystallized ligands [28–30], in particular the  !r88 
and  Ser277 interactions, which are also characteristic of 
the ZM241385 antagonist [27]. Hence, these interaction 
types are not characteristic of agonist activity. However, 
it has been reported in the literature that mutating these 
residues has a stronger influence on agonist activity than 
upon the antagonist activity of the  A2AR ligands, but not 
on the binding to the  A2AR [37–39]. As for the co-crys-
tallized  A2AR antagonists (PDB ID: 5IU4 3UZA, 5K2A, 
4EIY, 3EML, 5NM2, 5JTB, 5UVI, and 5UIG), these only 
show interactions with  Phe168,  Asn253, and  Glu169 resi-
dues. !erefore, the type of predicted interaction is not 
indicative of receptor activation by the triazoloquinazo-
lines. However, the docking model used enriched  A2AR 
agonists (exhibited higher docking score distribution) 
over  A2AR antagonists and  A2AR inactives (compounds 
that do not bind to the  A2AR). !is suggested an inves-
tigation (using molecular dynamics) into whether the 
 His250 movement would di$er between selective versus 
non-selective  A2AR agonist binding (discussed in the sup-
porting information) and also to investigate whether the 
motion of  Val84 would vary upon agonist and antagonist 
binding. !is could allow discrimination between these 
di$erent classes of compounds.
Fig. 2 Docking studies predicted molecular interactions similar to those observed for triazoloquinazolines in the  A2AR protein crystal structure (PDB 
ID: 2YDO). Distinct binding modes are shown for compounds 1 and 4. a Compound 1 hydrogen bonds via the nitrogen of the quinazoline ring with 
 Asn253 and via the imidazo ring with  Glu169. The triazole ring is !-stacked with  Phe168, and the phenyl group in quinazoline is !-stacked with  His250 
b Compound 4 shows !-stacking with  Phe168. It can be seen that the  A2AR selective agonist 1 is predicted to bind deeper within the binding site 
and interacts with  His250 and  Asn253, which is consistent with binding modes observed in crystallographic data (PDB IDs: 4UG2, 4UHR, 3QAK, 2YDO 
and 2YDV). The essential role of  His250 in shaping the binding site was supported by MD simulation. Yellow spheres indicate lipophilic contacts, red 
arrows show hydrogen bond acceptors and purple disks indicate aromatic interactions
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Analysis of!MD Simulations reveals that!a!shift in! Val84 
is!one requirement for!receptor activation by! A2AR ligands
!e analysis of the active and inactive forms of the avail-
able  A2AR crystal structures is in accordance with reports 
in the literature, which mention that  Val84 in TM3 has 
to move by approximately 2 Å upon agonist binding to 
avoid a steric clash between the ligand and the receptor 
[29–31]. !is gave rise to the hypothesis that the motion 
of this residue might discriminate between agonist and 
antagonist binding (Fig."3a).
MD simulations (100 ns) were performed for the co-
crystallized structures (PDB IDs: 5IU4 and 2YDO), which 
exhibited the largest di#erences observed in the distance 
between the $-carbons of  Val84 in TM3, and  Leu249, a 
relatively fixed residue in TM6 (12.96 Å and 14.53 Å, see 
methods for details). !e same MD analysis was carried 
out for the apo structure of the  A2AR (PDB ID: 5IU4), the 
docked triazoloquinazolines 1, 4 and 5 with the highest 
predicted a%nities, compound 6 (with lowest predicted 
a%nity), CHEMBL3799351 (a potent antagonist), and 
CGS21680 (the selective and potent  A2AR agonist). All 
these compounds were docked into the orthosteric site 
of the inactive form of the  A2AR protein crystal struc-
ture (PDB ID: 5IU4), Additional file"1: Figure S4. For the 
first 50 ns the structures were considered to be relaxing 
to an annealed state. For the subsequent 50 ns the agonist 
bound structures showed an increase of the C$ distances 
between  Val84 and  Leu249, with an increased distance 
equivalent to the active protein crystal structure (PDB 
ID: 2YDO). Compound 6, the apo structure, and the 
antagonist bound structures did not exhibit this increase 
in C$ distances and instead showed a slight decrease in 
the C$ distances for the antagonist bound structures in 
comparison to the apo structure and compound 6.
To gain further insights from the change in the C$ dis-
tances between  Val84 and  Leu249 for the agonist bound 
structures (which are the systems of interest in this 
study), longer simulations of 500 ns were carried for com-
pounds 1, 5, and CGS21680, in addition to the active and 
inactive cocrystal structures (PDB IDs: 2YDO and 5IU4). 
!e simulations were run in duplicate.
!e same trends were observed in the longer simula-
tions. Over the first 50 ns the structures were annealing, 
and for the rest of the simulation (the last 450 ns) com-
pounds 1, 5 and CGS21680 increased their C$ distances 
between  Val84 and approaching the distance observed for 
the active protein crystal structure (PDB ID: 2YDO), as 
shown in Fig." 3b, c. Hence, the increase in the distance 
between  Val84 and  Leu249 residues observed upon  A2AR 
agonist binding appears to serve as a useful conforma-
tional descriptor for receptor activation by  A2AR ligands.
Characterisation of!triazoloquinazolines a"nity constant 
at!adenosine  A2AR
We sought to" validate the docking studies by quantify-
ing the a%nity of each compound at the  A2AR using a 
Fig. 3 a The aligned and superimposed active (PDB ID: 2YDO in blue) and inactive conformations (PDB ID: 5IU4 in grey) of the  A2AR protein crystal 
structures. The  Val84-Leu249 C! distances were measured for the active and inactive conformations and were 14.53 Å and 12.96 Å respectively 
b The moving average trend-lines (bin-size of 20 frames) are for the  Val84-Leu249 C! distances of the apo structure (PDB ID: 5IU4) and the docked 
and the co-crystallized structures (PDB ID: 5IU4 and 2YDO use the same color code as 3A) of the  A2AR over a simulation of 100 ns. Compounds 1, 
5 and CGS21680 are docked into the inactive form of the  A2AR protein crystal structure (PDB ID: 5IU4). The variations in the computed distances 
for compounds 1, 5 and CGS21680 were similar - all increased their average distances over time, moving closer to the average distance observed 
in the active protein crystal structure (PDB ID: 2YDO). c Violin plots for distance distributions (same color code of Fig. 3b) for the last 450 ns of the 
simulations shows higher  Val84-Leu249 distances for the agonist bound to the  A2AR in comparison to the antagonist bound to the  A2AR. Hence, 
the increase in the  Val84-Leu249 inter-residue distance upon  A2AR agonist binding serves as a promising conformational descriptor for receptor 
activation by  A2AR ligands. A statistical analysis was performed on the distance distributions for the last 450 ns using a Mann-Whitney test and a 
Kolmogorov-Smirnov test. The di"erences in medians of the distance distributions for each of the agonists versus the antagonist were significant at 
a p value < 0.05, and the p value for the Kolmogorov-Smirnov test was < 2.2 !  10" 16
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NanoBRET binding assay. In this experiment, we used 
N-terminally tagged  A2AR with Nanoluciferase (Nluc) 
that will emit bioluminescence in close proximity with 
the fluorescent probe, CA200645, in the presence of Nluc 
substrate. Firstly, we determine the a!nity constant of 
CA200645 in our expression system. CA200645 has been 
extensively used to characterise ligand binding properties 
at adenosine receptor subtypes [40–42]. Using HEK293 
cells we determined the disassociation constant  (KD) of 
CA200645 at the Nluc-A2AR to be 65 nM (Fig." 4a). We 
next extended our studies to use a classical competition 
binding assay ([43, 44]) where non-fluorescent ligands 
compete for binding at the Nluc-A2AR with CA200645. 
Using this approach, we determined the pKi for NECA as 
6.36 ± 0.09 and CGS21680 as 6.39 ± 0.04 while isoprena-
line (a non-selective agonist of #-adrenoceptors) failed 
to displace CA200645 (Fig."4b). We next determined the 
rank order of a!nities for the" six triazoloquinazolines 
compounds at the  A2AR to be: cmpd 4 > cmpd 2 > cmpd 
6 > cmpd 1 = cmpd 3 > cmpd 5 (note: under condition 
tested, cmpd 5 was unable to fully displace CA200645) 
(Fig."4c, d).
Identifying AR subtype selectivity of!triazoloquinazolines
Identification" of AR subtype selectivity of triazolo-
quinazolines was performed using previously character-
ised yeast strains expressing human  A1R,  A2AR or  A2BR 
[45]. $e  A3R cannot be functionally expressed in yeast 




































































































Fig. 4 Characterisation of ligands targeting  A2AR/PDE10A using a NanoBRET-based ligand binding assay. a Kinetic binding curve of CA200645 at 
Nluc-A2AR expressed HEK293T cells. After 19 minutes association with 40 nM CA200645, CGS21680 was injected to give a final concentration of 
10 µM in order to displace the fluorescent probe. The curve was fit into “association then dissociation” model built in Prism 8.4.3. b Competition 
of CA200645 (300 nM) by reference compounds including CGS21680, NECA, and isoprenaline at equilibrium. c Competitive binding curves of 
triazoloquinazolines in correspond to of 300 nM CA200645. Both curves (panel B and C) were fitted using the “one-site Ki” equation where  KD and 
concentration of hot ligand were set to 65 nM and 300 nM, respectively. Data points are the mean ± SEM from 3–27 repeats performed in duplicate. 
(D) The summary of binding a!nities  (pKi) of tested ligands.  pKi values were calculated from inhibition of CA200645 binding at equilibrium to 
Nluc-A2AR-expressed HEK293T cells. 
# Cmpd 5 did not fully displace binding of CA200645 under condition tested. Statistical significance (*p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001) compared to CGS21680 was determined by one-way ANOVA with Dunnett’s post-test 
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(Knight et!al., 2016), therefore we utilised CHO-K1 cells 
stably expressing  A3R (CHO-K1-A3R). Testing the com-
pounds in these systems identified compounds 1, 2, 3, 
4, 5 to be  A2AR agonists, whilst compounds 1, 2, 3 are 
 A2AR-selective (Fig.! 5, Additional file! 1: Table! S2).! It is 
interesting to note that compound 6 was able to bind to 
the  A2AR!but given that in the yeast based assay it failed 
to elicit a functional response, we suggest it maybe an 
 A2AR antagonist.
To further verify the e"cacy of compounds against the 
 A2AR, we assayed their ability to stimulate cAMP produc-
tion using CHO-K1 cells stably expressing human  A2AR 
(CHO-K1-A2AR). All compounds tested were observed 
to be partial agonists, relative to CGS21680, with a rank 
order of potency of CGS21680 > 5 = 4 > 1 = 3 > 6 > 2 
(Fig.! 6; Table! 1). Antagonism with ZM241385 displayed 
non-classical antagonism, which is presumed to be due 
to the dual e#ects upon endogenous PDE10A (Addi-
tional file!1: Figure S5). For compound 6, treatment with 
ZM241385 solely reduced  Emax and basal levels, with no 
e#ect on the response range (Fig.!6; Table!1). ZM241385 
has been suggested to be an inverse agonist at the  A2AR 
potentially explaining these e#ects [30]. Importantly, all 
compounds were able to stimulate cAMP production 
in the absence of the  A2AR, or in the presence of 1 µM 
ZM241385, presumably from inhibition of PDE10A. 
$us, we observe a significant increase in e"cacy of 
compounds 1–5 via the additional action upon the  A2AR 
(Fig.!6; Table!1), which could be attributed to an additive 
action in elevating intracellular cAMP levels.
Dual PDE 10A inhibition and! A2AR agonism is!anti!
proliferative in!CHO-K1-A2AR cells
Both CHO-K1 and CHO-K1-A2AR cells displayed 
concentration-dependent inhibition of cell prolifera-
tion when stimulated with forskolin (Additional file! 1: 
Figure S6, Table! S3), confirming the anti-proliferative 
e#ects of cAMP. However, sole activation of the  A2AR, 
via CGS21680 stimulation, had no anti-proliferative 
e#ects upon either cell type (Additional file!1: Figure S6, 
Table!S3). In contrast stimulation with compound 1 dis-
played  A2AR-dependent inhibition of cell growth. Com-
pounds 3–5 show anti-proliferative e#ects in CHO-K1 
cells, which increased in terms of both potency and e"-
cacy when the  A2AR was expressed (Additional file! 1: 
Figure S6, Table! S3). Compound 2 appeared to be anti-
proliferative regardless of the cell type tested whereas 
Compound 6 displayed little anti-proliferative action 
implying that that sole inhibition of PDE 10A has little 
e#ect upon the proliferation of CHO-K1 cells (Additional 
file!1: Figure S6, Table!S3).
Dual PDE 10A inhibition and! A2AR agonism 
is!anti-proliferative in!Lung carcinoma cells
Having established that the compounds 1–5 appear to 
have dual activity in CHO-KI cells where the  A2AR was 
over expressed we then extended our studies to a series of 
lung carcinoma cells: two lung squamous cell carcinomas 
(LUSC): LK-2 and H520, and two lung adenocarcinoma 
cells (LUAC): H1563 and H1792, which express di#er-
ing levels of the four adenosine receptor subtypes and 
PDE10A (Fig.!7a). Using these cell lines, we investigated 
the e#ects of compounds of our dual-target compounds 
upon cAMP production and proliferation (Fig.!7). Note, 
compound 2 was not analysed for cAMP production in 
this study due to apparent o#-target toxic e#ects upon 
CHO-K1 cell proliferation—a feature also noted in all 
four lung carcinoma cell lines.
LK-2 cells express the  A1R,  A2BR and very low levels 
of PDE10A, but lacked expression of the  A2AR (Fig.!7a). 
In these cells compound 3 and to a lesser extent com-
pound 4 were able to stimulate cAMP production 
(Fig.! 7a, Additional file! 1: Table! S4). However, only 
forskolin and compound 3 (Fig.! 7a, Additional file! 1: 
Table!S5) displayed any anti-proliferative actions. $us, 
in the absence of significant PDE10A or  A2AR expres-
sion, compound 1 and 5 displayed little activity. Com-
pound 4! is an agonist for the  A2BR so presumably this 
explains its ability to stimulate cAMP production. $e 
action of compound 3 was somewhat of a surprise and 
may suggest it has additional activities beyond  A2AR 
and PDE10A. By means of a comparison, H520 cells 
express all four ARs, but no PDE 10A. In these cells, we 
were able to observe stimulation of cAMP accumulation 
when exposed to all compounds except for compound 
6, which displayed low potency and e"cacy (Fig.! 7, 
(See figure on next page.)
Fig. 5 Dose-response curves for NECA, CGS21680 and compounds 1–6 in either the  A1R and GPA1/G!i1/2,  A2AR and GPA1/ G!s, or the  A2BR (with 
GPA1/G!s expressed in yeast strains). The e"cacy of the compounds (1–6) was measured against  A3R in CHO-K1-A3R cells. Reporter gene activity 
in yeast was determined using #-galactosidase assays, after 16-hours stimulation with either: NECA (a), CGS21680 (b) compound 1 (c), compound 
2 (d), compound 3 (e), compound 4 (f), compound 5 (g), compound 6 (h), whereas cAMP inhibition was determined when in CHO-K1-A3R cells 
which were co-stimulated with each of the compounds 1–6 and 1 µM Forskolin. In general, the triazoloquinazolines 1–5 exhibited agonistic activity 
against the adenosine receptor sub-types, with compounds 1–3 being selective  A2AR agonists. The data is represented as either percentage of 
the response obtained upon stimulating each receptor  (A1R,  A2AR, or  A2BR) with NECA stimulation, or as a percentage response relative to 100 µM 
Forskolin simulation in the  A3R ± SEM of 4–6 individual replicates
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Additional file! 1: Table! S4). "e increase in activity of 
the compounds was also apparent for proliferation 
assays, where compounds 1, 3–5 all displayed anti-
proliferative activity with higher a#nity and e#cacy 
than that observed in the LK-2 cells (Fig.!7, Additional 
file! 1: Table! S5). "is data highlights the potential of 
the compounds to prevent proliferation when the  A2AR 
is expressed. Likewise, in H1792 cells we observe the 
expression of all four ARs and an increase in PDE10A 
expression, relative to H520 cells (Fig.! 7). Again, we 
observed the ability of all compounds to elevate cAMP 
levels, whilst compounds 1, 3, 4 and 5 act in an anti-
proliferative manner (Fig.!7, Additional file!1: Tables S4, 
S5). "e same was also apparent for H1563 cells, which 
in contrast to H1792 cells express much higher levels 
of PDE10A (Fig.!7, Additional file!1: Tables S4, S5). By 
comparing the observed potencies for proliferation and 
cAMP assays, across all cell types, for all anti-prolif-
erative compounds, a strong correlation was observed 
(Fig.!7B, r = 0.80, 95 % CI; 0.85–0.91). "is suggests that 
through improving e#cacy in terms of cAMP produc-
tion, an increased e#cacy can also be achieved in terms 
of proliferation inhibition.
Finally, to provide convenient means by which to com-
pare the anti-proliferative activities of the compounds 
tested in this study, we multiplied the potency term 
(a#nity) for the compounds by their e#cacy (span of 
antiproliferation)—generating a ‘proliferation factor’ 
term as described previously [46]. Using this analysis, 
we can observe that compounds 1, 3, 4 and 5, all display 
improved e#cacy when both PDE10A and  A2AR are pre-
sent in the cells (Fig.!7). In contrast, compound 6 displays 
no anti-proliferative activity in any cell type tested whilst 
CGS21680 is only anti-proliferative in H1563 cells (Fig.!7, 
Additional file! 1: Table! S5), suggesting these are more 
sensitive to proliferation inhibition. In contrast, forsko-
lin displays near equal activity in all cell types tested. As 
described earlier, compound 3 displayed activity in all 
four NSCLC cell lines suggesting it may display o$ target 
e$ects. Significantly, it is worth highlighting that com-
pound 4 displayed higher e#cacy when the  A2BR was 
most abundantly expressed in cells. "is directly corelates 
with it being non-selective at the di$erent AR subtypes 
and suggests it may be a pan-AR/PDE10A compound.
Conclusions
In this work, a novel structure-based approach has been 
successful in identifying triazoloquinazolines as the first 
dual ligands that activate the  A2AR and inhibit PDE10A 
simultaneously. Docking of the triazoloquinazolines 1–6, 
which are known PDE10A inhibitors, was performed 
on the orthosteric site of the  A2AR (PDB ID: 2YDO). It 
is demonstrated experimentally using a BRET-based 
ligand-binding assay that these ligands indeed bind to 
the  A2AR. "e rank order of a#nity for the six triazolo-
quinazolines at the  A2AR was found to be: cmpd 4 > cmpd 
2 > cmpd 6 > cmpd 1 = cmpd 3 > cmpd 5.
Functional analysis in yeast-screening assay and in 
mammalian cells demonstrated that compounds 1–5 
were  A2AR agonists and revealed that compounds 1–3 are 
selective for the  A2AR. It is suggested that the observed 
 A2AR sub-type selectivity for 1–3! is attributed to their 
predicted interactions with the  His250 residue, which is 
an interaction present only in the selective co-crystal-
lized  A2AR agonists, such as CGS21680 and UK432097. 
It was further demonstrated by MD simulation analysis 
that this residue undergoes conformational changes only 
when selective  A2AR agonists are bound and not when 
non-selective agonists bind to  A2AR. "is could contrib-
ute to shaping the orthosteric site to favor selectivity of 
 A2AR agonists. Moreover, MD analysis highlighted the 
motion of  Val84 in TM3 as an essential requirement for 
 A2AR activation.
Compounds 1 and 3–5 exhibited promising concen-
tration-dependent anti-proliferative e$ects in lung squa-
mous cell carcinoma cells and lung adenocarcinoma 
cells, which correlated with co-expression of  A2AR and 
PDE10A and increased cellular levels of cAMP. Com-
pound 1 (as a selective  A2AR agonist and a PDE10A 
inhibitor) exhibited increased potency for both cAMP 
accumulation and anti-proliferative actions, which 
increased in tandem with the combined target expression 
 (A2AR and PDE10A) across the NSCLC cell lines, from 
LK-2-H520-H1792-H1563. Hence, the structure-based 
approach proposed in this work has been successfully 
validated using binding and functional assays, and it pro-
vides a template for generating  A2AR agonists as part of a 
dual-target design objective.
Fig. 6 CGS21680 and compounds 1–6 elevated cAMP in  A2AR stably expressed in CHO-K1 cells, which were antagonized by ZM241385.  A2AR stably 
expressed in CHO-K1 cells (CHO-K1-A2AR) were stimulated for 30 minutes with: CGS21680 (a), compound 1 (b), compound 2 (c), compound 3 (d), 
compound 4 (e), compound 5 (f), or compound 6 (g), after which the cAMP levels were determined. Subsequently compounds were antagonized 
with either 100 pM, 10 nM or 1 µM ZM241385, which decreased the cAMP levels to the same level of CHO-K1 cells (no  A2AR stably expressed). Data 
represented are relative to the response of CGS21680, ± SEM of 4–9 individual replicates
(See figure on next page.)
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Methods
Design approach for!the!discovery of!dual ligands 
at!the! A2AR and!PDE10A
Triazoloquinazolines were shortlisted as candidates of 
dual ligands at the  A2AR and PDE10A since this chemi-
cal series were predicted to show activity based on 
ligand- and structure- based techniques [33]. !e focus 
was on discovering compounds that elicited an eleva-
tion of cAMP by the activity of ligands having dual 
e"ects, simultaneously agonists at  A2AR and inhibitors of 
PDE10A.
From the ZINC database, eleven purchasable tria-
zoloquinazolines that were experimentally determined 
as PDE10A inhibitors were identified using a search for 
the triazoloquinazoline substructure with the following 
criteria: Uniprot ID: Q9Y233 and  IC50 < 10 µM. Identi-
fied triazoloquinazolines had the following ZINC IDs: 
3,154,141, 3,141,002, 6,206,233, 9,937,921, 9,939,949, 
2,968,902, 14,728,559, 424,907, 13,229,753, 44,924,158, 
and 8,747,709. !ese were downloaded for subsequent 
docking into the orthosteric site of the  A2AR protein crys-
tal structure.
Selection of!the! A2AR protein crystal structure 
for!shortlisting triazoloquinazoline candidates as! A2AR 
agonists
All the active forms of the  A2AR protein crystal struc-
ture with the following PDB IDs (4UG2, 4UHR, 3QAK, 
2YDO, and 2YDV) and the inactive forms with the fol-
lowing PDB IDs (5IU4, 3UZA, 5K2A, 4EIY, 3EML, 
5NM2, 5JTB, 5UVI, and 5UIG) were downloaded into 
MOE [47]. It has been reported in the literature that  Val84 
in TM3, which is located in the orthosteric site, has to 
shift its position upon agonist binding owing to a steric 
clash with the ligand, which may contribute to the 2 Å 
shift observed in H3 [29–31]. To evaluate the change in 
the interaction upon agonist binding, the distance was 
calculated from a single amino acid residue to  Val84. !is 
gave a frame of reference to compare structures. !e 
‘fixed’ amino acid residue selected was  Leu249 in TM6. 
!is was achieved by aligning all the active and inactive 
forms of the  A2AR protein crystal structures (using the 
sequence editor > alignment > align/superimpose option). 
!en, the mean RMSD displacement from the mean of 
all the aligned structures was calculated for  Leu249, which 
turned out to be low (0.40 Å) confirming that it is reason-
ably static in its relative position.
For each PDB ID of the active and inactive forms of 
the  A2AR crystal structures, the distance between the 
#-carbons of  Val84 in TM3 and  Leu249 in TM6 was meas-
ured in MOE using the measure > distances option. 
Additional file$1: Table$S1 lists all the  Val84-Leu249 inter-
residue distance values. !e inter-residue distances of 
the active forms ranged from 14.30 to 14.53 Å, and for 
the inactive forms they ranged from 12.96 to 13.36 Å. !e 
largest displacement of the  Val84 residue was measured 
for the active form in PDB ID: 2YDO, and the distance 
was equal to 14.53 Å. !is can be compared to the inac-
tive form of the  A2AR protein crystal structure (PDB ID: 
5IU4), which had the minimum distance (12.96 Å). Given 
that  Val84 displayed the highest displacement from the 
 Leu249 residue in the protein crystal structure with the 
PDB ID: 2YDO, it was selected as the best candidate for 
shortlisting candidates of  A2AR agonists.
Ligand preparation
39 potent agonists and 38 potent antagonists of the  A2AR 
(Uniprot ID: P29274) with  EC50 and  IC50 values less 
than 1 µM and confidence scores equal to 9 were manu-
ally extracted from ChEMBL. 133  A2AR inactives were 
Table 1 Potency  (pEC50) and! range of! responses for! cAMP production upon! CGS21680 and! triazoloquinazoline 
stimulated cAMP accumulation in!CHO-K1-A2AR and!CHO-K1 cells
Data ± SEM of n individual replicates.!aNegative logarithm of agonist concentration producing half-maximal response.!bPercentage range of response observed 
upon agonist stimulation, relative to that obtained with CGS21680 stimulation in each cell type.!cChange in  pEC50 between CHO-K1 and CHO-K1-A2AR cells (" 
 pEC50 =  pEC50(CHO-K1-A2AR) -  pEC50(CHO-K1)).!dChange in range between CHO-K1 and CHO-K1-A2AR cells (" Range = Range (CHO-K1-A2AR) - Range (CHO-K1)).!ND 
Not determined, full dose-response curve not feasible.!Statistical di#erence, between CHO-K1-A2AR cells and CHO-K1 cells, was calculated using pair-wise t-tests, for 
each agonist (*p < 0.05, **p < 0.01, ***p < 0.001)
CHO-K1-A2AR CHO-K1 CHO-K1-A2AR vs. CHO-K1
pEC50
a Rangeb n pEC50
a Rangeb n "  pEC50
c "  Ranged
CGS21680 8.78 ± 0.2 86.33 ± 7.2 9 ND ND 4 – –
Cmpd 1 7.32 ± 0.2 61.14 ± 5.2*** 8 6.49 ± 0.3 20.19 ± 2.7 4 0.83 ± 0.5 40.95 ± 7.80
Cmpd 2 6.29 ± 0.5** 30.50 ± 8.1 6 4.85 ± 0.2 39.46 ± 3.9 4 1.44 ± 0.6 ! 8.96 ± 10.6
Cmpd 3 7.26 ± 0.3** 28.95 ± 6.3 6 5.90 ± 0.3 18.32 ± 2.3 4 1.21 ± 0.5 10.63 ± 8.70
Cmpd 4 7.55 ± 0.2 37.71 ± 2.9** 5 6.62 ± 0.2 18.75 ± 1.7 4 0.93 ± 0.6 18.96 ± 3.60
Cmpd 5 7.70 ± 0.4** 27.42 ± 4.4 6 6.30 ± 0.2 19.49 ± 1.7 4 1.28 ± 2.4 7.93 ± 6.1
Cmpd 6 6.52 ± 0.4 33.87 ± 5.3 6 6.35 ± 0.3 31.42 ± 4.6 4 0.17 ± 0.8 2.45 ± 9.9
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extracted from PubChem using SQL and the eleven pur-
chasable triazoloquinazolines were selected from the 
ZINC database. !e entire set of ligands were prepared 
for docking into the orthosteric site of the  A2AR protein 
crystal structure, with LigPrep 2.5 [48]. using the default 
settings and the Epik option, which introduces energy 
penalties associated with ionization and tautomerization 
[49].
Receptor preparation
Docking with Glide [50] was performed against the 
human  A2AR protein crystal structure (PDB IDs: 2YDO 
and 5IU4). !e protein structures were prepared using 
the Protein Preparation Wizard of Maestro 9.3 [51], fol-
lowing the default protocol, which accounts for energy 
refinement, hydrogen addition, pKa assignment, side-
chain rotational isomer refinement, and addition of 
missing residues and side-chains with Prime 3.1 [52]. 
Resolved water molecules were discarded, and the struc-
ture was centered using the co-crystallized ligand as the 
center of the receptor grid generated for each protein 
structure. !e co-crystal structures of  A2AR with Aden-
osine (PDB ID: 2YDO) and with ZM241385 (PDB ID: 
5IU4) were selected as target structures.
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Fig. 7 Lung squamous cell carcinoma and adenocarcinoma cells display increasing sensitivity to compounds 1, 3–5 in terms of proliferation, 
dependent upon combined  A2AR and PDE10A expression. Lung squamous cell carcinoma cells (LK-2 and H520) and lung adenocarcinoma cells 
(H1792 and H1563 were subjected to semi-quantitative RT-PCR analysis to determine expression of the  A1R,  A2AR,  A2BR,  A3R and PDE 10A, data 
represented relative to GAPDH expression, ± SEM of 3 individual replicates. Further, each cell line was stimulated with CGS21680 or compounds 
1, 3–6 for 30 minutes and cAMP levels determined. Data represented relative to the response obtained upon stimulation with 100 µM Forskolin, 
± SEM of 4–8 individual replicates. Additionally, all cells were stimulated with CGS21680, or 1, 3–6 for 72 hours and cell number determined using 
CCK-8. Data represented as a percentage of the cell number present after treatment with 1 % DMSO, ± SEM of 4–8 replicates. (B) Correlation plot 
for  pEC50 of each compounds ability to stimulate cAMP production vs. its  pIC50 for inhibiting proliferation. Data represented ± SEM. (C) Proliferation 
factor (pIC50 x span anti-proliferative  Additional file 1: Table S5) calculated for 1, 3–6, CGS21680s and forskolin at LK-2, H520, H1792 and H1563 cells. 
Bars represent the mean  Imax ± SEM, whilst individual data points are shown as a scatter plot.
Appendix   
 349 
 
Page 13 of 17Kalash!et!al. J Cheminform           (2021) 13:17  
Enrichment of!agonists by!the! A2AR docking model (PDB 
ID: 2YDO)
In an attempt to validate the  A2AR docking model, the 
set of prepared  A2AR agonists, antagonists and inactives 
were docked using Glide against the prepared protein 
structure.
!e Glide docking parameters used were extra preci-
sion (XP) and flexible ligand sampling, which obtained 
the best separation for the medians of docking score 
distributions for agonists versus antagonists and ago-
nists versus inactives of the  A2AR. !is implies that this 
docking model enriches the agonists. Additional file" 1: 
Figure S7 shows the separation of the medians for the 
 A2AR docking model: (A) !" 11.24 (agonists) (B) !" 7.88 
(antagonists) and (C) !"6.74 (inactives). Statistical analy-
sis was performed with R using a Mann-Whitney test on 
the agonist and antagonist docking score distributions, as 
well as agonist and inactive docking score distributions. 
!e di#erences in medians were significant at a p value of 
less than 0.05 [33].
Cut!o" generation for!compound selection as!candidates 
of! A2AR agonists from!the!docking model
!e Matthews correlation coe$cient (MCC), which takes 
into account true and false positives (agonists) and nega-
tives (antagonists), was computed (using a Python script 
[33]) for the docking scores of the agonists and antago-
nists against the  A2AR docking model. A search was 
performed for a docking score threshold that gave the 
highest MCC in order to shortlist promising candidates 
of  A2AR agonists, which displayed docking scores that are 
lower than the score with the highest MCC, and this gave 
a threshold of -7.33 for the  A2AR docking model.
Docking
!e eleven purchasable triazoloquinazolines, which were 
prepared with LigPrep, were docked against the  A2AR 
protein crystal structure (PDB ID: 2YDO). !e Glide 
docking parameters used were extra precision (XP) and 
flexible ligand sampling. !e parameters were deduced 
from docking experiments using known actives and 
inactives against the protein-docking model. !e  A2AR 
protein is fairly rigid as assessed by thermal stability (B 
factor) in Glide [53]. Six triazoloquinazolines (1–6) dis-
played docking scores that are lower than ! 7.33, which 
was the docking score with the highest MCC for the 
known agonists and antagonists. !eir chemical struc-
tures are depicted in Fig." 1. Additionally compounds 
1, 4 and 5 (with the highest predicted a$nities and the 
most potent agonists identified), compound 6 (which did 
not exhibit any agonist activity), CHEMBL3799351 (an 
antagonist with an  IC50 = 4.35 nM and confidence score 
equal to 9) and CGS21680 (the selective and potent  A2AR 
agonist) and adenosine (a non-selective adenosine recep-
tor agonist), were docked into the inactive form of the 
 A2AR protein crystal structure (PDB ID: 5IU4) for MD 
simulation and analysis. !e six triazoloquinazolines (1–
6) were then shortlisted for validation as  A2AR agonists in 
relevant biochemical assays.
MD simulations
Based on a structural analysis of the available  A2AR 
crystal structures, the distance between the %-carbons 
of  Val84 in TM3 and  Leu249 in TM6 was selected for 
investigation as a conformational descriptor for recep-
tor activation. !e two  A2AR co-crystallized structures 
(PDB IDs: 5IU4 and 2YDO), which exhibited the larg-
est di#erence in %-carbon distances between  Val84 in 
TM3 and  Leu249 in TM6 (12.96 Å versus 14.53 Å respec-
tively), were selected for molecular dynamics simula-
tion. Subsequently, compounds 1, 4, 5, and 6 that were 
docked into the orthosteric site of the inactive form of 
the  A2AR protein crystal structure (PDB ID: 5IU4) were 
subjected to a 100 ns MD simulation protocol. Like-
wise, CHEMBL3799351, CGS21680 and adenosine were 
docked into the orthosteric site of the inactive form of 
the  A2AR protein crystal (PDB ID: 5IU4) to obtain simu-
lations of control compounds. !e apo structure (PDB 
ID: 5UI4) was also selected for the same analysis.
!e starting structures were prepared using Maestro 
9.3 following the default procedure for protein prepara-
tion. !e protocol adds missing residues and sidechain 
information with Prime 3.1 [52], and uses the “Cap ter-
mini” option that adds the coordinates to the residue. 
Next, “Analyze network” in the interactive hydrogen 
bond optimizer was used to check on the assignments of 
hydrogen orientations in the hydrogen bonding network. 
!ey were subsequently optimized. All MD simulations 
described in this study were performed using Desmond 
3.2, available in the Schrödinger software package Release 
2016-3 with the default force field OPLS3 [54]. An 
orthorhombic box was used to build the model systems 
with periodic boundary conditions in an isothermal–iso-
baric ensemble with a constant number of particles (NPT 
ensemble). !e system temperature was kept at 300 K, 
and the pressure was kept at atmospheric pressure. !e 
definition of transmembrane regions was taken from the 
OPM database [55]. !e receptor structures were embed-
ded in a pre-equilibrated palmitoyloleoyl-phosphatidyl-
choline membrane (bilayer) and solvated with simple 
point charge water and 0.15 M NaCl. All other parame-
ters were set to default values (refer to"Additional file"1: 
Table"S6 in supporting information). !e 100 ns simula-
tions were carried out with Desmond 3.2 via command 
line on the computer cluster CALCULON (University 
of Cambridge) by using 20 central processing units. For 
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each compound, the simulations were performed twice, 
and the trajectories obtained were analyzed with the 
software VMD. !en plots were obtained for the RMSD 
values of  His250 in TM6, and the "-carbons distances 
between  Val84 in TM3 and  Leu249 in TM6 for the simu-
lated systems over 100 ns using the seaborn library [56]. 
!e same protocol was repeated for the 500 ns simula-
tions for compounds 1, 5, CGS21680, and the  A2AR pro-
tein crystal structures (PDB IDs: 2YDO and 5UI4) (each 
performed in duplicate).
Materials
Triazoloquinazolines 1–6 were supplied from Ambinter 
(Orléans, France), and CGS21680, NECA and ZM241385 
from Tocris Biosciences (Abingdon, UK) (%purity ! 95). 
All compounds were stored in 10 mM stock solutions in 
DMSO. Rolipram was purchased from Cayman chemi-
cals (Michigan USA), and other laboratory reagents were 
from Sigma-Aldrich (Poole, UK), of analytical grade.
Mammalian cell culture
CHO-K1 (gifted by Dr. Ewan St. John Smith, University 
of Cambridge, UK) CHO-K1-A2AR and CHO-K1-A3R 
cells (gifted by Prof. Karl-Norbert Klotz, University of 
Wuerzburg, Germany), were routinely cultured in Hams 
F-12 nutrient mix, supplemented with 10 % fetal bovine 
serum (FBS). H520, H1563, H1792 and LK-2 cells (gifted 
by Dr. Whalid Khaled, University of Cambridge, UK) 
were grown in RPMI media + 10 % FBS. All media was 
further supplemented with 1X antibiotic, antimycotic 
solution (Sigma Aldrich, Poole, UK). Culturing of all cell 
types was done at 37 °C in a humidified atmosphere con-
taining 5 %  CO2.
Generation of!CHO-K1 cell line stably expressing the! A2AR
CHO-K1 cells stably expressing the  A2AR cells were 
generated via transfection with 500 ng pcDNA3.1-A2AR 
(cDNA.org), per well of a 24-well plate, which was per-
formed with FuGENE HD (Promega, Wisconsin, USA), 
at a 1:3 (w/v) DNA:FuGENE ratio. Prior to adding 
800 µg/ml G418 (Sigma Aldrich, Poole, UK), the cells 
were further cultured for 48 hours. !en every 48 hours, 
G418 containing media were replaced until foci of cells 
were attained, which were left to grow to 100 % conflu-
ency. Afterwards, each well was tested for the ability of 
CGS21680 to elevate cAMP, performing further cultur-
ing with appropriately responding clones as described.
Phosphodiesterase 10A inhibition assays
A PDE10A assay kit (BPS Bioscience, San Diego, CA) 
was used to test the PDE10A inhibition of compounds 
1–6 as described in the manufactures protocol. 400 pg of 
purified PDE10A was used per reaction, and the plates 
were read using a TECAN infinite M200.
Yeast methods
Generation of yeast strains was done according to previ-
ously reported protocols, and they have been routinely 
grown as previously described [45]. Yeast cells expressing 
either the  A1R,  A2AR, or  A2BR were treated with either 
NECA, CGS21680 or compounds 1–6, in order to meas-
ure the activity of each, as previously described [45].
Bioluminescence Resonance Energy transfer (BRET)-based 
ligand binding of!triazoloquinazolines
HEK293T cells were seeded in 6-well plates at density of 
 106 cells/well and grown overnight at  37oC in DMEM/
F12 medium supplemented with 10 % FBS and 1 % antibi-
otic/antimycotic. Cells were then transfected with 1.5 µg 
Nluc-A2AR construct (a gift from Dr. Stephen Briddon, 
and Professor Steven Hill, University of Nottingham, UK) 
per well using PEI method. !e ratio of DNA:PEI used 
for this transfection was 1:6# in 150 mM NaCl [57]. Cells 
were grown overnight, harvested and seeded at a density 
of 50,000 cells/well into PLL-coated white 96-well plates 
(Greiner, UK) in complete growth medium and cul-
tured for a further 24 h. On the day of the assay, culture 
medium was discarded and replaced by 80 µl BRET bu$er 
which consist of PBS supplemented with 0.9 mM  CaCl2, 
0.5 mM  MgCl2, and 1 % BSA (w/v). !e assay was started 
by adding 10 µl of furimazine, the substrate of Nluc (Pro-
mega, UK) (diluted in BRET bu$er) to a final concentra-
tion of 0.4 µM and the plate was incubated in the dark at 
room temperature for 5 minutes.
For association-dissociation kinetic experiments, fol-
lowing furimazine incubation, 40 nM of CA200645 (pur-
chased from Hello Bio, Bristol, UK) was added and the 
plate was immediately read. After 19 minutes stimula-
tion, CGS21680 was injected to give a final concentration 
of 10 µM. Whereas for competition association assays, 
after incubation with furimazine, CA200645 (300 nM) 
in the presence of unlabelled ligand (in a range of 10 pM 
to 100 µM) were added simultaneously. BRET signal was 
recorded for either 50 minutes or 20 minutes, for kinetic 
experiments or competition assay as appropriate, on a 
Mithras LB940 plate reader allowing sequential integra-
tion of signal detected from fluorescent probe CA200645 
and Nluc. !e BRET ratio corresponds to the ratio of 
light emission from acceptor (red fluorescent probe, 
long pass filter > 610 nm) over donor (Nluc 460 nm). 
Ligand-induced %BRET was used to construct the asso-
ciation-dissociation kinetic of the fluorescence probe and 
competition binding curve of unlabelled ligands.
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To determine  KD value of CA200645, the signals from 
kinetic assay was fit into “association then dissociation” 
equation which was built in Prism 8.4. With the purpose 
of validating BRET-based competition assay, several ref-
erence compounds including CGS21680, NECA, and 
isoprenaline were also included. Binding a!nities were 
calculated from competition assay by fitting data to non-
linear regression using “one-site, fit Ki” model built in 
Prism 8.4. "e concentration and  KD values of ‘hot’ ligand 
were set to 300 nM and 65 nM, respectively.
cAMP accumulation assays
Prior to assay, harvesting of cells was performed with trypsin 
containing 0.05 % EDTA, they were then washed with 
PBS, and subsequently resuspended in stimulation bu#er 
(PBS Proliferation assays containing 0.1 % BSA and 25 µM 
rolipram). Seeding of cells was done at 2000 cells  well! 1 
of a 384-well white optiplate, and then they were stimu-
lated at room temperature with compounds 1–6 (ranging 
100 pM-10 mM) for 30 minutes. "e cells were subsequently 
lysed, and the measurement of cAMP levels was done using 
a LANCE cAMP detection kit (PerkinElmer), and the plates 
were read with a Mithras LB940 microplate reader.
Proliferation assays
To test the e#ect of compounds 1–6 upon proliferation, 
various cell types were seeded onto clear 96-well plates 
at proper densities for each; CHO-K1 (2000 cells  well! 1), 
CHO-K1-A2AR (2000 cells  well! 1), H520 (2500 cells  well! 1), 
H1563 (2500 cells  well! 1), H1792 (2500 cells  well! 1), LK-2 
(2500 cells  well! 1). "is was done in suitable media, and 
they were cultured for 24 hours. After the subsequent addi-
tion of compounds 1–6 (ranging 316 nM ! 100 µM), cells 
were allowed to grow further for 72 hours. Quantification 
of changes in cell number was done by adding 5 µl CCK-8 
reagent to each well, accompanied by incubation at 37 °C for 
1–3 hours. "e determination of  OD450 was done using a 
Mithras LB940 micro-plate reader at 450 nm.
RT-PCR
Extraction of RNA from H520, H1792, H1563 and LK-2 
cells was done using a RNAqueous®-4PCR Total RNA 
Isolation Kit (Life Technologies, Paisley, UK) as per the 
manufacturer’s instructions. "en, DNAse I treatment 
was performed to remove the contamination by genomic 
DNA. Subsequently, the quantification of the degree 
of purity of RNA samples was performed using a Nan-
oDrop™ Lite spectrophotometer ("ermo Scientific, 
UK). "e samples that were used in cDNA synthesis are 
those of yields > 100 ng/µL and  A260/280 ratios > 1.9. "e 
cDNA synthesis was done using a QuantiTect reverse 
transcription kit (Qiagen, Manchester, UK), for which 
a total of 1 µg of freshly isolated RNA was consumed 
per reaction. RT-PCR was subsequently implemented 
according to what has been previously reported[58]. "e 
RT-PCR that has been done used gene specific primers 
to human: GAPDH (Sense 5’–TGC ACC ACC AAC TGC 
TTA GC– 3’; Antisense 5’-GGC ATG GAC TGT GGT CAT 
GAG–3’), A1R (Sense 5’-CCA CAG ACC TAC TTC CAC 
ACC–3’; Antisense 5’–TAC CGG AGA GGG ATC TTG 
ACC–3’, Primerbank ID ! 115305570C1), A2AR (Sense 
5’-CGC TCC GGT ACA ATG GCT T–3’; Antisense 5’–
TTG TTC CAA CCT AGC ATG GGA–3’, Primerbank ID 
! 156142194C1), A2BR (Sense 5’–TGC ACT GAC TTC 
TAC GGC TG–3’; Antisense 5’–GGT CCC CGT GAC CAA 
ACT T–3’, Primerbank ID ! 22907046C1), A3R (Sense 
5’–GGC CAA TGT TAC CTA CAT CACC–3’; Antisense 
5’–CCA GGG CTA GAG AGA CAA TGAA–3’, Primerbank 
ID ! 4501953A1) and PDE10A (Sense 5’-TGA TGA CTT 
TTC TCT CGA CGT TG–3’; Antisense 5’–AAG CCA CCT 
ACA CAG TGT CTC–3’, Primerbank ID ! 359465520C1). 
"en, gel electrophoresis (using 2 % agaorse gels) was 
performed to resolve PCR products. "e imaging of gels 
was subsequently done using a G Box iChemi gel docu-
mentation system employing GeneTools analysis soft-
ware (Syngene, Cambridge, UK) and densitometry.
Data analysis
Data analysis was performed using GraphPad Prism 8.2.1 
(San Diegeo, CA). All data for !-galactosidase assays 
were normalized to the responses resulting from NECA 
stimulation, whereas the data for cAMP inhibition/accu-
mulation assays were normalised to those obtained upon 
stimulation with 100 µM Forskolin or CGS21680. As for 
proliferation assays, the normalization of all data was 
done relative to the responses obtained upon treating 
cells with 1 % (v/v) DMSO. Subsequently, a three-param-
eter logistic equation was used for fitting each set of nor-
malized data !-galactosidase or cAMP data, in order to 
calculate  pEC50/pIC50 and  Emax values. Also, the fitting 
of the proliferation data was done using a three-param-
eter logistic equation constraining the basal value to 100 
and the system maximum to the  IMax value obtained for 
compound 2, since it elicited the maximum inhibition of 
cellular proliferation in all cell types tested. A one-way 
ANOVA with Dunnett’s post-test, or Student’s t-test was 
used to assess the statistical significance for all assays, 
where p < 0.05 was considered to be significant.
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Abstract 36 
Agonist bias at G protein-coupled receptors has attracted considerable interest, although its 37 
relevance for physiologically-produced agonists is not always clear. Here, using primary 38 
human cells and gene editing techniques, we demonstrate for the first time, endogenous 39 
agonist bias with physiological consequences for the calcitonin-like receptor (CLR). We 40 
reveal that by switching the accessory protein: receptor activity-modifying protein (RAMP) 41 
associated with CLR we can re-route the physiological pathways activated by the stimulating 42 
peptide agonists. These results have revealed a unique role in calcium-mediated nitric oxide 43 
signalling for the little-understood peptide adrenomedullin 2 and distinct pro-proliferative 44 
effects of calcitonin-gene related peptide (CGRP) and adrenomedullin in cardiovascular 45 
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cells. This work reveals that CLR-based agonist bias occurs naturally in human cells and 1 
has a fundamental purpose for its existence. We anticipate this will be a starting point for 2 
more studies into RAMP function in native environments and its importance in endogenous 3 
GPCR signalling. 4 
 5 
Introduction 6 
G protein-coupled receptors (GPCRs) form the largest protein family in the human genome. 7 
~30% of marketed drugs target these receptors and therefore understanding their signalling 8 
pathways is not simply an academic exercise. For many years it had been incorrectly 9 
assumed that agonist-occupied GPCRs signalled through a single pathway to elicit their 10 
response. However, there is now overwhelming evidence to suggest that many GPCRs exist 11 
in multiple receptor conformations and can elicit numerous functional responses, both G 12 
protein- and non-G protein-dependent. Furthermore, different agonists, acting at the same 13 
receptor have the potential to activate different signalling pathways to varying extents; a 14 
concept referred to as biased agonism or signalling bias1,2. While the therapeutic promise 15 
of biased agonists is obvious3: it allows design of ligands that actively engage with one 16 
beneficial signalling outcome while reducing the contribution from those that mediate more 17 
undesirable effects, it is not without controversy. For example, recent doubt has been cast 18 
on validity of developing synthetic biased agonists against the μ-opioid receptor – a GPCR 19 
that has been considered the trailblazer for therapeutic potential of biased agonism4. Thus, 20 
further investigations into the role of agonist bias and its physiological importance, 21 
particularly its relevance to endogenous agonists, are required to bridge the gap between 22 
heterologous studies and in-vivo investigations. 23 
 24 
While there are many well-studied GPCRs that exhibit signalling bias, including 25 
adrenoceptors, and the aforementioned μ-opioid receptor, we have chosen to focus upon 26 
the calcitonin-like receptor (CLR). Like many other GPCRs, CLR can couple to multiple G 27 
proteins and β-arrestins. Importantly, when co-expressed with one of three receptor activity 28 
modifying proteins, (RAMPs, see below), it can be activated by distinct endogenous 29 
agonists; calcitonin-gene related polypeptide (CGRP), adrenomedullin (AM) and 30 
adrenomedullin 2/intermedin (AM2). This makes it a good system to investigate the role of 31 
bias for such endogenous ligands. CGRP, an abundant neuropeptide, is the most potent 32 
microvascular vasodilator known. While it is thought to be cardioprotective, it has also been 33 
implicated in diseases such as migraine5. AM is released by the vascular endothelium and 34 
is also a potent vasodilator that can modulate vascular tone, it is involved in angiogenesis, 35 
and is elevated in some cancers and heart failure6-8. AM2 is also a vasodilator and highly 36 
expressed in the heart and vasculature9,10. It can cause sympathetic activation, have 37 
antidiuretic effects, and is upregulated in cardiac hypertrophy and myocardial infarction11.  38 
 39 
Molecularly, CLR and its close relative, the calcitonin receptor (CTR), are classical class B 40 
GPCRs. CLR is pleiotropically coupled, predominately activating Gas although there are 41 
reports of couplings to both Gi/o and Gq/11/142,12 families. These Ga subunits promote 42 
activation/inhibition of adenylyl cyclase and phospholipase C to generate intracellular 43 
second messengers including cAMP and mobilise intracellular Ca2+ (Ca2+i) which then 44 
activate their respective intracellular signalling cascades. Beyond the Ga subunits CLR has 45 
.CC-BY-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted February 15, 2021. ; https://doi.org/10.1101/2020.12.21.423730doi: bioRxiv preprint 




been reported to couple to b-arrestins13-13 inducing internalisation, although it has been 1 
suggested that this interaction can also lead to its own signalling events possible promoting 2 
cell growth and proliferation14. Despite this high potential for agonist-induced pleiotropy, 3 
CLR remains most closely associated with adenylyl cyclase activation and generation of 4 
cAMP. It is unknown whether this is representative of CLR’s true signalling pattern in the 5 
endogenous setting. 6 
 7 
Additional complexity is added to the pharmacology of the CLR since it has an absolute 8 
requirement for the formation of a heterodimer with a RAMP15,16. In overexpression studies, 9 
each of the three RAMPs have been shown to differentially influence the affinity and agonist 10 
bias of the CGRP family of peptides at the CLR17,18. CLR in complex with RAMP1 generates 11 
the CGRP receptor since CGRP has been demonstrated to be the most potent of the three 12 
agonists at this receptor for generation of cAMP. Likewise, CLR-RAMP2 generates the 13 
adrenomedullin 1 receptor (AM is the most potent at this receptor) and CLR-RAMP3 14 
produces the AM2 receptor (here AM and AM2 are approximately equipotent). To date the 15 
cognate receptor for AM2 and its physiological role remain unknown; no receptor shows 16 
marked selectivity for it. While these is an abundance of evidence of GPCR signalling bias 17 
in recombinant cell systems, and in this case CLR-mediated bias12,19, documented 18 
examples using natural agonists and endogenously expressed human receptors are 19 
currently lacking. We wished to ascertain whether signalling bias at the CLR occurs in 20 
primary cells and whether it plays a role in cellular function. We have chosen to focus our 21 
research on RAMP1 and RAMP2 as the CGRP and AM1 receptors are the best described. 22 
 23 
Using human endothelial cells which endogenously express the AM1 receptor (CLR-24 
RAMP2), we demonstrate for the first time that biased agonism is present and has a 25 
fundamental role in the function of peptide hormones acting on primary human cells. 26 
Moreover, through deletion of the endogenous RAMP2 and replacing it with RAMP1, we 27 
highlight that not only is the RAMP essential for CLR function and CGRP peptide family 28 
signalling in primary cell systems but that RAMPs direct the pattern of agonist bias observed. 29 
Furthermore, we document previously unreported actions for the CGRP-based peptide 30 
agonists; AM2, in particular, emerges as an agonist uniquely biased to elevate calcium-31 
mediated nitric oxide (NO) signalling while both CGRP and AM display distinct pro-32 
proliferative effects in cardiovascular cells. The work we describe here reveals that GPCR 33 





Endothelial cells exclusively express functional CLR/RAMP2 (AM1 receptor) 39 
While there are many reports of biased agonism for GPCRs in recombinant systems (e.g. 40 
19,20), few examples have been documented in primary human cells. Given the reported roles 41 
of CGRP, AM and AM2 in the cardiovascular system we have focussed our studies upon 42 
these peptides, and their receptors in primary human endothelial cells (both HUVECs and 43 
human umbilical artery endothelial cells (HUAECs)). Both endothelial cell lines appear to 44 
express the AM1 receptor since we could only detect transcripts for CLR and RAMP2 using 45 
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qRT-PCR (Figure 1 and Figure S1A). This was confirmed functionally, since when the 1 
endothelial cells were stimulated with agonists and cAMP accumulation quantified, the rank 2 
order of potency was AM>AM2>CGRP (Figure 1B, Figure S1B and Table S1). Furthermore, 3 
application of the selective AM1 receptor antagonist AM22-52 which, at 100nM, abolished 4 
agonist induced cAMP accumulation while 100nM olcegepant (a CGRP receptor selective 5 
antagonist) had little effect (Figure S2A,B). An important factor in confirming receptor-6 
specific agonist bias is to ensure that competing receptors are not present in the system. 7 
The closely related calcitonin receptor (CALCR/CTR) not only interacts with RAMPs21 but 8 
has also be documented to bind CGRP21. Endothelial cells appear to not express the CTR 9 
since we were unable to detect the presence of its transcript or obtain a significant functional 10 
response upon application of two CTR agonists (calcitonin or amylin) (Figure S2C). Thus, 11 
based upon these data, we suggested that endothelial cells specifically express the AM1 12 
receptor alone (CLR-RAMP2) and are a useful primary cell line with which to study potential 13 
endogenous agonist bias.  14 
 15 
Endogenous agonist bias at the CLR-RAMP2 receptor  16 
For studies of biased agonism, it is not simply the ability of different ligands to activate the 17 
canonical second messenger pathway to varying extents that is important, but their ability 18 
to differentially activate a multitude of downstream pathways. Having established that our 19 
primary endothelial cells express only one of the receptor-RAMP complexes responsive to 20 
our three peptides: CGRP, AM and AM2, we next sought to quantify the extent of 21 
endogenous agonist-induced biased signalling through CLR-RAMP2 at other pathways. 22 
Beyond coupling to Gas, in recombinant systems, it has been shown that the CLR can couple 23 
to the Gaq family of G proteins to mobilise Ca2+i 19. Consistent with these previous reports 24 
we were able to observe concentration-dependent increases in Ca2+i in both HUVECs and 25 
HUAECs upon application of AM and AM2 but little or none with CGRP (Figure 1C, Figure 26 
S1C and Table S1). Importantly, all responses could be abolished with the co-treatment of 27 
the Gaq/11/14 inhibitor YM-25489022 (Figure S2D) suggesting the response observed was 28 
purely Gaq/11/14-mediated and thereby confirming CLR-based pleiotropy in primary 29 
endothelial cells. Interestingly, at the CLR-RAMP2 receptor in both endothelial cell lines, 30 
AM2 produced the most potent response and not AM suggesting that a non-cognate agonist 31 
can have a distinct and more potent effect than the cognate agonist at certain pathways 32 
endogenously.  33 
 We subsequently turned our attention to the extracellular signal-regulated kinase 34 
(ERK) pathway (assayed after 5 minutes stimulation) where we found that, again, the 35 
‘cognate’ agonist (AM) was not the most potent. Perhaps surprisingly, CGRP (the agonist 36 
reported to be the least potent at cAMP production at the AM1 receptor) was the most potent 37 
at stimulating ERK1/2 phosphorylation (Figure 1D, Figure S1D and Table S1). Thus, despite 38 
this being designated an AM1 receptor, it is CGRP and not AM that produces physiologically 39 
relevant signalling via the ERK1/2 pathway. 40 
 41 
Physiological consequences of CGRP-based peptide agonist bias in primary 42 
endothelial cells  43 
As we were exploring the AM1 receptor in its native environment, we sought to discover 44 
whether the distinct patterns of agonist bias we have observed with CGRP, AM and AM2 45 
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were reflected further downstream as physiological bias. Here we considered two potential 1 
physiological outcomes with important therapeutic potential – the generation of NO (a vital 2 
modulator of vascular homeostasis) and cell proliferation. NO, generated through 3 
endothelial nitric oxide synthase (eNOS) in endothelial cells23 promotes 4 
vasorelaxation/dilation in a cGMP dependent manner24. In both HUVECs and HUAECs we 5 
observed that all three agonists could evoke NO synthesis in the order of potencies 6 
AM2>AM>CGRP (Figure 1E, Figure S1E and Table S1) although both AM and CGRP were 7 
partial agonists for this pathway with the potencies closely resembling the trends observed 8 
for Ca2+i mobilisation. Indeed, a direct correlation between Ca2+i mobilisation and NO 9 
production in endothelial cells was confirmed through application of YM-254890 which 10 
abolished all NO release (Figure S2E). Such observations are consistent with the role of 11 
increases of Ca2+i concentrations leading to eNOS function24 but to the best of our 12 
knowledge have not been demonstrated previously for AM2.  13 
 Beyond NO production we also measured the long-term cell proliferation (72 hours) 14 
response to the three peptides in both endothelial cell lines. Again, the different peptides 15 
had varying effects on proliferation, with CGRP most potently promoting cell growth (Figure 16 
1F, Figure S1F and Table S1). This is consistent with the data we describe for 17 
phosphorylation of ERK1/2 suggesting proliferation is not mediated via a cAMP-dependent 18 
pathway. This was further corroborated by the observation that application of the non-19 
selective adenylyl cyclase activator forskolin induced a concentration dependent inhibition 20 
of cell proliferation. Together, this data suggests that CLR exerts important cellular effects 21 
in a Gas-independent manner thus unveiling previously undocumented abilities for CGRP 22 
to promote proliferation in human cells through the AM1 receptor.  23 
 To provide a means of comparison of the extent of agonist bias observed in the 24 
endothelial cells (Figure 1G), and to remove potential confounding issue of system bias 25 
(note, system bias may arise due to the differential expression of signalling components or 26 
cofactors in the cellular background of choice) we fitted our data with operational model of 27 
receptor agonism27 for both endothelial cells (Figure 1H-J and Figure S1G-H and Table S1). 28 
There was a strong similarity in the signalling profiles between the two endothelial cells 29 
across the five different pathways (Figure 1H) with significant correlations in potency (Figure 30 
S3C; r = 0.73 – 95% confidence interval 0.35 – 0.90; p < 0.01) and the transducer coefficient 31 
(Figure 1I) (Figure S3C; !/KA; r = 0.94 – 95% confidence interval 0.84 to 0.98; p < 0.0001) 32 
suggesting primary endothelial cells share common AM1 receptor signalling properties. 33 
Finally, this analysis reinforced the notion that AM2 is biased towards Ca2+i mobilisation and 34 
NO production while CGRP favours pERK1/2 activation and cell proliferation.  35 
 36 
AM1 receptor-mediated cAMP accumulation and pERK1/2 activation exemplify agonist 37 
bias 38 
The mechanism by which adenylyl cyclase is regulated involves competition between Gs 39 
(activation) and members of the Gi/o (inhibition) family of G proteins.  Semi-quantitative RT-40 
PCR in both endothelial cell lines revealed the presence of the same Ga subunits (Figure 41 
S3D-E) and both β-arrestin1 and 2 in both cell lines including members of Gi/o family. We 42 
and others have documented how the AM1 receptor (in agreement with other class B 43 
GPCRs) can couple to the inhibitory G proteins21,28,29 although this is often observed in 44 
overexpression systems and is cell type dependent. Application of pertussis toxin (PTX), 45 
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which ADP-ribosylates the inhibitory G proteins (with the exception of Gz), to the HUVECs 1 
revealed a dose-dependent increase in cAMP accumulation (Figure 2A) and a suppression 2 
of ERK1/2 phosphorylation upon application of CGRP and AM2 but not AM (Figure 2B). This 3 
data, consistent with our previously reported work19 suggests that only the non-cognate 4 
agonists (CGRP and AM2) are able to recruit Gi/o proteins to the CLR, and, particularly in 5 
the case of CGRP, the purpose of this is to bias the response away from cAMP and towards 6 
other pathways such as pERK1/2. This is highly likely to contribute to the differences seen in 7 
physiological outcomes such as proliferation, outlined above.  8 
 This did however pose the question as to how AM modulates the pERK1/2 response. 9 
Inhibition of protein kinase A (PKA) had no significant effect (Figure 2C) however 10 
antagonism of Gq/11/14 signalling did reduce the potency of AM-mediated pERK1/2 activation 11 
(Figure 2D). More strikingly, inhibition of the exchange proteins directly activated by cAMP 12 
(EPAC)1/2 activation significantly attenuated both the potency and magnitude of the 13 
maximal response (Figure 2E). Taken together, these data highlight the wide array of 14 
different G protein couplings and their interlinking actions upon downstream signalling 15 
events for the AM1 receptor. These couplings have not been engineered so are not 16 
enhanced by overexpression artefacts and thereby represent pure endogenous agonist 17 
bias.   18 
 19 
RAMP isoform is essential for CLR-mediated agonist bias. 20 
One of the advantages of using recombinant cell lines and/or model cell organisms is the 21 
ability to switch the expressed GPCR or RAMP to observe effects on agonist bias. However, 22 
these recombinant systems do not allow for observations of physiological bias. Thus, we 23 
next sought to determine the effects of CGRP-based agonist bias in primary cells where the 24 
endogenous RAMP had been switched using gene deletion followed by lentiviral 25 
reintroduction. We chose the HUVEC cell line with which to perform the gene editing since 26 
we have been able to grow HUVECs beyond passage P6 to P14 before loss of CGRP based 27 
signalling responses are observed (Figure S4), and it is necessary to grow them past P6 to 28 
develop the RAMP2 null cells. We used lentiviral CRISPR-Cas9 to knockout the RAMP2 29 
gene from the HUVECs. We used a pooled sgRNA strategy using three sgRNAs in separate 30 
lentivirus (Figure S5A) which were selected using a puromycin resistance cassette (Figure 31 
S5B) to increase our efficiency of editing. We transduced HUVECs at a high multiplicity of 32 
infection (MOI) of 10, ensuring that each cell was infected by several lentivirus to increase 33 
the likelihood of achieving a deletion. Then sgRNA editing efficiency in the remaining cell 34 
pool was assessed by PCR amplification of targeted region, Sanger sequencing and TIDE30 35 
analysis: all demonstrating an editing efficiency greater than 95%. This was then followed 36 
by analysis by qRT-PCR for receptor and RAMP mRNA. The expression of CLR remained, 37 
but RAMP2 was lost suggesting degradation through nonsense-mediated mRNA decay 38 
(NMD) (Figure S5C). It is also important to note that the gene editing did not have any impact 39 
upon the cells rate of proliferation (Figure S5E) and the Gɑ subunit/β-arrestin profile also 40 
remained consistent with the wild type HUVECs (Figure S5D). Finally, convinced that the 41 
cells were as near to wild type HUVECs as possible, except lacking RAMP2, we assessed 42 
their signalling properties following stimulation with all three agonists. In all cases the 43 
responses were abolished, although the extent of signalling for the positive controls 44 
.CC-BY-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted February 15, 2021. ; https://doi.org/10.1101/2020.12.21.423730doi: bioRxiv preprint 




remained intact (Figure S5F-J). Thus, these data confirm, that loss of RAMP2 in HUVECs 1 
abolishes CLR function. 2 
 We next introduced, using lentiviral overexpression and blasticidin selection, the 3 
open reading frame of RAMP1 into our HUVEC∆RAMP2 cell line so, in effect, switching the 4 
expressed GPCR from the AM1 receptor to the CGRP receptor. mRNA levels were 5 
quantified demonstrating successful introduction of a high level of RAMP1 expression 6 
(Figure 3A). We next performed cAMP accumulation assays using CGRP, AM and AM2 7 
confirming that a functional CLR receptor was formed in these modified HUVECs (Figure 8 
3B and Table S2). Reassuringly, we now observed that CGRP was the most potent agonist 9 
for the stimulation of cAMP – as expected for a cell line expressing the CGRP receptor 10 
(CLR-RAMP1). Perhaps more interestingly, CGRP was also the most potent at mobilising 11 
Ca2+i (Figure 3C and Table S2) and this was also the case in the associated NO production 12 
(Figure 3E and Table S2). Comparison of the ERK1/2 phosphorylation (Figure 3D and Table 13 
S2) highlighted that AM was now the most potent agonist; a clear switch from wild type 14 
HUVEC cells where CGRP was the most potent. This followed to proliferation where AM 15 
was also the most potent ligand, although both AM2 and CGRP could also promote growth 16 
(Figure 3F and Table S2) and was in contrast to the wild type HUVECs where neither could 17 
cause proliferation. Thus switching the RAMP in the HUVEC cell line appears to have had 18 
a dramatic effect on the agonist bias observed and the functional consequence (Figure 3G,H 19 
and Table S2) – beyond just cAMP accumulation as would be excepted. However, it should 20 
be noted that as RAMP1 expression was high we should be cautious in our direct 21 
comparisons between the wild type HUVECs and our RAMP1-HUVEC cell line.  22 
 23 
Endogenous agonist bias at the CLR-RAMP1 in primary human cardiac myocytes. 24 
In order to provide a comparison for RAMP1-HUVEC signalling with a primary cell line that 25 
endogenously expressed the CGPR receptor we turned to primary human cardiomyocytes 26 
(HCMs) since these cells only expressed CLR and RAMP1 (Figure 4A); analogous to 27 
endothelial cells, HCMs also do not express a functional CTR (Figure 4A and Figure S6A). 28 
To confirm that the mRNA expression translated to functional receptor expression we 29 
performed cAMP accumulation assays for the CGRP family of peptides (Figure 4B and 30 
Table S2). Here, CGRP was the most potent agonist followed by AM2 and AM, a pattern 31 
consistent with the expression of the CGRP receptor20 (also confirmed by application of 32 
100nM olcegepant to inhibit cAMP accumulation for all three agonists (Figure S6B) while 33 
100nM AM22-52 (Figure S6C) had little effect). Intriguingly, upon application of PTX to 34 
HCMs we were unable to observe any significant change in the potency or maximal 35 
signalling for any of the three peptide agonists (Figure S6D) although the transcript for Gai2 36 
was lower than in the endothelial cells (Figure S5E) and this Ga subtype has previously 37 
been suggested to be important for PTX-sensitive effects from CLR19. In contrast to the wild 38 
type HUVECs but analogous to the RAMP1-HUVEC cells, not only was CGRP able to 39 
stimulate Gq/11/14-mediated-Ca2+i mobilisation in HCMs but it was the most potent agonist 40 
(Figure 4C and Table S2). When quantifying ERK1/2 phosphorylation we again observed that 41 
the cognate ligand (CGRP) was not the most potent (Figure 4D and Table S2), but as in 42 
HUVECs, it was the least potent ligand at cAMP accumulation that was the most potent for 43 
ERK1/2 phosphorylation. AM was the most potent at stimulating ERK1/2 phosphorylation, 44 
demonstrating that it can produce functionally relevant signalling responses at the CLR-45 
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RAMP1. The order of potency for the three agonists for ERK1/2 phosphorylation was 1 
replicated in the long-term cell proliferation assays (Figure 4F and Table S2) with AM 2 
remaining the most potent. All three peptide agonists could also evoke Gq/11/14-mediated-NO 3 
production (Figure 4E, Figure S6F,G and Table S2) although their responses were less 4 
distinct from each other.  5 
 Analysis of the RAMP1-HUVEC signalling profile suggested a close overlap with the 6 
properties of HCMs (Figure 5 and Table S2) for the five different signalling pathways as well 7 
as an opposing signalling profile to HUVECs. We confirmed this using correlation plots 8 
(Figure 5A-F) of both potency and the transducer coefficient Log(!/KA), obtained from 9 
application of the operational model of receptor agonism27 (values can be found in Table S2 10 
and Table S3). Whilst a positive correlation was detected between RAMP1-HUVECs and 11 
HCMs (potency; r = 0.55 – 95% confidence interval, 0.051 to 0.82; p < 0.05; transducer 12 
coefficient; r = 0.52 – 95% confidence interval, 0.009 to 0.81; p < 0.05), a negative correlation 13 
was observed between HUVECs and RAMP1-HUVECs (potency; r = -0.54 – 95% 14 
confidence interval, -0.83 to -0.04; p < 0.05; transducer coefficient; r = -0.58 – 95% 15 
confidence interval, -0.84 to -0.10; p < 0.05). We did not observe any correlations between 16 
HUVECs and HCMs which, in part appears due to the HCMs having reduced capacity to 17 
release NO. Finally, when we extended our analysis to determine the change in transducer 18 
coefficient normalised to cAMP accumulation mediated by the non-cognate (for RAMP1-19 
CLR or RAMP2-CLR) agonist AM2 (Figure 5G and 5H) it becomes apparent how closely 20 
aligned the signalling properties in RAMP1-HUVECs and HCMs are. 21 
  22 
 23 
Discussion 24 
We have shown for the first-time that the CGRP family of endogenous peptides demonstrate 25 
biased agonism at the endogenous CLR in a physiological system; and that the RAMP 26 
expressed dictates the intracellular response and ultimately the physiological outcome 27 
(Figure 5). Many receptors have been shown to demonstrate agonist bias; but for the most 28 
part this has been shown through synthetic ligands designed to target certain receptor 29 
pathways2. We have now shown that this is a process that can occur physiologically to direct 30 
different outcomes. Through elucidating distinct patterns of signalling bias that each peptide-31 
receptor-RAMP produces, we have shown that bias is a naturally occurring phenomenon in 32 
a range of human cardiovascular cells. Furthermore, while we have only begun to scratch 33 
the surface of how important bias is physiologically, it is now clear it is an intrinsic part of 34 
endogenous CLR function, and we anticipate this is the case for many more GPCRs that 35 
exhibit signalling bias in over-expression studies. We have also demonstrated the 36 
importance of studying GPCR second messenger signalling with the endogenous receptor 37 
in its native environment, with the distinct signalling patterns of AM2 we have uncovered 38 
providing a good example of this. 39 
 We have confirmed, as anticipated by the co-expression models, that endogenous 40 
CLR is unable to function without RAMP expression through CRISPR-Cas9 KO of the 41 
endogenous RAMP. This provides, to the best of our knowledge, the first example of 42 
CRISPR-Cas9 interrogation of GPCR function in a primary cardiovascular cell. Furthermore, 43 
we have shown that the expression of a different RAMP in the HUVECs can switch the 44 
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signalling bias of the CLR and associated peptide agonists, thus providing additional 1 
evidence that RAMP targeting could become a powerful therapeutic tool25. 2 
 We have compared the pharmacology of these receptors in terms of cAMP 3 
accumulation to reports compiling multiple values from independent publications using the 4 
human receptor in transfected systems20. It was reassuring therefore to observe that CGRP, 5 
AM, and AM2 displayed similar trends in cAMP potency at CLR-RAMP1/2 in the primary 6 
cells to those seen in recombinant co-expression studies, as well as in the gene edited 7 
RAMP1-HUVECs which reflected the cAMP data from transfected systems (Figure 5I). In 8 
addition, we have performed a comprehensive analysis of the mechanisms used by RAMP2-9 
CLR complexes to stimulate ERK1/2 phosphorylation in endothelial cells (Figure 2). It is 10 
apparent that each agonist uses unique mechanisms to activate ERK1/2. For both CGRP 11 
and AM2 it is mediated in a Gi/o-dependent manner, while AM uses a combination of Gq/11/14 12 
signalling and EPAC activation. None of the agonists appear to mediate their ERK1/2 13 
stimulation through the so-called cognate pathway, cAMP accumulation. The data 14 
presented is ERK1/2 phosphorylation after 5 minutes and it will be of interest to determine 15 
the mechanisms and spatial locations that facilitating long term ERK1/2 phosphorylation.  16 
 What has become clear in this study is that each of the endogenous ligands have 17 
very specific potencies at each pathway measured, whether it is at CLR-RAMP2 in 18 
HUVECs/HUAECs or CLR-RAMP1 in HCMs or RAMP1-HUVEC cells. Each peptide 19 
generates their own unique signalling profile (Figure 5J-L). In a concentration-dependent 20 
manner, they individually recruit distinct G proteins in a manner regulated by the RAMP. 21 
This leads to a specific pattern of second messenger production and therefore a ‘signalling 22 
barcode’ for the cell to interpret and produce further physiologically necessary downstream 23 
responses. Expression analysis reveals in our three primary cell lines that each only 24 
expresses mRNA above the detection threshold for one RAMP and the CLR. Combined with 25 
the cAMP signalling profile for each it appears that endothelial cells and HCM are a excellent 26 
primary model cell types for the analysis of how the CLR-RAMP2 and CLR-RAMP1 signal 27 
in vivo. 28 
 It is worth noting that the present method of classifying receptors for CGRP and AM 29 
is based upon their potencies at cAMP production in addition to their affinities in binding 30 
assays26. This method arose due to the assumption that cAMP was the most physiologically 31 
relevant pathway. Here, we have demonstrated that significantly different potencies are 32 
observed for agonists and these lead to physiologically relevant outcomes. As such we need 33 
to carefully consider how we classify CGRP-related receptors in the future, and more widely 34 
all GPCRs that exhibit agonist bias. 35 
 We can also consider this work in the wider context of the organs and systems these 36 
cells are found in as this sheds light on some of the pathways, and involvement of bias in 37 
some of the established roles of CGRP family peptides in the cardiovasculature. It has long 38 
been recognised that all three peptides show pleiotropic signalling, activating multiple G 39 
proteins and signalling pathways33 (and indeed this continues in current literature34-36), but 40 
it has previously not been possible to fit this into any framework. We suggest our current 41 
observations on RAMP-directed bias may assist with this. 42 
AM has a multitude of important roles in vascular homeostasis6; one of which is 43 
regulating endothelial barrier function37. It is thought to cause barrier stabilisation and protect 44 
against infection mediated junctional protein disappearance, all brought about initially 45 
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through cAMP production38. This is supported by our work demonstrating AM produces a 1 
potent cAMP response and is biased towards this pathway. It is also well documented that 2 
AM is a potent vasodilator known to mediate some of its vasodilatory effects through NO 3 
release from vascular endothelial cells25,39 which we have pharmacologically profiled here.  4 
 In contrast, the precise role of AM2, which is also found in endothelial cells, has been 5 
unclear. We now provide evidence that AM2 is a potent stimulator of Ca2+i mobilisation and 6 
NO synthesis. It is possible therefore that this plays a vital role at least in umbilical 7 
endothelial cell physiology, and indeed wider vascular physiology. Thus, the novel finding of 8 
AM2’s greater potency than AM at eliciting NO release via Ca2+i mobilisation may have great 9 
therapeutic potential. 10 
 Interestingly, in vascular endothelial cells CGPR inhibits adenylyl cyclase through Gi/o 11 
and predominantly signals through pERK1/2, and proliferation. The link between pERK1/2 and 12 
cellular metabolism/proliferation is well established40-42, as well as in endothelial cells 13 
specifically43-45. We have shown that where an agonist has biased signalling towards ERK1/2 14 
phosphorylation, this is carried through to long term cellular proliferation. Importantly, this 15 
shows overall that two non-cognate ligands, often not considered significant for receptor 16 
function, do in fact have important signalling and physiological roles/capabilities. In addition, 17 
we have demonstrated that endogenous pERK1/2 can come from a variety of sources 18 
depending on the stimulating ligand. Together this shows that the CLR initiates a multitude 19 
of intracellular pathways beyond simply Gs and cAMP/PKA in physiologically relevant cells. 20 
Therefore, our data adds further evidence that AM for CLR-RAMP2 and CGPR for CLR-21 
RAMP1 should only be considered the cognate ligands in terms of Gs-mediated cAMP 22 
signalling, and when looking at the physiology of RAMP2 in endothelial cells and the 23 
vasculature as a whole, CGRP and AM2 should be considered alongside AM for their 24 
different and potentially complementary roles. 25 
 On the heart, there are multiple reports that CGRP has a cAMP-mediated positive 26 
inotropic and chronotropic effect5,46,47, and our data showing its strong response in cAMP 27 
accumulation assays on human myocytes (combined with its overall bias towards this 28 
pathway) supports this. There are contrasting reports in the literature over AM’s effect on 29 
heart contractility7,48; with some suggestions that it is a positive inotrope acting in the same 30 
cAMP driven manner as β-adrenoceptor agonists49, while others report it having negative 31 
inotropic effects50,51. Here we show that AM promotes a cAMP response through CLR-32 
RAMP1 in human cardiomyocytes, but it has weak potency. This may provide some 33 
context/explanation for the contradictory literature reports. Furthermore, our report has 34 
clearly revealed that cAMP is not AM’s primary signalling pathway in HCMs and that it is 35 
biased towards pERK1/2 and cell proliferation rather than cAMP and positive inotropy. 36 
Nevertheless, evidence suggests that AM has an important role in the human heart. This 37 
includes the observed elevation of AM in the failing heart52. Here, we have utilised 38 
proliferating human ventricular myocytes in vitro and shown that AM (but not CGRP or AM2) 39 
exhibits signalling bias specifically towards pERK1/2 and enhancing proliferation in these 40 
cells. This work highlights AM as a novel peptide hormone that may promote cardiac 41 
regeneration naturally in vivo, and provides a cellular mechanism for this. This may also 42 
explain the elevation of AM in heart failure6 and the clinical trial data showing that AM 43 
administration reduces infarct size27. For AM2, its effect on contraction of the heart is 44 
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blocked by both inhibitors of PKA and PKC (i.e. Gq/11/14-coupling), suggesting multiple 1 
signalling pathways are activated by this peptide in-vivo54. 2 
 It should be noted that not all studies reveal pleiotropic signalling for the CGRP family 3 
of peptides, either involving direct measurements of G protein coupling in cell-free systems55 4 
or second messenger generation in cells12. We suggest that there is cell membrane (e.g. 5 
lipid composition) and cell line-specific factors (e.g. expression of G proteins) that influence 6 
the observed bias. 7 
 In summary, we have gone beyond previous studies in recombinant systems to 8 
observe agonist bias. While we have focused upon CLR-RAMP complexes, our ability to 9 
switch the RAMP means we are, in effect, switching the expressed receptor and therefore 10 
has general applicability to all GPCRs. Our data highlights how endogenous agonist bias 11 
can have profound consequences for the cell and how important cell background is in 12 
regulating this process. This work may even go as far as to suggest that to fully understand 13 
bias at a GPCR, it has to be considered in its native environment. While our work takes an 14 
important step closer to understanding how the CGRP family of peptides and receptors 15 
function on a cellular level in the human cardiovascular system, it also highlights the 16 
importance of endogenous agonist bias as a concept and emphasises its long-term 17 
consequences for drug design. 18 
 19 
Materials and Methods 20 
Cell Culture  21 
HUVECs and HUAECs (were both sourced from PromoCell, Germany) were cultured in 22 
Endothelial Cell Growth Media (ECGM) (PromoCell). Human Cardiac Myocytes 23 
(PromoCell,) were grown in Cardiac Myocyte Growth Media (CMGM) (PromoCell). All cell 24 
lines were cultured in media containing 10% heat inactivated Fetal Bovine Serum (FBS) 25 
(Sigma, USA). Cells were grown in 25cm2 flasks or 75cm2 flasks depending on cell density 26 
required. They were passaged approximately every 4 days depending on confluency with a 27 
final volume of 10ml produced from 1ml of the previous cell culture and 9ml of the growth 28 
medium in 75cm2 flasks, or 1ml using 4ml in 25cm2 flasks, and used from passage 2-6 (with 29 
the exception of HUVEC∆RAMP2 and RAMP1-HUVEC). All cells grown with 1% antibiotic 30 
antimycotic solution (100x Sigma, USA). The cells were maintained in an incubator (37 °C, 31 
humidified 95% air, 5% CO2) between passaging. 32 
 33 
Genome Engineering 34 
HUVECs with the RAMP2 gene knocked out were generated by CRISPR/Cas9 homology 35 
directed repair as described previously56. The sgRNA sequences were designed (5’-36 
CGCTCCGGGTGGAGCGCGCCGG-3’), (5’-TCCGGGTGGAGCGCGCCGGCGG-3’), and 37 
(5’-CCCGCGTCTCCCTAGGACCCGA-3’) for Cas9 targeting to the human RAMP2 gene 38 
(Sigma, US). All guides were delivered in the LV01 vector (U6-gRNA:ef1a-puro-2A-Cas9-39 
2A-tGFP) vector provided by (Sigma-Aldrich, US). Sequences were verified by Sanger 40 
sequencing. The control cell line was established by transduction of LV01 vector not 41 
containing sgRNA targeted to RAMP2 gene. HUVEC cells were seeded in 6 well plates at a 42 
cell density of 160,000 cells/well and maintained at 37°C in 5% CO2 with Complete 43 
Endothelial Cell Growth Media containing 100μg/ml streptomycin (Sigma-Aldrich, US). 44 
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24hrs after seeding virus containing individual sgRNA/Cas9 constructs were pooled and 1 
transduced into cells at a high MOI of 10, ensuring that each cell is infected by several 2 
lentivirus and increasing the likelihood of achieving KO. Transduction was performed in 3 
media containing 8μg/ml Polybrene (Sigma, USA). Cells were cultured for 24hrs then treated 4 
with Puromycin (1μg/ml) (Thermo Fisher Scientific, UK) for 3 days to select for transduced 5 
cells. Cells then cultured without puromycin and expanded before cells were collected for 6 
genotyping by Sanger sequencing, qRT-PCR, and functional assays. All data shown were 7 
from cells expanded from these colonies. RAMP1 expression achieved through transduction 8 
of virus containing RAMP1 MISSION TRC3 Open Reading Frame (ORF) plasmid (pLX_304) 9 
(Sigma, US) into RAMP2 KO-HUVECs. HUVEC cells were seeded in 6 well plates at a cell 10 
density of 160,000 cells/well and maintained at 37°C in 5% CO2 with Complete Endothelial 11 
Cell Growth Media containing 100μg/ml streptomycin (Sigma, US). 24hrs after seeding, 12 
virus containing the ORF construct was transduced into cells in media containing 8μg/ml 13 
Polybrene. Cells were cultured for 24hrs then treated with blasticidin (5μg/ml) (Thermo 14 
Fisher Scientific, UK) for 6 days to select for transduced cells. Cells were collected for 15 
genotyping by qRT-PCR and expanded for functional assays. All ‘HUVEC RAMP1’ data 16 
shown were from cells expanded from these colonies. 17 
 18 
Immunofluorescence 19 
HUVEC cells were seeded in Cell Carrier Ultra 96 well plate (Perkinelmer, Boston, MA, US) 20 
at a cell density of 160,000 cells/well and maintained at 37°C in 5% CO2 with Complete 21 
Endothelial Cell Growth Media containing 100μg/ml streptomycin. Cells were washed twice 22 
with PBS, fixed with 4% paraformaldehyde (PFA) in PBS (10 mins, RT) then washed three 23 
times with PBS. The cells were permeabilized with 0.05% Tween 20 in PBS (60 mins, RT), 24 
and then incubated with 10% goat serum in PBS (60mins, RT). The cells were then 25 
incubated in primary antibody for cas9 protein (Cell signalling technology, MA, US) 7A9-26 
3A3, diluted 1/700 in PBS/0.05% Tween/3% BSA) at 4°C, overnight and protected from light. 27 
The cells were washed three times with PBS and incubated with AlexaFluor 488 goat anti-28 
mouse (Invitrogen A11001, 1/500) (1hr, RT) protected from light. Cells were washed three 29 
times with PBS, then nuclei were stained with Hoechst (Invitrogen) (1/2000 in PBS, 10mins, 30 
RT). Cells were then washed three times with PBS w/o Mg2+ or Ca2+i and imaged at 20x 31 
magnification (Cell Voyager 7000S, Yokogawa). 32 
 33 
Sequencing of genomic loci 34 
Genomic DNA was extracted from virally transduced HUVEC cells by: collecting 35 
approximately 10,000 cells, washing in PBS (sigma-Aldrich, US) and then lysing with 36 
DirectPCR Lysis Reagent (Viagen Biotech, US) containing Proteinase K (Qiagen, Germany) 37 
at 0.4mg/ml. The lysate was incubated at 55°C for 4 hrs; 85°C, for 10mins; 12°C for 12hrs. 38 
PCR reaction was then set up in (20μl) as follows: 2x Flash Phusion PCR Master Mix 39 
(Thermo Fisher, US) (20μl), forward primer (5’- AATTCGGGGAGCGATCCTG -3’) 40 
(Eurogentec, Belgium) (1μl)(10μm), reverse primer (5’- GAGACCCTCCGAAAATAGGC -3’) 41 
(Eurogentec, Belgium) (1μl)(10μm), DNA (100ng/μl)(1μl), ddH2O (7μl). The product was 42 
amplified by PCR using the following program: 98°C, 1min; 35x (98°C, 10secs; 55°C, 43 
10secs; 72°C, 15secs), 72°C, 1min; 4°C, hold. PCR clean-up was performed prior to 44 
sequencing using the Illustra GFX PCR DNA and Gel-band Purification Kit (Illustra, 45 
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Germany) according to manufacturer’s instructions. Editing of RAMP2 gene was confirmed 1 
by Sanger sequencing (Eurofins) and TIDE analysis30. 2 
 3 
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) 4 
HUVECs were cultured as above in Complete Endothelial Cell Growth medium and plated 5 
in a 24 well plate at 100,000 cells/well. Media was then removed, and cells were washed in 6 
PBS (Sigma, UK). RNA was extracted and genomic DNA eliminated using an RNA 7 
extraction kit (QIAGEN, Germany) as per manufacturer’s instructions. The yield and quality 8 
of RNA was assessed by measuring absorbance at 260 and 280 nm (Nanodrop ND-1000 9 
Spectrophotometer, NanoDrop technologies LLC, Wilmington DE USA). RNA was used 10 
immediately for the preparation of cDNA using the Multiscribe reverse transcriptase. For the 11 
preparation of cDNA 100ng of RNA was reverse transcribed using Taq-man reverse 12 
transcription kit (Life Technology, MA, USA) according to manufacturer’s instructions. 13 
Reactions were performed on a thermal Cycler as following: 25°C, 10mins; 48°C, 30mins; 14 
95°C, 5mins. cDNA was stored at -20°C. 15 
 16 
For each independent sample, qPCR was performed using TaqMan Gene Expression 17 
assays according to manufacturer’s instructions (Life Technologies, MA, USA) for GAPDH 18 
(Hs02786624_g1), CALCR (Hs01016882_m1), CALCRL (Hs00907738_m1), RAMP1 19 
(Hs00195288_m1), RAMP2 (Hs01006937_g1), RAMP3 (Hs00389131_m1) and plated onto 20 
fast microAmp plates containing 2μl cDNA, 1μl Taq-man probe, 10μl Taq-man fast universal 21 
master mix (Applied Biosystems) and 10μl ddH2O. PCR reactions were performed on ABI 22 
7900 HT real time PCR system (Thermo Fisher Scientific, UK). The program involved the 23 
following stages: 50°C, 2 mins; 95 °C, 10mins, the fluorescence detection over the course 24 
of 40x (95°C, 15secs; 60°C, 1min). Data are expressed as relative expression of the gene 25 
of interest to the reference gene GAPDH where: Relative expression = 2-((Cq of gene of 26 
interest) – (Cq of GAPDH)). For the genes where no mRNA was detected these samples 27 
are omitted from graphs and labelled accordingly, as indicated in the figure legends. 28 
 29 
In vivo assays 30 
Measurement of intracellular cAMP 31 
All primary cell lines were cultured as above. On the day of the experiment media was 32 
removed and cells washed with PBS, before being dissociated with Trypsin-EDTA 0.05% 33 
(Gibco, UK) and then resuspended in PBS/BSA (0.1%) (Sigma, UK).  Cells were 34 
immediately plated for use in cAMP assay as per manufacturer’s instructions and as 35 
described previously21, reagents used were provided by the LANCE® cAMP detection assay 36 
kit (PerkinElmer, Boston, MA, USA), in 384 well optiplates (PerkinElmer (Boston, MA, USA)) 37 
at 2000 cells/well in 5μl aliquots. Human αCGRP, hAM and hAM2 (Bachem, Switzerland) 38 
were diluted in PBS/BSA (0.1%) with 250μM IBMX (Sigma, UK), and used from 10pM to 39 
10µM. Cells were incubated with compound for 30mins prior to adding detection buffer as 40 
described previously28,57. Plates were incubated for a further 60 mins (RT) and then read on 41 
a plate reader (Mithras LB 940 microplate reader (Berthold technologies, Germany)). All 42 
responses were normalised to 100µM forskolin (Tocris, UK). Antagonist studies were 43 
performed in the same way through co-stimulation of the relevant concentration. Alongside 44 
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control treated cell. Experiments with PTX (Sigma, UK) required pretreatment (16hrs) prior 1 
to assays 2 
 3 
Measurement of Phospho-ERK1/2 (Thr202/Tyr204) 4 
Primary cells were grown to in 6 well plates, on the day of the experiment media was 5 
replaced with serum free media 4hrs prior to cell harvesting. Tyrpsin-EDTA was used to 6 
dissociate the cells and they are spun down, counted and re-suspended HBSS/BSA (0.1%). 7 
Ligands were also diluted in HBSS/BSA. Cells were then plated on 384 well plates in 8μl 8 
aliquots at a density of 20,000 cells/well. Next, ligands were added (4μl) for 5min stimulation 9 
at room temperature. Cells were then lysed as per to manufacturer’s instructions with 4μl of 10 
lysis buffer (Cisbio phosphor-ERK1/2 cellular assay kit, Invitrogen, UK) for 30mins shaking 11 
at room temperature. The 2 specific antibodies; were pre-mixed in a 1:1 ratio. 4μl of this was 12 
added to each well and the plate incubated for a further 2hrs. Then fluorescence emissions 13 
were read at 665nm and 620nm using a Mithras LB940 microplate reader. Antagonist 14 
studies were performed in the same way through co-stimulation with PTX, Rp-8-Br-cAMPS, 15 
YM-254890, or ESI-09 as appropriate alongside control treated cell.  16 
 17 
 18 
Measurement of Intracellular Calcium mobilisation 19 
All cell lines were plated at 20,000 cells/well on 96 well black clear-bottom plates (Costar, 20 
UK) 24hrs before the experiment. Media was removed, and cells were washed with Hank’s 21 
Balance Salt Solution (HBSS) (Lonza, Switzerland) before cells were loaded with 10µM 22 
Fluo-4/AM (Invitrogen, US) in the dark at room temperature for 30mins. Cells were then 23 
washed twice with calcium-free HBSS, then were left in 100µl calcium-free HBSS for the 24 
duration of the assay. In conditions where Gaq/11/14 signalling is inhibited, cells were pre-25 
treated with 100nM YM-254890 (Alpha Laboratories, UK) (30mins)22. All assays were 26 
performed using the BD Pathway 855 Bioimaging Systems (BD Biosciences, UK), which 27 
dispenses ligands (20µl) and reads immediately for 2mins. Data was normalised to the 28 
response seen with 10µM Ionomycin. 29 
 30 
Measurement of Cell Proliferation 31 
Both endothelial cell lines and HCMs were seeded at a density of 2500 cells/well in a clear 32 
flat bottom 96-well plate (Corning, UK) and incubated at 37°C in 5% CO2. After 24 hrs, cells 33 
were exposed to test compounds or vehicle, in complete endothelial cell growth media 34 
(HUVECs) or myocyte growth media (HCMs). Cells were incubated for a further 72hrs at 35 
37°C in 5% CO2. After 72 hrs incubation, 5μl of Cell Counting Kit – 8 (CCK-8, Sigma, UK) 36 
was added to each well and cells were then incubated for another 2 hrs at 37°C in 5% CO2 37 
and in the dark. The absorbance of each well was measured using a Mithras LB940 38 
microplate reader with an excitation of 450 nm. The absorbance is directly proportional to 39 
the number of viable cells. Cell proliferation was calculated as a percentage of number of 40 
cells treated with vehicle alone. 41 
 42 
Measurement of Nitric Oxide Production 43 
Endothelial cells and HCMs were cultured as above. 24 hours prior to assay cells were 44 
plated on Costar 96 well black clear bottom plates at 40,000 cells/well. The assay was 45 
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performed according to manufacturer’s protocol. Briefly; cells pre-incubated with NO dye 1 
and assay buffer 1 (Fluorometric Nitric Oxide Assay Kit, Abcam, UK) for 30mins at 37°C in 2 
5% CO2. Any inhibitors requiring 30mins pre-treatment (YM/L-NAME/DMSO control) were 3 
added at this point. Ligand stimulation occurred immediately after this for 15 mins at 37°C 4 
C in 5% CO2. Stain and ligand solution were removed, assay buffer II was added, and wells 5 
were read immediately. The absorbance was measured using a Mithras LB940 microplate 6 
reader with an excitation/emission of 540/590 nm. Endothelial cell responses were 7 
normalised to 10µM acetylcholine58. HCM responses were normalised to 10µM 8 
isoproterenol59.60. 9 
 10 
Statistical analysis 11 
Data analysis for cAMP accumulation, Ca2+i mobilisation, NO accumulation, pERK1/2 12 
activation and cell proliferation assays were performed in GraphPad Prism 8.4 (GraphPad 13 
Software, San Diego). Data were fitted to obtain concentration–response curves using either 14 
the three-parameter logistic equation using to obtain values of Emax and pEC50 or the 15 
operational model of agonism27. Statistical differences were analysed using one-way 16 
ANOVA followed by Dunnett’s post-hoc (for comparisons amongst more than two groups) 17 
or unpaired Student’s t test with Welch’s correction (for comparison between two groups). 18 
To account for the day-to-day variation experienced from the cultured cells, we used the 19 
maximal level of cAMP accumulation from cells in response to 100μM forskolin stimulation 20 
was used as a reference, 10μM ionomycin for Ca2+i assays, 10μM phorbol 12-myristate 13-21 
acetate (PMA) for pERK1/2 activation, 10μM acetylcholine for NO production and 10μM 22 
VEGF for cell proliferation. Emax values from these curves are reported as a percentage of 23 
these controls, and all statistical analysis has been performed on these data. Where 24 
appropriate the operational model for receptor agonism27 was used to obtain efficacy (t) and 25 
equilibrium disassociation constant (KA) values. In both cases, this normalization removes 26 
the variation due to differences in days but retains the variance for control values. The 27 
means of individual experiments were combined to generate the curves shown. Having 28 
obtain values for t and KA these were then used to quantify signalling bias as the change in 29 
Log(t/KA) as described previously18;24. Error for this composite measure was propagated by 30 
applying the following equation.  31 
 32 
"##$%&	()* = ,(()*!)" + (()*#)" 33 
 34 
Where, SEMA and SEMB are the standard error of measurement A and B. 35 
Correlations between pEC50 values or transducer coefficients Log (t/KA) were assessed by 36 
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Figure 5  
 
 
Figure 5. CGRP signalling bias in RAMP1 expressing HUVECs correlates with that in 
human cardiomyocytes. A-C) the correlation of Log agonist potencies ± SEM for CGRP, 
AM and AM2 stimulated cAMP accumulation, mobilisation of Ca2+i, NO production, 
intracellular ERK1/2 phosphorylation and cell proliferation in RAMP1 expressing HUVECs 














































































































































































































































































































































































































































95% confidence interval -0.70 to 0.256
N.S.
AM2












































95% confidence interval -0.826 to -0.044
p<0.05 p=0.036
AM2












































































95% confidence interval -0.70 to 0.256
N.S.
AM2





















































































































































.CC-BY-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted February 15, 2021. ; https://doi.org/10.1101/2020.12.21.423730doi: bioRxiv preprint 
Appendix   
 383 
 29 
and HCMs (A), HUVECs and HCMs (B) and HUVECs and RAMP1 expressing HUVECs (C) 
was analysed by a scatter plot and Pearson's correlation coefficients (r) were calculated. A 
significant positive correlation was observed for RAMP1 expressing HUVECs and HCMs. 
The presence of a line indicates a positive correlation. D-F) as for A-C except the 
transduction coefficient Log (!/KA) was calculated. A significant positive correlation was 
observed for RAMP1 expressing HUVECs and HCMs as indicated by the presence of a line. 
G) Signalling bias plots were calculated as ∆∆Log(!/KA) for CGRP in the three cell lines, 
HUVECs, RAMP1 expressing HUVECs and HCMs for each pathway. Values have been 
normalised to a reference agonist (AM2) and the reference pathway (cAMP) for all three cell 
lines. H) as for G except the calculated values are for AM. I) Log potency ratios (as measured 
by the accumulation of cAMP) calculated as Log (EC50AM2/EC50 agonist). Data are 
compiled from12,19. HUVECs and HUAECs are shown in red and green respectively, HCMs 
in cyan and RAMP1-HUVECs in blue. J-L) Schematic representation of the signalling bias 
produced by CGPR (J), AM (K) and AM2 (L), and the intracellular ‘signalling codes’ they 
bring about based on the potencies recorded at individual pathways in HUVECs, RAMP1-
HUVECs and HCMs. 
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